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effectiveness of inhaled corticosteroids (ICS) alone and
ICS used in combination with a long-acting beta2
agonist (LABA) in the treatment of chronic asthma in
adults and children aged over 12 years. 
Data sources: Major electronic bibliographic
databases, e.g. MEDLINE and EMBASE, were searched
up to February/March 2006 (and updated again in
October 2006). 
Review methods: A systematic review of clinical and
cost-effectiveness studies was conducted. Cost
comparison and cost-consequence analyses were
performed where appropriate. 
Results: The assessment of clinical effectiveness was
based on the 67 randomised controlled trials selected
from the 5175 reports identified through the
systematic literature search. The most frequently
reported relevant outcomes were lung function,
symptoms, use of rescue medication and adverse
events. The trials varied considerably. In the trials that
compared low-dose ICS versus ICS and high-dose ICS
versus ICS, there were few significant differences in
clinical effectiveness, although a few of the trials had
assessed non-inferiority between the comparators
rather than superiority. At doses of 400, 800 and 
‘high-level’ doses of 1500 or 1600 g/day,
beclometasone dipropionate (BDP) appears to be the
current cheapest ICS product both with the inclusion
and exclusion of chlorofluorocarbon (CFC)-propelled
products. A significant treatment benefit for
combination ICS/LABA therapy across a range of
outcomes compared with ICS alone was identified
[when the ICS was double the accepted clinically
equivalent dose of the ICS in the combination inhaler,
and dry powder inhalers (DPIS) were used to deliver
the drugs]. When a formoterol fumarate
(FF)/salmeterol (SAL) combination inhaler and a
budesonide (BUD)/FF combination inhaler were 
each compared with their constituent drugs 
delivered in separate inhalers, there were very few
statistically significant differences between the
treatments across the various efficacy outcomes and
the rate of adverse events. Combination inhalers were
more often cheaper than doubling the dose of ICS
alone. However, the costs were highly variable and
dependent on both the dose required and the
preparation used in the trials. The estimated mean
annual cost of FP/SAL combination varied from being
£94 cheaper to £109 more expensive than the
alternative of BUD at a higher dose. The BUD/FF
combination varied from being £163 cheaper to 
£66 more expensive than the higher dose of either
BUD or FP . When the combination inhalers were
compared to each other, the results were mixed, 
with the FP/SAL combination significantly superior 
on some outcomes and the BUD/FF combination
superior on others; however, meta-analysis showed 
that there were no significant differences between 
the two treatments in the rate of adverse events.
Taking an ICS with a LABA as either of the two
currently available combination products, FP/SAL and
BUD/FF, is usually cheaper than taking the relevant
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Development (WIHRD), University of Southampton, UK 
2 Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, Universities of Exeter and
Plymouth, Exeter, UK
* Corresponding authorconstituent drugs in separate inhalers. At very high
doses of BUD (1600 g/day), however, the BUD/FF
combination inhaler can be up to £156 more expensive
than having the same drugs in separate inhalers. In
terms of the relative costs associated with taking one of
the combination inhalers, at low dose (400 g BUD or
200 g FP/day) the cheapest combination inhaler is
FP/SAL as a pressurised metered dose inhaler (pMDI)
(Seretide Evohaler). However, this is only slightly
cheaper than using BUD/FF as a DPI (Symbicort
Turbohaler). At higher dose levels (800 g BUD or 500
g FP/day) FP/SAL as either pMDI aerosol (Seretide
Evohaler) or a DPI (Seretide Accuhaler) is the cheapest
combination product available, but again only slightly
cheaper than the DPI BUD/FF combination (Symbicort
Turbohaler). It should be highlighted, however, that the
three head-to-head trials that compared the effects of
FP/SAL with BUD/FF used the FP/SAL DPI combination
inhaler, Seretide Accuhaler. 
Conclusions: The evidence indicates that there are
few consistent significant differences in effects between
the five ICS licensed for use in adults and adolescents
over the age of 12 years, at either low or high dose.
On average, BDP products currently tend to be the
cheapest ICS available and tend to remain so as the
daily ICS dose required increases. There is evidence
that the addition of a LABA to an ICS is potentially
more clinically effective than doubling the dose of ICS
alone, although consistent significant differences
between the two treatment strategies are not
observed for all outcome measures. The cost
differences between combination therapy compared
with ICS monotherapy are highly variable and
dependent on the dose required and the particular
preparations used. For the combination therapies of
ICS/LABA there are potential cost savings with the use
of combination inhalers compared with separate
inhalers, with few differences between the two
treatment strategies in terms of effects. The only
exception to this cost saving is with BUD/FF at doses
higher than 1200 g/day, where separate inhaler
devices can become equivalent to or cheaper than
combination inhalers. Neither of the two combination
inhalers (FP/SAL or BUD/FF) is consistently superior in
terms of treatment effect. A comparison of the costs
associated with each combination therapy indicates that
at low dose FP/SAL delivered via a pMDI is currently
the cheapest combination inhaler but only marginally
cheaper than BUD/FF delivered as a DPI. At higher
doses, both the FP/SAL combination inhalers (PMDI 
and DPI) are marginally cheaper than BUD/FF (DPI).
Future trials of treatment for chronic asthma should
standardise the way in which outcome measures 
are defined and measured, with a greater focus on
patient-centred outcomes. For informing future
cost–utility and cost-effectiveness analyses from 
a UK NHS perspective, there is a need for 
longitudinal studies that comprehensively track 
the care pathways followed when people 
experience asthma exacerbations of different 
severity. Further research synthesis, quantifying 
the adverse effects of the different ICS, is required 
for treatment choices by patients and clinicians to be
fully informed.
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ContentsGlossary
Chlorofluorocarbon (CFC) A propellant used
in pressured metered dose inhalers. Currently
being replaced by hydrofluoroalkane (HFA)
propellants.
Cortisol A corticosteroid hormone that is
involved in the response to stress; it increases
blood pressure and blood sugar levels and
suppresses the immune system.
Ex-actuator Used in reference to drug
delivery. The content per actuation which is
reflected in the labelled strength of the drug.
Ex-actuator means metered – the amount of
drug that is delivered from the mouthpiece to
the patient.
Ex-valve Used in reference to drug delivery.
The content per actuation which is reflected in
the labelled strength of the drug. Ex-valve
means metered – the amount of drug delivered
from the inhaler into the mouthpiece.
Forced expiratory volume (FEV1) The
volume of air exhaled in 1 second of forced
blowing into a spirometer.
Forced vital capacity (FVC) The total
amount of air that a person can forcibly blow
out after full inspiration, measured in litres.
Hydrofluoroalkane (HFA) A propellant used
in pressured metered dose inhalers.
Replacement for chlorofluorocarbon (CFC)
propellants.
Hypothalamic–pituitary–adrenal axis (HPA
axis) A major part of the neuroendocrine
system that controls reactions to stress and has
important functions in regulating various body
processes such as digestion, the immune system
and energy usage.
I2 A measure used to quantify heterogeneity
in a meta-analysis. It describes the percentage
of the variability in effect estimates that is due
to heterogeneity rather than sampling error
(chance). A value greater than 50% may be
considered to represent substantial
heterogeneity.
PC20 The provocative concentration of
methacholine to induce a 20% decline in FEV1.
PD20 A value obtained in methacholine
challenge testing to indicate severity of asthma.
Peak expiratory flow rate The maximum
rate at which air is expired from the lungs
when blowing into a peak flow meter or
spirometer.
Spacer Device attached to an inhaler to
maximise the delivery of the drug to the lungs.
A spacer consists of a container, usually in two
halves that fit together. One end fits to a
mouth-piece or a face-mask (e.g. for young
children). The other end fits to the inhaler.
Spirometry A pulmonary function test,
measuring lung function.
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Glossary and list of abbreviations
Technical terms and abbreviations are used throughout this report. The meaning is usually clear from
the context, but a glossary is provided for the non-specialist reader. In some cases, usage differs in the
literature, but the term has a constant meaning throughout this review.List of abbreviations
A&E Accident and Emergency
ACQ-5 Asthma Control Questionnaire
ACTH adrenocorticotropic hormone
AE adverse event
AMD adjustable maintenance dose
ANCOVA analysis of covariance
ANOVA analysis of variance
APM Asthma Policy Model
AQLQ Asthma Quality of Life
Questionnaire 
ASUI Asthma Symptom Utility Index
AZ AstraZeneca
b.d. twice a day
BDP beclometasone dipropionate
BMD bone mineral density
BNF British National Formulary
BTS British Thoracic Society
BUD budesonide
CEA cost-effectiveness analysis
CEAC cost-effectiveness acceptability
curve
CFC chlorofluorocarbon
CI confidence interval
CIC ciclesonide
CMA cost minimisation analysis
COPD chronic obstructive pulmonary
disease
CRD Centre for Reviews and
Dissemination
CS clinically significant
CSS clinically significant severe
CUA cost–utility analysis
DES-CIC desisobutyryl-ciclesonide
DPI dry powder inhaler
ED emergency department
EMEA European Agency for the
Evaluation of Medicinal Products
ER emergency room
FD fixed dose
FDA Food and Drug Administration
FEF25–75% forced expiratory flow between 25
and 75% of vital capacity
FEV1 forced expiratory volume in
1 second
FF formoterol fumarate
FP fluticasone propionate
FVC forced vital capacity
GINA Global Initiative for Asthma
GOAL Gaining Optimal Asthma Control
GSK GlaxoSmithKline
HFA hydrofluoroalkane
HPA hypothalamic–pituitary–adrenal
HRQoL health-related quality of life
ICER incremental cost-effectiveness ratio
ICS inhaled corticosteroid (e.g.
budesonide)
IQR interquartile range
ITT intention-to-treat
LABA long-acting beta2 agonist (e.g.
salmeterol or formoterol)
MDI metered-dose inhaler
MEF maximal expiratory flow
MF mometasone furoate
continued
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viiiList of abbreviations continued
MHRA Medicines and Health Care
Products Regulatory 
Agency
NICE National Institute for Health and
Clinical Excellence
NS not significant
NSD no statistically significant
difference
NW nocturnal wakings
OCS oral corticosteroids
OR odds ratio
PC plasma  cortisol
PCA prescribing cost analysis
PEF peak expiratory flow rate
pMDI pressurised metered-dose 
inhaler
PP per protocol
pQCT peripheral quantitative computed
tomography
PSA probabilistic sensitivity analysis
PSC posterior subcapsular cataract
PSS Personal Social Services
QALY quality-adjusted life-year
QCT quantitative computed
tomography
q.d. four times a day
RCT randomised controlled trial
RR relative risk
SABA short-acting beta2 agonist (e.g.
salbutamol or terbutaline)
SAL salmeterol
SD standard deviation
SE standard error
SEM standard error of the mean
SF-36 Short Form questionnaire with 
36 Items
SFD symptom-free day
SFN symptom-free night
SG standard gamble
SIGN Scottish Intercollegiate Guidelines
Network
SMART Salmeteral Multicenter Asthma
Research Trial
SMART Symbicort Maintenance and
Reliever Therapy
SMD standardised mean difference
SNS Salmeterol Nationwide
Surveillance
SR slow release
SS symptom score
ST standard therapy
TCM total cortisol metabolites
TTO time trade-off
VAS visual analogue scale
WMD weighted mean difference
WTP willingness to pay
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Current asthma management
Various strategies are used in the prevention and
management of asthma. Pharmacological
management includes, among other drugs, inhaled
corticosteroids (ICS) and short- and long-acting
beta2 agonists (SABAs/LABAs). Both ICS and
LABAs are inhaled controller medications that
need to be taken on a long-term daily basis for
maximum symptom control. Medication delivery
can be via a number of different types of inhaler
device; these differ in the efficiency with which
they deliver the drug to the lower respiratory tract. 
There are currently five ICS available as licensed
preparations for the treatment of asthma:
beclometasone dipropionate (BDP), budesonide
(BUD), fluticasone propionate (FP), mometasone
furoate (MF) and ciclesonide (CIC). Two of the
ICS are available as licensed preparations in
combination with LABA: FP used in combination
with salmeterol (FP/SAL), and BUD used in
combination with formoterol fumarate (BUD/FF).
Objectives
The objectives of this health technology
assessment are:
● to identify, appraise and synthesise, where
appropriate, the current evidence base on the
clinical effectiveness and cost-effectiveness of
ICS alone and ICS used in combination with a
LABA in the treatment of chronic asthma in
adults and children aged over 12 years
● to identify the costs associated with the different
treatments
● to provide estimates of cost-effectiveness, where
possible, of the different treatment options.
An accompanying health technology assessment has
been conducted in children aged under 12 years.
Methods
The assessment was conducted within the context
of the British Thoracic Society (BTS)/Scottish
Intercollegiate Guidelines Network (SIGN)
Guideline on the management of asthma.
A literature search was conducted on a number of
electronic bibliographic databases (e.g. MEDLINE,
Cochrane CENTRAL and EMBASE) up to February/
March 2006 (and updated again in October 2006). 
Only trials testing different drugs using the same
inhaler device/propellant were included. Therefore
trials testing, for example, BDP via a pressurised
metered dose inhaler (pMDI) versus BUD via a
dry powder inhaler (DPI) were excluded, as were
trials testing, for example, BDP via
hydrofluoroalkane (HFA)-propelled pMDI versus
BUD via chlorofluorocarbon (CFC)-propelled
pMDI. The scope of the review was to consider the
effectiveness of the inhaled steroids, as opposed to
their delivery devices. Some clinical trials were
specifically designed to evaluate device effects
using clinically inequivalent doses. These were
therefore excluded to reduce the likelihood of
confounding. 
A flexible framework was used to allow different
types of economic analyses and a cost comparison
or a cost–consequence comparison was conducted. 
Results
Clinical effectiveness review
Of 5175 reports identified through systematic
literature searching, 113 reports describing 84
studies were included. Of these, 67 were fully
published RCTs, seven were systematic reviews,
and 10 were post-2004 conference abstracts.
The 67 trials varied considerably. While there is a
comparatively large evidence base for the more
established ICS (BDP, BUD, FP) compared with
the newer ICS (MF and CIC), it was not possible
to perform pair-wise comparisons for all the five
comparators due to a lack of direct head-to-head
RCTs. In many cases quantitative meta-analysis
was not appropriate or feasible.
The most frequently reported relevant outcomes
were lung function, symptoms, use of rescue
medication and adverse events. Exacerbations and
health-related quality of life were reported less
frequently, and differences in the ways in which
these were defined between the individual trials
meant that few comparisons could be made.
Executive summaryxii
Low-dose ICS versus ICS
Twenty-two RCTs were identified that compared
the five ICS at low doses (400–800 µg BDP/day or
equivalent). In general, all the ICS were associated
with favourable changes from baseline to end-
point across efficacy outcomes. Overall, there is
little evidence to reject the hypothesis that there is
no significant difference in clinical effectiveness
between the different ICS, although a few of the
trials had assessed non-inferiority between the
comparators rather than superiority. A summary
of results is given below:
● BDP versus BUD (five RCTs): there were few
statistically significant differences between the
comparators on a range of outcomes assessed
across the five trials. One trial showed a significant
difference in terms of morning and evening PEF
in favour of BUD, but no difference in measures
of forced expiratory volume in 1 second (FEV1). A
further trial showed a significant difference in
favour of BDP on a measure of FEV1. Only one
trial reported on adverse events. 
● FP versus BDP (six RCTs): five trials reported
no statistically significant differences between
FP and BDP across the outcomes assessed. One
further trial showed a treatment benefit in
favour of FP compared with BDP across a
number of outcomes. 
● FP versus BUD (five RCTs): four trials showed
no statistically significant differences between
FP and BUD. In a further trial, symptom
measures favoured treatment with FP, but no
differences on measures on lung function were
observed. Meta-analysis of two trials showed
BUD to be associated with significantly fewer
adverse events than FP.
● CIC versus BUD (one RCT): no significant
differences across measures of lung function,
symptoms or exacerbation rates were observed
between the comparators. Non-inferiority in
terms of lung function measures was
demonstrated for CIC.
● MF versus BUD (two RCTs): at a nominally
equivalent dose ratio of 1:2 (MF, BUD), there was
a statistically significant difference in favour of
MF for the outcome of FEV1. No significant
differences were shown for the other lung
function outcomes or symptoms. At a dose ratio
of 1:1 there was a significant treatment benefit in
favour of MF on both measures of lung function
and symptoms. Adverse event rates were
comparable between the two treatment arms. 
● CIC versus FP (two RCTs): at nominally
equivalent dose ratios of 1:1 there were no
statistically significant differences between the
comparators on measures of lung function,
symptoms, use of rescue medication or number
of exacerbations. Non-inferiority was
demonstrated for lung function.
● MF versus FP (one RCT): at accepted levels of
dose equivalence there were no significant
differences between the comparators. At a 1:2
dose ratio (MF, FP) there were statistically
significant differences in favour of FP on lung
function measures and nocturnal awakenings.
No trials were identified that directly compared
either BDP with MF or BDP with CIC.
High-dose ICS versus ICS
Twenty-four trials that compared ICS with ICS at
high doses (800–2000 µg BDP/day or equivalent)
were included. As with low-dose ICS versus ICS,
there were few differences between the ICS where
statistical tests had been reported. Again, some of
the trials had assessed non-inferiority between the
comparators. A summary of results is given below:
● BDP versus BUD (two RCTs): there were no
statistically significant differences between the
comparators on measures of lung function. The
only statistically significant difference was for
the number of exacerbations in favour of BUD.
● FP versus BDP (10 RCTs): in seven trials there
were no statistically significant differences
between the comparators on any of the outcome
measures assessed. One trial showed significant
differences in favour of FP for lung function
measures and the number of exacerbations. No
significant differences were observed for
symptom measures. Treatment with FP was
favoured in one trial for the outcome of
HRQoL, whereas symptom scores were
significantly lower with BDP treatment in
another. There were no further significant
differences, however, on any other outcome
measure assessed. Across the 10 trials adverse
event rates were comparable. 
● HFA BDP versus HFA FP (one RCT): no
statistically significant differences on measures
of lung function and symptoms were shown.
Non-inferiority was demonstrated for lung
function measures in an intention-to-treat
analysis, but not in a per-protocol analysis.
● FP versus BUD (six RCTs): there was a
treatment benefit in favour of FP on some
measures of lung function in two trials. Four
trials showed no statistically significant
differences between the comparators across a
range of different outcomes. A meta-analysis of
three trials showed no significant differences in
the number of adverse events. 
● MF versus BUD (one RCT): a treatment benefit
in favour of MF on a measure of FEV1 was
Executive summaryobserved. There were no further significant
differences between the comparators.
● CIC versus FP (three RCTs): data are
commercial in confidence.
● MF versus FP (one RCT): there were no
statistically significant differences on any
outcome measure between the two comparators.
No trials were identified that directly compared
either BDP with either MF or CIC, BUD with CIC
or MF with CIC. 
ICS versus ICS/LABA
Ten RCTs evaluated the effectiveness of
combination ICS/LABA therapy (FP/SAL or
BUD/FF) versus a higher dose of ICS alone. Half of
the trials used the FP/SAL combination inhaler and
the other half used the BUD/FF combination
inhaler. ICS doses, when used in combination with
LABAs, varied from 200 to 800 µg/day for BUD and
from 200 to 500 µg/day for FP. When used alone the
ICS doses varied from 400 to 1600 µg/day for BUD
and from 500 to 1000 µg/day for FP. Overall, the
ICS dose when used alone was at approximately
double the accepted clinically equivalent dose that
was used in the combination with the LABA.
The general findings indicated a significant
treatment benefit for combination therapy across a
range of outcomes compared with ICS alone,
when the ICS was double the accepted clinically
equivalent dose of the ICS in the combination
inhaler. This applied to both of the combination
inhalers. However, it should be highlighted that
these findings are only applicable to DPIs.
An additional nine trials assessed the effects of
adding a LABA to a similar dose of ICS in each of
the trial arms. Six evaluated the FP/SAL
combination and three the BUD/FF combination.
In all the trials a similar ICS dose was used in
both arms. The results showed that ICS/LABA
combination therapy was statistically superior to
ICS alone across most of the outcomes.
ICS/LABA versus ICS/LABA
FP/SAL combination inhaler and BUD/FF
combination inhaler each compared with their
constituent drugs delivered in separate inhalers
were assessed in three and two RCTs, respectively.
An additional trial compared the FP/SAL
combination inhaler against BUD + FF in
separate inhalers. The ICS doses were similar in
both treatment modalities, and ranged from 200
to 1000 µg/day for FP and 800 µg for BUD. There
were very few statistically significant differences
between the treatments across the various efficacy
outcomes and the rate of adverse events. Non-
inferiority was demonstrated for some outcomes.
Meta-analysis of adverse events showed no
statistically significant differences between
combination versus separate inhaler therapy.
Three RCTs evaluated the combination inhalers
versus each other. Daily ICS doses were 800 µg for
BUD and 500 µg for FP. All were delivered via a
DPI rather than a pMDI. The results were mixed,
with the FP/SAL combination significantly
superior on some outcomes and the BUD/FF
combination superior on others. Meta-analysis
showed that there were no significant differences
between the two treatments in the rate of adverse
events.
Economic analyses
Low-dose ICS versus ICS
At doses of 400 µg/day, BDP–CFC-propelled
devices appear to be the current cheapest ICS,
and remain so but at a higher annual cost if CFC-
propelled products are excluded from the analysis.
Excluding CFC-propelled products at this dose
level diminishes the overall cost differences
between the five ICS, with CIC products only
marginally more expensive than BDP–CFC-free
devices. At this dose FP and MF are consistently
the two most expensive drugs, at almost two to
three times the annual cost of taking BDP.
At the maximum low dose of 800 µg/day,
BDP–CFC-propelled products remain the cheapest
available. At these doses, if CFC-propelled
products are excluded then FP products can be on
average the cheapest ICS product available if the
mean is weighted by market share. On the whole,
when only CFC-free products are considered, the
mean annual cost of both BUD and BDP
increases. For FP, CIC and MF there are currently
no CFC-propelled products available, therefore
their costs remain constant. However, the use of
weighted averages to represent the cost associated
with each ICS tends to conceal the wide variations
in costs.
High-dose ICS versus ICS
At a dose level of 1500–1600 µg/day, BDP–CFC-
propelled products appear to be the current
cheapest ICS available, and remain so if CFC-
propelled products are excluded from the analysis.
Excluding CFC-propelled products and using
current prices cause a substantial increase in the
weighted mean annual cost of taking BDP at this
dose level. On average, BUD (only available as
one preparation at this high dose level) is the
most expensive ICS drug, whether CFC-
containing products are excluded or not. 
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Based on the nine included trials, combination
inhalers were more often cheaper than doubling the
dose of ICS alone. However, the costs were highly
variable and dependent on both the dose required
and the preparation used in the trials. The
estimated mean annual cost of FP/SAL combination
varied from being £94 cheaper to £109 more
expensive than the alternative of BUD at a higher
dose. The BUD/FF combination varied from being
£163 cheaper to £66 more expensive than the
higher dose of either BUD or FP.
ICS/LABA versus ICS/LABA
Taking an ICS with a LABA as either of the two
currently available combination products, FP/SAL
and BUD/FF, is usually cheaper than taking the
relevant constituent drugs in separate inhalers. At
very high doses of BUD (1600 µg/day), however,
the BUD/FF combination inhaler can be up to
£156 more expensive than having the same drugs
in separate inhalers. In terms of the relative costs
associated with taking one of the combination
inhalers, at low dose (400 µg BUD or 200 µg
FP/day) the cheapest combination inhaler is
FP/SAL as a pMDI (Seretide Evohaler). However,
this is only slightly cheaper than using BUD/FF as
a DPI (Symbicort Turbohaler). At higher dose
levels (800 µg BUD or 500 µg FP/day) FP/SAL as
either pMDI aerosol (Seretide Evohaler) or a DPI
(Seretide Accuhaler) is the cheapest combination
product available, but again only slightly cheaper
than the DPI BUD/FF combination (Symbicort
Turbohaler). It should be highlighted, however,
that the three head-to-head trials that compared
the effects of FP/SAL with BUD/FF used the
FP/SAL DPI combination inhaler, Seretide
Accuhaler. The relative effectiveness of the Seretide
Evohaler as a pMDI compared with the Symbicort
Turbohaler can therefore not be commented on.
Conclusions
The evidence reviewed indicates that there are few
consistent significant differences in effects between
the five ICS licensed for use in adults and
adolescents over the age of 12 years, at either low
or high dose. On average, BDP products currently
tend to be the cheapest ICS available at starting
doses and to remain so as the daily ICS dose
required increases. The exclusion of CFC-
propelled products may increase the mean annual
cost of both BDP and BUD, but should have no
effect on the cost of MF, FP or CIC, as all products
for these drugs are CFC-free. The higher cost of
BUD and BDP may decrease the overall cost
differences between the ICS comparators.
However, it should be noted that although the 
use of weighted averages to calculate these costs
can provide a useful way of representing the 
major differences between the drugs, these often
conceal the wide variations in the costs of
individual products containing each drug. These
costs will also inevitably be sensitive to year-on-
year shifts in the market share or price of
individual products.
There is evidence that the addition of a LABA to
an ICS is potentially more clinically effective than
doubling the dose of ICS alone, although
consistent significant differences between the two
treatment strategies are not observed for all
outcome measures. The cost differences between
combination therapy and ICS monotherapy are
highly variable and dependent on the dose
required and the particular preparations used. For
the combination therapies of ICS/LABA there are
potential cost savings with the use of combination
inhalers compared with separate inhalers, with few
differences between the two treatment strategies in
terms of effects. The only exception to this cost
saving is with BUD/FF at doses higher than
1200 µg/day, where separate inhaler devices can
become equivalent to or cheaper than
combination inhalers. The evidence regarding the
relative effects of the two combination inhalers
available is mixed. Neither of the two combination
inhalers (FP/SAL or BUD/FF) is consistently
superior in terms of treatment effect. A
comparison of the costs associated with each
combination therapy indicates that at low dose
FP/SAL delivered via a pMDI is currently the
cheapest combination inhaler. However, this is
only marginally cheaper than BUD/FF delivered as
a DPI. At higher doses, both the FP/SAL
combination inhalers (PMDI and DPI) are
marginally cheaper than BUD/FF (DPI).
Recommendations for further
research
Future trials of treatment for chronic asthma should
standardise the way in which outcome measures are
defined and measured, with a greater focus on
patient-centred outcomes such as HRQoL and
symptoms. There is also a need for longitudinal
studies that comprehensively track the care
pathways followed when people experience asthma
exacerbations of different severity. Further research
synthesis, quantifying the adverse effects of the
different ICS, is required for treatment choices by
patients and clinicians to be fully informed.
Executive summary
xivNatural history of asthma
Definition
Asthma is a chronic inflammatory disorder of the
airways, leading to airway narrowing from both
inflammatory processes and constriction of the
smooth muscle in airway walls
(bronchoconstriction). Remodelling is a
characteristic part of the pathological process,
consisting of mucus gland and smooth muscle
hypertrophy and increased collagen deposition in
the airway walls. Asthma is characterised by
widespread, variable airflow obstruction and
increased responsiveness of the airways to various
stimuli. Resulting symptoms include recurring
episodes of wheezing, breathlessness, chest
tightness and coughing, particularly at night or in
the early morning. Common symptom triggers
include respiratory infections, allergens such as
pollens, moulds, animal fur and house dust mite,
cold and exercise.1,2
Diagnosis
There is no confirmatory diagnostic test or
investigation for asthma. It is usually diagnosed on
the basis of symptoms (wheeze, shortness of
breath, chest tightness and cough) together with
objective tests of lung function such as peak
expiratory flow rate (PEF) and forced expiratory
volume in 1 second (FEV1). Typical asthma
symptoms tend to be variable, intermittent, worse
at night and provoked by triggers (e.g. allergens
or exercise). Variability of PEF and FEV1, either
spontaneously over time or in response to therapy,
is a characteristic feature of asthma which is also
often used in diagnosis.1
Asthma severity
Assessing asthma severity is difficult and depends
on the level of treatment. In the UK, asthma
severity is graded according to the amount of
medication an individual needs to keep symptoms
under control and is based on the British Thoracic
Society/Scottish Intercollegiate Guidelines
Network (BTS/SIGN) Guideline on the
Management of Asthma described in more detail
in the section ‘Asthma management in the UK’
(p. 6). The Global Initiative for Asthma (GINA)
classifies asthma severity as intermittent or
persistently mild, moderate or severe based on
combined assessments of symptoms and lung
function (Table 1). Severity varies amongst
individuals, does not necessarily correlate with the
frequency or persistence of symptoms and can
change in one individual over time. When an
individual is already on treatment, the
classification of severity is based on the clinical
features present and the step of the daily
medication regimen that the individual is
currently on. Under this classification, the
presence of one of the features of severity is
sufficient to place an individual in that category.
Individuals at any level of severity can have severe
exacerbations.2
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TABLE 1 GINA classification of asthma severity
Step Symptoms/day Symptoms/night PEF or PEF variability
FEV1 (%)
STEP 1 <once a week <2 times per month 80 <20
Intermittent Asymptomatic and normal PEF 
between exacerbations
STEP 2 >once per week but <once per day >2 times per month 80 20–30
Mild persistent Exacerbations may affect activity
STEP 3 Daily >once per week 60–80 >30
Moderate persistent Exacerbations affect activity
STEP 4 Continuous Frequent 60 >30
Severe persistent Limited physical activity
Source: Pocket Guide for Asthma Management and Prevention.2A cross-sectional study of 12,203 patients from 393
general practices in the UK, performed by Neville
and colleagues in 1994–5, reported that the
majority of individuals with asthma in the UK are
treated at Steps 1 and 2 of the BTS/SIGN
Guideline (Figure 1).3 This is particularly so for
people between the ages of 16 and 45 years, with
more patients treated at Step 3 in the younger and
older populations.
Asthma exacerbations
There is no generally accepted definition of an
exacerbation, although it can be regarded as “a
sustained worsening of the individual’s condition
from the stable state and beyond normal day-to-
day variations in symptoms, that is acute in onset
and necessitates a change in regular medication”.4
Asthma exacerbations are characterised by a
progressive increase in shortness of breath, cough,
wheeze or chest tightness or a combination of
these symptoms, accompanied by a decrease in
PEF. Exacerbations can be triggered by a variety of
stimuli, including allergens, viral infections,
pollutants and drugs. Exacerbations are variable
in severity and frequency both between individuals
and within the same individual over time, and
appropriate treatment will reflect both the severity
and the frequency of exacerbations. Minor
exacerbations may be treated by the individual
using high doses of inhaled short-acting beta2
agonists (SABAs) or an increased dose of inhaled
corticosteroid (ICS), although sometimes a short
course of systemic corticosteroids or other
treatments are also needed.1 More severe
exacerbations, although less common, can
potentially be life-threatening, and may require
hospitalisation, treatment and monitoring until
symptoms have stabilised. 
Asthma control
The aims of the pharmacological management of
asthma are the control of symptoms, including
nocturnal symptoms and exercise-induced asthma,
prevention of exacerbations and the achievement
of the best possible lung function, with minimal
side-effects.1 A fixed level of lung function or
symptom control is not normally defined as
individuals may have different treatment goals and
may wish to balance these against potential side-
effects. The updated 2006 GINA also provides a
classification of levels of asthma control that can
be used as a basis for ongoing treatment decisions
(Table 2). 
Prognosis
Asthma usually develops in childhood but may
occur for the first time at any age. There is no
cure for asthma, although people may experience
Background
2
0
5
10
15
20
25
%
30
35
40
45
50
0–5 6–15 16–30
Age group (years)
31–45 46–64 >65
below Step 1
Step 1
Step 2
Step 3
Step 4
Step 5
FIGURE 1 Percentage of individuals at each step of the BTS/SIGN Guideline by age group. From a cross-sectional study performed by
Neville and colleagues in 1994–5.3long periods of ‘remission’ during which
symptoms are less evident or absent.
Epidemiological studies of the natural history of
lifetime lung function in healthy subjects suggest
that FEV1 increases during normal growth in
childhood, followed by a stable phase in
adolescence and early adulthood and a slow
decline in FEV1 after the age of 32 years. The
maximum level of FEV1 achieved and the rate of
decline determine the severity of lung function
impairment later in life in symptomatic adults.
Risk factors associated with smaller increases in
lung function and lower maximally attained levels
of lung function in children and adolescents
include lower respiratory tract infections and
passive and active smoking.6–8 The rate of decline
is generally greater in people with asthma than in
the general population,9 possibly as a result of
deterioration in potentially reversible disease or
the development of persistent obstruction following
airway remodelling.10 The normal between-subject
variation in maximally achievable FEV1 is reflected
in reference values used to calculate lung function
as a percentage of that predicted for a person of
similar height, sex, age and race (weight is also
sometimes considered) without a diagnosis of
asthma (e.g. FEV1 % predicted).
Epidemiology of asthma
Incidence and prevalence in the UK
Asthma UK estimate that there are 5.2 million
people with asthma in the UK; this includes
700,000 people over the age of 65 years and
590,000 teenagers, approximately 2.9 million
women and girls and 2.3 million men and boys.11
The Health Survey for England commissioned by
the Department of Health in 2001 included data
on respiratory symptoms obtained from interviews
with 15,647 adults aged 16 years or over. The
prevalence of lifetime doctor-diagnosed asthma
was 13% in men and 16% in women (Figure 2).
Approximately 1% of men and women reported a
diagnosis within the preceding 12 months.12
The 1998 figures from the General Practice
Research Database with a sampling frame of 211
general practices in England and Wales indicated
that the prevalence of treated asthma in men aged
15 years and over ranged from 44.5 to 89.4 per
1000 patients, with an age-standardised rate of
73.2 per 1000. For women the rate of treated
asthma was slightly higher, with a range of
52.2–88.0 per 1000 patients, with an age-
standardised rate of 76.5 per 1000.13 As treatment
in the UK is strongly influenced by the BTS/SIGN
Guidelines (see the section ‘Asthma management
in the UK’, p. 6), it may also be useful to consider
asthma prevalence in terms of the treatment steps
in the guidelines. 
Mortality
Asthma deaths are rare; there were 1266 reported
deaths due to asthma in 2004 (Figure 3). Most of
these (70%) were in people over the age of
65 years; asthma deaths were more common in
women than in men (64 versus 36%). Several
audits and case–control studies of asthma deaths
in the UK have been conducted and suggest that
risk factors fall into four categories: (1) disease
severity, (2) medical care factors both prior to and
during the fatal episode, (3) health behaviour such
as reduced concordance with prescribed
medication, poor inhaler technique and reduced
contact with primary care services and (4) adverse
psychosocial factors. Therefore, a proportion of
deaths due to asthma are preventable, especially
in those under the age of 65 years.14–18
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TABLE 2 GINA classification of levels of asthma control
Characteristic Controlled (all the following) Partly controlled  Uncontrolled
(any measure 
present in any week)
Daytime symptoms  None (twice or less per week)  More than twice per week
Limitations of activities None Any
Nocturnal symptoms/awakening  None Any
Need for reliever/rescue medication None (twice or less per week) More than twice per week
Exacerbations  None <80% of predicted 
personal best (if known)
Source: Global Initiative for Asthma.5
Three or more
features of partly
controlled asthma
present in any weekBackground
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FIGURE 2 Percentage of men and women with a lifetime doctor-diagnosis of asthma, 2001. Source: Health Survey for England
2001.12
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FIGURE 3 Asthma deaths by age and sex, registrations in 2004. Source: Office of National Statistics.19Impact of asthma on health-related
quality of life
Health-related quality of life (HRQoL) refers to
the impact of disease and treatment on daily life.
In contrast to the physiological outcome measures
used to define control, the aim of HRQoL
measurement is to assess the impact asthma has
on a person’s daily functioning and emotional
well-being.20 Studies indicate that patients with
asthma have impaired HRQoL, and that
morbidity as expressed by HRQoL in patients with
asthma is substantial.21
When considering the impact of asthma, it is
important to acknowledge the differences that
may exist between control of disease, as defined by
clinical measures, and its impact on HRQoL. It
should not be assumed that meeting clinical
treatment goals will necessarily be meaningful to
patients, in terms of improvements in HRQoL.22
There is a wide range of disease-specific health
status measures available to assess quality of life in
individuals with asthma. These include the Asthma
Quality of Life Questionnaire (AQLQ),23 the Mini
Asthma Quality of Life Questionnaire (Mini
AQLQ),24 the Living With Asthma Questionnaire
(LWAQ),25 the St George’s Respiratory
Questionnaire (SGRQ)26 and the Asthma Bother
Profile (ABP).27 The most commonly used
instrument in adults is the AQLQ, which was
developed by Juniper and colleagues in the early
1990s.23 The AQLQ is a well-accepted, reliable,
valid and responsive 32-item questionnaire
divided into four domains (symptoms, emotional
function, activity limitation and environmental
stimuli). Each item is assessed on a seven-point
scale (higher score indicates less impairment)
based on an individual’s recall of their condition
over the previous 2 weeks. Individual domain
scores and overall scores (mean of all 32
questions) are calculated in the AQLQ assessment.
A within-group change of 0.5 points from baseline
is regarded as the minimum meaningful clinically
relevant change for each domain. A change of one
point for each domain is considered a moderate
change in HRQoL.28
The advantage of using disease-specific measures
of HRQoL is the clear relevance of the
instruments to the affected population. However,
the instruments do not make it easy to compare
outcomes across different diseases (e.g. for
purposes of resource allocation), therefore generic
instruments such as the Short Form with 36 Items
(SF-36),29 the Nottingham Health Profile (NHP),30
the Sickness Impact Profile (SIP)31 and the
EuroQol instrument (EQ-5D),32 have also been
used to assess the impact of asthma on quality of
life.
There is some evidence of a weak to moderate
correlation between individual clinical measures
(e.g. lung function) and HRQoL.33,34 Moy and
colleagues retrospectively examined data from two
completed clinical trials, which included
individuals with mild asthma and moderate to
severe asthma.33 Using the AQLQ, they reported
that lung function alone was not an independent
predictor of HRQoL. Asthma severity, defined by
the combination of lung function, symptoms, and
reliever medication use, was correlated with
HRQoL, although these parameters accounted for
less than half of the variation in HRQoL.33
Carranza Rosenzweig and colleagues performed a
retrospective analysis of data from randomised
clinical trials (RCTs) in individuals with persistent
asthma, suggesting that the impact of asthma on
HRQoL is not fully accounted for by objective
measures such as lung function.34
It is not surprising that objective and subjective
measures of the impact of asthma differ. This is a
common finding in the general literature on
health state valuation.35 Individuals differ in the
value they place on the many disturbances of 
daily life and well-being that result from asthma,
resulting in differences across HRQoL scores. 
For example, there may be variation in the
perception of asthma symptoms (regardless of
clinical status) and adaptation to the condition
over time.
Bateman and colleagues, while recognising that
individual measures such as lung function may be
poor predictors of HRQoL, presented findings
from empirical analyses that suggest that
individuals with well-controlled asthma can
achieve near-maximal AQLQ scores, representing
little or no impact of asthma on their lives.22 The
study suggests that if individuals achieve
guideline-based composite control they will
achieve larger improvements in HRQoL than if
success in only a single measure is achieved.
Conversely, failure to achieve control in a single
parameter does not necessarily predict failure in
terms of HRQoL improvements. Nishiyama and
colleagues also reported a significant relationship
between lung function and HRQoL in individuals
with well-controlled asthma.36 In this study,
although correlations between physiological
measures and HRQoL were weak to moderate,
maintaining PEF above 80% of the predicted value
was significantly associated with better HRQoL.
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summary measures of cost-effectiveness e.g. cost
per quality-adjusted life-year (QALY), health state
values associated with the different scenarios of
asthma health status (e.g. by severity, or by level of
control) are necessary. The literature on studies
reporting health state values for individuals with
asthma is discussed in Chapter 4.
Current service provision
Asthma management in the UK
As stated previously, the management of asthma in
the UK is largely based on the BTS/SIGN
Guideline developed by the British Thoracic
Society (BTS) and the Scottish Intercollegiate
Guidelines Network (SIGN).1 The Guideline is
evidence-based and was developed in
collaboration with Asthma UK, the Royal College
of Physicians of London, the Royal College of
Paediatrics and Child Health, General Practice
Airways Group and the British Association of
Accident and Emergency Medicine using SIGN
methodology adapted for UK-wide utilisation. The
Guideline recommends strategies for non-
pharmacological management of both chronic and
acute asthma. Only the pharmacological
management of chronic asthma is relevant 
to this appraisal and is described in more detail
below.
The Guideline advocates a stepwise approach to
pharmacological management, which aims to
achieve early control and to maintain control by
stepping up treatment when control is poor and
stepping down treatment when control is good
(Figure 4). At all levels, there is an emphasis on
checking inhaler technique, concordance with
existing therapy and avoidance of trigger factors
before the level of therapy is increased. Regular
review of treatment level and asthma control is
also recommended at all levels, so that individuals
are maintained at the lowest possible step of the
Guideline.
At Step 1 (mild intermittent asthma), inhaled
SABAs are recommended as the agent of choice,
to be prescribed as needed. A review of asthma
management with possible movement to 
Step 2 (introduction of regular preventer therapy)
is indicated if an individual has had exacerbations
of asthma in the last 2 years, is using inhaled
SABAs three times per week or more or is
symptomatic three times per week or more, or
waking on one occasion per week. There is no
exact threshold at which movement to Step 2
should be considered as it varies between
individuals. The recommended preventer therapy
at Step 2 is an ICS at a starting dose of 400 µg/day
[beclometasone dipropionate (BDP) equivalent;
given as 200 µg twice daily]. This dose can 
then be titrated to the lowest dose at which
effective control of asthma is maintained. 
Step 3 involves the introduction of an additional
therapy. Again, the exact threshold at which 
this should be considered has not been
established. The first choice of add-on therapy is a
long-acting beta2 agonist (LABA), although other
agents can be used, such as leukotriene receptor
antagonists, theophyllines and slow-release beta2
agonist tablets. If asthma control remains
suboptimal after the addition of a LABA, the dose
of ICS may be increased to 800 µg/day (BDP
equivalent) with or without the LABA. If asthma
control still remains suboptimal, despite treatment
with 800 µg/day of ICS, other agents should be
trialled before moving to Step 4. In Step 4, if
control remains inadequate on 800 µg/day of an
ICS plus a LABA (or following an unsuccessful
trial of a LABA), the following further
interventions may be considered: increasing the
dose of ICS to 2000 µg/day, adding in a
leukotriene antagonist, adding in a theophylline
preparation or adding in a slow-release beta2
agonist tablet. In Step 5, continuous or frequent
courses of oral corticosteroids can be introduced.
The aim of treatment at this level is to control
asthma symptoms using the lowest possible dose
of oral corticosteroids or, if possible, to go back to
Step 4 (i.e. eliminate oral corticosteroids
altogether).
Once control of asthma is achieved, it is
recommended that treatment be stepped down to
the lowest possible level.
A large proportion of individuals with asthma are
managed within primary care, often within nurse-
led asthma clinics. As part of the new General
Medical Services contract and Quality Outcomes
Framework in England/UK, GPs are encouraged to
perform annual reviews on all registered
individuals with asthma within their practice.37
Figures for England for 2004–5 suggest that most
practices are achieving the targets for asthma set
out within the framework (91% of the total points
achievable were awarded).38
Discussions with clinicians both locally and
nationally suggest that although the Guideline
forms the basis of most pharmacological treatment
of asthma in the UK, there is some variation 
from these recommendations in practice.
Background
6Examples of this include the introduction of
combination inhalers at an earlier stage (possibly
eliminating the need for Step 2) and a greater
preference for combination inhalers over separate
inhalers (for the concomitant administration of a
LABA and an ICS) in some patient groups
(children, those more at risk of severe
exacerbation) than others.
Asthma management plans (action
plans)
The use of written plans to aid individuals in the
self-management of their asthma symptoms has
been shown to lead to reduced utilisation of
healthcare resources, days off work or school and
improvements in nocturnal asthma symptoms39
and to protect against death from asthma.40 The
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STEP 5: Continuous or frequent use of oral steroids
Use daily steroid tablet in lowest dose providing adequate control
Maintain high dose inhaled steroid at 2000 g/day*
Consider other treatment to minimise the use of steroid tablets
Refer patient for specialist care
STEP 3: Add-on therapy
1.  Add inhaled long-acting 2 agonist (LABA)
2.  Assess control of asthma:
  ■  good response to LABA – continue LABA
  ■  benefit from LABA but control still inadequate – continue LABA and 
    increase inhaled steroid dose to 800 g/day* (if not already on this dose)
  ■  no response to LABA – stop LABA and increase inhaled steroid to 
   800  g/day*. If control still inadequate, institute trial of other therapies (e.g. 
    leukotriene receptor antagonist or SR theophylline)
STEP 4: Persistent poor control
Consider trials of:
■  increasing inhaled steroid up to 2000 g/day*
■  addition of a fourth drug e.g. leukotriene receptor antagonist, 
 SR  theophylline,  2 agonist tablet
STEP 1: Mild intermittent asthma
Inhaled short-acting 2 agonist as required
* BDP or equivalent
STEP 2: Regular preventer therapy
Add inhaled steroid 200–800 g/day*
400 g is an appropriate starting dose for many patients
Start at dose of inhaled steroid appropriate to severity of disease
FIGURE 4 Summary of stepwise asthma management in adults. Source: BTS/SIGN Guideline.1use of action plans is advocated in the BTS/SIGN
Guidelines.1 The evidence for their efficacy in
people with moderate to severe asthma, treated
primarily within the secondary care setting, is
particularly good.41–43 Plans based on symptom
scores and on measurements of PEF have both
been found to be effective.44 The aim of such
plans is to provide individuals with information
that allows them to respond to changes in their
asthma control, either by changing their level of
treatment or by seeking advice from a health
professional at the first signs of an asthma
exacerbation. Despite this evidence of
effectiveness, there is some indication in the
literature that asthma management plans are not
very popular with health professionals or with
individuals.45 Action plans that incorporate an
individual’s personal experience of their disease
are likely to be more successful.46
Concordance
Improving concordance with ICS therapy is
recognised as an important aim for education 
and management. Since the effects of ICS can 
take several days or maybe even weeks both to
manifest themselves following initiation of therapy
and to decline following cessation of therapy, there
may appear to be little incentive for individuals to
take these medications, as prescribed, for long
periods. Anxiety surrounding the risk of adverse
events (AEs) with ICS may also affect concordance.
A systematic review conducted in 2000 by
Cochrane and colleagues identified 10 studies that
reported concordance with ICS measured using
electronic devices contained within the inhaler
device.47 All but one of these studies was
conducted in adults. Overall, patients took the
recommended doses of medication on 20–73% of
days. Average concordance, measured as the ratio
of doses taken to doses prescribed, ranged from
63% to 92%.47 Concordance measured in these
studies is likely to be better than that seen in the
community, since patients were aware that their
concordance with prescribed treatment regimens
was under scrutiny. A study that used records 
from the General Practice Research Database in
the UK and included 284,733 individuals
prescribed ICS over a 10-year study period found
that only 42% of individuals obtained a repeat
prescription for ICS within the expected
timeframe of the preceding prescription.48 A
further UK study, conducted in a general practice
in Nottinghamshire, reported that 39% of 
patients on regular corticosteroids had requested
less than 80% of the expected dose. The authors
comment that this may be due to non-
concordance or due to individuals adjusting their
ICS dose as a result of improvements in asthma
control.49 Some education programmes have been
shown to improve concordance in adults and may
also play a role in improving concordance within
families.50
Description of technology under
assessment
ICS
Products available
There are currently five ICS licensed for use in
adults in England and Wales.
● Beclometasone dipropionate (BDP) was the
first ICS available in the UK, introduced in
1972. It is available in metered-dose inhalers
(MDIs) with chlorofluorocarbon (CFC)
propellants and in breath-activated MDIs in
both proprietary [Becloforte (Allen and
Hanburys) and Becotide (Allen and Hanburys)]
and non-proprietary formulations [AeroBec
(3M), AeroBec Forte (3M), Beclazone Easi-
Breathe (IVAX), Filair (3M), Filair Forte (3M),
Pulvinal BDP (Trinity)], MDIs with non-CFC
propellants [Qvar (IVAX)], dry powder inhalers
(DPIs) [Asmabec Clickhaler (Celltech),
Becodisks (Allen and Hanburys), Easyhaler
(Ranbaxy)] and hard capsule powder inhalers
[BDP Cyclocaps (APS)].
● Budesonide (BUD) is available in MDIs with
CFC propellants in both proprietary [Pulmicort
(AstraZeneca, AZ)] and non-proprietary
formulations [Novolizer (Meda)], DPIs
[Pulmicort Turbohaler (AZ)] and hard capsule
powder inhalers [BUD Cyclocaps (APS)].
● Fluticasone propionate (FP) is available in
MDIs with non-CFC propellants [Flixotide
Evohaler (Allen and Hanburys)] and in DPIs
[Flixotide Accuhaler, Flixotide Diskhaler (Allen
and Hanburys)].
● Ciclesonide (CIC) is available in MDIs with
non-CFC propellants [Alvesco (Altana)].
● Mometasone furoate (MF) is available in DPIs
[Asmanex Twisthaler (Schering-Plough)].
Devices
Several types of inhaler device have been
developed in order to deliver drugs directly to the
airways, rather than rely on absorption of oral
preparations.
MDIs are pressurised inhalers, some of which are
breath activated. They contain the drug either as a
suspension in a carrier liquid or as a solution
which is delivered through a CFC or
Background
8hydrofluoroalkane (HFA) propellant. HFA
propellants were phased in to replace CFC
propellants when it was realised that the latter
have ozone-depleting properties. Studies show
that HFA propellants deliver a greater proportion
of fine particles than CFC propellants in the same
device, resulting in a greater proportion of the
drug being deposited in the small airways.51 Use
of a spacer device in conjunction with an MDI can
also alter patterns of lung deposition52 and
increase the total proportion of actuator dose
delivered to the lower airways.
DPIs require less coordination by an individual in
order to achieve correct inhaler technique.
However, lung deposition is flow dependent,
requiring a forceful, deep inhalation to trigger the
device correctly. The higher the flow rate, the
smaller is the particle size and the better the lung
deposition.53
There is a wide variety of available delivery
systems based on these three types of inhaler
device. Inhaler technique, individual preference
and cost are all factors that may guide healthcare
providers in their choice of inhaler device.
Although potentially important in the decision as
to which ICS might be best suited to an individual,
the comparison of inhaler devices is beyond the
scope of this appraisal.
Inhaler technique
The ability to use an inhaler correctly is essential if
the anticipated dose of an agent is to be
successfully delivered to the correct area within the
lungs. The method of assessment of inhaler
technique in clinical trials has varied and includes
a physician rating of correct technique and an
evaluation of the percentage of patients not
complying with the individual tasks necessary for
successful inhalation such as expiration prior to
inhaling, inhaling deeply and breath holding at
the end of the inhalation. A systematic review of
the assessment of correct inhaler technique
identified 15 studies that evaluated inhaler
technique using a variety of inhaler devices
(including MDIs and DPIs).47 Physicians assessed
inhaler technique as ‘good’ in between 5 and 86%
of patients. Coordination of MDI activation with
onset of inspiration was cited as a particular task
which individuals found difficult (17–68% of
individuals were unable to do this in this set of
studies).47 In several studies, education greatly
improved technique, but the amount of
improvement was variable (from 6 to 46% in one
study54).
Mechanism of action
ICS suppress inflammation in the lungs and are
therefore the mainstay in the prophylactic
treatment of chronic asthma. Regular treatment
with ICS reduces inflammation, swelling and
mucus production in the lungs, resulting in better
airflow in and out of the airways, fewer
exacerbations, better control of symptoms and
lung function and ultimately a reduction in
hospital admissions and deaths from asthma.55–57
The anti-inflammatory effects may take from 1 to
3 weeks to become apparent58 and it may take up
to 12 weeks of regular daily treatment before
maximum benefit is seen. However, the length of
time taken to achieve maximal treatment benefit is
dependent on both asthma severity at baseline
and the outcome measure used to assess treatment
effect.58,59 Those with severe asthma when ICS
treatment is started may take longer to achieve
maximal treatment effect than those with mild
asthma.58 The efficacy of ICS therapy for asthma
depends on the agent being delivered in the
correct dose (see the section ‘Concordance’, p. 8)
to the correct site within the airways (see the
previous section). ICS are often referred to by
individuals with asthma as ‘preventers’.
Pharmacology
The mechanism of action of corticosteroids in
asthma has not been fully elucidated. However,
corticosteroids are known to exert their effects by
binding to a glucocorticoid receptor located in the
cytoplasm of target cells. Once activated, the
drug–receptor complex moves into the nucleus of
the cell and binds to the DNA and directly or
indirectly regulates the transcription of target
genes. Control of inflammation is believed to be a
result of an increase in the transcription of anti-
inflammatory genes and a decrease in the
transcription of inflammatory genes.60 The
potency of a given corticosteroid is governed by
the affinity of the drug to bind to the
glucocorticoid receptor. Receptor affinity is usually
measured relative to dexamethasone. Of the
currently available compounds, MF has the
highest relative receptor affinity, followed by FP
and the active metabolites of BDP (17-BDP
monopropionate) and CIC (des-CIC) (Table 3).
Two of the currently available ICS (BDP and CIC)
are prodrugs, that is, a pharmacologically inactive
compound which is activated by esterases found
only in the lungs.60
Due to the ubiquitous nature of the glucocorticoid
receptor, corticosteroids act on a wide range of cell
types and are therefore capable of producing
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inflammatory actions (see the next section). By
administering corticosteroids directly to the
airways via inhaler devices, smaller doses of the
drug are required, drug concentrations at the site
of action are higher and the likelihood of systemic
side-effects is reduced.
The bioavailability of ICS determines the extent of
systemic side-effects and is a measure of the rate
and extent at which the drug reaches the target
site and the systemic circulation. After inhalation,
a large proportion of the dose may be swallowed,
the proportion depending on inhaler device and
technique. Oral bioavailability depends on
absorption characteristics from the gastrointestinal
tract, lipophilicity of the compound and the extent
of first-pass metabolism. It ranges from 1% (FP) to
26% (active metabolite of BDP) for currently
available compounds (Table 3). Pulmonary
bioavailability depends on the amount deposited
in the lungs, will differ for different delivery
devices and ranges from 11% for MF delivered via
a DPI to 52% for the active metabolite of CIC61–67
(Table 3).
Once it reaches the circulation, most of the
absorbed drug binds to plasma proteins; less than
1% remains unbound for CIC, increasing to 13%
unbound for BDP.61–67 Only the unbound fraction
is pharmacologically active. All currently available
ICS are cleared by the liver.
Adverse events
AEs associated with ICS use can be categorised
into local or systemic events. There appears to be
a wide spectrum of level of concern amongst
clinicians about the occurrence of AEs as a result
of therapy with ICS. Anecdotally, some clinicians
appear to be very aware of the risk of systemic
AEs, whereas others are reassured by the low
frequency at which they are encountered in
practice.
Local AEs are the most commonly observed and
although they do not cause significant morbidity,
they may lead to diminished concordance. The
most frequently occurring local AEs are
dysphonia, oropharyngeal candidiasis, cough,
throat irritation and reflex bronchoconstriction.
● Dysphonia is reasonably common in individuals
using ICS.68 Although the exact mechanism of
dysphonia is unknown, it is thought to be
related to vocal cord inflammation.69 Measures
that reduce deposition of the drug around the
larynx therefore help to alleviate symptoms.
These can include the use of a spacer device or
alternative inhaler device, slowing the speed of
inhalation, holding post-inspiratory breath for a
longer period and decreasing the dose and
frequency, although in some cases temporary
withdrawal of medication may be necessary.
● Oral candidiasis occurs less commonly than
dysphonia, being reported in approximately
4–13% of adult ICS users and 1% of
children.70,71 Its prevalence is positively
correlated with total daily dose and with dosing
frequency.72,73 Other risk factors include
concomitant antibiotic therapy, concomitant
nasal or systemic corticosteroids and
immunosuppression. Candida overgrowth is
usually the direct result of local corticosteroid
inhibition of the normal host defence functions
Background
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TABLE 3 Pharmacodynamic and pharmacokinetic characteristics of currently available ICS
ICS RRA Oral bioavailability  Pulmonary bioavailability (%)  Comments Ref.
(%) (device)
BDP 53 15–20 55–60 (HFA–MDI) 61
17-BMP 1345 26 36 (CFC–MDI) Active metabolite of BDP 61
BUD 935 11 18 (CFC–MDI) 62,63
FP 1800 <1 17 (DPI)
26 (CFC–MDI)
29 (HFA–MDI) 64,65
CIC 12 <1 – 66
Des-CIC 1200 <1 52 (HFA–MDI) Active metabolite of CIC 66
MF 2300 <1 11 (DPI) 65,67
17-BMP , 17-BDP monopropionate; CFC–MDI, metered dose inhaler with CFC propellants; Des-CIC, desisobutyryl-
ciclesonide; HFA–MDI, metered dose inhaler with HFA propellants; RRA, relative receptor affinity. of neutrophils, macrophages and T lymphocytes
at the oral mucosal surface. Therefore,
overgrowth can be reduced by use of a spacer
device, decreasing the dosing frequency and
rinsing the mouth after drug administration.
● The AEs of cough, throat irritation and
bronchoconstriction are thought to be caused
primarily by upper airway irritation by the
propellants or surfactants present in the
aerosol. This reaction, which may be most
marked after upper respiratory tract infections,
can prevent adequate deposition of the ICS in
the lungs, and thereby cause a worsening of
asthma symptoms. These post-inhalation
symptoms can be reduced by pretreatment with
a bronchodilator, use of a spacer device, use of a
slow inhalation technique or a change to a dry
powder formulation.68
Systemic AEs occur as a result of the amount of
drug that reaches systemic circulation by
absorption through the lungs or the
gastrointestinal system. As previously outlined, this
is influenced by the pharmacokinetics of the ICS,
the site of deposition and inter-individual
characteristics that may influence the risk of
systemic AEs. Accurate assessment of systemic AEs
associated with ICS use is often confounded by the
concomitant use of other steroid preparations,
such as oral or nasal ICS.72,74,75 The most
commonly occurring systemic AEs potentially
associated with long-term ICS use are adrenal
suppression, growth retardation in infants,
children and adolescents, osteoporosis, skin
thinning and easy bruising, cataract formation and
glaucoma.
The effects of ICS on suppression of
hypothalamic–pituitary–adrenal (HPA) function
have been well documented.75–77 In general,
studies have indicated that HPA axis suppression
is associated with the use of doses exceeding the
equivalent of 1500 µg/day of BDP or BUD in
adults (the equivalent of 400 µg/day of BDP or
BUD in children). The effect appears to be more
marked with BDP than with BUD.78–82 Dose-
ranging studies in adults and children indicate
that single doses of FP exhibit three-fold greater
adrenal suppression than BUD, on a microgram
equivalent basis.83 One RCT compared the effects
of FP 1500 µg/day and BUD 1600 µg/day with
placebo in both healthy participants and
participants with moderately severe asthma over a
7-day duration.84 The trial used the outcomes of
urinary levels of total cortisol metabolites (TCM),
morning serum cortisol levels and osteocalcin
levels as markers of corticosteroid absorption. The
results indicated that FP had a greater effect on
the two markers of the HPA axis (TCM and
morning serum cortisol levels) than BUD,
although neither difference was significant.
Conversely, BUD was associated with a significant
difference in reduced osteocalcin concentration
levels in both healthy and asthmatic participants
relative to FP.
Cases of adrenal crisis associated with ICS use
have also been documented in the literature.85,86 A
survey of the frequency of adrenal crisis associated
with ICS use85 showed that from an initial 2912
questionnaires, 33 cases of adrenal crisis were
identified. Twenty-eight of the cases were
identified in children and five in adults. Of these
33 patients who had received ICS in the range
500–2000 µg/day, 30 (91%) had received FP, one
(3%) FP and BUD and two (6%) BDP. In all these
patients except one, the duration of oral
corticosteroid therapy in the previous 12 months
was estimated to be less than 21 days.
Overall, although the biochemical changes in
markers of HPA axis suppression are unequivocal,
their clinical importance remains unclear, and
even at high doses of ICS there remains significant
inter-individual variability with many patients
demonstrating little or no evidence of adrenal
suppression.78,79
Although these biochemical changes are
unequivocal, their clinical importance remains
unclear, and even at high doses of ICS there
remains significant inter-individual variability, with
many patients demonstrating little or no evidence
of adrenal suppression.78,79
One of the major concerns of long-term ICS use is
the potential for AEs on bone turnover, resulting
in an increased risk for osteoporosis and fracture.
This is mediated through the inhibition of
osteoblast function (bone formation) and by
increasing osteoclast function (leading to increased
bone resorption). These act indirectly by
inhibiting intestinal calcium absorption and renal
calcium reabsorption, causing secondary
hyperparathyroidism. A number of studies have
assessed the effects of high-dose ICS use on
markers of serum osteoclastin and urinary
hydroxyproline.87,88 These studies have shown
mixed results, with some demonstrating decreased
bone formation and increased bone reabsorption
in a dose-dependent manner,87,88 whereas others
have shown no effects on plasma osteoclastin
concentrations at doses of BDP and BUD as high
as 2000 µg/day.89 Similarly, high doses of both
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urinary calcium excretion, intestinal calcium
absorption, serum calcium, phosphate or
parathyroid hormone levels.90,91 In relation to
bone density, there is limited evidence from two
studies that high-dose ICS use for a duration of
3 years was associated with an 18% reduction in
lumbar spine density91 and a reduction in both
lumbar spine and femoral neck density.92
However, in both of these studies all patients had
previously received treatment with oral
corticosteroids. Additional evidence from a cross-
sectional study of patients treated with ICS at a
median cumulative dose of 876 µg/day over a 
6-year period indicated that there was a negative
association between cumulative steroid dose and
bone mineral density (BMD) at the lumbar spine,
femoral neck, Ward’s triangle and trochanter, both
before and after the adjustment for the effects of
age and sex.93 A doubling of the dose of ICS was
associated with a decrease in BMD at the lumbar
spine of 0.16 standard deviation (SD) [95%
confidence interval (CI) 0.04 to 0.28]. Decreases of
a similar magnitude were observed at the femoral
neck, Ward’s triangle and trochanter. The majority
of the study participants were from a primary care
population with relatively mild asthma, so that
potentially neither the underlying disease itself
nor a substantial use of oral corticosteroids were
probable confounders. Additionally, the study
participants were between 20 and 40 years of age,
so that the confounding effects of age and
menopausal status were minimised. However, the
exact implications of the findings of an association
between cumulative dose of ICS and reductions in
BMD from the study would need to be verified in
a longitudinal study, particularly since bone loss
with oral corticosteroid therapy is time dependent
and most rapid in the first 12–24 months of
treatment duration.94
Three further studies conducted in children have
shown that doses of BDP and BUD up to
800 µg/day did not affect bone density,95,96 and
the lumbar spine density of children receiving
BDP 300–400 µg/day for 6 months was not
different from that of the control group.97 Overall,
the long-term consequences of administering ICS
for many decades from early childhood are not
known.
There is evidence that the use of high-dose ICS is
associated with skin thinning and easy
bruising.98,99 One study showed that skin
thickness measured by an ultrasound scan was
significantly reduced by 15–19% in patients on
BDP 1000–2250 µg/day compared with controls.98
In addition, the prevalence of bruising was
significantly higher at 48% in this patient
population compared with 12% in the control
population.98 The results of a further survey also
indicated that easy bruising was the commonest
reported symptom, with the use of ICS occurring
in almost half of the patients.99 The relative risk of
easy bruising was more than double that of a
population of a similar age and sex distribution
not taking ICS. This risk also increased with age,
dose and duration of therapy.99 The presence of
skin bruising can be considered a visible marker of
the AEs of ICS therapy on collagen turnover in
connective tissue. However, it is unclear whether
early susceptibility to skin bruising relates to
effects on collagen in other systemic tissues such
as bone.100 Therefore, the absence of skin bruising
cannot necessarily be taken as a guide to the safety
of a given dose of ICS.
Posterior subcapsular cataract (PSC) is a well-
recognised complication of treatment with oral
corticosteroids, with the incidence increasing with
both dose and duration of treatment.101,102 The
incidence also depends on the individual’s age
(particularly in children) and ethnic origin, with
Hispanic people being more susceptible to
development of PSCs.101 However, the evidence of
an association between ICS use and development
of a PSC is equivocal and often confounded by
previous exposure to oral corticosteroid therapy.
Three studies have reported no association
between long-term low- and high-dose ICS
therapy in adults and the prevalence of
PSCs.103–105 A further population-based survey
reported that after adjustment for age and sex, the
relative prevalence ratio for corticosteroid versus
no corticosteroid exposure was 1.9 (95% CI 1.3 to
1.9) for posterior subcapsular, 1.5 (95% CI 1.2 to
1.9) for nuclear and 1.1 (95% CI 0.9 to 1.3) for
cortical cataracts.106 The relative prevalence ratio
of posterior subcapsular cataracts for a lifetime
dose of BDP of >2000 µg/day was 5.5 (95% CI 
2.3 to 13.0).106
There have also been case reports suggesting that
ICS use may be associated with the development
of ocular hypertension or open-angle
glaucoma.107,108 The results of one case–control
study showed that after adjustment for age, sex,
diabetes, systemic hypertension and the use of
ophthalmic or oral corticosteroids, there was no
association between current use of inhaled or
intranasal corticosteroids and an increased risk for
ocular hypertension or open-angle glaucoma.
However, those patients who were using high
doses of corticosteroid on a regular basis for
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123 months or more were at a small, significantly
increased risk, with an odds ratio (OR) of 1.44
(95% CI 1.10 to 2.06).109
LABAs
Products available
There are currently two LABAs licensed for use in
adults in England and Wales:
● Salmeterol (SAL) is available in MDIs with non-
CFC propellants [Serevent (Allen and
Hanburys)] and in DPIs [Accuhaler (Allen and
Hanburys) and Diskhaler (Allen and
Hanburys)].
● Formoterol fumarate (FF) (previously known as
eformoterol) is available in MDIs with non-CFC
propellants [Altimos Modulite (Trinity-Chiesi)]
and in DPIs [Oxis Turbohaler (AZ) and Foradil
(Novartis)].
Combination products available
There are currently two combination products
containing an ICS and a LABA licensed for use in
adults in England and Wales:
● BUD combined with FF (BUD/FF) is available
in DPIs [Symbicort Turbohaler (AZ)].
● FP combined with SAL (FP/SAL) is available in
MDIs with non-CFC propellants [Seretide
Evohaler (Allen and Hanburys)] and DPIs
[Seretide Accuhaler (Allen and Hanburys)].
Mechanism of action of LABAs
LABAs produce sustained bronchodilation
(relaxation of the airways), improving airflow in
and out of the lungs. In contrast to SABAs (e.g.
salbutamol, terbutaline), which are used for quick
relief of symptoms, these compounds are
administered on a regular basis for the long-term
control of symptoms. 
Pharmacology
The two currently available LABAs (SAL and FF)
are highly selective beta2 adrenoceptor agonists
which produce a bronchodilator effect lasting for
at least 12 hours after a single inhalation. They act
principally on smooth muscle beta2 adrenoceptors,
which are widely distributed throughout the
bronchial tree; the highest density of beta2
adrenoceptors is found in the alveoli.110 Both
agents are highly potent (i.e. they are effective at
low concentrations). Comparative studies suggest
that the potency ratio is approximately 5:1
(FF:SAL) for both systemic side-effects seen in
healthy volunteers111,112 and bronchodilator effects
seen in people with asthma.113 Onset of
bronchodilation with FF is within 2–3 minutes
whereas the onset of bronchodilation with SAL
takes approximately 10 minutes and the maximal
effect may not be apparent for several hours.114 FF
is more lipophilic than SAL and has a much
higher degree of intrinsic agonist activity.115 In
addition to bronchodilator effects, LABAs also
provide protection from a number of stimuli
causing bronchial hyper-responsiveness, such as
methacholine, cold air, exercise, hyperventilation
and histamine.116 Despite some indication of anti-
inflammatory activity in laboratory experiments,
neither SAL nor FF has been shown to have anti-
inflammatory effects in patients with asthma,117,118
although preliminary evidence suggests that
LABAs might have some mild anti-inflammatory
effects when given in combination with ICS (see
the section ‘Combination inhalers’, p. 15) as a
result of inadvertent potentiation of the effects of
the ICS.119 The main AEs of LABAs relate to their
systemic activity (see the next section). Both drugs
are relatively well tolerated at recommended doses
but their therapeutic window is fairly narrow.111
Adverse events
Most AEs related to the use of LABAs are a result
of systemic absorption (due to stimulation of beta2
adrenoceptors in the heart, peripheral vasculature
and skeletal muscle) and are dose related. At
standard doses, AEs such as tachycardia, increase
in the QTc interval, hypokalaemia,
hyperglycaemia and tremor are minimal in most
individuals.116 At higher doses (which may be
relevant during an acute asthma attack), both SAL
and FF produce dose-related effects on heart rate,
diastolic and systolic blood pressure, QTc interval
and plasma potassium levels.111
Tolerance
Tolerance to the effects of regular LABA exposure,
as a result of down-regulation of beta2
adrenoceptors, may result in a diminution of
response and associated worsening of disease
control. This has been the subject of much basic
and clinical research.120–125 Although down-
regulation of beta2 adrenoceptors has been
demonstrated in laboratory studies, most large
clinical trials of LABAs have shown that tolerance
to the bronchodilator effects of LABAs is not a
significant clinical problem.115 Tolerance to the
bronchoprotective effects of LABAs against
bronchoconstrictor stimuli such as methacholine
challenge or exercise has been demonstrated in
clinical studies.126–129 Although bronchoconstrictor
challenges are considered to be a surrogate for
conditions during an asthma exacerbation,
whether these laboratory-conducted studies are
relevant to the everyday treatment of asthma with
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suggest that during regular LABA therapy there
might be a reduced response to SABA, although
some of the studies in this area are difficult to
interpret.115,130
Effect of LABAs on life-threatening asthma
attacks and asthma-related deaths
Concerns have been raised in the literature
regarding the association between treatment with a
LABA and an increased risk of death due to
asthma. This association, however, has remained
uncertain, since it can be suggested that a high
level of beta2 agonist use is probably correlated
with severity of asthma, and that those with more
severe asthma are at greater risk of death.131 Two
post-marketing surveillance studies have therefore
assessed the safety of SAL and salbutamol versus
either each other or placebo,132,133 and the US
Food and Drug Administration (FDA) has assessed
data from three clinical trials134,135 submitted in
support of the approval of Foradil Aerolizer for
marketing in the USA for reports of serious
asthma exacerbations.136
Salmeterol Nationwide Surveillance study (SNS)
The SNS study conducted in the UK in 1990–1,
randomised 25,180 patients with asthma who were
considered to require regular bronchodilator
treatment.132 Patients were randomised to receive
either SAL 50 µg twice daily (n = 16,787) or
salbutamol 200 µg four times daily (n = 8393) in
combination with their previously prescribed
asthma drugs for 16 weeks. Approximately three-
quarters of the patients were taking either an oral
or ICS. The incidence of drug-related serious AEs
was similar in both groups (1.19% versus 1.15%,
respectively), but a significantly lower rate of
severe, non-fatal asthma-related AEs was observed
in the SAL group compared with the salbutamol
group (9.9% versus 1.6%, respectively). The
incidence of the combined trial end-point of
respiratory and asthma-related deaths was not
significantly different between the SAL treatment
group and the salbutamol treatment group (0.07%
versus 0.02%, respectively).132
Salmeterol Multicenter Asthma Research Trial
(SMART)
SMART was a randomised, placebo-controlled
study that compared the effects of adding SAL or
placebo to usual asthma therapy.133 Patients were
randomised to receive either SAL 42 µg twice daily
via an MDI or placebo twice daily for 28 weeks.
The planned safety interim analysis was conducted
after 26,355 patients had been randomised. At
this point the trial was terminated as it was found
that the overall rate of death was higher in
patients treated with SAL compared with placebo.
The interim analysis indicated that the occurrence
of the primary outcome (combined respiratory-
related deaths or life-threatening asthma attacks)
was low and not significantly different between the
groups. However, there was a small but significant
increase in respiratory-related deaths (24 versus
11) and asthma-related deaths (13 versus three) in
patients receiving SAL compared with placebo.
Further post hoc analysis showed that compared
with placebo, a higher rate of asthma-related
deaths occurred in the SAL group in both white
(0.01% versus 0.07%) and African American
(0.04% versus 0.31%) patients. However, the
overall estimates of excess deaths attributable to
SAL were greater in the African American trial
patients due to a higher event rate. It was also
observed that the occurrence of asthma-related
deaths and life-threatening experiences were
similar in both groups in those patients using ICS
at baseline (16 versus 13, respectively). However,
overall the trial was not designed or conducted in
a manner that allowed for any conclusions to be
drawn regarding whether or not ICS significantly
modify the risk of death or risk of experiencing a
life-threatening episode purportively associated
with the use of SAL.133
Combined FF trials
Data from three pivotal randomised, placebo-
controlled, double-blind trials submitted to the
FDA by Novartis Pharmaceuticals in support of
the approval of Foradil Aerolizer for marketing in
the USA have been assessed for reports of serious
asthma exacerbations.134,135 Two of the trials were
conducted in adults and one in a paediatric
population. The two 12-week trials that were
conducted in adults compared the effects of FF
12 µg twice daily or 24 µg twice daily with either
albuterol 180 µg four times daily or placebo. Both
the 12 and 24 µg twice daily doses of FF were
significantly more beneficial in terms of
improvement in the primary end-point of FEV1 at
the 12-week follow-up. Neither of the trials
showed a statistically significant benefit for FF
24 µg twice daily compared with FF 12 µg twice
daily. However, the rate of serious asthma
exacerbations was higher in the FF 24 µg twice
daily dose group compared with the groups
receiving placebo or albuterol or the group
randomised to 12 µg twice daily of FF. In the two
12-week trials in adults/adolescents, nine patients
in the FF 24 µg twice daily group experienced a
serious asthma exacerbation, all of which required
hospitalisation. One patient died due to a
cardiorespiratory arrest. In comparison, two
Background
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non-fatal asthma exacerbation, both of which
required hospitalisation. In the trial that was
conducted in a paediatric population for 1 year, 11
patients in the FF 24 µg twice daily group had a
serious non-fatal asthma exacerbation compared
with eight patients in the FF 12 µg twice daily
group and no patients in the placebo group.
Summary of the risk of mortality or serious
asthma exacerbation associated with LABA use
The results from trials and post-marketing
surveillance studies provide conflicting evidence
on any increased risk of mortality or serious
asthma exacerbations associated with the use of a
LABA. The majority of prospective trials show a
decrease in exacerbation rates with the use of a
LABA either in addition to an ICS or used alone.
Additionally, no significant excess in mortality or
the rate of severe exacerbations is generally
observed. However, the majority of these trials
were relatively short-term and are usually not
powered to detect relatively rare AEs. In contrast,
post-marketing surveillance studies have shown
mixed results regarding an increased risk of either
severe AEs or mortality with LABA use. The
results of the SNS132 indicated that there were
fewer severe non-fatal AEs with the use of SAL
compared with salbutamol, and there were no
significant differences in the mortality rates
between the groups. In contrast, the results of
SMART133 showed that there was a significantly
higher rate of respiratory and asthma-related
deaths in the SAL group compared with the
placebo group. No difference in the primary
composite outcome was observed between the
groups. Likewise, the three trials that assessed the
use of FF indicated that there is an excess risk of
severe exacerbation associated with higher doses
of FF (24 µg twice daily,) compared with either
lower doses of FF (12 µg twice daily), albuterol or
placebo.
Overall, it is difficult to quantify the excess risk of
severe exacerbation associated with the use of
either SAL or FF, but it appears to be reasonably
rare. However, the degree to which this reflects the
use of a LABA alone, and may be attenuated by
the use of combination ICS plus LABA therapy,
warrants further investigation in future post-
marketing surveillance studies.
FDA actions on the use of LABAs. The FDA has
recently asked for a ‘black box’ warning to appear
on the labels of products containing SAL. The
labelling includes a warning about a small, but
significant, increased risk of life-threatening
asthma episodes or asthma-related deaths with the
use of SAL. A similar warning has also been
included in the prescribing information. The
labelling for FF remains unchanged.
Combination inhalers
Pharmacology
LABA and ICS affect different aspects of asthma
control and many studies have demonstrated the
superiority of the combination of agents over
increasing the dose of ICS.137–139 Whether the
combined effect is additive or synergistic (i.e. the
combined effect is greater than the sum of the
effects due to the individual agents) has been the
subject of much research, both basic and clinical,
and remains controversial.140–142
There are no apparent differences in systemic
pharmacodynamics or pharmacokinetics when
inhaled FP and SAL are given separately or in
combination.143
Economic aspects of asthma
The research literature on economic aspects of
asthma is large and diverse. Although it is
dominated by economic evaluations comparing
the cost-effectiveness of alternative treatments for
asthma, it also includes cost-of-illness studies, cost
analyses of particular treatments, longitudinal
studies, regression analyses of claims databases
and other studies to elicit patient preferences
about different types of treatment and care
provision.
Our aim in the following sections is to (1) give a
broad overview of those economic aspects of
asthma that have been identified in the research
literature, focusing especially on studies conducted
in the UK and/or focusing on asthma in adults,
and (2) attempt to identify the key causal
relationships and trade-offs that seem to exist
between resource use and the nature of chronic
and acute asthma in adults, in order to
characterise best the decision problem and model
structure. It is not, therefore, intended to be
totally comprehensive in terms of either the
economic issues covered or the research literature
included on each issue.
NHS cost impacts of asthma
People with asthma place various demands on the
NHS budget, ranging from the cost of prescribed
asthma medications to various levels of planned
and unplanned health service use [e.g. GP and
nurse consultations, secondary care outpatient
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visits and hospital admissions]. There is some
evidence that adults with asthma place relatively
smaller demands on health services than children
with asthma.
Cost-of-illness studies of asthma consistently show
relatively high ‘indirect costs’ (including, for
example, the estimated cost of lost days of work or
school) compared with the direct healthcare costs
of service use.144 They sometimes also show the
dominant role of people with severe asthma in
generating the bulk of asthma-related healthcare
costs.
Gupta and colleagues have published the most
recent well-conducted cost-of-illness study of
asthma in the UK.145 Overall, they estimated that
the cost to the NHS of asthma in 2000 was £754
million, of which 78.8% (£594 million) was due to
community-dispensed prescriptions, 12.7% (£96
million) was due to GP consultations and 8.4%
(£63 million) was due to hospital admissions. This
contrasts with most international studies, in which
hospital costs account for a higher proportion of
the costs associated with healthcare use.144 Of the
NHS costs associated with hospital admissions,
over 86% (£54.7 million) were due to non-elective
admissions (i.e. probably to treat asthma
exacerbations). More recent estimates by the UK’s
Lung and Asthma Information Agency (and cited
in the Asthma UK Cymru report Asthma in Wales
today) suggest that this cost to the NHS has
increased to £889 million annually.146 In a
different study, cited in the same Asthma UK
report, difficult-to-control asthma was estimated to
cost the NHS £680 million per year.
Other data in the study by Gupta and colleagues
suggest that, compared with children, adults (aged
15 years and over) contribute proportionately less
to both the primary care and secondary care NHS
costs (Table 4). These data also suggest that among
adults there is one hospital admission for asthma
for every 13–15 GP consultations (for asthma),
whereas among children there is an asthma-
related hospital admission for every eight GP
consultations.
The Prescriptions Cost Analysis database147 details
the number and cost of all prescriptions dispensed
in the community in England. Listing of drug
classes (by 317 BNF subparagraphs) shows that
expenditure in 2005 on corticosteroids for
respiratory conditions cost the NHS £436 million.
Although only 15th in terms of the number of
prescriptions, this is the third largest component
of the total cost of community-dispensed drugs in
England (after lipid-regulating drugs £625 million
and proton pump inhibitors £446 million).
Corticosteroids for respiratory conditions cost the
NHS more than double the amount spent on
many other major drug classes, such as
angiotensin-converting enzyme inhibitors,
antipsychotic drugs and intermediate and long-
term insulins.
Of the £436 million spent on respiratory
corticosteroids, £276 million was spent on
combination inhalers (Symbicort and Seretide)
(Figure 5).
Effective drug treatment for asthma relies upon
the correct use of various inhaler devices. It is
therefore conspicuous that the extra cost of related
education and support to encourage correct
inhaler technique has usually not been included in
economic analyses comparing drug treatments [for
example, respiratory nurse education on the
correct use of pressurised MDIs (pMDIs)]. This
omission may be particularly important in
younger age groups.
Cost to individuals with asthma, their
carers and society
Financial cost of medicines
In most countries people have to pay all or a part
of the cost of their asthma medications. In the
UK, NHS prescriptions are subsidised for most
adults (by a fixed fee per prescription), and are
free of charge for children (aged 16 years and
under), pregnant mothers (until 1 year after
Background
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TABLE 4 GP consultations and hospital admissions for asthma in the UK
Age group (years) Weekly number of GP consultations  Annual number of hospital admissions 
(per 100,000 in age group) in 2002 (per 100,000 in age group) in 2000–1
0–14 46 292
15–44 25 84
45+ 21 83
Source: Gupta and colleagues.145birth), those aged 60 years or over and those who
meet certain income-related criteria. In addition,
people with certain chronic conditions, such as
insulin-dependent diabetes or epilepsy, are
exempt from all NHS prescription charges, but
asthma is not one of these exempt conditions.148
Across the UK, approximately 50% of individuals
are eligible to pay prescription charges, but only
13% of prescriptions dispensed actually incur a
charge.148
Patient charges for medicines may also play a part
in non-concordance with recommended treatment.
Although in the short term this might be a cost
saving, the longer term health consequences of
not taking prescribed medications may generate
considerable cost impacts. People are known to
employ a variety of strategies to reduce or avoid
prescription charges: they do not have their
medicines dispensed in full; they substitute
cheaper over-the-counter medicines; or they
sometimes skip doses to make the prescription last
longer. For example, a survey of Citizens Advice
clients showed that 28% did not have their
medicines dispensed in full, and over one-third of
these people had long-term conditions.148 In
comparison with other countries however, a recent
large survey of adults in a number of countries
showed that only 4% of people in the UK report
not collecting a prescription or skipping
medication doses because of cost (compared with
9, 11, 12 and 21% in Canada, New Zealand,
Australia and the USA, respectively).149
Other financial costs
Economic evaluations and cost-of-illness studies
have not usually measured the use of resources
such as medical equipment and consumables to
support asthma self-medication and self-
monitoring. Such equipment and consumables
include nebulisers, inhalers and peak flow
meters.150 Also, families may incur costs as part of
asthma allergen avoidance strategies (such as dust-
mite-proof bedding, or house renovations to
reduce carpeting or damp and mould).
People with asthma also inevitably have to pay
more of the various costs of attending more
frequent primary care or hospital consultations,
for example, for travel, car parking and child
care.151
Indirect costs to individuals with asthma, carers
and society
Cost-of-illness studies in a number of countries
suggest that a significant proportion, usually 50%
or more, of all costs due to asthma are due to the
‘indirect costs’ of lost days at work (or school),
which may be estimated by asthma morbidity and
treatment, and/or by premature deaths due to
asthma.144 Adults may lose work days as a result of
either their own asthma, or due to looking after
children or other dependents with asthma. Two
early studies estimated the annual number of
working days lost due to asthma in the UK to be
5.7 or 7 million, corresponding to an estimated
50% and 90%, respectively, of all asthma
costs.152,153
Other time costs to individuals and carers include
healthy time lost (either work or leisure), the time
that individuals put into the process of receiving
healthcare and the time that carers put into caring
for friends and relatives with asthma.154 These
costs are in principle measurable, but much
harder to value – including the thorny issue of
whether some ‘time costs’, such as lost leisure
time, should be counted as a reduction in quality
Health Technology Assessment 2008; Vol. 12: No. 19
17
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
2005 no. of prescriptions (14.1 million)
Beclamethasone
Budesonide
Fluticasone
Mometasone
Ciclesonide
Symbicort
Seretide
2005 net ingredient cost (£436 million)
FIGURE 5 Number and cost of community-dispensed prescriptions for ICS in England 2005. Source: NHS Health and Social Care
Information Centre.147of life (i.e. outcome) rather than counted as a
monetary input to the process of producing better
health.
Healthcare resource use and asthma
severity
Some published studies have specifically examined
the relationship between asthma severity and
resource use and costs. Few of these are UK-based
studies. Nevertheless, the positive association
between asthma severity, whether defined using
the GINA classification or other methods, and
healthcare costs seems strong in a range of health
systems.155,156
A Spanish study, using an internationally
recognised system for classifying people’s asthma
as mild, moderate or severe, found that the
average annual asthma-related cost was 
US$1336, US$2407 and US$6393, respectively.157
A minority of people with severe asthma 
incurred 41% of the total costs. Also, both indirect
and direct costs increased with higher levels of
asthma severity.
Jakeways and colleagues analysed data from a
1991 cross-sectional survey of 2633 adults (general
population) in Nottingham, UK, and calculated
the odds ratios for experiencing a range of asthma
symptoms, including an ‘attack of shortness of
breath’ following strenuous activity, in the past
year (25.7% of those surveyed). The relationship
between the risk of an asthma attack and FEV1
predicted was strongest for values of FEV1
predicted below 75%.158 Since asthma
exacerbations are known to be a key driver of
asthma-related healthcare costs (see below), this
can be regarded as further evidence of a
relationship between asthma severity and costs.
However, a US-based study of 2378 people with
severe and difficult-to-treat asthma found no
association between FEV1 and the level of
healthcare use.159
Healthcare resource use and level of
symptom control
Although much asthma medication is prescribed
as prophylactic therapy, and some asthma-related
healthcare consultations are for routine clinical
reviews, a sizeable proportion of medication use
and many consultations occur in response to
worsening symptoms. It is therefore possible that
there might be a strong relationship between
degree of asthma (symptom) control and resource
use. As a result, the level of use of healthcare
resources is sometimes suggested as a possible
measure of effectiveness of asthma treatments.150
Vollmer and colleagues, in a prospective US-based
study, found that those with three or four control
problems experienced rates of acute care episodes
that were 3.5 times higher (95% CI: 2.9 to 4.3)
than those for people with no reported control
problems at the beginning of the study year.160
Interestingly, they also noted that poor asthma
control predicted higher levels of both acute and
routine healthcare use.
A key indicator of poor symptom control is a
greater frequency of use of reliever medication
(e.g. inhaled salbutamol), which has implications
for medication costs. Also, anecdotally, poor
asthma symptom control may prompt better
adherence to maintenance medication.
The key driver of the higher costs of having poor
symptom control appears to be the resource
consequences of asthma exacerbations.
Exacerbations and healthcare 
resource use
Asthma exacerbations (or asthma ‘attacks’) are one
of the key acute events which lead to the
consumption of additional medications or to
patient-initiated healthcare consultations. They
are also the likely cause of the more expensive
types of asthma-related healthcare use, such as
A&E attendances and hospital admissions.
For example, in a UK-wide cohort study of 12,203
people with asthma followed for 1 year, those who
experienced an attack incurred over three times as
much healthcare cost as those who did not (£381
versus £108; 1997 NHS costs).161 Further
breakdown of these costs showed that most of this
difference was due to hospital stays (£169 versus
£7, over the year) and medication costs (£129
versus £75). Figure 6 shows how the proportion of
people with asthma admitted to hospital in each
age group is broadly related to the proportion
experiencing asthma attacks.
A recent international comparative study
examined whether changes in hospital admissions
for asthma (between 1990 and 2000) might be
related to changes in the national level of
consumption of ICS and other asthma drugs.162
Overall, a negative relationship was found between
falling admissions and increased use of respiratory
drugs in nine of 11 developed countries. The UK
was one of three countries where this negative
regression coefficient between hospital admissions
and asthma drug sales volumes was statistically
significant. The relationship was stronger for
temporal changes in ICS drug use (using a pooled
Background
18estimate from a random effects model). Although
these findings will potentially reflect a number of
factors that may have changed over time, such as
the prevalence and severity of asthma, and
proportion of people with asthma being treated,
the pattern of decline in asthma-related hospital
admissions in many countries, including the UK,
is consistent with a beneficial effect of the
corresponding increasing use of asthma drugs.
There is also a documented relationship between
the cost of treating an exacerbation, especially
secondary care costs, and the severity of the
exacerbation.163
It should be noted that many of these published
studies predate the existence of NHS Direct, NHS
Walk-in Centres and GP out-of-hours cooperatives.
In the UK these services now provide either a new
pathway to some of the more long-standing
providers of acute care (e.g. GPs, A&E
departments), or provide emergency care and
advice in their own right. It is possible that these
services, by being better publicised and more
accessible than traditional models of healthcare
delivery, have made it easier for people with
asthma to obtain care or advice when they
experience symptoms or have other asthma-
related queries.
Healthcare resource use and other
factors
In addition to asthma severity and level of asthma
symptom control, there are other published
studies which have documented a relationship
between asthma-related resource use and:
● co-morbidities (such as allergic rhinitis,
diabetes)164,165
● age of adults (with older age groups incurring
higher costs)165
● sex (females being more likely to use care for
asthma)
● self-management programmes
● health service organisation and accessibility (e.g.
balance of primary care provided by nurses
versus GPs, availability and use of telephone
advice lines)165,166
● HRQoL.160,165,167
Summary points of the economic
impact of asthma 
● Asthma has considerable economic impacts
beyond the resources used in providing
healthcare. These impacts comprise lost days of
work by asthma sufferers and their families, and
lost days of school among children.
● Of the costs incurred for providing healthcare
for people with asthma, a high proportion is
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FIGURE 6 Annual incidence of asthma attacks and usage of secondary care in the UK, by age group. Source: Hoskins and
colleagues.161associated with the use of hospital services.
Asthma exacerbations, both their frequency and
their severity, appear to be the major driver of
the cost of using health services.
● As asthma severity increases and level of asthma
control decreases, the costs to the health system
increase. There may be interaction effects, but
we are not aware that they have been explicitly
studied (e.g. poorly controlled severe asthma
may lead to more consumption of healthcare
resources than the separate effects added).
People with difficult-to-control asthma may be
another subgroup which generate more
healthcare costs, but they have been less
studied.
● Although there has been a great deal of
research to examine the cost-effectiveness of
switching to alternative treatments for people
with poorly controlled asthma, there do not
appear to have been any economic evaluations
of stepping down treatment in individuals
whose asthma is well controlled.
● In the last 10 years there have been considerable
changes in the range of available NHS services
for people with asthma, especially those for
urgent care and advice – such as NHS Direct,
Walk-in Centres and GP after-hours
cooperatives. These may have changed the
pathways by which people access healthcare, and
perhaps also altered the balance of self-care and
formal care. In addition, the cost and cost-
effectiveness of allergen avoidance strategies to
reduce asthma symptoms have not been studied.
● There are some dynamic inter-relationships
between resource use (costs) and the level of
actual or perceived symptom control. For
example, patient charges for medication may be
a factor in poor concordance with prophylactic
therapy, and therefore symptom deterioration
(and ultimately higher healthcare costs). Also,
the lack of perceived symptoms may encourage
a gradual reduction in the use of prophylactic
therapies, resulting in a costly exacerbation of
asthma symptoms.
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20Aims and objectives
Assessment aim
The aim of this health technology assessment is to
assess the clinical and cost-effectiveness of ICS,
used alone or in combination with a LABA, for the
treatment of chronic asthma in adults and children
aged 12 years and over and to provide guidance
to the NHS in England and Wales.
Objectives
The objectives were as follows:
● to identify, appraise and synthesise, where
appropriate, the current evidence base which
addresses the specific research questions on
clinical effectiveness listed above
● to identify the costs associated with the different
treatments
● to identify, appraise and synthesise, where
appropriate, the current evidence base which
addresses the specific research questions on
cost-effectiveness listed above
● to provide estimates of cost-effectiveness, where
possible, of the different treatment options.
Definition of the decision
problems
There are five ICS available as licensed preparations
in this population: BDP, BUD, FP, MF and CIC.
The drugs may all be administered via different
devices, including pMDIs, with or without a spacer,
and DPIs. Assessment of the effect of the device on
the dose of corticosteroid delivered to the airways
and, by extension, the effect of the device on the
clinical effectiveness of ICS, is not included in this
report. Similarly, the effect of the propellant (CFC
versus HFA) used in the MDIs is not considered.
In addition, two corticosteroids under
consideration are available as licensed
preparations in combination with LABA: FP/SAL
(Seretide) and BUD/FF (Symbicort).
For each ICS, the appropriate comparators are the
other ICS. For each combination inhaler, the
appropriate comparators are the other
combination inhaler and ICS alone.
The BTS/SIGN Guideline1 is the context in which
the decision problem is set, outlined in the section
‘Asthma management in the UK’ (p. 6). Using the
steps in the Guideline, the following specific
research questions were identified:
Q1. At low doses (200–800 µg BDP/day or
equivalent), which is the most clinically and
cost-effective of the five ICS? (Step 2 of the
Guideline)
The relevant population for which this intervention
should be considered is asthmatics who have been
treated at Step 1 or Step 2 of the Guideline 
[i.e. they have either not been treated with
corticosteroids previously or have received low doses
(as defined above) of ICS].
Q2. At high doses (800–2000 µg BDP/day or
equivalent), which is the most clinically and
cost-effective of the five ICS? (Step 4 of the
Guideline)
The relevant population for which this intervention
should be considered is asthmatics who have been
treated at Steps 2–3 of the Guideline (i.e. they have
been treated with ICS previously in conjunction
with other treatments such as LABA). They should
not be steroid-naïve.
Q3. Which is the more clinically and cost-effective
approach to introducing a LABA into a
treatment regimen: 
(a) to increase the dose of ICS alone or to
add a LABA to treatment with an ICS?
(Steps 2–3 of the Guideline)
(b) to continue with an ICS alone or to add a
LABA to treatment with a similar dose of
ICS using a combination inhaler? (Steps
2–3 of the Guideline)
The relevant population for which this intervention
should be considered is asthmatics who have been
treated at Step 2 of the Guideline (i.e. they have
been treated with low-dose ICS previously). They
should not be steroid-naïve.
Question 3a is viewed as the more clinically
relevant of the two sub-questions, because if patients
remain uncontrolled on lower dose ICS alone,
treatment protocols in line with the BTS/SIGN
Guideline would indicate that either the ICS dose is
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Chapter 2
Decision problemsincreased or a LABA is added to the lower dose of
ICS. However, the literature searches conducted for
the present assessment also identified trials in which
a LABA was added to the ICS treatment regimen
without the dose of ICS alone being increased.
Although this treatment strategy is not in line with
that advocated in the BTS/SIGN Guideline, for
completeness these studies are included in the
clinical effectiveness review as a separate sub-
question. This sub-question is not addressed in the
cost-effectiveness evaluation.
Q4. Which is the more clinically and cost-effective
treatment: 
(a) FP and SAL in a combination inhaler or
given in separate inhalers? 
(b) BUD and FF in a combination inhaler or
given in separate inhalers? 
Q5. Which is the more clinically and cost-effective
treatment: FP and SAL in a combination
inhaler or BUD/FF in a combination inhaler?
(Step 3 of the Guideline)
The relevant population for which this intervention
should be considered is asthmatics who have been
treated at Step 2 of the Guideline (i.e. they have
been treated with low-dose ICS previously). They
should not be steroid-naïve.
Within the context of the BTS/SIGN Guideline, it
is generally accepted that the following are
clinically equivalent doses: BDP 400 µg, BUD
400 µg, FP 200 µg, CIC 200 µg and MF 200 µg.
Studies which compare these drugs at these drug
ratios, delivered through the same device, are
therefore the most appropriate method for testing
this hypothesis.
The clinical effectiveness of treatments for asthma
can be assessed against a wide variety of outcome
measures, which can be broadly divided into the
following categories:
● objective measures of lung function (e.g. FEV1,
PEF)
● symptoms [e.g. nocturnal waking, morning
cough, symptom-free days (SFDs) and
symptom-free nights (SFNs), symptom scores]
● use of rescue medication (e.g. SABA, short
courses of oral corticosteroids)
● acute exacerbations, defined in a number of
ways (e.g. increase in symptoms or medication
or contact with health services)
● AEs
● HRQoL
● mortality.
Although there is some evidence of the minimally
perceived change in PEF considered to be
clinically relevant by patients, for the majority of
the above outcome measures it is unclear for
which, if any, there is a generally accepted
definition of the minimum level of change that is
clinically significant.
Decision problems 
22Methods for reviewing
effectiveness
A peer-reviewed protocol was published in May
2006 on the website of the National Institute for
Health and Clinical Excellence (NICE) and
circulated among the consultees, outlining the
agreed scope and methodology for this
assessment.168 This was based on the scope of the
appraisal as published by NICE.169
The scope proposed that the assessment be
conducted within the context of the stepwise
approach as advocated by the BTS/SIGN
Guideline on the management of chronic asthma.1
As far as possible, the contents of this Guideline
have been taken into account in the assessment of
clinical effectiveness.
An over-arching philosophy of the assessment of
clinical effectiveness was the need to capitalise,
where possible, on existing evidence syntheses of
the effectiveness of ICS and LABAs for chronic
asthma. The rationale was to reduce duplication
and to ensure that the assessment was manageable.
A number of systematic reviews of
pharmacotherapy for chronic asthma have been
published in The Cochrane Database of Systematic
Reviews. Some of these are relevant to the scope of
this assessment,56,170–173 although in places their
aims and inclusion criteria vary from those of the
current assessment. Where possible, we have
adopted the rigorous methods employed in those
reviews, and added to the data presented in them.
Identification of studies
A search strategy for electronic bibliographic
databases was devised and tested by an
experienced information scientist (Appendix 3).
Once finalised, it was applied to a number of
databases, including The Cochrane Database of
Systematic Reviews (CDSR); The Cochrane
Central Register of Controlled Trials; Database of
Abstracts of Reviews of Effectiveness (DARE); the
NHS Economic Evaluation Database (NHS EED);
MEDLINE (Ovid); EMBASE (Ovid); National
Research Register; Current Controlled Trials; ISI
Proceedings (Web of Knowledge); Science Citation
Index (Web of Knowledge); and BIOSIS.
Searches were run up to February/March 2006,
and were restricted to studies published in
English. An update search was conducted in
October 2006.
The drug manufacturers’ submissions to NICE,
which we received in August 2006, were also
searched for potentially relevant trials.
Additional searches of MEDLINE, EMBASE,
DARE, the Health Technology Assessment (HTA)
Database and Cochrane Database of Systematic
Reviews were conducted to identify systematic
reviews of the long-term AEs associated with either
ICS use alone or in combination with a LABA. For
the full search strategy and search dates, see
Appendix 3.
All identified studies were downloaded into a
Reference Manager database for storage and
retrieval as necessary. A keywording system was
devised to enable each reference to be categorised
according to prespecified inclusion and exclusion
criteria (see the next section).
Inclusion and exclusion criteria
The inclusion and exclusion criteria were specified
a priori based on the scope issued by NICE,169 as
agreed in the published protocol.168
Intervention
Trials reporting evaluations of the following ICS
were included:
● BDP
● BUD
● CIC
● FP
● MF.
Trials reporting evaluations of the following ICS
combined with LABAs in the same inhaler (i.e.
combination inhalers) were included:
● BUD/FF
● FP/SAL.
Trials reporting ICS delivered by pMDIs (CFC and
HFA excipients) and by DPIs were included, but
those using nebulisers were excluded.
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Chapter 3
Assessment of clinical effectivenessTo be included, the treatment had to last for
longer than 4 weeks.
Comparators
● The ICS were compared with each other.
● The combination inhalers were compared with
each other and with ICS only. They were also
compared with ICS and LABAs administered in
separate inhalers.
● Trials testing only different doses of the same
agent were not included as these were outside
the scope of the assessment. (NB. Cochrane
systematic reviews of different doses of BUD,174
BDP175 and FP176 are available). However, trials
which compared more than one dose of an ICS
against a different ICS were included.
● Trials testing different ICS by different inhalers
or propellants were not included (e.g. DPI
versus pMDI or HFA pMDI versus CFC pMDI).
The role of delivery device has been assessed by
a published systematic review.177,178 The review
found that there was no evidence for differences
in effectiveness between different types of hand-
held inhaler. However, some clinical trials of
different ICS identified in our literature search
were specifically designed to demonstrate
superiority of one device over another, or in
some cases that one inhaler device can be used
to achieve comparable asthma control at a lower
ICS dose than an alternative device. For this
reason, we chose to limit the review to
comparisons of different ICS via the same type
of inhaler or propellant in order to reduce any
potential confounding associated with devices.
● Trials reporting comparisons between ICS and
placebo were sought and included in order
potentially to support economic modelling (e.g.
model parameters). Details of these studies are
not reported in the assessment of clinical
effectiveness.
Types of studies
● Fully published RCTs or systematic reviews of
RCTs were considered. Double blinding was not
a prerequisite for inclusion, although blinding
was assessed as part of critical appraisal (see the
section ‘Critical appraisal strategy’, p. 25).
Indicators of a ‘systematic’ review include
explicit search strategy, inclusion criteria, data
extraction and assessment of quality.
● Trials reported in abstracts or conference
presentations from 2004 onwards were retrieved;
however, their details were not extracted,
critically appraised or analysed. Bibliographic
details are listed in Appendix 6. (NB. The
exception to this was where an abstract was
available which provided data supplementary to
a fully published trial report of a particular
study. This occurred in a handful of cases).
● Where unpublished full trial reports were
available (e.g. as supplied by the drug
manufacturers in their submissions to NICE),
these were included.
Population
● Adults and children aged 12 years and over
diagnosed with chronic asthma were included.
Studies in which the patient group were
asthmatics with a specific related co-morbidity
(e.g. bronchitis or cystic fibrosis) were not
included, except for chronic obstructive
pulmonary disease (COPD) as requested in the
NICE Scope.
● Studies reporting the treatment of acute
exacerbations of asthma were not included.
● Trials reporting the effectiveness of ICS with
LABAs were included only if the patients had
been previously treated with an ICS. Trials
assessing the effectiveness of initiating
treatment with ICS in combination with LABAs
in steroid-naïve patients are not within the
context of the BTS/SIGN Guideline (see the
section ‘Asthma management in the UK’, p. 6).
Outcomes
At the inclusion/exclusion screening stage, studies
reporting one or more of the following outcomes
were included:
● objective measures of lung function (e.g. FEV1,
PEF)
● symptoms (e.g. SFDs and SFNs)
● incidence of mild and severe acute
exacerbations (e.g. mild – requiring
unscheduled contact with healthcare
professional; severe – requiring hospitalisation,
systemic corticosteroids or visit to A&E
department)
● use of systemic corticosteroids (e.g.
prednisolone)
● AEs of treatment 
● HRQoL
● mortality.
A list of specific measures for each of these
outcomes was devised for the data analysis (see the
section ‘Narrative synthesis’, p. 26).
Titles and abstracts of studies identified by the
searches were screened by one reviewer based on
the above inclusion/exclusion criteria. A second
reviewer checked a random 10% of these. Any
discrepancies were resolved through discussion and
involvement of a third reviewer where necessary.
Assessment of clinical effectiveness
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were requested for further assessment. All full
papers were screened independently by one
reviewer and checked by a second. Any
discrepancies were resolved by discussion with
involvement of a third reviewer where necessary.
All included papers were keyworded in the
Reference Manager database as to their
intervention and comparator, and were coded for
the synthesis framework (see the section ‘Methods
of data synthesis’, next column) to allow efficient
retrieval of subsets of studies for analysis.
As far as possible, all included papers describing a
particular trial were linked together to form a ‘set’
of studies. One of the papers (usually the seminal
journal article reporting the key efficacy and safety
results) was designated the primary publication,
with the remaining papers classed as secondary
publications.
All included trials were cross-referenced with the
relevant Cochrane reviews to ascertain whether or
not they had already been included in the
reviews.56,170–173 Those that were included were
keyworded in our Reference Manager database
accordingly. Conversely, the bibliography of
included studies in the relevant Cochrane reviews
were cross-referenced with our list of included
studies and our inclusion criteria to ascertain
whether there were any relevant studies in those
reviews that had not been identified by our search.
Data extraction strategy
All trials, except those included in the relevant
Cochrane reviews, were fully data extracted. Data
were entered into a structured template by one
reviewer and checked by a second. Any
discrepancies between the data extracted and the
original trial report were resolved and the data
extraction was finalised (see Appendix 4). Data on
the studies that met our inclusion criteria which
were also included in the Cochrane reviews are
available from the Cochrane reviews
themselves.56,170–173
Critical appraisal strategy
The methodological quality of the trials
supplemental to the Cochrane reviews was
assessed according to criteria specified by the
Centre for Reviews and Dissemination (CRD)179
(see Appendix 4). Quality was assessed by one
reviewer and their judgements were checked by a
second. Where there was disagreement, a third
reviewer was consulted and a final judgement
agreed. Judgements about the quality of the trials
included in the Cochrane reviews can be found by
consulting the relevant review.56,170–173
Methods of data synthesis
Results of the included trials were synthesised
narratively (see the next section) with use of meta-
analyses where possible and where appropriate
(see the section ‘Meta-analysis’, p. 26). A
framework was devised for the analysis and
presentation of results, based on the stepwise
approach recommended in the BTS/SIGN
Guideline for the management of asthma.1
The review questions were as follows:
1. Which ICS is the most effective at low doses
[200–800 µg/day BDP/BUD equivalent (for FP,
CIC and MF, the equivalent doses are
100–400 µg per day)]? (Step 2 of the
Guideline)
2. Which ICS is the most effective at high doses
(800–2000 µg/day BDP/BUD equivalent (for FP,
CIC and MF, high dose is greater than 400 µg
per day)]? (Step 4 of the Guideline)
3. Which is the more clinically effective approach
to introducing a LABA into a treatment
regimen:
(a) to increase the dose of ICS alone or to add
a LABA to treatment with ICS using a
combination inhaler? (Steps 2–3 of the
Guideline)
(b) to continue with an ICS alone or to add a
LABA to treatment with a similar dose of
ICS using a combination inhaler? (Steps
2–3 of the Guideline)
4. Which is the more clinically effective treatment: 
(a) FP and SAL in a combination inhaler or
given in separate inhalers? 
(b) BUD and FF in a combination inhaler or
given in separate inhalers? 
5. Which is the most-effective: a combination
inhaler containing BUD/FF or a combination
inhaler containing FP/SAL? (Step 3 of the
Guideline)
Each included trial was coded according to which
of the review questions it was relevant. For
example, a trial comparing 200 µg/day of BDP
with 200 µg/day of BUD was assigned to review
question 1, as it evaluated low-dose ICS. Some
trials were relevant to more than one review
question as they tested multiple doses of inhaled
steroids, some of which were relevant to review
question 1 (i.e. low-dose), and some which were
relevant to question 2 (i.e. high-dose). In a
minority of cases, a pair-wise comparison of ICS
fell into both the high- and low-dose categories.
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compared with 500 µg/day of FP, the FP arm falls
into the high-dose category by an additional
100 µg. In cases such as these, where one arm of
the trial marginally crossed the high-dose
threshold, the study was classified as being
relevant to review question 1 (low-dose), with a
caveat for the analysis and interpretation of the
results.
Each review question was stratified according to a
number of pair-wise comparisons of the inhaled
steroids and, where relevant, LABAs (where
evidence allows). In addition, some trials were
included in more than one pair-wise comparison
as they evaluated two or more ICS (e.g. a three-
arm trial comparing FP with BUD and BDP).
Trials were also divided according to whether or
not a parallel-group or cross-over design was used.
It is generally considered inappropriate to pool
these designs together within a meta-analysis.180
Where necessary, trials were then further divided
according to the nominal dose ratio employed,
following the approach used in the Cochrane
review of FP compared with BUD or BDP.170 Some
trials aimed to test the equipotency of newer
steroids such as FP using half the dose of older
steroids such as BDP and BUD. Therefore,
corresponding dose ratios of 1:2 are common in
the literature. Separate analyses of the ratios were
necessary to reduce the risk of confounding
associated with comparing trials with differing
doses.
In summary, the framework comprised sets of
trials grouped according to review question, pair-
wise comparison, study design and dose ratio. For
example:
1. review question1 – low-dose ICS
(a) pair-wise comparison: FP versus BDP
(i) parallel-group trial 1:1 ratio
(ii) parallel-group trial 1:2 ratio
(iii) cross-over trial 1:1 ratio
(iv) cross-over trial 1:2 ratio.
It was expected that this framework would result
in generally smaller sets of studies in each
analysis, as opposed to a larger set with potentially
more statistical power to identify effects. However,
a framework such as this was essential in order to
embed the review within the context of the
BTS/SIGN Guideline1 (as stipulated in the scope
for the appraisal issued by NICE) and to reduce
the likelihood of confounding due to differences
in trial design and dose ratio.
Narrative synthesis
As described above, the narrative synthesis
comprises a framework whereby trials are
summarised according to which review question,
pair-wise comparison, study design and dose ratio
they were relevant. The results sections are
organised according to this framework.
Within each pair-wise comparison, all included
trials were tabulated for their key characteristics,
and described in the text (e.g. trial duration,
patient profile, outcome measures, methodological
quality). In addition, more detailed data on the
trials are available in Appendix 4 for those trials
which were supplemental to the Cochrane reviews
(and which underwent full data extraction).
Further details of the remaining studies are
available in the relevant Cochrane reviews.56,170–173
Each outcome measure is presented in turn and
the key results are reported in the text.
There are numerous ways of measuring and
reporting outcomes from asthma trials. For brevity
we report only the following measures:
● lung function – FEV1 (litres); FEV % predicted;
morning/evening PEF (litres per minute)
● symptoms – days/nights without symptoms;
symptom scores (total daytime; night-time;
daily)
● HRQoL – total HRQoL scores
● use of rescue medication – mean number of
puffs per day of SABA
● exacerbations – rate of mild or severe
exacerbations (where the authors’ definition of
exacerbations is not covered by one of our
existing outcomes)
● AEs – rate of AEs; rate of serious AEs; rate of
withdrawals due to AEs; urinary/serum cortisol;
BMD; growth.
Meta-analysis
The feasibility and appropriateness of meta-
analysis were considered once narrative syntheses
had been completed. The decision to pool was
mediated by the likelihood that the trials were
clinically homogeneous and that the necessary
data were available. Potential clinical heterogeneity
was assumed if there were differences between
trials in
● dose 
● disease severity
● treatment duration.
To some extent, the potential for clinical
heterogeneity was reduced by virtue of the
Assessment of clinical effectiveness
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were grouped into sets according to whether or not
a high or a low dose of ICS was used. Nonetheless,
even within the low- and high-dose review
questions, the dose ranges are relatively wide (e.g.
800–2000 µg/day). It could also be argued that
dose is a proxy for severity, with less severe asthma
patients treated with lower doses, and vice versa,
although this is a generalisation. It was therefore
important to consider severity as a potential
source of heterogeneity. Furthermore, the
influence of trial duration cannot be discounted.
Although trials lasting around 3 months are
common, some are designed to evaluate longer
term effects on asthma control and AEs. Such
trials are likely to have differing aims and,
consequently, if they appeared to be diverse in
terms of the above factors, they were not pooled.
If pooling was considered appropriate, the data in
each trial were examined to ascertain whether or
not sufficient details were reported to facilitate
meta-analysis. The Cochrane Airways Group
kindly supplied their Review Manager software
files containing extracted and analysed data.
These files were edited to correspond to our
review questions and framework (i.e. they were
assembled into smaller sets of studies based on
dose, design and pair-wise comparisons). Data
from trials included in the Cochrane reviews which
did not meet the inclusion criteria for this review
were removed. Data from trials supplemental to
the Cochrane reviews were added, based on the
data extracted to our standardised template (as
described in the section ‘Data extraction strategy’,
p. 25).
For continuous outcome measures (e.g. lung
function, symptoms), mean values and SDs were
required in order to calculate mean differences.
These were entered where available from the trial
reports. Where SDs were not reported we
converted them from standard errors, p-values or
CIs provided in the trial reports (where available),
using standard equations within a spreadsheet.
Authors were not contacted to supply missing data.
Where trials report multiple comparisons, there is
potential for ‘double counting’ if all comparisons
are included in the same meta-analysis. Where
outcomes are dichotomous (e.g. rate of AEs), the
rate and the number of patients in the common
comparator can be halved. Where outcomes are
continuous (e.g. lung function), the effect estimate
can be halved, but a corresponding measure of
variance around the halved estimate has to be
imputed. In this assessment, where there were
multiple comparisons within a meta-analysis and
the data were dichotomous, the event rate and
number of patients in the common comparator
were halved. There were no instances where there
were multiple comparisons within a meta-analysis
and data were continuous.
Cross-over trials were only pooled where data were
reported to facilitate appropriate analysis. Many
cross-over trials report results as if the trial used a
parallel-group design and pooling is not advisable
as this results in a unit of analysis error.180 In such
cases, cross-over trials were described narratively,
with appropriate caveats.
Pooled data were expressed separately in terms of
change from baseline to end-point and as end-
point values. Trials were pooled within a meta-
analysis as either one of these, but not both. We
chose not to impute change values where not
reported by authors as it requires estimations of
the variance around mean differences, which
involves assumptions about within-patient
differences.180 Data were not available to allow
within-patient differences to be estimated (e.g.
from an appropriate correlation coefficient).
As mentioned, many of the data were continuous
and, where it was apparent that the same
measurement scale had been used across studies, a
weighted mean difference (WMD) was used to
summarise treatment effects. If it appeared that
different measurement scales were employed, a
standardised mean difference (SMD) was used.
Dichotomous data (e.g. rate of AEs) were pooled
using odds ratios. The 95% CIs were used for all
measures of effect. A fixed-effects model was used,
with a random-effects model used if statistical
heterogeneity was apparent. Statistical
heterogeneity was measured using a 2 test with
p < 0.10 as the level of significance. The I2
statistic was also used, whereby a value in excess of
50% indicates substantial heterogeneity.180
Results
Quantity and quality of research
available
A total of 5175 publications were identified
through literature searching (Figure 7). Of these,
4365 were excluded based on title and abstract.
Full reports for the remaining 807 were requested
for more in-depth screening (NB. searches for this
report were combined with the accompanying
report on ICS in children under the age of
12 years. Consequently, a proportion of the 807
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Of these, 113 records describing 84 studies were
included.
Of the 84 studies:
● 10 were conference abstracts published from
2004 onwards (Appendix 6).
● Seven were systematic reviews (of which five
were Cochrane reviews) (see the section ‘Related
systematic reviews’, p. 153).
● 67 were RCTs (of which 38 had been included
in the Cochrane reviews).
Literature searches were updated in October 2006.
A further 245 publications were identified, of
which 26 full papers were retrieved for further
inspection. Of these 26, nine appear relevant and
would be eligible for inclusion in any future
update and their bibliographic details are listed in
Appendix 5 (eight RCTs and one systematic
review).
Tables 5–10 provide a breakdown of the number of
RCTs for each pair-wise comparison by review
question (NB. Numbers do not add up to 67 as
some trials had multiple arms and were common
to more than one comparison).
The 67 RCTs are described in the following
sections in terms of their characteristics and their
results.
Review question 1 – effectiveness of
low-dose ICS
Low-dose corticosteroids are defined as
200–800 µg per day of BDP/BUD or their
equivalent (for FP, CIC and MF, the equivalent
doses are 100–400 µg/day). This is comparable to
Step 2 of the Guideline.
Assessment of clinical effectiveness
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Identified on searching
(after duplicates removed)
n = 5175
Titles and abstracts 
inspected n = 5175
Excluded
n = 4368
Full copies retrieved
n = 807
Papers inspected
n = 807
Included n = 113 papers 
describing 84 studies
Excluded
n = 694
FIGURE 7 Flowchart of identification of published studies for
inclusion in the systematic review of clinical effectiveness
TABLE 5 Breakdown of studies for review question 1 – 
low-dose ICS
Pair-wise comparison No. of RCTs included
BDP and BUD 5
FP and BDP 6
HFA BDP and HFA FP 0
FP and BUD 5
CIC and BDP 0
MF and BDP 0
CIC and BUD 1
MF and BUD 2
CIC and FP 2
MF and FP 1
MF and CIC 0
Total 22
TABLE 7 Breakdown of studies for review question 3a – 
ICS versus ICS + LABA (ICS dose higher when used alone)
Pair-wise comparison No. of RCTs included
FP vs FP/SAL 2
BUD vs FP/SAL 3
BUD vs BUD/FF 4
FP vs BUD/FF 1
Total 10
TABLE 6 Breakdown of studies for review question 2 – 
high-dose ICS
Pair-wise comparison No. of RCTs included
BDP and BUD 2
FP and BDP 10
HFA BDP and HFA FP 1
FP and BUD 6
CIC and BDP 0
MF and BDP 0
CIC and BUD 0
MF and BUD 1
CIC and FP 3
MF and FP 1
MF and CIC 0
Total 24To recap, 22 RCTs evaluated low-dose ICS
(Table 11). The following subsections describe the
characteristics and results of these trials.
BDP and BUD (review Q1 – low-dose ICS)
Study characteristics
Five RCTs evaluated the effectiveness of BUD
compared with BDP, published between 1985 and
2004 (Table 12). Two were parallel designs182,183
and the other three were cross-over studies.184–186
The trials were all small studies, containing less
than 100 patients.
The majority of studies contained two relevant
arms; however, in one study there was more than
one comparison. Rafferty and colleagues184
compared a daily dose of 800 µg/day of BDP with
two different regimens of BUD. The total daily
dose in both BUD regimens was 800 µg per day,
but one group took two puffs daily whereas the
other took four.
There were five comparisons at the same nominal
daily dose ratio of 1:1, from five trials. One trial
was a comparison of total daily doses of
400 µg/day185 and four were comparisons of a total
daily dose of 800 µg/day.182–184,186
The five studies used the same delivery device for
both inhaled steroids. Rafferty and colleagues184
(BDP – brand not specified, GSK; BUD –
Pulmicort, AZ), Dal Negro and colleagues182 (BDP
– Pulvinal, Chiesi Famaceutici; BUD – Pulmicort
Turbuhaler, AZ), Tjwa185 (BDP – Becotide Rotacap
Rotahaler, GSK; BUD – Pulmicort Trubuhaler, AZ)
and Jäger and colleagues186 (BDP – Beclomet
Easyhaler, Ranbaxy; BUD – Pulmicort Turbuhaler,
AZ) all used DPIs for delivery. Parakh and
colleagues183 used MDIs but did not provide any
further details of the devices.
In terms of treatment duration, the trials were
relatively similar in length, ranging from 8 to
12 weeks. Three trials lasted for 8 weeks182,185,186
and one for 12 weeks.183 In the final study, the
length of treatment was described as ‘variable’.184
For the first month of each treatment period,
patients received their normal maintenance dose
of oral prednisolone plus either BDP or BUD.
During the second and subsequent months,
prednisolone was reduced by 1 mg until treatment
with this drug was withdrawn or asthmatic
symptoms ‘broke through’, or when prednisolone
was withdrawn. This was taken as the end-point of
each treatment period.
The age range of patients included in the RCTs,
where reported, varied from 15 to 72 years. Two
studies reported mean ages of approximately
40–50 years182,186 and one trial simply recorded
that patients were aged 18 years or over.185 One of
the trials included patients described as having
‘mild to moderate’ asthma,186 one study included
patients with severe asthma taking oral
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TABLE 8 Breakdown of studies for review question 3b – 
ICS versus ICS + LABA (ICS dose similar in both treatments)
Pair-wise comparison No. of RCTs included
FP vs FP/SAL 6
BUD vs BUD/FF 3
Total 9
TABLE 11 Breakdown of studies for review question 1 – 
low-dose ICS
Pair-wise comparison No. of RCTs included
BDP and BUD 5
FP and BDP 6
HFA BDP and HFA FP 0
FP and BUD 5
CIC and BDP 0
MF and BDP 0
CIC and BUD 1
MF and BUD 2
CIC and FP 2
MF and FP 1
MF and CIC 0
Total 22
TABLE 9 Breakdown of studies for review question 4 –
combination inhaler versus separate inhalers
Pair-wise comparison No. of 
RCTs 
included
FP/SAL (combination) vs BUD + FF (separate) 1
FP/SAL (combination) vs FP + SAL (separate) 3
BUD/FF (combination) vs BUD + FF (separate) 2
Total  6
TABLE 10 Breakdown of studies for review question 5 –
combination inhaler versus combination inhaler
Pair-wise comparison No. of 
RCTs 
included
FP/SAL (combination) vs BUD/FF (combination) 3
Total 3Assessment of clinical effectiveness
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ABLE 12
Characteristics of studies (BDP and BUD)
Study
Design
Intervention
P
atients
Outcomes
Dal Negro et al.,
1999
182
RCT
P
arallel-group
1.
BDP 200 µg q.d.s. (daily total 800
µg)
2.
BUD 200 µg q.d.s. (daily total 800 µg)
Delivery device: 
1.
DPI (Pulvinal, Chiesi Farmaceutici)
2.
DPI (T
urbuhaler
, AZ)
Duration:
8 wks
Run-in period:
2 wks
Number randomised
32
Mean age (years)
1.
42.3
2.
41.6
Baseline FEV
1
% predicted
1.
68.7 ±
14.1
2.
70.6 ±
9.1
P
revious ICS treatment (drug and dose)
BDP MDI at a constant dose 1000 
µg for
previous 8 wks
FEV
1
PEF
FEF
25–75%
MEF
50
Symptom scores
Daily rescue medication use
AEs
P
arakh 
et al.,
2004
183
RCT
P
arallel-group
Single-blind
1.
FP 50
µg 4 puffs b.d. (daily total 400
µg)
2.
BUD 200
µg 2 puffs b.d. (daily total 800
µg)
3.
BDP 200
µg 2 puffs b.d. (daily total 800
µg)
Delivery device:
MDI (no further details on devices reported)
Duration:
12 wks
Run-in period:
2 wks
Number randomised
42
Age range (years)
15–45
Baseline FEV
1
% predicted
Not reported
P
revious ICS treatment (drug and dose)
Not reported
Symptom scores
FVC
FEV
1
FEV
1
/FVC
PEF
Withdrawals
Jäger 
et al., 
2000
186
RCT
Multi-centre
Cross-
over
Open-label
1.
BDP 400
µg b.d. (daily total 800 
µg)
2.
BUD 400
µg b.d. (daily total 800 
µg)
Delivery device:
1.
DPI (Beclomet Easyhaler
, R
anbaxy)
2.
DPI (Pulmicort T
urbuhaler
, AZ)
Duration:
8 wks
Run-in period:
2 wks before randomisation
Number randomised
79
Mean age (years)
1.
51 ±
1
6
2.
50 ±
1
4
Baseline FEV
1
% predicted
1.
75 ±
1
8
2.
78 ±
1
8
P
revious ICS treatment (drug and dose)
Continued treatment with either BDP or
BUD 800–1000 µg/day
P
rimary outcome
Morning PEF
Secondary outcome
FEV
1
(litres)
Evening PEF
FVC
Diurnal variation in PEF
Asthma symptom scores day and night
P
atient-rated treatment efficacy scores
P
atient-rated acceptability of device
Salbutamol 
inhalations per day
Serum cortisol levels 
AEs
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T
ABLE 12
Characteristics of studies (BDP and BUD) (cont’d)
Study
Design
Intervention
P
atients
Outcomes
R
afferty 
et al.,
1985
184
RCT
Cross-
over
Double-blind
1.
BDP 200
µg 1 puff q.d.s. (daily total 800
µg)
+ placebo
2.
BUD 200
µg 2 puffs b.d. (daily total 800
µg)
+ placebo
3.
BUD 200
µg 4 puffs q.d. (daily total 800
µg)
+ placebo
Delivery device:
1.
CFC–pMDI (GSK
a
)
2.
+ 3. CFC–pMDI + Inhalet spacer
(Pulmicort, AZ
a
)
Duration:
V
ariable
Run-in period:
Not reported
Number randomised
40
Age range (years)
23–72
Baseline FEV
1
% predicted
Not reported
P
revious ICS treatment (drug and dose)
5 mg oral prednisolone/day and inhaled BDP
400 
µg daily for at least 9 months
R
eduction in daily prednisolone
(mg/day)
Tjwa, 1995
185
RCT
Cross-
over
1.
BDP 200
µg 1 actuation b.d. (daily total
400
µg)
2.
BUD 200
µg 1 actuation b.d. (daily total
400
µg)
Delivery device:
1.
DPI (Becotide R
otacap, R
otahaler
, GSK)
2.
DPI (Pulmicort T
urbuhaler
, AZ)
Duration:
8 wks
Run-in period:
Not reported
Number randomised
16
Age (years)
>18
Baseline FEV
1
% predicted
40–85
P
revious ICS treatment (drug and dose)
Inhaled steroid 150–800 
µg/day
FEV
1
FVC
Morning PEF
Evening PEF
Daytime wheeze score/daytime
breathlessness score
Daytime cough score
Night-time wheeze score
Night-time breathlessness score
Night-time cough score
Daytime SABA use (puffs/day)
Night-time SABA use (puffs/day)
Bronchial responsiveness to histamine 
(PC20 FEV
1
)
b.d., twice daily; FVC, forced vital capacity; MEF
, maximal expiratory flow; PC20, the provocative concentration of methacholin
e to induce a 20% decline in FEV
1
; q.d., once daily;
q.d.s., four times daily; wk, week.
a 
Not stated explicitly
, but deduced from the text.corticosteroids184 and another study included
patients with ‘moderately severe’ asthma.185 The
other two studies did not comment on
severity,182,183 although one reported a baseline
FEV1 % predicted of around 70%.182 In general, it
appears that the trials were similar in terms of the
severity of the constituent patients.
The studies varied in terms of their aims, and
hence the way in which they assessed effectiveness.
Two studies aimed specifically to compare the
effectiveness of different DPI devices.185,186 One of
these aimed to test the hypothesis that there
would be no statistically significant differences
between the two inhalers,186 although it does not
appear to be an equivalence/non-inferiority trial.
In the other study, it is not explicitly stated
whether the intention was to assess equivalence or
superiority. Rafferty and colleagues184 aimed to
assess the relative efficacy of the same dose of
BUD and BDP in reducing the need for oral
steroids. The purpose of the study by Dal Negro
and colleagues182 was to compare the two steroids
in order to correlate measures of lung function
with serum eosinophil cationic protein. Parakh
and colleagues183 aimed to compare the relative
effectiveness of BUD, BDP and FP in an Indian
patient population [NB. The comparison of FP
and BDP from this study is reported in the section
‘FP and BDP (review Q1 – low-dose ICS)’, p. 34,
and the comparison between FP and BUD is
reported in the section ‘FP and BUD (review Q1 –
low-dose ICS)’, p. 41].
Reported methodological quality was poor. Details
of randomisation methods, whether or not this
was concealed and whether or not intention-to-
treat (ITT) analysis had been performed were
lacking. Only one of the two cross-over studies
reported a wash-out period.185 In the other, no
details were given on any attempts to eliminate
carry-over effects.184
Results
Due to limitations in the data reported by the
trials and differences in study design, meta-
analysis was rarely possible. The results of this
comparison are mostly presented narratively.
Lung function
Four of the RCTs reported measures of lung
function; however, variability in methods of
measurement and reporting meant that meta-
analysis was not always possible.
Parallel 1:1 dose ratio studies. The two parallel 1:1
ratio trials, both comparing 800 µg/day, reported
FEV1 (litres). In the trial by Parakh and
colleagues,183 there was an increase of 0.51 litres
for the BDP group and 0.66 litres for the BUD
group between baseline and end-point (p >0 . 0 5
at end-point). In the trial by Dal Negro and
colleagues,182 there was an increase of 0.48 litres
for BDP and 0.22 litres for BUD between baseline
and end-point. The difference between groups at
end-point was reported as not being statistically
significant but the results in the meta-analysis in
Figure 8 do not confirm this (mean difference
0.55 litres, 95% CI 0.13 to 0.97, p = 0.015).
The end-point values for the two trials were pooled
in a fixed-effects meta-analysis. At end-point there
was a statistically significant difference in favour of
BDP (WMD 0.46, 95% CI 0.11 to 0.82) (Figure 8).
Dal Negro and colleagues182 reported FEV1 %
predicted normal. There was an increase of 13.7%
in the BDP group and 8% in the BUD group
between baseline and end-point (no statistical
significance value reported).
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Review: Corticosteroids – review Q1 – low-dose ICS
Comparison: BDP  and BUD (adults): Parallel 1:1 ratio
Outcome: FEV1 (litres) at end-point
Study
or subcategory
BDP
Mean (SD)
BUD
Mean (SD)
WMD (fixed)
95% CI
Weight
%
WMD (fixed)
95% CI NN
Dal Negro et al. 1999
182  16 2.68  (0.60) 16  2.13  (0.60)
11 2.38  (0.48) 10  2.14  (0.99)
  72.55 0.55 (0.13 to 0.97)
Parakh et al. 2004
183       27.45 0.24 (–0.44 to 0.92)
Total (95% CI) 27                               26 100.00 0.46 (0.11 to 0.82)
Test for heterogeneity: 2 = 0.59, df = 1 (p = 0.44), I2 = 0%
Test for overall effect: Z = 2.57 (p = 0.01)
–1 –0.5 0 0.5 1
Favours BUD Favours BDP
FIGURE 8 FEV1 (litres) at end-point (parallel 1:1 dose ratio studies)Morning and evening PEF were reported by Dal
Negro and colleagues.182 Data have been
estimated from a graph. There was an increase of
70 l/minute for the BDP group and 40 l/minute for
the BUD group in morning PEF. The difference at
end-point between the groups was not statistically
significant (p-value not reported). There was an
increase of 65 l/minute for the BDP group and
35 l/minute for the BUD group in evening PEF.
The difference at end-point between the groups
was not statistically significant (p-value not
reported).
Cross-over 1:1 dose ratio studies. Jäger and
colleagues186 reported no significant differences
between treatments in FEV1 (litres), and
morning/evening PEF.
Tjwa185 reported changes in FEV1 % predicted
during the course of treatment. Increases were
observed in both groups but the difference was not
statistically significant (p = 0.86). Also reported
are mean values for PEF during the second month
of treatment. The mean between group difference
in morning PEF was 17 l/minute (95% CI 2 to
32 l/minute, p < 0.05), in favour of BUD. For
evening PEF the mean difference was 13 l/minute
(95% CI –0.3 to 27 l/minute, p = 0.054), in favour
of BUD.
Rafferty and colleagues184 reported that there
were no significant differences between treatments
for mean morning or evening PEF during the last
month of adequate control (no p-values given). 
For morning PEF, end-point values were 215.7 
(SD 110.0) l/minute and 203.7 (SD 107) l/minute
for BDP and BUD, respectively. For evening PEF,
corresponding values were 238.2 (SD 109.26) and
232.7 (SD 108.3) l/minute.
Symptoms
Parallel 1:1 dose ratio studies. Both of the parallel
1:1 ratio studies reported symptom scores, albeit
using different scoring methods. Dal Negro and
colleagues182 measured five different symptoms on
a four-point rating scale (where 0 = none, 
3 = severe, no reference supplied) and produced
an overall summary score. There was a reduction
of 3.1 points in the BDP group, compared with a
reduction of 2 points in the BUD group. There
was no significant difference between groups in
scores at end-point (no statistical significance value
reported).
Parakh and colleagues183 measured symptoms but
do not provide details of the scoring system used.
Reductions in scores were 34.8 and 34.1 in the
BDP and BUD groups respectively (the between-
group difference was not statistically significant,
p > 0.05).
Cross-over 1:1 dose ratio studies. Jäger and
colleagues186 measured day- and night-time
symptoms using a four-point rating scale (0 = no
symptoms; 3 = severe symptoms, no reference
supplied). Scores for individual items were
summed and were presented as mean percentage
of maximum symptom scores. Scores decreased for
both treatments, but with no significant difference
between them (p-value reported).
Tjwa185 measured symptoms using a scoring
system that appears similar to that used by Jäger
and colleagues.186 Scores are presented for
individual symptoms, but an overall summary
score is not presented.
Rafferty and colleagues184 reported that there
were no significant differences between treatments
for symptom scores during the last month of
adequate control (no p-values given). End-point
scores were 9.66 (SD 10.44) and 11.48 (SD 11.1) in
the BDP and BUD groups, respectively. No details
are provided on the scoring system used other
than that patients used a visual analogue scale
labelled ‘no symptoms’ at one end and ‘severe
symptoms’ at the other.
Health-related quality of life
None of the trials reported this outcome.
Use of rescue medication
Parallel 1:1 dose ratio studies. Dal Negro and
colleagues182 reported changes in use of
salbutamol, which reviewers have estimated from a
graph. There was a reduction of 1.6 and 0.7 puffs
per day in the BDP and BUD groups, respectively,
between baseline and end-point. The difference
between groups at end-point was not statistically
significant (no p-value reported).
Cross-over 1:1 dose ratio studies. The mean
number of daily salbutamol inhalations per day
was described as ‘comparable’ between the two
treatments in the study by Jäger and colleagues.186
No statistically significant differences in day- or
night-time use of SABAs were reported in the
study by Tjwa.185
Exacerbations
Dal Negro and colleagues182 reported a reduction
in 24-hour bronchospasm attacks of 0.8 and 0.3 in
the BDP and BUD groups, respectively, from
baseline to end-point. Differences between groups
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of the other studies reported exacerbations.
Adverse events
Parallel 1:1 dose ratio studies. No ‘adverse
reactions’ were reported by Dal Negro and
colleagues.182 Negligible increases in morning
serum cortisol were reported in both groups: 0.5
and 1 µg/100 ml in the BDP and BUD groups,
respectively. Parakh and colleagues183 did not
report safety as an outcome.
Cross-over 1:1 dose ratio studies. Jäger and
colleagues186 reported three AEs (4%), two with
BDP and one with BUD. Treatment was reported
to have no effect on morning serum cortisol levels.
Safety was not reported in the trials by Tjwa185
and Rafferty and colleagues.184
Summary
Five RCTs of varying size and design compared
BDP with BUD at ‘low’ doses in patients
predominantly with mild to moderate asthma.
They compared similar doses of the two drugs,
ranging from 400 to 800 µg/day. There were few
statistically significant differences between the
drugs across the outcome measures.
FP and BDP (review Q1 – low-dose ICS)
Study characteristics
Six RCTs, published between 1999 and 2004,
evaluated the effectiveness of BDP compared with
FP (Table 13). All six studies were parallel designs,
and ranged in size from a single-centre study with
20 patients to a multi-centre trial with 399 patients.
Three of the studies contained two arms,187–189 in
which one regimen of BDP was compared with one
regimen of FP. One study contained three arms, in
which FP was compared with BDP and BUD183
[this study is also referred to in the sections ‘BDP
and BUD (review Q1 – low-dose ICS)’, p. 29 and,
‘FP and BUD (review Q1 – low-dose ICS)’, p. 41].
The remaining two studies each contained four
arms.190,191 However, in one of these,191 only two
of the arms are relevant to this particular section
as they evaluated low doses of BDP and FP [the
other two arms evaluated high-doses and are
reported in the section ‘FP and BUD (review Q2 –
high-dose ICS)’, p. 67]. The remaining study190
can be divided into two separate two-arm
comparisons of BDP against FP, each with a dose
ratio approximating 1:2 (Table 13).
In all six studies, comparisons of FP against BDP
were at, or approximated, a nominal daily dose
ratio of 1:2. The total daily doses of FP:BDP that
were compared were 200:400 µg (two
studies187,190), 250:400 µg (one study188),
400:800 µg (three studies183,190,191), 500:800 µg
(one study190) and 750–1500 µg (one study191). A
study by Szefler and colleagues189 did not compare
a single daily dose of each drug but instead
compared sequentially increasing doses of FP with
sequentially increasing doses of BDP, at a 1:2 dose
ratio, over an 18-week period (100:200 µg in
weeks 1–6, 400:800 µg in weeks 6–12 and
800:1600 µg in weeks 12–18).
All studies employed the same delivery device for
both the inhaled steroids. This was an MDI
(Raphael and colleagues, FP – Flovent Inhalation
aerosol, BDP – Flovent Inhalation Aerosol and
Beclovent Inhalation Aerosol, all GSK;190 Szefler
and colleagues, FP – Flovent CFC, GSK, and BDP
– Vanceril CFD, Schering-Plough;189 Ige and
colleagues, FP – Fluvent, BDP – Becotide, both
GSK,188 no further details of devices were given by
Parakh and colleagues183 or Prasad and
colleagues187) or an MDI with spacer (no details
about devices are reported by Medici and
colleagues191) (Table 13).
The duration of the treatments in most of the
studies was relatively short, being 6 weeks (the low-
dose comparison of Szefler and colleagues189),
8 weeks (by Ige and Sogaolu188) or 12 weeks (by
Parakh and colleagues,183 Prasad and colleagues,187
Raphael and colleagues190). An exception is the 
12-month study by Medici and colleagues.191
The age of patients included in the RCTs ranged
from 12 to 83 years. The mean age was reported
in five of the studies, and ranged between 28 and
40 years. Two studies mentioned that baseline
asthma severity was mild to moderate.188,191 The
severity of asthma was not mentioned in the
remaining studies, but in two of the studies it can
be inferred from the reported baseline percentage
of predicted FEV1 as being moderate189 or
moderate to severe.190
In four of the studies the primary aim was to
compare the efficacy of FP against that of
BDP183,187,188,190 at a dose ratio of (or
approximating) 1:2. One study was described by
the authors as “a feasibility study rather than a
comparative trial” (Szefler and colleagues,189
p. 411), with the objective of comparing the
relative beneficial and systematic effects for two
ICS in a dose–response relationship. The
remaining study191 aimed primarily to investigate
effects of FP and BDP on bone mass and
metabolism. None of the efficacy studies specified
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T
ABLE 13
Characteristics of studies (FP and BDP)
Study
Design
Intervention
P
atients
Outcomes
P
arakh 
et al.,
2004
183
RCT
P
arallel-group
Single-blind
Drug(s):
1.
FP 50
µg 4 puffs b.d. (daily total 400
µg)
2.
BUD 200
µg 2 puffs b.d. (daily total 800
µg)
3.
BDP 200
µg 2 puffs b.d. (daily total 800
µg)
Delivery device:
1, 2, 3. MDI (no further details on devices reported)
Duration:
12 wks
Run-in period:
2 wks
Number randomised
42
Age range (years)
15–45 (stated that age did not differ
significantly between treatment groups)
Baseline FEV
1
% predicted
Not reported
P
revious ICS treatment (drug and dose)
Not reported
Symptoms
FEV
1
PEF
FVC
Withdrawals
P
rasad 
et al.,
2004
187
RCT
P
arallel-group
Double-blind
Drug(s): 
1.
FP 50
µg 2 puffs b.d. (daily total 200
µg)
2.
BDP 100
µg 2 puffs b.d. (daily total 400 µg)
Delivery device:
1, 2. MDI (no further details about devices reported)
Duration:
12 wks
Run-in period:
Not reported
Number randomised
74
Mean age (years) (range)
1, 2. 28 (12–60)
Baseline FEV
1
% predicted
<80
P
revious ICS treatment (drug and dose)
Not reported directly but inferred from
symptom scores that patients would have
needed 400 µg/day BDP at time of enrolment
FEV
1
PEF
FEV
1
/FVC
Symptoms
R
aphael 
et al.,
1999
190
RCT
Multi-centre
P
arallel-group
Double-blind
Drug(s): 
1.
FP 44
µg 2 puffs b.d. (daily total 200
µg 
ex
valve)
2.
FP 110
µg 2 puffs b.d. (daily total 500
µg 
ex
valve)
3.
BDP 42
µg 4 puffs b.d. (daily total 400
µg 
ex
valve)
4.
BDP 42
µg 8 puffs b.d. (daily total 800
µg 
ex
valve)
Delivery device: 
1, 2. MDI (Flovent Inhalation Aerosol, GSK)
3. MDI (Inhalation Aerosol, GSK)
4. MDI (Beclovent Inhalation Aerosol, GSK)
Duration:
12 wks
Run-in period:
2 wks
Number randomised
399
Mean age (years) (±
SD, range)
1.
38.4 (±
1.4, 13–70)
2.
37.8 (±
1.3, 13–72)
3.
41.5 (±
1.5, 13–83)
4.
39.8 (±
1.7, 12–72)
Baseline FEV
1
% predicted
46–65
P
revious ICS treatment (drug and dose)
8–12 puffs/day of BDP or triamcinolone
acetomide for at least 1
month prior to
enrolment
FEV
1
FEF
25–75%
FVC
Morning and evening PEF 
SABA use
Daily asthma symptom score
% days with no rescue SABA use
% days with no symptoms 
Asthma exacerbations 
AEs
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T
ABLE 13
Characteristics of studies (FP and BDP) (cont’d)
Study
Design
Intervention
P
atients
Outcomes
Szefler 
et al.,
2002
189
RCT
Multi-centre
P
arallel-group
Open-label
Drug(s): 
1.
FP serially increased doses: 88 
→
704
µg q.d.
(daily total 100 
→
800
µg 
ex
valve)
2.
BDP serially increased doses: 168 →
1344
µg q.d.
(daily total 200 
→
1600
µg 
ex
valve)
Delivery device:
1.
MDI + spacer (Flovent CFC, GSK)
2.
MDI + spacer (V
anceril CFC, Schering-Plough)
Duration:
21 wks (dose escalation every 6 wks)
Run-in period:
3 wks
Number randomised
30
Mean age (years) (±
SD)
1.
29.58 (±
7.21)
2.
30.27 (±
7.64) (range 18–55)
Mean baseline FEV
1
% predicted (±
SD)
1.
75.07 (±
11.16)
2.
73.33 (±
11.08)
P
revious ICS treatment (drug and dose)
No use of ICS within 6 months before
enrolment
Cortisol
FEV
1
Methacholine PC20
Exhaled nitric oxide
Exercise max. absolute fall in 
FEV
1
Exercise fall in area under curve 
(explanation not given)
Sputum eosinophilis +0.2 (%)
Neutrophilis (%)
Eosinophilic cationic protein
Symptoms
R
escue medication usage
Ige and Sogaolu,
2002
188
RCT
Single-centre
P
arallel-group
Open-label
Drug(s): 
1.
FP 220 µg/day (daily total 250 
µg
ex
valve)
2.
BDP 400 µg/day
Delivery device: 
1.
pMDI (Fluvent, GSK
a
)
2.
pMDI (Becotide, GSK)
Duration:
8 wks
Run-in period:
1 wk
Number randomised
20
Mean age (years) (±
SD, range)
1.
36.00 (±
15.46, 16–56)
2.
29.30 (±
15.20, 16–61)
Baseline FEV
1
% predicted
1.
83.5 (SD 13.37)
2.
76.8 (SD 8.55)
P
revious ICS treatment (drug and dose)
400 
µg SABA for 1 wk screening
FEV
1
PEF
Symptoms
R
escue medication usage
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T
ABLE 13
Characteristics of studies (FP and BDP) (cont’d)
Study
Design
Intervention
P
atients
Outcomes
Medici 
et al.,
2000
191
RCT
P
arallel-group
Double-blind
Drug(s): 
1.
FP 200
µg b.d. (daily total 400
µg)
2.
BDP 400
µg b.d. (daily total 800
µg) 
3.
FP 375
µg b.d. (daily total 750
µg)
4.
BDP 750
µg b.d. (daily total 1500
µg)
Only groups 1 and 2 reported in this section
Delivery device: 
1, 2, 3, 4. MDI + spacer (no other details about
devices reported)
Duration:
12 months
Run-in period:
4 wks
Number randomised
69
Mean age (years) (±
SD)
1.
39 (±
8)
2.
38 (±
8)
3.
38 (±
10)
4.
40 (±
10) 
(range 20–55 across all groups)
Baseline FEV
1
% predicted
Mean baseline % predicted PEF
: 78.4–97.8
across groups
P
revious ICS treatment (drug and dose)
BDP 800
µg q.d. or 1500
µg q.d. depending
on the dose of ICS use prior to entry
P
rimary outcome
BMD of the distal radius
Secondary outcomes
Cortisol
Biochemical markers of bone
metabolism
Lung function: PEF and FEV
1
AEs
FEF
, forced expiratory flow
.
a 
Not stated explicitly
, but deduced from the text.a null hypothesis in terms of equivalence or
superiority. Reasons for carrying out the efficacy
studies included an identified need to compare
simultaneously FP, BUD and BDP in the same
trial,183 extending knowledge of effects of FP in
Nigeria188 and India,187 and a need for
simultaneous testing of FP and BDP at a range of
doses commonly used to treat asthma.190
The reported methodological quality was generally
inadequate. Details of randomisation and allocation
concealment procedures were not always reported.
Results
Parallel 1:2 dose ratio studies
All outcomes reported here for comparisons
between FP and BDP refer to parallel 1:2 dose
ratio studies. The study by Szefler and
colleagues189 involved three periods with
incrementally increasing doses (6 weeks each of
100:200, 400:800 and 800:1600 µg FP:BDP).
However, only the 100:200 µg comparison is
reported here because the later comparisons (7–12
and 13–18 weeks) are not independent of the drug
use in the preceding weeks.
Lung function
Five of the studies provided quantitative data on
lung function. However, these data are not
appropriate for meta-analysis because either there
is only one study per outcome (e.g. for FEV1 %
predicted187), or the doses are not strictly
comparable across the studies. For example,
although three studies reported the change in
FEV1 at a nominal dose ratio of (approximately)
1:2 (FP:BDP), each study involved different 
actual doses (100:200 µg,189 250:400 µg188 or
400:800 µg183).
FEV1 at end-point. In the three comparisons of
FEV1 at end-point for FP and BDP, FEV1 was
consistently higher in FP-treated than in BDP-
treated patients, with the difference decreasing
with increasing dose (Table 14). However, these
differences were either not tested statistically189 or
were reported in the primary studies as not
statistically significant.183,188
Change in FEV1 from baseline to end-point. The
change in FEV1 from baseline to end-point was
compared for FP and BDP in five cases. The
increase in FEV1 was consistently larger for
patients in the FP group (Table 15). However,
statistical significance cannot be ascertained for
the individual comparisons because SDs are
reported only for the start (baseline) and end-
point in three of comparisons.183,188,189 In the
remaining two comparisons, an overall test of the
difference between the drugs was carried out for
two dose regimes combined (200:400 µg/day and
500:800 µg/day, FP:BDP)190 (Table 15). For the
combined comparison, the difference between
drugs was statistically significant (p = 0.006).190
Change in FEV1 % predicted. Only one study, by
Prasad and colleagues,187 reported a quantitative
comparison between FP and BDP of the change in
the FEV1 % predicted from baseline to end-point.
The FEV1 % predicted increased in both patient
groups by approximately 35%, and the difference
was not significant (mean ± SD FP 34.70 ± 4.15;
BDP 36.94 ± 6.31; unpaired t-test, p > 0.05).
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TABLE 14 FEV1 at end-point for FP and BDP at a nominal dose ratio approximating 1:2
FP:BDP doses (g/day) Mean ± SD FEV1 for FP (litres)  Mean ± SD FEV1 for BDP (litres) Ref.
100:200 3.40 ± 0.61 3.28 ± 0.68 189
250:400 3.06 ± 0.35 2.10 ± 0.41 188
400:800 2.395 ± 0.771 2.389 ± 0.488 183
TABLE 15 Change from baseline in FEV1 at end-point for FP and BDP at a nominal dose ratio approximating 1:2 
FP:BDP doses (g/day) Mean ± SD change in FEV1 Mean ± SD change in FEV1 Ref.
for FP (litres)  for BDP (litres) 
100:200 0.36 (n = 15) 0.27 (n = 15) 189
200:400 0.31 ± 0.50 (n = 99) 0.18 ± 0.41 (n = 104) 190
250:400 0.85 (n = 10) –0.13 (n = 10) 188
400:800 0.53 (n = 11) 0.52 (n = 11) 183
500:800 0.36 ± 0.50 (n = 101) 0.21 ± 0.49 (n = 95) 190Change in morning PEF. Only one study, by
Raphael and colleagues,190 quantitatively reported
the change in morning PEF from baseline to end-
point. As mentioned above, Raphael and
colleagues190 compared the effects of two doses
each of FP and BDP in a two-arm study (200:400
and 500:800 µg/day FP:BDP). The mean ± SD of
the change in morning PEF for these dose
regimens were, respectively, 15.8 ± 50.0:0.7 ±
42.0 and 22.8 ± 42.2:7.2 ± 41.0 l/minute. For
both dose regimens the change in morning PEF is
clearly higher in patients treated with FP. The
primary study reports a significant overall
difference in effects between the drugs (ANOVA
excluding dose as a factor p  0.001); a separate
analysis of treatment effects for each dose regimen
is not reported.
Change in evening PEF. As with the change in
morning PEF, the study by Raphael and
colleagues190 was the only one that quantitatively
evaluated effects of FP and BDP on the change in
evening PEF. The mean ± SD of the change in
evening PEF is FP 7.8 ± 44.0:BDP 2.10 ±
47.0 l/minute for the lower dose regimen and 
FP 14.2 ± 38.0:BDP 9.7 ± 36.0 l/minute for the
higher dose regimen. For both dose regimens the
change in evening PEF is higher in patients
treated with FP. Overall, this difference between
treatments (excluding the effects of dose) is
significant [analysis of variance (ANOVA)
excluding dose as a factor, p = 0.06].
Symptoms
Change in percentage of symptom-free days. The
change from baseline to end-point in the
percentage of symptom-free days was reported
quantitatively only by Raphael and colleagues.190
As with the morning and evening PEF,
comparisons are available for two dose regimens
of each treatment (the details of these are given
above). The mean ± SD change in percentage of
symptom-free days is 14.0 ± 32.0 FP and 
4.9 ± 33.0 BDP for the lower-dose regimen and
8.7 ± 28.0 FP and 4.4 ± 29.0 BDP for the higher
dose regimen. For both dose regimens the largest
improvement of symptom scores was in FP-treated
patients. The overall treatment effect (excluding
the effects of dose) was significant (ANOVA
excluding dose as a factor, p = 0.027).
Change in symptom scores. The change from
baseline to end-point in symptom scores was
reported at two dose regimens of each inhaled
steroid (referred to as relatively ‘low’ and ‘high’, as
described above) by Raphael and colleagues.190 In
another study with a single-dose regimen, Parakh
and colleagues183 provided baseline and final
symptom scores but did not include a relevant
estimate of the variance (Table 16). In the study by
Raphael and colleagues,190 the decrease in
symptom scores was largest for FP-treated patients
whereas in the study by Parakh and colleagues,183
the largest decrease in symptom scores was for
BDP-treated patients (Table 16). Overall, for both
dose regimens combined, the change in symptom
scores reported by Raphael and colleagues was
statistically significant (p = 0.024).190 However, in
the study by Parakh and colleagues, the difference
between drugs cannot be tested statistically.183
Nocturnal awakening. Three studies provide
quantitative data on the effects of FP and BDP on
nocturnal awakening. However, meta-analysis is
not possible for these studies as the time units
were either not stated (by Raphael and
colleagues190) or differed between studies (Ige and
Sogaolu188 reported sleep disturbances per month,
whereas Prasad and colleagues187 reported night-
time awakening per week).
Raphael and colleagues190 reported that there was
no significant difference between the FP and BDP
patient groups in the change in nocturnal
awakenings from baseline to end-point (12 weeks)
(p = 0.458). These data are for overall comparisons
of FP to BDP; they do not distinguish the separate
lower and higher dose comparisons that were
included within the study (200–400 and
500–800 µg/day; details are given above).
Ige and Sogaolu188 reported that the percentage
reduction in the frequency of weekly night-time
awakening was significantly higher for FP than
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TABLE 16 Change in symptom scores for FP and BDP at a nominal dose ratio approximating 1:2
FP:BDP doses  Mean ± SD change in symptom score  Mean ± SD change in symptom score  Ref.
(g/day) for FP for BDP 
200:400 –0.24 ± 0.70 (n = 99) –0.05 ± 0.61 (n = 104) 190
400:800 –30.2 (n = 11) –38.4 (n = 11) 183
500:800 –0.26 ± 0.60 (n = 101) –0.15 ± 0.58 (n = 95) 190BDP, although it is not clear to which time periods
the statistics presented refer. The mean ± SD of
the weekly frequency of night-time awakening at
end-point (8 weeks) was 0.1 ± 0.32 for FP and
3.5 ± 1.27 for BDP.
Data reported by Prasad and colleagues187 on the
change in frequency of sleep disturbance per month
for FP and BDP patient groups are difficult to
interpret due to ambiguity of the data description
(the tabulated data appear to show an increase in
awakening frequency from baseline whereas the text
describes a decrease). However, Prasad and
colleagues report that the change in sleep
disturbance per month did not differ significantly
between FP and BDP patient groups (p > 0.05).
Use of rescue medication
Change in use of rescue medication. One study, by
Raphael and colleagues,190 quantitatively reported
the change from baseline to the end of the study in
the use of rescue medication. As described above,
Raphael and colleagues190 compared two dose
regimens each of FP and BDP. The mean ± SD
change in use of rescue medication (puffs per day)
is –0.9 ± 2.0 FP and 0.0 ± 2.0 BDP for the lower
dose regimen and –0.5 ± 2.0 FP and –0.3 ± 2.0
BDP for the higher dose regimen. For both dose
regimens the largest improvement (reduction in
use of rescue medication) was in FP-treated
patients. The overall treatment effect (excluding
the effects of dose) was significant (ANOVA
excluding dose as a factor, p = 0.004).
Exacerbations
Of the six studies, four did not comment on
asthma exacerbations. In the study by Prasad and
colleagues,187 the mean number of exacerbations
per month did not differ significantly between the
drug treatments (p > 0.05). The mean ± SD
reduction in number of exacerbations per month
was 18.13 ± 1.85 for FP and 17.35 ± 2.00 for BDP.
These numbers appear high, probably reflecting a
broad definition of exacerbations (no definition is
provided in the paper). Medici and colleagues191
also reported that the rate of exacerbations did not
differ significantly between the FP and BDP
treatments; they noted that one patient receiving
the BDP 800 µg/day treatment required a short
course of corticosteroids due to an asthma
exacerbation. However, Medici and colleagues191
did not define the rate of exacerbations or provide
statistics for the comparison.
Adverse events
Three of the six studies reported the presence or
lack of adverse events due to one or both of the
drug treatments. Of these, Szefler and
colleagues189 provided plasma cortisol estimates
for FP and BDP and commented that overnight
plasma cortisol was suppressed in a dose-
dependent manner for all patients. Szefler and
colleagues also provided quantitative data on
plasma cortisol but these are difficult to interpret
as the outcome units are not specified and the
measures of variance (SD or coefficient of
variation) are not clearly identifiable.
Raphael and colleagues190 reported that three
patients from each treatment group were
withdrawn due to symptoms possibly related to the
use of study medication (headache, insomnia,
jitters, tachycardia, oedema, muscle pain, fatigue,
light-headedness, rash or hoarseness). They also
reported that, overall (combining both the
relatively low- and high-dose comparisons; details
are given above), there were no significant
differences between FP and BDP in the incidence
of AEs potentially related to the study treatment
(range 9–15%, p = 0.664).
In the remaining study, Medici and colleagues191
noted that AEs were reported by a similar number
of patients in the FP and BDP groups, with no
withdrawals having been due to AEs. The
geometric mean of the morning serum cortisol
concentration (in nmol/l) estimated by Medici and
colleagues191 remained within the normal range
for both FP- and BDP-treated patients throughout
the 12-month study period.
The authors also provided a detailed evaluation of
the impact of FP and BDP on BMD (in g/cm3) and
other bone metabolism markers. They reported
median changes from baseline in trabecular,
integral and compact BMD measurements for
both the radius and tibia (i.e. six outcomes).
Changes in these six outcomes at either 6 or
12 months from baseline did not differ
significantly between FP- and BDP-treated patients
(p > 0.05 in all cases; Wilcoxon rank-sum test).
Changes from baseline in the BMD of the lumbar
spine also did not differ between FP and BDP at
6 months (p > 0.05). However, changes in lumbar
bone mineral density at 12 months were
significantly different, with a net increase in FP-
treated patients (median 0.020 with quartile range
–0.005 to 0.033 g/cm3) but a decrease in BDP-
treated patients (median –0.003 with quartile
range –0.016 to 0.009 g/cm3).
Medici and colleagues191 also reported a statistically
significant change from baseline at 12 months in
another bone metabolism marker, osteocalcin
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bone formation activity is lower in patients taking
800 µg/day BDP than in patients taking 400 µg/day
FP (p = 0.047). However, absolute concentrations
and percentage changes from baseline suggest that
the difference would not be clinically significant.191
Summary
Six RCTs of varying size and design compared
low-dose FP with BDP. In almost all cases, the
measured outcomes for lung function either
favour treatment with FP over treatment with BDP
or indicate no difference between the drugs. In
most cases the differences cannot be tested
statistically but where differences were statistically
significant the changes in morning PEF and
evening PEF and the change in FEV1 from
baseline to end-point each favour FP.
Changes in symptom scores and symptom-free
days generally favour the use of FP over BDP. An
exception is that Parakh and colleagues183 found a
greater improvement in symptom scores under
treatment with BDP; however, the results are not
analysable statistically. The incidence of nocturnal
awakening was either reduced more by FP than by
BDP, or showed no difference between the drugs.
The use of rescue medication was reduced to the
largest extent in FP-treated patients.
In the cases where exacerbations were recorded,
the incidence did not differ between FP and BDP
patient groups. In general, there were no
differences in AEs between patients treated with
FP and those treated with BDP. However, an
exception is for the baseline to end-point change
in lumbar bone mineral density, which at 12 weeks
had increased in the FP patient group but
decreased in the BDP patient group.
FP and BUD (review Q1 – low-dose ICS)
Study characteristics
Five parallel group RCTs183,192–195 evaluated the
effectiveness of BUD compared with FP, published
between 1994 and 2004 (Table 17). Four studies
were multi-centre studies where the study sample
sizes ranged between 157 and 281 participants,
whereas the fifth study was a single-centre study
where the sample size was 42.183 No power
calculation was undertaken for this latter study;
however, adequate power calculations were made
for the other four studies.
All five included studies had two-arm comparisons
of BUD versus FP, although one study183 also had
a third intervention arm of BDP and this arm is
therefore not reported here.
One trial192 stratified patients into two groups to
compare BUD and FP (low-dose 400 µg/day, high
dose 800 µg/day) to ensure there were equal
numbers of high- and low-dose patients in each of
the two treatment groups details (not stated
explicitly, but deduced from the text: FP –
Flixotide Diskhaler, no further details reported;
BUD – Pulmicort Turbohaler, AZ). However, the
dose ratio between the two randomised groups was
reported to be equal.
Four trials compared FP and BUD at a dose ratio
of 1:2. Two trials compared 200 µg/day of FP with
400 µg/day of BUD (no further details on devices
were reported by Langdon and Thompson194 and
only the details for FP – Becodisks Diskhaler,
Allen and Hanburys, could be deduced from the
paper by Connolly195) and two trials compared
400 µg/day of FP with 800 µg/day of BUD183,193
(no further details were reported about devices in
either study).
The devices used in three studies were DPIs
(Diskhaler for the FP groups and Turbohaler for
BUD),192,193,195 whereas the devices were MDIs for
both intervention groups in the other two
trials.183,194
The treatment duration was similar between the
included trials, ranging between 8 weeks in four
studies and 12 weeks in one study.
The aims of the trials were largely similar. The one
trial using equal doses of the two comparator
drugs used an alternative methodology of
reducing the standing doses in symptomatic
patients to compare efficacy. The authors argued
that dose reduction will result in a decrease in
lung function unless the steroid which is used has
greater potency. The trials using a 1:2 ratio of FP
to BUD were aiming to compare efficacy to see if a
potency ratio exists, and in the case of the two
trials using DPIs to see if this exists using these
devices. None of these studies described
themselves as equivalence trials and in those
where a power analysis was undertaken this was to
detect a difference between groups. However,
these trials did report that they were assuming
similar efficacy between the higher dose BUD and
lower dose FP. Parakh and colleagues’ trial also
aimed to compare simultaneously three
corticosteroids in an adult Indian population.183
The ages of participants in four trials are likely to
be similar. Three trials report age ranges of
18–70 years192,193,195 and one trial reports a mean
age of approximately 47 years.194 The other
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ABLE 17
Characteristics of studies (FP and BUD)
Study
Design
Intervention
P
atients
Outcomes
Basran 
et al.,
1997
192
RCT
Multi-centre
P
arallel-group
Open-label
Drug(s):
1.
FP 100 or 200
µg b.d. (daily total 200 or 400
µg)
2.
BUD 100 or 200
µg b.d. (daily total 200 or 400
µg)
Delivery device:
1.
DPI Diskhaler (Flixotide, no manufacturer reported
a
)
2.
DPI (Pulmicort T
urbuhaler
, AZ)
Duration:
8 wks
Run-in period:
2 wks
Number randomised
176
Age range (years)
18–60 
Baseline FEV
1
% predicted
>40
P
revious ICS treatment
Either BUD or FP at either 400 or 800
µg
FEV
1
FVC
Morning and evening PEF
Diurnal variation in PEF
Day
- and night-time asthma
symptom score
Day
- and night-time SABA use
Langdon and
Capsey
, 1994
193
RCT
Multi-centre
P
arallel-group
Open-label
Drug(s):
1.
FP 200
µg b.d. (daily total 400
µg)
2.
BUD 400
µg b.d. (daily total 800
µg)
Delivery device:
1.
DPI Diskhaler (Flixotide, GSK
a
)
2.
R
eservoir DPI (no further details about device reported)
Duration:
8 wks
Run-in period:
2 wks
Number randomised
281
Mean age (range) (years)
1.
39 (18–68) 
2.
41 (18–68)
Baseline FEV
1
% predicted
>50
P
revious ICS treatment
No previous ICS treatment or either BUD or
BDP up to 600
µg
Morning and evening PEF
Diurnal variation in PEF
Daily asthma symptom score
Day
- and night-time rescue 
SABA use
P
atient-assessed degree of 
asthma control
Physician-assessed success of 
treatment
Morning plasma cortisol
Langdon and
Thompson,
1994
194
RCT
Multi-centre
P
arallel-group
Open-label
Drug(s): 
1.
FP 50
µg 2 puffs b.d. (daily total 200
µg)
2.
BUD 200 b.d. (daily total 400
µg)
Delivery device: 
1, 2. MDI (no further details about devices reported) 
Duration:
8 wks
Run-in period:
2 wks
Number randomised
157
Mean (±
SD) age (years)
1. 47.6 (±
15.2) 
2. 46.2 (±
17.4) 
Baseline FEV
1
% predicted
>50
P
revious ICS treatment 
Mild to moderate asthma – BDP or BUD no
dose reported
FEV
1
FVC
Clinic PEF
Morning PEF
Evening PEF
Daily asthma symptom score
Daytime rescue SABA use
Night-time rescue SABA use
Morning plasma cortisol
P
atient-assessed degree of 
asthma control
Physician-assessed success of 
treatment
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ABLE 17
Characteristics of studies (FP and BUD) (cont’d)
Study
Design
Intervention
P
atients
Outcomes
Connolly
,
1995
195
RCT
Multi-centre
P
arallel-group
Open-label
Drug(s): 
1.
FP 100
µg b.d. (daily total 200
µg)
2.
BUD 200
µg b.d. (daily total 400
µg)
Delivery device: 
1.
DPI Diskhaler (Becodisk Diskhaler
, Allen and
Hanburys
a
)
2.
R
eservoir DPI (no further details about devices
reported) 
Duration:
8 wks
Run-in period:
2 wks
Number randomised
190
Age range (years)
18–70 
Baseline FEV
1
% predicted
>50
P
revious ICS treatment
BDP or BUD with a range of doses
Change in morning PEF 
Change in diurnal variation in
PEF 
% symptom-free days
% symptom-free nights
% rescue SABA
-free days
% rescue SABA
-free nights
Physician-assessed level of
overall asthma control
P
atient-assessed level of overall 
asthma control
Morning plasma cortisol
P
arakh 
et al.,
2004
183
RCT
Single-centre
P
arallel-group
Single-blind
Drug(s): 
1.
FP 50
µg 4 puffs b.d. (daily total 400
µg)
2. BUD 200
µg 2 puffs b.d. (daily total 800
µg)
3. BDP 200
µg 2 puffs b.d. (daily total 800
µg)
Delivery device:
1, 2, 3. MDI (no details about devices reported) 
Duration:
12 wks
Run-in period:
2 wks
Number randomised
42
Age range (years)
15–45 
Baseline FEV
1
% predicted
Not reported
P
revious ICS treatment (drug and dose)
Not reported
Symptoms
FEV
1
PEF
FVC
Withdrawals
a 
Not stated explicitly
, but deduced from the text.trial183 included a slightly younger group of
patients (range 18–45 years). The severity of
asthma was similarly mild to moderate across the
included trials and four trials explicitly required
patients to be symptomatic/inadequately
controlled. In the trial by Basran and colleagues192
all patients were already on higher doses of ICS,
whereas in the remaining trials some of the
patients were steroid-naïve and others were taking
ICS. Baseline FEV1 % predicted was reported in
four of the included trials to be either >40 or
>50. The fifth trial183 did not report baseline
FEV1 % predicted.
The quality of the included trials was generally
adequate. The method of randomisation was
described and appropriate in all trials except that
by Parakh and colleagues,183 which did not report
the method used. In two trials the allocation
concealment used a central coding of
randomisation schedules,192,194 but in the
remainder the method of allocation was unclear.
ITT analysis was reported to be undertaken in all
but two trials.183,193 These factors reduce the
possibility of selection biases and measurement
biases, respectively.
Results
Lung function
Parallel design, 1:1 dose ratio. Basran and
colleagues192 reported values for baseline and end-
point FEV1 (litres) for BUD and FP groups,
respectively, but did not present a change value.
These values are not presented with an estimate of
variance and therefore do not allow change from
baseline results to be estimated. They did,
however, report a p-value of the difference
between the treatment groups in the change from
baseline and this was not statistically significant
(p = 0.22).
For morning and evening PEF (litres per month),
Basran and colleagues192 again only reported
values at baseline and at end-point for the two
comparison groups, but the p-value is of the
difference between the treatment groups in the
change from baseline. There was no statistically
significant difference in the change from baseline
scores for the two groups for either morning or
evening PEF (p = 0.35 and 0.69, respectively).
Parallel design, 1:2 dose ratio. In the two trials
reporting a dose ratio of 1:2 with FP at 200 µg/day
and BUD at 400 µg/day, only Langdon and
Thompson194 reported data on FEV1 (litres).
Change from baseline in the FP group was 0.07
(SD 0.34) and in the BUD group 0.81 (SD 0.44),
but this was reported not to be statistically
significantly different between the two groups (no
p-value given). The difference in the mean change
in morning PEF to the last 4 weeks of treatment
between the FP and BUD groups of the Connolly
trial195 was 39.70 (SD 50.0) for FP versus 26.10
(SD 48.0) for BUD. No statistical significance test
was reported. The change from baseline in
morning PEF in the FP group versus the BUD
group of the Langdon and Thompson194 trial was
32.70 (SD 55.1) versus 24.70 (SD 44.5),
respectively (not statistically significantly different,
p = 0.36). Similarly, there was no statistically
significant difference in the change from baseline
evening PEF between the two groups [FP 18 (SD
35.6); BUD 18 (SD 36.3)] although no p-value was
reported.
In the two trials reporting higher doses (FP
400 µg/day and BUD 800 µg/day), Langdon and
Capsey,193 looking at the use of DPI inhalers,
reported mean morning PEF values between the
two groups but only presented data on the change
from baseline morning and evening PEF in a
figure. At week eight, the adjusted mean morning
PEF in the BUD group was 404.0 and in the FP
group was 423.6 (difference 19.6, 95% CI 5.1 to
34.2, p = 0.009) in favour of FP. The adjustment
was made due to differences in baseline values and
this should be considered when interpreting the
results. Estimating the change from baseline
results for morning PEF from figures presented in
the publication would suggest a change of
23 l/minute for BUD and 35 l/minute for FP at the
eighth week (p < 0.05). Estimating the change
from baseline results for evening PEF from figures
presented in the publication would suggest a
change of 16 l/minute for BUD and 22 l/minute
for FP at the eighth week (p = 0.057). No data
were reported for mean evening PEF at week
eight. Similarly, in the trial by Parakh and
colleagues183 no changes from baseline results
were presented. At the 12-week end-point mean
FEV1 values were 2.40 (SD 0.78) in the FP group
and 2.15 (SD 1.00) in the BUD group. These
figures were not statistically significantly different
but as the analysis also included a third
comparison group (BUD) there was unlikely to
have been a pairwise comparison between the
BUD and FP groups. No data on morning or
evening PEF were presented.
Two of the four studies provided data (mean and
SD) on end-point FEV1 that allowed them to be
combined in a meta-analysis (Figure 9). Pooling the
data using a fixed-effects model showed no
difference between the two groups [WMD 0.00
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was not significant (p = 0.49, I2 = 0%).
Two of the four studies provided data (mean
change and SD) on morning PEF that allowed
them to be combined in a meta-analysis
(Figure 10). Pooling the data using a fixed-effect
model showed a trend towards greater
improvement with FP but this was not statistically
significant [WMD 11.07 (95% CI: –0.31 to 22.44),
p = 0.06]. Heterogeneity was not statistically
significant at p = 0.63, I2 =0%.
Symptoms/health-related quality of life
Parallel design, 1:1 dose ratio. Asthma symptom
scores were recorded on a four-point scale 
(0 = none and 3 = severe) in the Basran and
colleagues trial.192 In both arms there was an
observed improvement in symptom scores (no
data were provided of the change score), but the
difference in the change in scores for symptoms
during the day or during the night was not
statistically significantly different between the two
arms (p = 0.50 daytime score and 0.42 night-time
score).
Parallel design, 1:2 dose ratio. Of the two studies
of lower dose FP (200 µg) and BUD (400 µg),
Langdon and Thompson194 noted that mean
symptom scores (on a 10-point scale where
0 = none and 9 = severe) fell during both
treatments (FP 3.1 at baseline versus 2.4 at end-
point, BUD 3.2 at baseline versus 2.9 at end-
point) but that this was reported to be statistically
significantly greater in the FP group (p = 0.08). In
the Connolly trial,195 a statistically significant
difference was observed in the change in number
of symptom-free days in favour of FP (24% FP
versus 0% BUD, p = 0.05). The proportion of
symptom-free nights increased during treatment
Health Technology Assessment 2008; Vol. 12: No. 19
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Review: Corticosteroids – review Q1 – low-dose ICS
Comparison: BUD  and FP (adults): parallel 1:2 ratio
Outcome: Absolute  FEV1 (litres)
Study
or subcategory
FP
Mean (SD)
BUD
Mean (SD)
WMD (fixed)
95% CI
Weight
%
WMD (fixed)
95% CI NN
Langdon and 
Thompson 1994
194   
81 2.13  (0.77)  76 2.16  (0.81)
11 2.39  (0.77)  10 2.14  (0.99)
 90.50 –0.03 (–0.28 to 0.22)
Parakh et al. 2004
183       9.50   0.25 (–0.51 to 1.01)
Total (95% CI) 92 86 100.00   0.00 (–0.24 to 0.23)
Test for heterogeneity: 2 = 0.47, df = 1 (p = 0.49), I2 = 0%
Test for overall effect: Z = 0.03 (p = 0.98)
–4 –2 0 2 4
Favours BUD Favours FP
FIGURE 9 End-point FEV1 (litres) FP versus BUD, parallel 1:2 nominal dose ratio
Review: Corticosteroids – review Q1 – low-dose ICS
Comparison: BUD  and FP (adults): parallel 1:2 ratio
Outcome: Change in morning PEF (l/min)
Study
or subcategory
FP
Mean (SD)
BUD
Mean (SD)
WMD (fixed)
95% CI
Weight
%
WMD (fixed)
95% CI NN
Connolly 1995
195    80 39.70  (50.00) 76  26.10  (48.00)
69  32.70 (55.10)  65  24.70 (44.50)    
  54.74 13.60 (–1.78 to 28.98)
Langdon and 
Thompson 1994
194
 45.26   8.00 (–8.91 to 24.91)
Total (95% CI) 149 141 100.00 11.07 (–0.31 to 22.44)
Test for heterogeneity: 2 = 0.23, df = 1 (p = 0.63), I2 = 0%
Test for overall effect: Z = 1.91 (p = 0.06)
–100 –50 0 50 100
Favours BUD Favours FP
FIGURE 10 Change in morning PEF, FP versus BUD, parallel 1:2 nominal dose ratioin both groups but this was again reported to be
greater in the FP group than the BUD group (FP
29% versus 17%, p = 0.05).
Symptom scores were reported in the paper by
Parakh and colleagues.183 No details of the type of
measurement scale were reported. They stated
that changes were not statistically significantly
different between study groups, although this is
likely to be based on a comparison of the three
arms of the trial, as discussed earlier.
Use of rescue medication
Parallel design, 1:1 dose ratio. Basran and
colleagues192 reported no statistically significant
differences in the change from baseline in SABA
use between the BUD and FP arms (p = 0.31
daytime use and 0.25 night-time use). Values for
these outcomes are presented for baseline and
end-point, but no data are given for the change
from baseline SABA use.
Parallel design, 1:2 dose ratio. No data on the use
of rescue medication in terms of puffs per day
were reported in the included trials in this
category.
Exacerbations
Parallel design, 1:1 dose ratio. No data on
exacerbation rates was reported in the Basran and
colleagues trial.192
Parallel design, 1:2 dose ratio. No data on
exacerbation rates were reported in the included
trials in this category.
Adverse events
Parallel design, 1:1 dose ratio. The overall
incidence of AEs was similar in both treatment
groups in the Basran and colleagues trial192 (43/83
BUD versus 56/93 FP), although no statistical
significance testing was undertaken. Two AEs in
the BUD group and three in the FP group were
classified as serious.
Parallel design, 1:2 dose ratio. Proportions of
patients with AEs were generally higher in the FP
arms of the included studies than in the BUD
arms, as can be seen in Figure 11. No statistical
significance testing was undertaken in any of these
studies.
Three of the four studies provided data that
allowed them to be combined in a meta-analysis
(Figure 11). Pooling the data using a fixed-effect
model showed a statistically significantly more
favourable AE profile with BUD [odds ratio (OR)
2.28 (95% CI 1.59 to 3.26, p < 0.00001].
Heterogeneity was not significant at p = 0.13,
I2 = 50.4%. It is important to note that although
these three trials had a dose ratio of 1:2, they did
not all have the same dose of FP and BUD.
Four patients in the FP arm of the Langdon and
Thompson trial194 discontinued due to AEs. Two
were due to serious AEs, although this is reported
to be unlikely to be related to therapy in one 
and during the run-in period in the other, 
and two to less severe AEs. Six patients
discontinued due to AEs from the BUD arm; 
four were reported to be asthma related, one due
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Review: Corticosteroids – review Q1 – low-dose ICS
Comparison: BUD  and FP (adults): parallel 1:2 ratio
Outcome: Adverse events
Study
or subcategory
FP
n/N
BUD
n/N
OR (fixed)
 95% CI
Weight
%
OR (fixed)
95% CI
 Connolly 1995
195
 Langdon and Thompson 1994
194
 Langdon and Capsey 1994
193        
  69/78  59/91
  48/81  38/76
110/139 84/136
 15.72
 39.96
4.16 (1.84 to 9.41)
1.45 (0.77 to 2.73)
2.35 (1.37 to 4.01)  44.32
Total (95% CI) 298                   303 100.00 2.28 (1.59 to 3.26)
Total events: 227 (FP), 181 (BUD)
Test for heterogeneity: 2 = 4.03, df = 2 (p = 0.13), I2 = 50.4%
Test for overall effect: Z = 4.47 (p < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours FP Favours BUD
FIGURE 11 Adverse events, FP versus BUD, parallel nominal 1:2 ratioto low cortisol and one to pregnancy. One patient
in each arm of the Connolly195 trial discontinued
due to AEs.
Summary
Parallel design, 1:1 dose ratio. On measures of
lung function, no differences were observed
between those treated with BUD and those treated
with FP. There were also no differences between
the two treatments on symptoms, use of rescue
medication or AEs.
Parallel design, 1:2 dose ratio. No differences on
measures of lung function were reported between
BUD and FP for either the lower or higher dose
studies. Reports of symptoms were favourable for
FP compared with BUD. AE profiles, however, were
statistically significantly more favourable for BUD.
CIC and BUD (review Q1 – low-dose ICS)
Study characteristics
One RCT,196 published in 2005, evaluated the
effectiveness of CIC compared with BUD
(Table 18). An unpublished report containing more
extensive results for this trial was made available
to us by the manufacturer but is considered
commercial in confidence.197 The trial was a
parallel-group, multi-centre RCT which
randomised 405 patients. There were three
treatment groups comparing the two drugs in a
1:2 dose ratio: 400 µg BUD, 200 µg CIC given in
the morning and 200 µg CIC given in the
evening. CIC was delivered by HFA–MDI (not
specifically stated – Alvesco, made by Altana) and
BUD by MDI (BUD-100, Cipla), and treatment
was continued for 12 weeks.
Patients’ ages ranged from 18 to 69 years, with
median ages for the treatment groups of
29–32 years. Patients had been managed on low to
medium doses of ICS, with daily ICS doses of
500 µg/day of BDP or equivalent 4 weeks before
baseline. The mean FEV1 predicted across the
trial’s arms was 92.94%.
The method of randomisation (a computer-
generated randomisation list with coded labelling)
reported by the trial was adequate, but the method
used to conceal the allocation to treatment arms
was unclear. Patients in the CIC groups were
blinded to treatment by use of an identical
placebo MDI device, but patients in the BUD
group were reported to have received the drug on
an open-label basis. All patients received two puffs
from a white-labelled device in the morning and
two puffs from a blue-labelled device in the
evening. ITT analysis was assessed to be partially
adequate, including all patients who received at
least one dose of study medication.
The rationale of the study was to test the non-
inferiority of CIC compared with BUD in terms of
efficacy as measured by change in the primary
outcome measure, FEV1 (litres). A two-sided 95%
CI for differences between the treatment groups
was used to test the primary hypothesis for non-
inferiority. A sample size of 100 patients per
treatment group was calculated to ensure 90%
power to establish the non-inferiority of
160 µg/day CIC (evening dose) to 400 µg/day
BUD. The non-inferiority acceptance limit for
FEV1 was –0.20 litres.
Results
For some outcomes means were calculated using
the least-squares method, as indicated by LS in the
text. Results presented are for ITT analysis, unless
stated otherwise.
Lung function
FEV1 (litres). Niphadkar and colleagues196 did
not report changes from baseline FEV1 for the
three treatment groups, but did report the LS
mean difference between the groups’ changes
from baseline. The difference between patients
who received 200 µg CIC in the morning and
patients in the 400 µg/day BUD group was –0.036
litres (95% CI –0.120 to 0.045). The difference
between the change in those who received an
evening dose of 200 µg CIC and those who
received 400 µg/day BUD was 0.022 litres (95% CI
–0.061 to 0.105). These differences were not
statistically significant, and superiority of morning
or evening CIC versus BUD was not demonstrated
(p = 0.383 and p = 0.598, respectively). The non-
inferiority of CIC to BUD was demonstrated as the
lower CIs exceeded the acceptance level of
–0.2 litres. [Commercial-in-confidence data
removed.]
Morning PEF. As with FEV1, Niphadkar and
colleagues196 reported the results of a comparison
between the two CIC groups and the BUD group’s
change from baseline, but did not report the
actual mean changes from baseline [Commercial-
in-confidence data removed].
Evening PEF. For evening PEF, Niphadkar and
colleagues196 reported between-group comparisons
for change from baseline evening PEF of
–1.1 l/minute (95% CI –12.4 to 10.3, p = 0.855)
for morning CIC versus BUD and 4.0 l/minute
(95% CI –7.5 to 15.5, p = 0.490) for evening CIC
versus BUD. [Commercial-in-confidence data
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T
ABLE 18
Characteristics of studies (BUD and CIC)
Study
Design
Intervention
P
atients
Outcomes
Niphadkar
et
al., 2005
196
RCT
Multi-centre
P
arallel group
Double-blind, 
double-dummy
(CIC) or open-
label (BUD)
1.
CIC 160
µg 
ex-actuator a.m. q.d. + placebo p.m. (daily
total 200
µg 
ex
valve)
2.
CIC 160
µg 
ex-actuator p.m. q.d. + placebo a.m. (daily
total 200
µg 
ex
valve)
3.
BUD 200
µg b.d. (daily total 400
µg)
Delivery device: 
1, 2. HF
A MDI (CIC, Alvesco, made by Altana
a
)
3. MDI (BUD
-100, Cipla)
Duration:
12 wks
Run-in period:
2–2.5 wks
Number randomised
405
Mean age (range) (years)
31 (18–65)
29 (18–63)
32 (18–69)
Baseline FEV
1
% predicted
94
93
92
P
revious ICS treatment (drug and dose)
Constant dose of ICS (
500
µg/day BDP
,
200–250
µg/day FP
, 400
µg/day BUD, or
equivalent)
P
rimary outcome
Change in FEV
1
(litres) 
Secondary outcomes
Difference in FEV
1
(litres)
between randomisation and
study visits
FVC
Morning and evening PEF
Diurnal PEF fluctuation
Asthma symptom scores
R
escue medication use
AEs
a 
Not specifically stated in the text.removed]. Non-inferiority of CIC to BUD was
demonstrated as the lower CIs exceeded the
acceptance level of –25 l/minute.
Symptoms
Niphadkar and colleagues196 assessed asthma
symptoms using a five-point scale (0 = no
symptoms, 4 = awake most of the night or unable
to perform daily activities; no reference given for
scale). The percentages of symptom-free days were
89, 91 and 93% for the morning CIC, evening
CIC and BUD groups, respectively (p = not
significant for both comparisons with BUD). The
percentage of days that were free of nocturnal
awakenings was 100% in each group.
[Commercial-in-confidence data removed].
Health-related quality of life
Niphadkar and colleagues196 did not report this
outcome.
Use of rescue medication
Niphadkar and colleagues196 did not report this
outcome.
Exacerbations
Niphadkar and colleagues196 did not report this
outcome. [Commercial-in-confidence data
removed].
Adverse events
AEs were reported by 24 patients (17.1%) in the
morning CIC group, 32 (24.4%) in the evening
CIC group and 28 (21.1%) in the BUD group.
Comparisons between the two CIC groups and the
BUD group were not statistically significant
(p = 0.443 and 0.558, respectively, calculated by
reviewer). Severe AEs were rare, occurring in seven
patients (5.0%) in the morning CIC group, one
patient (0.8%) in the evening CIC group and two
patients (1.5%) in the BUD group. Differences
between the groups were not statistically
significant (p = 0.174 for morning CIC versus
BUD, p = 1.0 for evening CIC versus BUD). One
patient in each of the morning CIC and BUD
groups withdrew due to AEs (0.7 and 0.8%,
respectively), but no patients in the evening CIC
group withdrew for this reason.
Summary
One published parallel-group RCT196 evaluated
the effectiveness of CIC compared with BUD. The
study was of reasonable methodological quality,
although open-label BUD was used. The trial
demonstrated the non-inferiority of CIC to BUD
for the primary outcome measure of change from
baseline FEV1, and also for morning and evening
PEF. There was no significant difference between
the CIC groups and the BUD group in terms of
symptom-free days, [Commercial-in-confidence
data removed]. There was no statistically
significant difference between the two drugs in
terms of AEs, severe AEs or discontinuations due
to AEs.
MF and BUD (review Q1 – low-dose ICS)
Study characteristics
Two multi-centre, parallel-group RCTs compared
BUD with MF (Table 19). The RCT by Corren and
colleagues198 included 262 patients and ran for
8 weeks and that by Bousquet and colleagues199
lasted for 12 weeks and randomised 730 patients.
Patients in the study by Corren and colleagues198
were randomised in an approximately 2:2:1 ratio
to one of three treatment groups: placebo, once-
daily 440 µg MF (daily metered dose) and once-
daily 400 µg BUD (daily metered dose). Every
morning, patients in the placebo arm took two
inhalations from two placebo DPIs and patients in
the active treatment arms took two inhalations
from the treatment DPI plus two inhalations from
a placebo DPI (no details about the devices were
reported; MF made by Schering-Plough). The
daily dose ratio was approximately 1:1 for the two
active treatment arms.
The study by Bousquet and colleagues199 had four
treatment arms; 100 µg MF twice daily plus
placebo, 200 µg MF twice daily plus placebo,
400 µg MF twice daily plus placebo, and 400 µg
BUD twice daily. Daily dose ratios were therefore
1:4, 1:2 and 1:1, respectively. Patients in the MF
arms took one inhalation from each of two DPIs
(either one active and one placebo, or two active
DPIs) in the morning and again in the evening
(no details about devices were reported; MF made
by Schering-Plough). Patients randomised to BUD
took one inhalation from each of two Turbohaler
DPI devices, morning and evening [Pulmicort
Turbuhaler, AZ (not explicitly stated, but deduced
from the text)]. No placebo Turbohaler was
available, so only evaluators were blind to
treatment group allocation.
Corren and colleagues198 aimed to compare the
efficacy and safety of MF and BUD delivered via
DPI. Bousquet and colleagues199 aimed to
compare the efficacy and safety of the two drugs
delivered via DPI (MF) or Turbohaler DPI (BUD).
Patients in the two studies were of similar ages.
Patients in the study by Corren and colleagues198
ranged in age from 12 to 82 years, with a mean
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T
ABLE 19
Characteristics of studies (MF and BUD)
Study
Design
Intervention
P
atients
Outcomes
Corren 
et al.,
2003
198
RCT
Multi-centre
P
arallel-group
Double-blind, 
double-dummy 
Placebo
- and
active-
controlled
1.
MF 200
µg b.d. (≈
440
µg 
ex-valve) 
2.
BUD 160 b.d. (≈
400
µg 
ex-valve) 
3.
Placebo
Delivery device:
1, 2. MF DPI (made by Schering-Plough) 
Duration:
8 wks
Run-in period:
Not reported
Number randomised
262
Mean age (years)
37.67
Baseline FEV
1
% predicted
73.37
P
revious ICS treatment (drug and dose)
200–2000 
µg q.d. of FP
, BUD, BDP
, flunisolide
or triamcinolone
P
rimary outcome
FEV
1
(litres)
PEF (morning and evening)
Secondary outcomes
FEF
25–75%
FVC
Asthma symptoms
Albuterol use
Nocturnal awakenings
Physician-evaluated response-to
-
therapy scores and compliance
P
ercentage of asthma symptom-
free days
a
AEs
Bousquet 
et al.,
2000
199
RCT
Multi-centre
P
arallel-group
Evaluator
-blind
active-
controlled
1.
MF 100
µg b.d. (daily total 200
µg) + placebo
2.
MF 200
µg b.d. (daily total 400
µg) + placebo
3.
MF 400
µg b.d. (daily total 800
µg) + placebo
4.
BUD 400
µg b.d. (daily total 800
µg) + placebo
Delivery device:
1, 2, 3. MF DPI (made by Schering-Plough)
4. DPI T
urbuhaler (Pulmicort, AZ
a
)
Duration:
12 wks
Run-in period:
Not reported
Number randomised
730
Mean age (range) (years)
41(12–76)
Baseline FEV
1
% predicted
76.8
P
revious ICS treatment (drug and dose)
As previously prescribed inhaled ICS
P
rimary outcome
Change from baseline to end-
point in FEV
1
(litres)
Secondary outcomes
FVC 
PEF
Symptom scores
Nocturnal awakenings requiring
salbutamol use as rescue
medication
Daily salbutamol use
Physician evaluation of response
to therapy 
AEs
a 
Not stated explicitly
, but deduced from the text.age of 37.67 years, and those in the study by
Bousquet and colleagues ranged from 12 to
76 years, with a mean age of 41 years. Corren and
colleagues did not describe the severity of
patients’ asthma, but reported that the baseline
mean percentage of predicted FEV1 ranged from
71.6 to 75.1% for the three treatment groups.
Bousquet and colleagues199 did not describe the
severity of patients’ asthma in their RCT. The
baseline mean percentage of predicted FEV1
ranged from 76.0% in the BUD group to 77.9% in
the 400 µg twice-daily MF group.
All patients in both trials had used ICS before the
studies started. FP was the most widely used ICS
in the trial by Corren and colleagues,198 being
taken by 37% of patients at a mean dose of
388 µg/day. Just over one-quarter (26%) of
patients had taken BDP at a mean dose of
328 µg/day, with a further 20% having used
696 µg/day triamcinolone. The remaining patients
had used BUD (8%) or flunisolide (8%) at daily
doses of 664 and 1136 µg, respectively. In the trial
by Bousquet and colleagues,199 patients had used
the following mean doses of ICS: 699 µ/day BDP,
662 µg/day BUD, 659 µg/day flunisolide,
438 µg/day FP or 416 µg/day triamcinolone.
FEV1 (litres) was used as the primary outcome by
both studies (Bousquet and colleagues199 also
reported FEV1 percentage of predicted value),
although Corren and colleagues198 used both
FEV1 (litres) and PEF as primary outcomes.
Neither study used a strictly ITT method of
efficacy analysis. One patient in the study by
Corren and colleagues and 10 patients in the
study by Bousquet and colleagues199 appear to
have been excluded from analyses due to missing
efficacy data. Both studies used an adequate
method of randomisation, although it is not clear
whether allocation to treatment groups was
concealed in either study.
Results
Results for the comparison between 400 µg MF
twice daily plus placebo and 400 µg BUD twice
daily (i.e. the 1:1 dose ratio) in the trial by
Bousquet and colleagues199 are reported in the
section ‘MF and BUD (review Q2 – high-dose
ICS)’ (p. 85), as this MF dose falls into the ‘high-
dose’ category (review question 2).
Lung function
Parallel 1:1 dose ratio studies. Corren and
colleagues198 reported a significant difference
between the two active treatment arms in terms of
FEV1 change at end-point and percentage change
at end-point. The mean FEV1 value changed by
0.19 ± 0.04 litres in the MF group and
0.03 ± 0.04 litres in the BUD group (p < 0.01).
These represent changes of 8.9 and 2.1% for the
two groups, respectively (p < 0.01).
Corren and colleagues198 reported that the change
from baseline morning PEF was statistically
significantly greater in the MF group 
(19.96 ± 4.15 l/minute) than in the BUD group
(0.54 ± 4.08 l/minute; p < 0.01). In terms of
change from baseline in evening PEF scores, MF
patients had a mean change of
19.04 ± 4.19 l/minute, compared with
4.93 ± 4.13 l/minute in the BUD group. MF was
statistically significantly better than BUD
(p < 0.05). However, baseline mean PEF values
(both morning and evening) were lower in the MF
group than in the BUD group. The difference
between MF and BUD groups for evening PEF was
statistically significant (p <0.05). These
unbalanced baseline values may have influenced
the results at end-point.
Parallel 1:2 or 1:4 dose ratio studies. Change from
baseline FEV1 and percentage of predicted FEV1
value were presented by Bousquet and
colleagues.199 The 200 µg twice-daily MF group
reported a mean change from baseline FEV1 that
was statistically significantly greater than change
in the BUD group (0.16 ± 0.03 l/minute versus
0.06 ± 0.03 litres in the BUD group, p < 0.05).
Similarly, the end-point percentage of predicted
FEV1 was statistically significantly different
between the 200 µg twice-daily MF group
(81.6 ± 1.2%) and BUD (77.9 ± 1.1%; p < 0.05).
In the 100 µg twice-daily MF group, change from
baseline (0.10 ± 0.03 litres) and end-point
percentage of predicted FEV1 (79.6 ± 1.1%) were
not statistically significantly different from the
BUD group.
Bousquet and colleagues199 did not find a
statistically significant difference between MF and
BUD in terms of change in morning PEF. Change
from baseline to end-point was
24.75 ± 5.3 l/minute in the BUD group compared
with 18.20 ± 5.3 l/minute in the 100 µg twice-daily
MF group and 37.84 ± 5.4 l/minute in the 200 µg
twice-daily MF group. Changes in evening PEF
were not presented, but were reported to be
similar to changes in morning PEF.
Symptoms
Parallel 1:1 dose ratio studies. Total morning and
evening asthma symptom scores were reported by
Corren and colleagues198 using the total score of
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(0 = none; no reference given). Mean morning
scores decreased for the MF group (i.e. patients’
symptoms improved) by 0.42 ± 0.12 points.
Patients in the BUD group also showed an
improvement in symptoms with a mean change in
morning score of –0.12 ± 0.11, but this was not
statistically significantly different from the MF
group. Evening asthma scores decreased in the
BUD (–0.11 ± 0.12) and MF groups
(–0.46 ± 0.12). The difference between the MF
group and the BUD group was statistically
significant (p < 0.05). Corren and colleagues also
reported a statistically significant difference in the
percentage of asthma symptom-free days, being
39.7 ± 3.4% in the MF group, compared with
26.8 ± 3.3% in the BUD group (p < 0.01).
In the trial by Corren and colleagues,198 the
percentages of patients with no nocturnal
awakenings due to asthma were 60.8, 78.8 and
81.1% for the placebo, MF and BUD groups,
respectively (p = not significant).
Parallel 1:2 or 1:4 dose ratio studies. Bousquet and
colleagues199 did not report symptom-free days,
but did report the change from baseline to end-
point in the mean number of nocturnal
awakenings requiring salbutamol rescue
medication. The mean number of awakenings was
0.36 in the 100 µg twice-daily MF group, 0.33 in
the 200 µg twice-daily MF group and 0.30 in the
BUD group. Differences between the groups were
not statistically significant.
Health related quality of life 
Neither study reported measures of HRQoL.
Use of rescue medication
Parallel 1:1 dose ratio studies. Corren and
colleagues198 reported that the mean average
decrease in use of albuterol for patients in the MF
arm was 0.91 ± 0.23 puffs, compared with a mean
decrease of 0.21 ± 0.23 puffs in the BUD group
(p < 0.05).
Parallel 1:2 or 1:4 dose ratio studies. Bousquet and
colleagues199 did not report symptom relief in
terms of puffs per day.
Exacerbations
Neither study reported rate of asthma
exacerbations.
Adverse events
Corren and colleagues198 reported that there were
no significant differences between the trial arms in
overall incidence of AEs. Treatment-related AEs
were experienced by 8% of the MF group and 9%
of the BUD group. One patient in the MF group
and two patients in the BUD group discontinued
due to AEs, which were unrelated to treatment.
Bousquet and colleagues199 reported that the
incidence of treatment-related adverse effects was
similar for all treatment groups (17–20%). Reports
of serious AEs were also similar across treatment
arms, and none of these were thought to be related
to treatment. Withdrawals due to AEs were reported
for six patients in the 100 µg twice-daily MF group,
one person in the 200 µg twice-daily MF 
group, three patients in the 400 µg twice-daily 
MF group and seven patients in the BUD group.
Summary
Two multi-centre, parallel-group RCTs compared
the efficacy and safety of BUD (delivered via a
Turbohaler or a DPI) with MF (delivered via a
DPI). Both studies used an adequate method of
randomisation, although neither study used a
strictly ITT method of efficacy analysis.
A statistically significant difference in FEV1
favouring MF was apparent when MF and BUD
were compared at a nominal dose ratio of 1:1.
Corren and colleagues198 also reported that the
change from baseline morning and evening PEF
values was statistically significantly greater in the
MF group than in the BUD group. Results from
1:2 and 1:4 dose ratio comparisons indicated that
a 200 µg twice-daily MF dose was also statistically
significantly more effective than 400 µg twice-daily
BUD in terms of FEV1 changes from baseline and
percentage of predicted FEV1 value.
MF does not appear to be statistically significantly
better than BUD in relieving morning asthma
symptoms, although one study found a statistically
significant improvement in evening asthma scores
with 400 µg MF compared with BUD. The study
also found a statistically significantly higher
percentage of symptom-free days in the MF group.
On the basis of the two studies discussed here, MF
appears to improve lung function compared with
400 µg BUD, and may have a slightly higher
impact on asthma symptoms. There do not appear
to be any statistically significant differences
between the drugs in terms of adverse effects.
CIC and FP (review Q1 – low-dose ICS)
Study characteristics
Two RCTs were identified which compared CIC
with FP200,201 (Table 20). An unpublished report of
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Pharma, the manufacturer of CIC (Alveso), as part
of their submission to NICE, and has been classed
as commercial-in-confidence. The non-inferiority,
parallel group study by Buhl and colleagues200 was
a multi-national, multi-centre trial with 529
participants.
The 12-week study by Buhl and colleagues200 had
two arms and compared CIC 200 µg/day (as a
single daily dose in the evening) with FP
200 µg/day (as two daily doses of 100 µg); the
dosing ratio was 1:1. Both drugs were delivered by
HFA–MDIs (CIC Alvesco, made by Altana;
however this is not specifically stated, nor are any
further details on the FP device reported).
The primary outcome was the change in FEV1
from beginning to end of treatment.
[Confidential information removed].
In the study by Buhl and colleagues,200 patients
were described as having mild to moderate
asthma. Their ages ranged from 12 to 74 years
and FEV1% predicted from 48 to 108%. 
Patients were eligible for the study if they had
been taking up to 500 µg/day of BDP or
equivalent. Both groups were generally similar at
baseline in terms of demographics and other
characteristics.
[Confidential information removed].
Buhl and colleagues200 did not describe the
processes used to randomise patients, conceal
allocation or blind the treatment. The power
calculation was adequate. A full ITT analysis was
not performed, although the majority of
participants were included in the efficacy analysis
(probably as an available case analysis).
[Confidential information removed].
Results
The study by Buhl and colleagues200 was designed
to show non-inferiority of CIC with FP. Both ITT
and per protocol (PP) results are presented in the
paper. ITT results are reported here.
[Confidential information removed].
Lung function
Parallel 1:1 dose ratio studies. FEV1 (litres). In the
study by Buhl and colleagues,200 least-squares
means were used for the analysis of FEV1 (litres).
The within-treatment mean difference standard
error (SE) in the CIC group was 0.489 (0.029),
p < 0.0001 and in the FP group 0.499 (0.029),
p < 0.0001. The between-treatment mean
difference was not significant (–0.010, 95% CI
–0.085 to 0.066, p = 0.801). Non-inferiority of
CIC to FP was demonstrated as the lower limit of
the 95% CI was above the predefined non-
inferiority acceptance limit of –0.2 litres in both
the ITT and PP analyses.
[Confidential information removed].
FEV1 % predicted. Buhl and colleagues200 did
not report on FEV1 % predicted.
Morning and evening PEF. Buhl and
colleagues200 used least-squares means for the
analysis of morning and evening PEF (litres per
minute). The morning PEF within-treatment mean
difference (SE) in the CIC group was 33 (4)
l/minute, p < 0.0001, and in the FP group was 36
(4) l/minute, p < 0.0001. The between-treatment
mean difference was not significant (–3, 95% CI
–13 to 7, p = 0.582). Non-inferiority of CIC to FP
was demonstrated as the lower limit of the 95% CI
was above the predefined non-inferiority
acceptance limit of –0.25 l/minute in both ITT
and PP analyses. Evening PEF values were
reported to have significantly improved over the
12 weeks following treatment with CIC and FP but
no further details were provided.
[Confidential information removed].
Morning and evening PEF. [Confidential
information removed].
Symptoms
Parallel 1:1 dose ratio studies. Buhl and
colleagues200 reported data on the median
percentages of days and nights without symptoms.
The median percentage of symptom-free days at
12 weeks in the CIC group was approximately 58%
and in the FP group 65%. The respective median
percentages for nights without symptoms were 100%
in both groups. The figures have been estimated
from graphs by the reviewers and no statistical
tests of significance were presented by the authors.
[Confidential information removed].
Buhl and colleagues200 reported median symptom
scores using a five-point scale (0 = no symptoms
to 4 = severe symptoms; not referenced) and
Hodges–Lehmann point estimates are presented.
The within-treatment difference for total asthma
symptom score in the CIC group was –0.75,
p < 0.0001 and in the FP group –0.86,
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T
ABLE 20
Characteristics of studies (CIC and FP)
Study
Design
Intervention
P
atients
Outcomes
Buhl 
et al.,
2005
200
RCT
Multi-centre
P
arallel
Double-blind 
Double-dummy
1.
CIC 200
µg
ex-valve p.m. q.d. (daily total 160
µg 
ex-actuator)
2.
FP 100
µg 
ex-valve b.d. (daily total 176
µg 
ex-actuator)
Delivery device: 
1, HF
A MDI (CIC Alvesco, made by Altana
a
)
2. HF
A MDI (no further details about device reported)
Duration:
12 wks
Run-in period:
1–4 wks: ICS was discontinued and salbutamol rescue
medication only given 
Number randomised
529
Median age (range) (years)
1.
41 (12–74)
2.
38 (12–74)
Baseline mean FEV
1
% predicted (range)
1.
75 (51–108)
2.
75 (48–92)
P
revious ICS treatment (drug and dose)
Up to 500
µg q.d. of BDP or equivalent
P
rimary outcome
Change in FEV
1
from beginning
to end of treatment
Co
-primary outcomes
Change in FVC and morning PEF
Secondary outcome
FVC
FEF
25–75%
Evening PEF
Asthma symptom scores
R
escue medication use
R
escue-medication-free days
Number of days and nights
without symptoms
Asthma exacerbations
AEs
a 
Not specifically stated in the text.p < 0.0001. The between-treatment difference was
not significant (0.07, 95% CI –0.11 to 0.29,
p = 0.387). The within-treatment difference for
daytime symptom scores was –0.43, p < 0.0001, in
the CIC group and –0.50, p < 0.0001, in the FP
group. The between-treatment group difference
was not significant (0.00, 95% CI –0.00 to 0.14,
p = 0.317). The within-treatment difference for
night-time symptom scores was –0.29, p < 0.0001,
in the CIC group and –0.33, p < 0.0001, in the FP
group. The between-treatment group difference
was not significant (0.00, 95% CI 0.00 to 0.10,
p = 0.530). CIs for the within-treatment
differences were not reported.
[Confidential information removed].
Health-related quality of life
Buhl and colleagues200 did not report on this
outcome.
Use of rescue medication
Parallel 1:1 dose ratio studies. Buhl and
colleagues200 used Hodges–Lehmann point
estimates in the analysis. The within-treatment
difference for the median number of puffs per 
day of rescue medication in the CIC group was
–1.00, p < 0.0001, and in the FP group –1.21,
p < 0.0001. The between-treatment difference was
not significant (0.14, 95% CI –0.00 to 0.43,
p = 0.130).
[Confidential information removed].
Exacerbations
Parallel 1:1 dose ratio studies. Buhl and
colleagues200 did not report on this outcome. 
[Confidential information removed].
Adverse events
Parallel 1:1 dose ratio studies. In the study by
Buhl and colleagues,200 97 participants (36%) in
the CIC group and 89 (34%) in the FP group
experienced an AE. A total of 270 AEs occurred
during the study. One serious AE occurred in 
each group, both thought not to be related to 
the study medication. Six patients in the CIC
group and three in the FP group withdrew 
because of AEs.
[Confidential information removed].
Summary
Two studies were identified which compared CIC
with FP. One of these is currently commercial-in-
confidence.
In the study by Buhl and colleagues,200 which used
a 1:1 dosing ratio (CIC 200 µg/day versus FP
200 µg/day), there were no statistically significant
differences between groups on any outcomes. FP
appeared to be more favourable for percentage of
symptom-free days, although no statistical tests
were reported. Non-inferiority was demonstrated
for FEV1 and morning PEF.
[Confidential information removed].
MF and FP (review Q1 – low-dose ICS)
Study characteristics
One parallel-group RCT, published in 2001,
investigated the effectiveness of MF compared
with FP (Table 21). The study was a multi-centre
parallel trial with 733 patients. The study, by
O’Connor and colleagues,202 comprised four arms
in which three doses of MF (200, 400 and
800 µg/day) were compared with one dose of FP
(500 µg/day). The comparisons are approximately
equivalent to rounded nominal dose ratios
(MF:FP) of 1:1 (400:500 µg/day), 1:2
(200:500 µg/day) and 2:1 (800:500 µg/day). The
500 µg/day dose of FP is slightly above the upper
threshold for a low-dose classification, but
500 µg/day FP is included in this section to permit
comparison with low-dose MF (dose ratios of 1:1
and 1:2). The 2:1 dose ratio covers high-dose
classifications for both drugs and accordingly is
reported in the section ‘MF and FP (review Q2 –
high-dose ICS)’, p. 87].
O’Connor and colleagues202 employed DPIs for
both MF and FP, but these were of different types:
a newly developed inhaler (MF–DPI) was used for
MF whereas FP was administered using a standard
Diskhaler formulation (FP-Flixotide Diskhaler,
GSK).
The study was of relatively short duration, lasting
12 weeks.202 The mean age of patients included in
the study was 41 years, ranging from 12 to
79 years. The enrolled patients had moderate
persistent asthma.
O’Connor and colleagues202 employed a large-
scale international dose-ranging study (with 60
centres in 20 countries) to compare the efficacy
and safety of several doses of MF administered
with a newly developed inhaler with a single dose
of FP administered with a standard inhaler. The
primary comparison was between 200 and
800 µg/day MF. If there was no significant
difference between them, pair-wise comparisons
between all three doses of MF against FP would be
performed.
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adequate, with randomisation by computer-
generated code, adequate ITT analysis and a
power calculation reported. However, details of
allocation concealment were not reported.
Results
The dose ratio comparisons reported here are for
rounded nominal dose ratios as described above.
Lung function
Parallel 1:1 dose ratio. The change from baseline
FEV1 value did not differ between patients treated
with 400 µg/day MF and 500 µg/day FP. The
change in FEV1 (mean ± SD) was the same
(0.16 ± 0.54 litres) for MF (n = 182) as for FP
(n = 184). The change in morning PEF 
(mean ± SD) was 29 ± 80.9 l/minute for MF and
32 ± 67.8 l/minute for FP (no p-values reported).
The change from baseline to end-point in the
evening PEF was not reported quantitatively.
However, the authors commented that the changes
in evening PEF were similar to changes in morning
PEF. Changes in both morning and evening PEF
values therefore appear to be independent of
whether MF or FP was used, although tests of
statistical significance for the small difference
between the two drugs were not reported.
Parallel 1:2 dose ratio. The change in FEV1
(mean ± SD) was 0.07 ± 0.54 litres for MF
(20 µg/day) and 0.16 ± 0.54 litres for FP
(500 µg/day) (p = not significant). The change in
morning PEF (mean ± SD) was
15 ± 67.5 l/minute for MF (200 µg/day) and
32 ± 67.8 l/minute for FP (500 µg/day). This
difference was statistically significant (p  0.05).
Symptoms
Parallel 1:1 dose ratio. O’Connor and
colleagues202 reported the occurrence of specific
symptoms (wheeze, difficulty in breathing or
cough), but did not report changes in overall
symptom score. The change from baseline in the
number of nocturnal awakenings was 0.01 for MF
and –0.14 for FP. This difference between the
drugs was not statistically significant.
Parallel 1:2 dose ratio. The change from baseline
in the number of nocturnal awakenings was 0.07
for MF-treated patients and –0.14 for FP-treated
patients. This difference was statistically significant
(p  0.05).
Use of rescue medicine
Parallel 1:1 dose ratio. O’Connor and
colleagues202 expressed the use of rescue
medication in micrograms of albuterol used per
day. The change from baseline to end-point was
–94.84 µg/day for MF-treated patients and
–52.06 µg/day for FP-treated patients. The
difference in rescue medication use between the
two drugs was not statistically significant.
Parallel 1:2 dose ratio. The change from baseline
in the use of albuterol rescue medication was
–13.23 µg/day for MF-treated patients and
–52.06 µg/day for FP-treated patients; this
difference between the treatments is not
statistically significant.
Exacerbations
O’Connor and colleagues202 noted that aggravated
asthma was one of the most frequent AEs leading
to the discontinuation of treatment. However, the
occurrence of asthma aggravation was not reported
separately from other AEs (summarised below).
Adverse events
Parallel 1:1 dose ratio. In the study by O’Connor
and colleagues,202 47 out of 182 patients treated
with MF (26%) and 53 out of 184 patients treated
with FP (29%) experienced treatment-related AEs.
Six patients who received MF and eight patients
who received FP did not complete their treatment
because of AEs. The most frequent AEs leading to
discontinuation were aggravated asthma, bronchitis,
pharyngitis and upper respiratory tract infection.
Parallel 1:2 dose ratio. Of 182 patients who were
treated with 200 µg/day MF, 36 (20%) experienced
treatment-related AEs. Of the patients treated with
500 µg/day FP, 53 out of 184 (29%) experienced
treatment-related AEs. Nine patients who received
MF and eight patients who received FP did not
complete their treatment because of AEs. The
most frequent AEs leading to discontinuation were
aggravated asthma, bronchitis, pharyngitis and
upper respiratory tract infection.
Summary
Only one RCT compared MF and FP. The limited
data suggest that the two drugs are very similar in
terms of clinical effectiveness when used in a 1:1
dose ratio. Results for a 1:2 dose ratio comparison
showed a degree of statistical significance for some
outcomes.
At the nominal dose ratio of 1:2, the change from
baseline in the morning PEF was significantly
larger for FP. The change in nocturnal awakening
also differed significantly between the two drugs,
being positive for MF and negative (i.e. an
improvement) for FP. These findings favour the use
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Characteristics of studies (MF and FP)
Study
Design
Intervention
P
atients
Outcomes
O
’Connor 
et al.,
2001
202
RCT
P
arallel-group
Double-blind
(dosage),
evaluator
-blind
(medication)
Drug(s): 
1.
MF 100
µg b.d. (daily total 200
µg)
2.
MF 200
µg b.d. (daily total 400
µg)
3.
MF 400
µg b.d. (daily total 800
µg)
4.
FP 250
µg b.d. (daily total 500
µg)
Delivery device:
1, 2, 3. MF DPI (Schering-Plough) 
4. DPI (Flixotide Diskhaler
, GSK)
Duration:
12 wks
Run-in period:
1–2 wks 
Number randomised
733
Mean age range (years)
41 (12–79) 
Baseline FEV
1
% predicted
75
P
revious ICS treatment (drug and dose)
As previously prescribed
P
rimary outcome
Mean change in FEV
1
from 
baseline to end-point
Secondary outcomes
PEF
FEF
25–75%
FVC
Asthma symptom scores
R
escue medication use
Nocturnal awakenings
Physician evaluation
AEsof 500 µg/day FP over 200 µg/day MF, in terms of
both clinical effectiveness and safety. An exception
is that a higher frequency of AEs occurred with FP
(29%) compared with MF (20%), but these
differences were not evaluated statistically.
Summary of Q1 – relative effectiveness of 
low-dose ICS
According to Step 2 of the BTS/SIGN Guideline,
the following drugs at the following doses
(excluding considerations of device) are
equivalent: BUD 200 µg/BDP 200 µg/FP 100 µg.
MF 100 µg is considered the appropriate
equivalent dose at this level, likewise CIC 100 µg
(by assumption). Similarly, BUD 400 µg/BDP
400 µg/FP 200 µg are considered equivalent,
alongside MF 200 µg and CIC 200 µg, and BUD
800 µg/BDP 800 µg/FP 400 µg, alongside MF
400 µg and CIC 400 µg.
In general, all of the ICS in this assessment were
associated with favourable changes from baseline
to end-point across efficacy and safety outcomes.
However, when evaluated in pair-wise
comparisons, there were few statistically significant
differences between them in terms of the
outcomes prioritised for this assessment (although
it was not always possible to discern whether
significance testing had been performed). From
the head-to-head comparisons of these drugs,
there is little evidence to reject the hypothesis that
there is no difference in clinical effectiveness
between them, with the exception of FP
demonstrating some greater effectiveness when
compared with BDP. The results are not so
consistently in favour of FP when compared with
equivalent doses of BUD or MF. In some cases
non-inferiority was assessed and demonstrated,
such as the comparison of CIC with equivalent
doses of FP or BUD.
As a brief summary:
● BDP versus BUD (five RCTs, all 1:1 dose ratio):
statistically significant differences only for lung
function, in favour of BUD.
● FP versus BDP (six RCTs, all 1:2 dose ratio):
few statistically significant differences, except
for one RCT which found significant 
differences in favour of FP across a range of
outcomes.
● FP versus BUD (five RCTs, four at 1:2 dose
ratio, one at 1:1 dose ratio): mixed findings.
Significant difference for symptoms in favour of
FP from one trial, significant difference for AEs
in favour of BUD from meta-analysis of two
trials.
● CIC versus BUD (one RCT, 1:2 dose ratio): no
significant differences. Non-inferiority
demonstrated for lung function.
● MF versus BUD (two RCTs, one at 1:1 dose
ratio, one at 1:2 dose ratio): at 1:1 dose ratio
significant differences in favour of MF for lung
function, symptoms and rescue medication. At
1:2 dose ratio MF significantly favourable only
for lung function.
● CIC versus FP (two RCTs, one at 1:1 dose ratio,
one at 1:2 dose ratio): no significant differences
at 1:1 dose ratio. Non-inferiority demonstrated
for lung function.
● MF versus FP (one RCT, with a 1:1 dose ratio
and a 1:2 dose ratio): no significant differences
at 1:1 dose ratio. At 1:2 dose ratio there were
significant differences in favour of FP on lung
function and nocturnal wakenings.
Tables 22–28 provide a visual illustration of the
results of pair-wise comparisons.
Review question 2 – effectiveness of
high-dose ICS
High dose is defined as 800–2000 µg/day
BDP/BUD equivalent (for FP, CIC and MF high
dose is >400 µg/day) (Step 4 of the Guideline)
To recap, 24 RCTs evaluated high-dose ICS
(Table 29). The following sub-sections describe the
characteristics and results of these trials.
BDP and BUD (review Q2 – high-dose ICS)
Study characteristics
Two double-blind, cross-over RCTs evaluated the
effectiveness of BDP compared with BUD
(Table 30).81,203 The two studies were small, with 28
patients in the single-centre study by Ebden and
colleagues81 and 15 patients in the multi-centre
study by Kaur and colleagues.203
Both of the RCTs contained two trial arms with
nominal 1:1 daily dose ratios, but the doses were
different. The study by Ebden and colleagues81
had two treatment periods, each of 6 weeks.
Treatment A consisted of three puffs of 250 µg
BDP and four puffs of placebo BUD twice daily
(total daily dose 1500 µg BDP). Treatment B
consisted of four puffs of 200 µg BUD and three
puffs of placebo BDP twice daily (total daily dose
1600 µg BUD). The cross-over trial by Kaur and
colleagues203 compared 1000 µg twice daily of
each drug (total daily doses 2000 µg), with a 
6-week treatment period for each. Treatment
drugs in the two RCTs were delivered via MDIs
(no details reported for Ebden and colleagues;81
BDP Beclate and BUD Budecort, both from 
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spacers.
Kaur and colleagues203 aimed to assess whether the
same doses of the two drugs produced clinically
important differences in side-effects, and Ebden and
colleagues81 aimed to compare the efficacy of similar
doses of the drugs. Neither of the trials clearly
stated what the primary outcome measure was.
Patients in the study by Ebden and colleagues81
had a mean age of 54 years (range from
19–72 years). However, those in the study by Kaur
and colleagues203 were considerably younger,
having a mean age of 28.6 years (no range
reported). Neither of the two RCTs provided any
details of the severity of asthma in the trial
populations or reported baseline FEV1 % predicted
values. The mean daily dose of BDP before entry
to the cross-over study by Ebden and colleagues
was 887.5 µg. Kaur and colleagues did not report
prior treatment for their RCT population.
The cross-over study by Kaur and colleagues203
used computer-generated random numbers to
assign patients to treatment groups, but the other
RCT81 did not describe the randomisation
procedure. Concealment of allocation was not
reported. The two studies were reported to have
been double-blind, but few details were provided
in the publications. Ebden and colleagues81 did
not report a wash-out period between treatments,
so it is possible that the effects of the first
treatment influenced results in the second half of
the trial. No power calculations were reported,
and it is possible that the study may be too small
to be statistically powered (n = 27). Results were
not analysed on an ITT basis. Kaur and
colleagues203 included a 1-week wash-out period
prior to cross-over, to reduce the likelihood of any
effects from the first treatment distorting results
during the second treatment. Analysis of trial data
was not ITT, and was based on only 13 of the 15
patients who completed the trial.
Results
It was not appropriate to pool the results of the
two BDP versus BUD RCTs in a meta-analysis due
to differences in doses. A narrative summary of
the key results is presented below.
Lung function
The mean change from baseline FEV1 value in the
cross-over study by Ebden and colleagues81 was
0.02 litres in the BUD group and –0.09 litres in
the BDP group (p = not significant). The mean
morning PEF for the last 3 weeks of treatment was
similar in the two groups. The mean was 314.1
[standard error of the mean (SEM) 4.0] l/minute
during BUD treatment and 311.2 (SEM
4.1) l/minute during BDP treatment. The mean
evening PEF during the last 3 weeks of treatment
was also very similar for the two treatments. The
mean scores were 335.9 (SEM 3.9) l/minute during
BUD treatment and 334.0 (SEM 3.7) l/minute
during BDP treatment. Significance values were
not reported for PEF scores. Ebden and
colleagues81 also compared lung function during
high-dose treatment with function during existing
treatment. They reported that nine of the 16
evaluable patients showed a significantly higher
value for at least one of morning PEF, evening
PEF or daily inhaled bronchodilator usage. Values
were only presented on graphs in the publication,
and no significance values were reported.
The cross-over study by Kaur and colleagues203
reported a significant change from baseline value
for both BDP and BUD treatment, but did not
report a significant difference between the two
treatments. Mean change from baseline FEV1 after
6 weeks was 0.58 litres with BDP treatment and
0.55 litres with BUD treatment. This study did not
report individual morning or evening PEF values.
Symptoms 
Neither of the cross-over studies81,203 reported
days or nights without symptoms or overall daily
symptom scores.
Health-related quality of life
HRQoL was not reported by either of the two RCTs.
Use of rescue medication
Ebden and colleagues reported that there were
three exacerbations of asthma which required oral
corticosteroid treatment. One patient required oral
corticosteroids during the BDP phase, and a
second patient required oral corticosteroids during
both treatment phases. The use of inhaled
bronchodilator during the last 21 days of treatment
was significantly greater during BDP treatment
than during BUD treatment. Median daily number
of puffs was 6.72 (range 0–22) during BUD and
7.81 (0–26) during BDP (p < 0.05). Kaur and
colleagues did not report use of rescue medication.
Exacerbations
Exacerbations were not reported in either of the
RCTs.
Adverse events
Ebden and colleagues81 did not report the overall
rate of side-effects, but commented that any side-
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Study
, design,
ICS in
Lung function
Symptoms
AEs
duration, device,
each trial
R
escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
Jäger 
et al.,
186
weeks,
BDP
NSD
NSD
NSD
NSD
C
2.5%
cross-
over
, open-label
BUD
1.1%
400 
µg BDP 
DPI; n
= 79
vs 400 µg 
Tjwa,
185
8 weeks, 
BDP
NSD
NSD
BUD
cross-
over
BUD
+
+
DPI; 
n 
= 16
Meta-analysis
BDP
+
P
arakh
et al.,
183
BUD
Dal Negro
et al.
182
P
arakh 
et al.,
183
12 BDP
NSD
weeks, parallel-group, 
BUD
800 
µg BDP
DPI, 
n
=3
2
vs 800 µg
Dal Negro
et al.,
182
8
BDP
NSD
NSD
NSD
BUD
weeks, 
parallel-group,
BUD
MDI; 
n
=4
2
R
afferty 
et al.,
184
BDP
NSD
NSD
NSD
variable, duration cross 
BUD
over
, MDI; n
= 40
C, use of rescue medication stated to be comparable between trial arms; NSD, no significant difference between trial arms; NW
, 
nocturnal waking; SFD, symptom-free days; 
SFN, symptom-free nights; SS, symptom score (varies between studies); + indicates that results favour this trial arm; blank cel
ls signify no data reported on that outcome. 
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BUD versus BDP (n
=
5 RCT
s)R
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Study
, design,
ICS in
Lung function
Symptoms
AEs
duration, device,
each trial
R
escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
P
arakh 
et al.,
183
BDP
800
µg BDP
parallel-group, 
vs 400
µg FP
single blind RCT
, 
FP
NSD
F
12 weeks, MDI, n
=4
2
P
rasad 
et al.,
187
BDP
400
µg BDP
parallel-group, 
vs 200
µg FP
double-blind RCT
, 
FP
NSD
NSD
NSD
12 weeks, MDI, n
=7
4
R
aphael 
et al.,
90
400
µg BDP
parallel-group, 
BDP
R
ange
vs 200
µg FP
;
double-blind RCT
, 
NSD
9–15%
800
µg BDP 
12 weeks, MDI, 
vs 500
µg FP 
n 
= 42 (combined 
FP
+
+
+
+
+
+
analysis of both doses)
Szefler 
et al.,
189
parallel-group, open-
BDP
200
µg BDP
label RCT
, 21 weeks, 
vs 100
µg FP
MDI + spacer
, 
FP
F
n
= 30
Ige and Sogaolu
188
, 
BDP
400
µg BDP
parallel-group, open-
NSD
vs 250
µg FP
label RCT
, 8 weeks, 
FP
+
pMDI, 
n
=2
0
800
µg BDP 
Medici 
et al.,
191
BDP
vs 400
µg FP
parallel-group, double-
1500
µg BDP 
blind RCT
, 12 months, 
FP
NSD
vs 750
µg FP
MDI + spacer
, n
=6
9
F
, results appear to favour this treatment group, but no tests of statistical significance reported; NSD, no significant differ
ence between trial arms; NW
, nocturnal waking; SFD,
symptom-free days; SFN, symptom-free nights; SS, symptom score (varies between studies); + indicates results favour this trial 
arm; blank cells signify no data reported on that
outcome.
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FP versus BDP (n
= 6 RCT
s)R
esults
Study
, design,
ICS in
Lung function
Symptoms
AEs
duration, device,
each trial
R
escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
Basran 
et al.,
192
parallel-group,
FP
60.2%
200 or 
open-label RCT
, 
400
µg FP
8 weeks, DPI, 
n
=
176 NSD
NSD
NSD
NSD
NSD
vs 200 or 
(results only reported 
BUD
51.8%
400
µg BUD
for FP vs 
BUD,
not by dose groups)
Meta-analysis
FP
Langdon and 
Thompson,
194
NSD
Connolly
,
195
BUD
Langdon and 
Thompson,
194
FP
+
+
+
59.3%
200 
µg FP
parallel-group,
NSD
vs
open-label RCT
, MDI, 
BUD
50%
400 
µg BUD
8 weeks, 
n 
= 157
Connolly
,
195
parallel-group, FP
88.5%
open-label RCT
, 
DPI Diskhaler or 
reservoir DPI, 
BUD
64.8%
8 weeks, n
=
190
Meta-analysis
400
µg FP vs
Langdon and 
FP
800
µg BUD 
Thompson,
194
and P
arakh 
et al.
183
BUD
NSD
200
µg FP
vs 
400
µg BUD
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FP versus BUD (n
=
5 RCT
s)
continuedR
esults
Study
, design,
ICS in
Lung function
Symptoms
AEs
duration, device,
each trial
R
escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
Langdon and Capsey
193
parallel-group,
FP
+
79.1%
open-label RCT
, 
DPI Diskhaler or 
NSD
400
µg FP vs
reservoir DPI, 
BUD
61.8%
800
µg BUD
8 weeks, 
n
=
281
P
arakh 
et al.,
183
FP
parallel-group,
single-blind RCT
, MDI,
NSD
12 weeks, n
=4
2
BUD
200
µg FP
Meta-analysis
FP
+
vs
Langdon and 
400
µg BUD
Thompson
194
and Langdon
and 
Capsey
193
BUD
400
µg FP vs
Connolly
195
800
µg BUD
NSD, no significant difference between trial arms; NW
, nocturnal waking; SFD, symptom-free days; SFN, symptom-free nights; SS, 
symptom score (varies between studies); 
+ indicates results favour this trial arm; blank cells signify no data reported on that outcome.
T
ABLE 24
FP versus BUD (n
=
5 RCT
s) (cont’d)
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Symptoms
AEs
duration, device,
each trial
R
escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
Niphadkar 
et al.,
196
CIC 200
µg 
parallel-group, 
1. CIC a.m.
ex-actuator double-blind 
RCT
, 
a.m., CIC 
12 weeks,
200
µg 
HF
A MDI or MDI,
2. CIC p.m.
ex-actuator
, 
n
= 405 
p.m. vs
3. BUD
BUD 400
µg 
C, results appear to be comparable between treatment groups, but no tests of statistical significance reported; F
, results appe
ar to favour this treatment group, but no tests of
statistical significance reported; NID, non-inferiority demonstrated; NSD, no significant difference between trial arms; NW
, no
cturnal waking; SFD, symptom-free days; 
SFN, symptom-free nights; SS, symptom score (varies between studies); blank cells signify no data reported on that outcome.
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BUD versus CIC (n = 1 RCT)
NSD
1 vs 3
2 vs 3
NID
1 vs 3
2 vs 3
NSD
1 vs 3
2 vs 3
NID
1 vs 3
2 vs 3
NSD
1 vs 3
2 vs 3
NID
1 vs 3
2 vs 3
C
NSD
1 vs 3
2 vs 3
[
C
o
m
m
e
r
c
i
a
l
-
i
n
-
c
o
n
f
i
d
e
n
c
e
d
a
t
a
 
r
e
m
o
v
e
d
]
[Commercial-in-
confidence data
removed]
[Commercial-in-
confidence data
removed]R
esults
Study
, design,
ICS in
Lung function
Symptoms
AEs
duration, device,
each trial
R
escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
400
µg MF 
Corren 
et al.,
198
parallel-
MF
+
+
+
NSD
++
8
%
vs 
group, double-blind, 
320
µg BUD
double-dummy RCT
, 
DPI, 8 weeks, 
n
=
262
BUD
9%
200
µg/
Bousquet 
et al.,
199
400
µg MF
parallel-group, 
vs evaluator
-blind, 
active-
800
µg BUD
controlled RCT
, DPI, 
12 weeks, n
= 730
NSD, no significant difference between trial arms; NW
, nocturnal waking; SFD, symptom-free days; SFN, symptom-free nights; SS, 
symptom score (varies between studies); +
indicates results favour this trial arm; blank cells signify no data reported on that outcome.
NSD
1 vs 3
NSD
1 vs 3
2 vs 3
NSD
1 vs 3
2 vs 3
NSD
1 vs 3
2 vs 3
4.3%
2.9%
2.2%
+
2 vs 3
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BUD versus MF (n
= 2 RCT
s)
1. MF
200
mg
2. MF
400 mg
3. BUDC
2 vs 3
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1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
200
µg/
O
’Connor 
et al.,
202
400
µg/MF
parallel-group, 
vs 500
µg FP
double-blind RCT
C, results appear to be comparable between treatment groups, but no tests of statistical significance reported; NSD, no signifi
cant difference between trial arms; NW
, nocturnal
waking; SFD, symptom-free days; SFN, symptom-free nights; SS, symptom score (varies between studies); blank cells signify no da
ta reported on that outcome; +, indicates results
favour this trial arm.
1. 200 
µg
MF
2. 400 
µg
MF
3. FP
C
2 vs 3
NSD 
1 vs 3
2 vs 3
+
1 vs 3
NSD
2 vs 3
NSD
1 vs 3
2 vs 3
20%
26%
29%
+
1 vs 3
R
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Lung function
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each trial
R
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Daily dose
number randomised
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FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
Buhl 
et al.,
200
parallel-group,
CIC 200
µg
double-blind, 
200
µg CIC 
double-dummy RCT
, 
C
NSD
NSD
vs 200
µg FP
HF
A MDI, 
12 weeks, n 
= 529
FP 200
µgF
Non-inferiority
(1:1 dose ratio)
C, results appear to be comparable between treatment groups, but no tests of statistical significance reported; F
, results appe
ar to favour this treatment group, but no tests of
statistical significance reported; NSD, no significant difference between trial arms; NW
, nocturnal waking; SFD, symptom-free d
ays; SFN, symptom-free nights; SS, symptom score
(varies between studies); blank cells signify no data reported on that outcome.
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FP versus CIC (n
= 1 RCT)
T
ABLE 28
FP versus MF (n
=
1 RCT)effects of treatment were considered to be minimal
by patients and physicians and did not require
cessation of treatment or withdrawal from the
study. Kaur and colleagues203 did not report rates
of AEs in the two trial arms, but did report
changes in serum cortisol. The mean 9 a.m. serum
cortisol level increased by 0.4 µg per 100 ml in the
BDP group and decreased by 0.85 µg per 100 ml
in the BUD group. The mean 4 p.m. serum
cortisol level decreased by 0.04 µg per 100ml in
the BDP group and decreased by 0.96 µg per
100 ml in the BUD group. The changes in serum
cortisol level were not found to be statistically
significant for either the 9 a.m. or the 4 p.m. level.
Analysis of individual patient data by Kaur and
colleagues203 found no significant difference
between the two treatment groups for the number
of patients with a >20% fall in either 9 a.m. serum
cortisol level (p > 0.5) or 4 p.m. serum cortisol
level (p > 0.1).
Summary
Two small, double-blind cross-over trials compared
1500–2000 µg BDP with 1600–2000 µg BUD.
There was limited reporting of outcome measures
appropriate for this systematic review. Neither of
the trials found a statistically significant difference
in lung function following treatment with the two
drugs. One of the studies reported that the mean
daily number of puffs of rescue medication was
statistically significantly higher in the BDP group.
In general, the two RCTs indicated that BDP and
BUD are similar in effects when used at 1:1 daily
dose ratios, except for use of rescue medication.
FP and BDP (review Q2 – high-dose ICS)
Study characteristics
Ten RCTs tested high doses of FP compared with
BDP (Table 31).191,204–212 The studies were
predominantly parallel in design but three trials
used cross-over designs.210–212 The studies varied
considerably in size (from 21 to 340 participants)
and length (from 6 weeks to 2 years). Only two
were undertaken in single centres.209,212 All
appeared to be superiority trials.
There were two parallel-group trials comparing 
FP with BDP in a nominal 1:1 dose ratio. 
Boe and colleagues205 randomised participants
(stratified by their pretrial dose of ICS) to either
2000 µg of FP daily or 1600 µg of BDP daily for
3 months. The study drugs were delivered by
Diskhaler DPI (Rotadisk, GSK – not explicitly
stated but deduced from the text). Fabbri and
colleagues204 randomised participants to either
1500 µg of FP daily or 1500 µg of BDP daily,
delivered by MDIs (no further details about
devices were reported), for 12 months. After
3 months, investigators were allowed to increase
the dose of the study drug to 2000 µg either
transiently or long term.
Five parallel group trials compared FP with BDP
in a nominal 1:2 (FP:BDP) dose ratio. Barnes and
colleagues206 randomised participants to either
1000 µg of FP or 2000 µg of BDP daily, delivered
by pressurised inhalers (no further details of
devices were reported), for 6 weeks. Egan and
colleagues209 compared 1000 µg of FP or 2000 µg
of BDP, daily by MDI (no further details of devices
were reported) for 2 years. The trial also
contained three open control groups of the same
age, although these are not discussed here.
Lorentzen and colleagues208 randomised
participants to either 1000 µg of FP or 2000 µg of
BDP daily, using MDIs (no further details of
devices were reported), for 1 year. Lundbäck and
colleagues’ study207 had three arms. Participants
took 500 µg of FP daily by either DPI Diskhaler
(Rotadisk, GSK – not explicitly stated but deduced
from the text) or a pressurised inhaler, or 1000 µg
of BDP daily by pressurised inhaler (the DPI
Diskhaler group is not reported here). The
randomised section of the trial lasted for 6 weeks.
At the end of this initial period the participants
had the option of continuing the trial on the same
study drugs for 12 months in order to assess long-
term efficacy (the participants on the FP Diskhaler
had to convert to a pressurised inhaler; the results
of this non-randomised second phase are not
reported here). Medici and colleagues’ study191
had four treatment arms comparing 400 µg of FP,
800 µg of BDP, 750 µg of FP and 1500 µg of BDP,
all daily by MDI (no further details were
reported), for 1 year. The lower doses of BDP and
FP have been reported earlier [see the section ‘FP
and BDP (review Q1 – low-dose ICS)’, p. 34].
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TABLE 29 Breakdown of studies for review question 2 – 
high-dose ICS
Pair-wise comparison No. of RCTs included
BDP and BUD 2
FP and BDP 10
HFA BDP and HFA FP 1
FP and BUD 6
CIC and BDP 0
MF and BDP 0
CIC and BUD 0
MF and BUD 1
CIC and FP 3
MF and FP 1
MF and CIC 0
Total 24Assessment of clinical effectiveness
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T
ABLE 30
Characteristics of studies comparing BDP and BUD
Study
Design
Intervention
P
atients
Outcomes
Ebden 
et al.,
1986
81
RCT
Cross-
over (no
washout
Double-blind
1.
BDP 250
µg 3 puffs b.d. (daily total 1500
µg) + placebo
4 puffs b.d.
2.
BUD 200
µg 4 puffs b.d. (daily total 1600
µg) + placebo
3 puffs b.d.
Delivery device:
1.
pMDI + spacer plus placebo
a
2.
pMDI + spacer plus placebo
a
Duration:
6 wks
Run-in period:
Not reported
Number randomised
28
Mean age (years)
54
Baseline FEV
1
(litres)
1.85
P
revious ICS treatment (drug and dose)
Not reported
FEV
1
FVC
PEF (morning and evening)
Daily SABA (puffs/day)
Daytime wheeze score
Morning serum cortisol
Serum cortisol 30 minutes post
250
µg tetracosactrin
K
aur 
et al.,
2005
203
RCT
Multi-centre
Cross-
over
Double-blind
1.
BDP 1000
µg b.d. (daily total 2000
µg)
2.
BUD 1000
µg b.d. (daily total 2000
µg)
Delivery device:
1.
MDI + spacer (Beclate, Cipla)
2.
MDI + spacer (Budecort, Cipla)
Duration:
6 wks
Run-in period:
1 wk
Number randomised
15
Mean age (±
SD) (years)
28.6 (±
8.0)
Baseline FEV
1
% predicted
Not reported
P
revious ICS treatment (drug and dose)
Not reported
Serum cortisol (9
a.m.) 
µg/100
ml
Serum cortisol (4
p.m.) µg/100
ml
24h urinary steroids mg/24
h
FVC (litres)
FEV
1
(litres)
a 
No further details about devices provided.All three of the cross-over trials compared FP with
BDP in a 1:2 dose ratio (FP:BDP). Bootsma and
colleagues212 compared 750 µg of FP daily with
1500 µg of BDP daily, using MDIs (no further
details of devices were reported), for 12 weeks.
Participants took placebo for 3 weeks during the
wash-out period. In the study by Pauwels and
colleagues,211 which had two arms, participants
were randomised to three different strata,
depending on their original dose of ICS: 500 µg
of FP or 1000 µg of BDP, 750 µg of FP or 1500 µg
of BDP and 1000 µg of FP or 2000 µg of BDP. All
were delivered by MDI (no further details
reported) and the trial lasted for 12 months, with
no wash-out period. Malo and colleagues’ study210
had two arms. Participants were randomised to
1000, 1500 or 2000 µg of BDP and half the
corresponding dose of FP daily, depending on
their previous levels of ICS. The drugs were
delivered using MDIs (no further details were
reported) and there was no wash-out period.
The average/median age of participants in the
trials ranged from mid-thirties to early fifties.
Almost all participants (except one patient212)
were previously taking either BDP or BUD with
doses ranging from 400 to 2000 µg/day. A number
of trials did not present data on baseline FEV1 %
predicted. However, for those that did, the mean
value ranged from 57 to 90%. Where stated,
authors generally described participants as
suffering from “moderate to severe” asthma.
Study quality was mixed. Although all trials
described themselves as randomised and double-
blinded, these procedures were rarely described in
any detail. Concealment of allocation was not
discussed in any of the trials. Unfortunately, most
trials did not state a primary outcome. Although
most focused on clinical efficacy outcomes, there
were a number of trials whose principal aim was to
determine effects on bone density/metabolism and
other possible systemic side-effects of
steroids.191,209–211 Pauwels and colleagues’ study211
was the only one analysed on an ITT basis. In the
study by Bootsma and colleagues,212 no carry-over
effects were detected for any variables.
Results
A meta-analysis was not undertaken due to
variation in the length of the trials and to
limitations in the data reported.
Lung function
FEV1 (litres). Parallel design, 1:1 dose ratio. Boe
and colleagues205 reported an increase in FEV1 of
0.19 and 0.06 litres in the FP and BDP groups,
respectively. The end-point mean values (SE) were
2.23 (0.11) and 2.16 (0.13) litres respectively.
There were no statistically significant differences
between treatments at any of the clinic visits (no 
p-value reported). In the study by Fabbri and
colleagues,204 the mean FEV1 increased from 2.14
and 1.81 litres for FP and BDP to 2.39 and
1.97 litres, respectively, over the 1-year treatment
period. The adjusted mean difference was
0.15 litres (95% CI 0.01 to 0.29, p < 0.05).
Parallel design, 1:2 dose ratio. In the study by
Barnes and colleagues,206 there was an increase in
FEV1 of 0.07 and 0.16 litres in the FP and BDP
groups, respectively. At end-point the adjusted
means were 1.95 and 1.89 litres, respectively. The
adjusted mean difference in end-point FEV1 was
non-significant, 0.66 litres (95% CI –0.07 to 0.19),
p = 0.343. There was significant difference between
groups at 12 months in the study by Lorentzen
and colleagues,208 in favour of FP (mean difference
0.12 litres, 95% CI 0.01 to 0.24, p = 0.044).
In the trial by Lundbäck and colleagues,207 the
adjusted mean change from baseline in FEV1 was
0.13 and 0.09 litres in the FP and BDP groups,
respectively. End-point values were 2.44 and
2.51 litres, respectively. There was no significant
difference between groups (no p-value reported).
Medici and colleagues191 did not formally analyse
lung function measures, but reported that mean
FEV1 values taken at bimonthly intervals over the
12-month study either remained similar or tended
to increase above baseline values. Egan and
colleagues209 did not measure this outcome.
Cross-over design, 1:2 dose ratio. Bootsma and
colleagues212 found no significant differences
between the two groups; the mean difference (SE)
between FP and BDP was 0.06 (0.07), 95% CI
–0.08 to 0.21. The other two trials did not report
this outcome.
FEV1 % predicted. Parallel design, 1:1 dose ratio.
Neither of the two studies reported this outcome
measure.
Parallel design, 1:2 dose ratio. Only Barnes and
colleagues206 reported this outcome measure.
There was an increase in FEV1 % predicted of 3
and 4% in the FP and BDP groups, respectively. At
end-point the adjusted means were 64 and 61%,
respectively [mean difference 2% (95% CI –2 to 6),
p = 0.358].
Cross-over design, 1:2 dose ratio. In the study by
Malo and colleagues,210 there was no significant
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ABLE 31
Study characteristics (FP and BDP)
Study
Design
Intervention
P
atients
Outcomes
Fabbri 
et al.,
1993
204
RCT
Multi-centre
P
arallel-group
Double-blind
Drugs:
1.
FP 750
µg b.d. (daily total 1500
µg)
2.
BDP 750
µg b.d. (daily total 1500
µg)
After first 3 months dose could be increased to 2000
µg
q.d. if needed
Delivery device:
1, 2. MDI ±
spacer 
Duration:
52 wks
Run-in period:
2 wks
Number randomised
274
Age range (years)
1.
17–77
2.
19–80
Baseline FEV
1
% predicted
Not stated
P
revious ICS treatment (drug and dose)
BUD or BDP 1000
µg but <2000
µg q.d.
PEF (morning and evening)
FEV
1
(litres)
Clinic PEF
FVC
Day and night symptom scores 
Use of study medication
Use of rescue medication
AEs
Morning plasma cortisol
24-hour urinary free cortisol
Asthma exacerbations
Barnes 
et al.,
1993
206
RCT
Multi-centre
P
arallel-group
Double-blind
Drugs: 
1.
FP 250 µg 2 puffs b.d. (daily total 1000 
µg)
2.
BDP 250 
µg 2 puffs b.d. from 2 inhalers (daily total
2000 
µg)
Delivery device: 
1, 2. MDI + placebo 
Duration:
6 wks
Run-in period:
2 wks
Number randomised
154
Median age (range) (years)
1.
50 (18–78)
2.
52 (20–75)
Baseline FEV
1
% predicted
1. 61
2. 57
P
revious ICS treatment (drug and dose)
BDP or BUD 1500–2000
µg q.d.
PEF (morning and evening)
FEV
1
(litres), (% predicted)
FVC
Clinic PEF
Day and night symptom scores 
Use of rescue medication
P
atient assessed asthma 
AEs
Plasma cortisol
Boe 
et al.,
1994
205
RCT
Multi-centre
P
arallel-group
Double-blind
Drugs:
1.
FP 1000
µg b.d. (daily total 2000
µg)
2.
BDP 800
µg b.d. (daily total 1600
µg)
Delivery device: 
1.
Diskhaler (R
otadisk, GSK
a
)
2.
Diskhaler (R
otadisk, GSK
a
)
Duration:
3 months 
Run-in period:
2 wks
Number randomised
134
Mean age (range) (years)
1.
51 (20–74)
2.
51 (27–75)
Mean baseline FEV
1
litres (±
SD) 
1.
2.04 (±
0.66)
2.
2.10 (±
0.93)
P
revious ICS treatment (drug and dose)
BDP or BUD 400–2000
µg q.d.
P
rimary outcome
PEF (morning and evening)
Secondary outcomes
Clinic PEF
FEV
1
(litres)
FVC
Day and night symptom score 
Use of bronchodilator
Serum cortisol
Plasma A
CTH
AEs
Asthma exacerbations
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T
ABLE 31
Study characteristics (FP and BDP) (cont’d)
Study
Design
Intervention
P
atients
Outcomes
Lundbäck 
et al.,
1993
207
RCT
Multi-centre
P
arallel-group
Double-blind
Drugs: 
1.
FP 125
µg 2 puffs b.d. (daily total 500
µg)
2.
FP 125
µg 2 puffs b.d. (daily total 500
µg)
3.
BDP 250
µg 2 puffs b.d. (daily total 1000
µg)
Delivery device:
1, 3. MDI + placebo
2. DPI Diskhaler (R
otadisk, GSK
a
) + placebo
Only groups 1 and 3 considered here
Duration:
6 wks
Run-in period:
2 wks
Number randomised
585
Mean age (±
SD, range) (years)
1.
46 (±
15, 18–78)
2.
45 (±
16, 16–91)
3.
46 (±
16, 15–90)
Baseline FEV
1
% predicted
Not stated
P
revious ICS treatment (drug and dose)
ICS 400–1000
µg q.d.
PEF (morning and evening)
FEV
1
(litres)
FVC
Clinic PEF
Day and night symptoms
Use of rescue medication
Plasma cortisol
Asthma exacerbations
Lorentzen 
et al.,
1996
208
RCT
Multi-centre
P
arallel-group
Double-blind
Drugs: 
1.
FP 250
µg 2 puffs b.d. (daily total 1000
µg)
2.
BDP 250
µg 4 puffs b.d. (daily total 2000
µg)
Delivery device: 
1, 2. MDI ±
spacer + placebo
Duration:
52 wks
Run-in period:
2 wks
Number randomised
213
Median age (range) (years)
1.
51 (18–77)
2.
54 (21–76)
Baseline FEV
1
% predicted
Not reported
P
revious ICS treatment (drug and dose)
BDP or BUD 1000–2000
µg q.d.
Clinic PEF
FEV
1
(litres)
FVC
AEs
Asthma exacerbations
Morning plasma cortisol
Egan 
et al.,
1999
209
RCT
Single-centre
P
arallel-group
Double-blind
Drugs: 
1.
FP 500
µg b.d. (daily total 1000
µg)
2.
BDP 1000
µg b.d. (daily total 2000
µg)
Delivery device:
1, 2. MDI + spacer
Duration:
108 wks
Run-in period:
2 wks 
Number randomised
33
Mean age (±
SD, range) (years)
1. 36 (±
8, 20–48)
2. 33 (±
10, 20–50)
Mean baseline FEV
1
(SD) (litres)
1. 2.91 (0.7)
2. 3.13 (1.1)
P
revious ICS treatment (drug and dose)
BDP or BUD 1000–2000
µg q.d. 
P
rimary outcome
Absolute BMD values
Secondary outcome
Biochemical markers of bone
turnover
Clinic PEF
AEs
continuedAssessment of clinical effectiveness
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T
ABLE 31
Study characteristics (FP and BDP) (cont’d)
Study
Design
Intervention
P
atients
Outcomes
Medici 
et al.,
2000
191
RCT
Multi-centre
P
arallel-group
Double-blind
Drug(s): 
1.
FP 200
µg b.d. (daily total 400
µg)
2.
BDP 400
µg b.d. (daily total 800
µg) 
3.
FP 375
µg b.d. (daily total 750
µg)
4.
BDP 750
µg b.d. (daily total 1500
µg)
Only groups 3 and 4 reported in this section
Delivery device: 
1, 2, 3, 4. MDI + spacer 
Duration:
52 wks
Run-in period:
4 wks
Number randomised
69
Mean age (±
SD) (years) 
1.
39 (±
8)
2.
38 (±
8)
3.
38 (±
10)
4.
40 (±
10)
Baseline FEV
1
% predicted (±
SD)
1.
79.9 (±
18.9)
2.
90.2 (±
14.0)
3.
75.0 (±
20.7)
4.
78.2 (±
14.8)
P
revious ICS treatment (drug and dose)
ICS 400–1600
µg q.d.
P
rimary outcome
BMD of the distal radius
Secondary outcome
PEF (morning and evening)
FEV
1
(litres)
Serum cortisol
Markers of bone metabolism
(serum and urine)
Use of rescue medication
Malo 
et al.,
1999
210
RCT
Multi-centre
Cross-
over (no
wash-
out)
Double-blind
Drugs: 
1.
FP daily dose half dose of BDP
b
2.
BDP 1000, 1500 or 2000
µg q.d.
b
Delivery device: 
1, 2. MDI 
Duration:
4 months for each treatment
Run-in period:
2 wks
Number randomised
67
Mean age (±
SD) (years)
48.4 (14.5)
Baseline FEV
1
% predicted (±
SD)
76 (±
18)
P
revious ICS treatment (drug and dose)
BDP or BUD 800–2000
µg q.d.
Daily asthma symptoms
FEV
1
(litres) (% predicted)
FVC 
Use of rescue medication
Skin bruising
Short synacthen test
Urinary cortisol, phosphorus,
calcium, 
N-telopeptides
Serum intact osteocalcin
Serum procollagen and specific
alkaline phosphatase
continuedHealth Technology Assessment 2008; Vol. 12: No. 19
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T
ABLE 31
Study characteristics (FP and BDP) (cont’d)
Study
Design
Intervention
P
atients
Outcomes
P
auwels 
et al.,
1998
211
RCT
Multi-centre
Cross-
over (no
wash-
out)
Double-blind
Drugs:
1.
FP 500 or BDP 1000
µg q.d.
c
2.
FP 750 or BDP 1500
µg q.d.
c
3.
FP 1000 or BDP 2000
µg q.d.
c
Delivery device:
1, 2, 3. MDI ±
spacer
Duration:
52 wks
Run-in period:
4
wks
Number randomised
340
Mean age (±
SD) (years)
FP/BDP 46.6 (±
14.6)
BDP/FP 46.2 (±
15.0)
Baseline FEV
1
% predicted (±
SD)
FP/BDP 78.4 (±
21.1)
BDP/FP 80.0 (±
20.7)
P
revious ICS treatment (drug and dose)
BDP 1000–2000
µg q.d. or BUD 800–1600
µg
q.d.
P
rimary outcome
Serum cortisol level
Secondary outcomes
FEV
1
(% predicted)
FVC
PEF (morning and evening)
Use of rescue medication
Symptom scores
Quality of life – Hyland’s Living
With Asthma Questionnaire 
(L
W
AQ)
Urinary bone markers
Dual-energy X
-ray 
absorptiometry (DEXA) – BMD
L2 to L4, hip (femoral neck,
trochanter and W
ard’s triangle)
AEs
Asthma exacerbations
Bootsma 
et al.,
1995
212
RCT
Single-centre 
Cross-
over
(3
wks wash-
out period)
Double-blind
Drugs: 
1.
FP 125
µg 3 puffs b.d. (daily total 750
µg)
2.
BDP 250
µg 3 puffs b.d. (daily total 1500
µg)
Delivery device:
1, 2. MDI + placebo 
Duration:
12 wks
Run-in period:
3 wks 
Number randomised
21
Mean age (±
SD) (years)
30.3 (±
7.4) 
Baseline FEV
1
% predicted (±
SD)
74.7 (±
18.1)
P
revious ICS treatment (drug and dose)
All but one used ICS before entering the study
(mean daily dose 790
µg q.d. (SE 54)
PEF (morning and evening)
FEV
1
Histamine and ultrasonically
nebulised distilled water
provocation test
Use of rescue inhaler
Asthma symptoms
AEs
Severity of symptoms (day and
night) 
Eosinophils
Serum cortisol
Serum and urinary markers of
bone turnover
a 
Not stated explicitly
, but deduced from the text.
b 
3 different doses of FP and BDP in each group depending on normal dose of ICS.
c 
Dose received depended on dose of current ICS.difference in the mean (SD) end-point FEV1 %
predicted between FP, 77.5% (17.1), and BDP,
77.5% (17.5), p = 0.7. Pauwels and colleagues211
also found no significant difference (results were
presented as a graph – it was not possible to
determine the values accurately). Bootsma and
colleagues212 did not report this outcome measure.
Morning and evening PEF (l/min)
Parallel design, 1:1 dose ratio. Boe and
colleagues205 only reported morning and evening
PEF as estimated increases per day over the
treatment period. Baseline and end-point values
were also reported, but for morning and evening
PEF combined.
The study by Fabbri and colleagues,204 which only
measured this outcome for the first 12 weeks,
reported that changes in both morning and
evening PEF were significantly greater in the FP
group. The mean difference, averaged over the
12-week period and adjusted for differences in
baseline values, country and use of spacer device,
for morning PEF was 15 l/minute (95% CI 6 to
25), p < 0.005, and 10 l/minute (95% CI 0 to 19,
p < 0.05) for evening PEF.
Parallel design, 1:2 dose ratio. Barnes and
colleagues206 reported an increase in morning PEF
of 14 and 30 l/minute in the FP and BDP groups,
respectively. At end-point the adjusted mean
values were 317 and 324 l/minute, respectively.
The adjusted mean difference for morning PEF at
end-point was –7 l/minute (95% CI –21 to 7),
p = 0.346. For evening PEF there was a decrease
of 1 l/minute in the FP group, compared with an
increase of 15 l/minute in the BDP group,
respectively. At end-point the adjusted mean
values were 336 and 348 l/minute, respectively.
The adjusted mean difference for evening PEF at
end-point was –13 l/minute (95% CI –26 to 1).
The p-value reported for the evening PEF (0.07)
was incompatible with the other values.
Lundbäck and colleagues207 found no significant
difference between the different treatment arms in
either morning or evening PEF. The adjusted
mean change from baseline in morning PEF was
19 and 14 l/minute in the FP and BDP groups,
respectively. End-point values were 383 and
394 l/minute, respectively. For evening PEF the
adjusted mean change from baseline was 11 and
14 l/minute in the FP and BDP groups,
respectively. End-point values were 400 and
411 l/minute, respectively. No p-values were
reported for between-group comparisons. Medici
and colleagues191 did not perform a formal
statistical analysis on lung function data. However,
mean daily morning and evening PEF values
either remained similar or tended to increase
slightly above baseline values (no data shown).
Egan and colleagues209 only reported clinic PEF,
rather than morning and evening PEF.
Cross-over design, 1:2 dose ratio. The mean (SE)
difference in treatment effect for morning PEF
between FP and BDP in the study by Bootsma and
colleagues212 was 5.57 l/minute (5.5), 95% CI 6.31
to 17.5 (note that it appears that the lower limit of
the CI is incorrect). The corresponding figures for
evening PEF were 2.69 l/minute (6.5), 95% CI
–10.9 to 16.3. The other two trials did not report
this outcome measure.
Symptoms
Days and nights without symptoms
Parallel design, 1:1 dose ratio. Fabbri and
colleagues204 reported an increase in the mean
percentage of symptom-free days of 19% in both
the FP and BDP groups between run-in and
12 weeks of treatment. Over the 12 weeks, values
were 38 and 41% for the two groups, respectively.
There were no significant differences between
groups (no p-values were presented). Increases in
mean percentage of symptom-free nights of 14
and 13% in the treatment groups, respectively,
were also reported. Over the 12 weeks, values were
61 and 63%, respectively. Again, there were no
significant differences between groups (no p-values
presented). Boe and colleagues205 did not report
this outcome measure.
Parallel design, 1:2 dose ratio. In the study by
Barnes and colleagues,206 there was an increase in
the percentage of symptom-free days of 14% in
the FP group and 9% in the BDP group. At end-
point the mean percentage of symptom-free days
for FP was 52% and for BDP 37%, p = 0.212.
There was an increase in the percentage of
symptom-free nights of 13 and 12%, respectively.
At end-point the mean percentage of symptom-
free nights for FP was 59% and for BDP 50%,
p = 0.854. Lundbäck and colleagues207 reported
that there were no statistical differences between
the groups for either symptom-free days or nights.
However, no data or p-values were provided. The
remaining three trials did not report on this
outcome.
Cross-over design, 1:2 dose ratio. The percentage
of symptom-free days or nights in the study by
Pauwels and colleagues211 did not differ
significantly (no p-values reported). The
percentage (SD) of symptom-free days at 6 months
Assessment of clinical effectiveness
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The corresponding figures for symptom-free
nights were 81.0 (33.3) and 79.0 (35.4). The other
two trials did not report on this outcome measure.
Daily symptom scores
Parallel design, 1:1 dose ratio. Boe and
colleagues205 measured both day and night
symptom scores using a scoring instrument (no
reference supplied). Day symptoms were measured
on a six-point scale (0 = no symptoms during the
day, 5 = symptoms so severe that you could not 
go to work or perform normal daily activities).
Night symptoms were measured on a five-point
scale (0 = no symptoms during the night, 
4 = symptoms so severe that you did not sleep at
all). At baseline the mean (SEM) daily scores were
1.70 (0.11) and 1.94 (0.11) and night scores were
0.77 (0.08) and 0.85 (0.08) in the FP and BDP
groups, respectively. Over the 12-week treatment
period these reduced significantly in both groups.
Corresponding values were 1.35 (0.13) and 1.60
(0.12) for daily scores and 0.62 (0.08) and 0.65
(0.08) for nightly scores. There were no significant
differences between groups (no p-value reported).
Fabbri and colleagues204 measured day and night
symptoms using a four-point scale (0 = no
symptoms, 4 = bad symptoms; no reference
supplied). Changes in scores were not presented,
other than that fewer than 10% of patients in either
group had median symptom scores of 2 or more.
Parallel design, 1:2 dose ratio. Barnes and
colleagues206 measured day and night symptoms
on a four-point scale (0 = none, 3 = poor; no
reference supplied). Changes in scores were not
reported, although the proportion of patients with
a day- or night-time symptom score of 0 was
reported. Lundbäck and colleagues207 measured
day and night symptoms using a four-point scale
(0 = no symptoms, 3 = bad symptoms; no
reference supplied). Limited data were reported.
Over weeks 1–6, median daytime scores were
significantly lower for BDP than for FP (p = 0.03).
Cross-over design, 1:2 dose ratio. Bootsma and
colleagues212 measured symptom scores
(dyspnoea) using a visual analogue scale ranging
from 0 to 100 mm (reference supplied). Lower
scores indicate fewer symptoms. There were no
significant differences between FP and BDP (no p-
value given). The end-point day score (SE) for FP
was 7.3 (21) and for BDP 6.4 (1.9). Corresponding
values for night scores were 5.6 (2.0) and 5.9 (2.2),
respectively. The other trials did not report this
outcome measure.
Health-related quality of life
Parallel design, 1:1 dose ratio. Neither study
presented data on these outcomes.
Parallel design, 1:2 dose ratio. No trials reported
on this outcome.
Cross-over design, 1:2 dose ratio. In the study by
Pauwels and colleagues,211 quality of life was
measured using the Hyland’s Living with Asthma
questionnaire (reference supplied). There was a
small significant difference in favour of FP. The
mean difference between end-point scores after
6 months was 0.02 (95% CI 0.00 to 0.04),
p < 0.05. The other two studies did not report this
outcome measure.
Use of rescue medication (mean puffs per day)
Parallel design, 1:1 dose ratio. Boe and
colleagues205 reported a decrease in mean puffs
per day of SABA use of 0.51 and 0.57 in the FP
and BDP groups, respectively. The end-point
mean (SE) numbers of puffs per day were 2.24
(0.24) and 2.35 (0.25), respectively. Reductions in
night use were 0.04 and 0.25 in the FP and 
BDP groups, respectively. End-point mean (SE)
number of puffs per night were 0.73 (0.14) 
and 0.51 (0.09). There were no significant
differences between groups (no p-values 
reported). Fabbri and colleagues204 did not
present results for rescue medication use in 
terms of mean puffs per day.
Parallel design, 1:2 dose ratio. In the study by
Barnes and colleagues,206 both treatment groups
reduced their use of rescue medication
(salbutamol) by three times per day. End-point
values were 10 for the FP group and 11 for the
BDP group, p = 0.866. There was a reduction of
one and two times per night for these groups,
respectively. Corresponding end-point values were
5 and 6, p = 0.875. Lundbäck and colleagues207
did not report the use of rescue medication in
terms of mean puffs per day. The other three trials
did not report this outcome measure.
Cross-over design, 1:2 dose ratio. In the study by
Bootsma and colleagues,212 the mean (SE)
difference in number of puffs per day between FP
and BDP was –0.25 (0.22) (95% CI –0.72 to 0.21).
The other two trials did not report this outcome
measure.
Exacerbations
Parallel design, 1:1 dose ratio. In the study by
Fabbri and colleagues,204 asthma exacerbations
were defined as increasing asthma symptoms
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SABA rescue therapy. There were 33 exacerbations
in 23 (16%) people in the FP group and 62
exacerbations in 37 (28%) people in the BDP
group, p < 0.05. The numbers of patients
experiencing a severe exacerbation were three
(2%) and 13 (10%) in these groups, respectively
(p < 0.02). Boe and colleagues205 reported that
there were three exacerbations during treatment
in the FP group and eight in the BDP group.
During follow-up there were one and two
exacerbations, respectively.
Parallel design, 1:2 dose ratio. Barnes and
colleagues206 reported that six patients taking FP
and two taking BDP were withdrawn due to
exacerbations. During the study by Egan and
colleagues,209 11 (65%) patients in the FP group
and six (38%) patients in the BDP group had one
or more exacerbations requiring a short course of
oral corticosteroids on at least one occasion 
(p-value not reported).
Lundbäck and colleagues207 only reported
exacerbation data for the non-randomised 
12-month study period, as opposed to the 6-week
randomised period of interest to the current
report. In the study by Lorentzen and
colleagues,208 62 (39%) patients in the FP group
and 26 (48%) patients in the BDP group had at
least one exacerbation (defined as an increase in
asthma symptoms necessitating a change in
therapy other than inhaled SABA). There was no
statistical difference between the two groups 
(p-value not reported). Medici and colleagues191
reported that there was no significant difference
between exacerbation rates in the high-dose
groups (no values were reported).
Cross-over design, 1:2 dose ratio. In the study by
Malo and colleagues,210 there were nine
exacerbations requiring oral steroids in the FP
group and eight in the BDP group, p=0.4. An
exacerbation was noted by the use of more than
eight puffs of rescue salbutamol in a 24-hour
period, effectiveness of rescue salbutamol lasting
more than 3 hours, waking due to asthma
symptoms or loss of a day at work because of
asthma symptoms. Pauwels and colleagues211
reported that exacerbation of asthma was the
reason for withdrawal in 10 of 28 patients.
Withdrawals due to exacerbation were numerically
more frequent under BDP than FP (seven and
three, respectively. There was no statistically
significant difference, p-value not reported).
Bootsma and colleagues212 did not report this
outcome measure.
Adverse events
Parallel design, 1:1 dose ratio. Boe and colleagues
stated that the number of side-effects was similar
in both groups and no life-threatening side-effects
or deaths occurred during the study. However, it
was not possible to extract data on the total
number of side-effects or the number of people
experiencing them. In the study by Fabbri and
colleagues,204 there were 276 AEs in 70% of FP
participants and 267 AEs in 73% of BDP
participants. About 16% of patients in the FP
group experienced a serious AE compared with
23% of patients in the BDP group; 8% of patients
withdrew from both groups due to AEs.
Parallel design, 1:2 dose ratio. In the study by
Barnes and colleagues,206 there were 71 AEs in 43
(52%) patients in the FP group and 60 AEs in 37
(51%) patients in the BDP group, p > 0.15. Eight
(10%) patients in the FP group and five (7%)
patients in the BDP group had serious AEs. The
numbers of withdrawals due to AEs were eight
(10%) and five (7%), respectively.
Egan and colleagues209 reported that the AE
profile and overall incidence of AEs were similar
for both groups, but no data were provided. In the
trial by Lorentzen and colleagues,208 equal
proportions of patients reported AEs, FP 114
(72%) and BDP 39 (72%). The number of patients
experiencing serious AEs in the FP group was 11
(7%) and in the BDP group three (6%). The
corresponding numbers of patients withdrawing
from the trial because of AEs were 20 (13%) and
five (9%) respectively.
In the study by Lundbäck and colleagues,207 the
numbers of people experiencing AEs in the MDI
FP group and MDI BDP group were 97 (50%) and
89 (46%) respectively. There was no statistically
significant difference between the groups (p-value
not reported). The corresponding values for the
number of people withdrawing due to AEs
(including exacerbations) were 13 and 16. Medici
and colleagues191 reported a similar number of
patients from both groups experiencing AEs but
no further details were provided. There were no
serious AEs.
Cross-over design, 1:2 dose ratio. In the study by
Bootsma and colleagues,212 there were no serious
AEs, however, it was not possible to extract any
further data. Pauwels and colleagues211 found a
similar number of AEs in both groups (FP, 217 in
66.8% of patients; BDP, 215 in 66.2% of patients),
which was not statistically significant (p-value not
reported). There were 13 serious AEs in 4% of
Assessment of clinical effectiveness
76patients in the FP group and 10 serious AEs in 3%
of patients in the BDP group. Twenty-eight
patients discontinued the study due to AEs,
thirteen in the FP group and 15 in the BDP
group. Malo and colleagues210 did not report on
this outcome measure.
Cortisol levels
Parallel design, 1:1 dose ratio. In the trial by Boe
and colleagues,205 the mean (SE) change from
baseline to end of treatment in serum cortisol was
–133.5 nmol/1 (26.5) and 40.4 nmol l/1 (26.9) in
the FP and BDP groups, respectively [p < 0.001,
from analysis of covariance (ANCOVA)]. At 14-week
follow-up the difference was not statistically
significant (p-value not reported). Fabbri and
colleagues204 found no difference in the analysis of
geometric mean cortisol levels between groups
(adjusted ratio of FP to BDP 1.10, 95% CI 0.89 to
1.37). There was no difference in the 24-hour
urinary cortisol levels between the groups.
Parallel design, 1:2 dose ratio. In the study by
Barnes and colleagues,206 the ratio of the FP
adjusted geometric mean to the BDP mean for
plasma cortisol concentration was 1.27 (95% CI
1.03 to 1.56), p = 0.026. Egan and colleagues209
did not find a statistically significant treatment
difference between FP and BDP at 12 months
(data were provided in a figure, but the reviewers
were unable to estimate the values). In the study
by Lorentzen and colleagues,208 the ratio of the FP
adjusted geometric mean to BDP was significantly
increased, 1.22 (95% CI 1.05 to 1.43), p = 0.01.
Lundbäck and colleagues207 did not find a
statistically significant difference between
geometric mean plasma cortisol levels. End-point
values for MDI FP and MDI BDP were 377 and
364 nmol/l, respectively (no p-values reported).
The geometric mean of the morning serum
cortisol concentration (in nmol/l) estimated by
Medici and colleagues191 remained within the
normal range for both FP- and BDP-treated
patients throughout the 12-month study period.
Cross-over design, 1:2 dose ratio. Bootsma and
colleagues212 found no significant difference
between groups (no p-value reported). The mean
cortisol end-point value was 0.61 µmol/l for FP
and 0.51 µmol/l for BDP. In the study by Malo and
colleagues,210 there was no significant difference in
urinary or plasma cortisol levels between
treatments. The end-point mean plasma cortisol
levels (SD) for FP and BDP were 410 (249) and
418 (245) µmol/dl, respectively, p = 0.7. The
corresponding values for mean 24-hour urinary
cortisol levels were 105 (64) and 109 (80) µmol/dl,
p = 0.6. Pauwels and colleagues found no
significant difference between treatments. The
mean serum cortisol end-point values (SD) for FP
and BDP were 13.31 (6.88) and 13.29 (6.26) µg%,
respectively (the authors state no differences
between groups, no p-values reported).
Bone mineral density
Parallel design, 1:2 dose ratio. Egan and
colleagues209 found a significant difference in
single-energy quantitative computed tomography
(QCT) of vertebral trabecular (T12 to L3) at 12
(p = 0.006) and 24 months (p = 0.004) in favour
of FP. The mean (SD) end-point value for BMD in
the FP group at 12 and 24 months was 154 (29.2)
and 153 (26.8) mg/cm3 respectively. The
corresponding values for BDP were 144 (19.5) and
145 (19.6) mg/cm3. There was a statistically
significant difference between groups in favour of
FP in dual-energy QCT at 24 months (p = 0.033)
but not at 12 months (no p-value given). The
mean (SD) end-point value in the FP group at 12
and 24 months was 155 (30.6) and 161
(24.2) mg/cm3, respectively. The corresponding
values for BDP were 148 (21.3) and 148
(24.6) mg/cm3. Dual-energy X-ray absorptiometry
of the spine, femoral neck and whole body were
essentially unchanged at 6, 12 and 24 months.
Single photon absorptiometry of the forearm
increased slightly over baseline at 6, 12 and
24 months in both groups but there were no
significant differences.
Medici and colleagues191 provided a detailed
evaluation of the impact of FP and BDP on BMD
(in g/cm3) and other bone metabolism markers.
Peripheral quantitative computed tomography
(pQCT) of the distal radius showed no significant
difference in the BMD between the two groups at
6 or 12 months. Overall, compared with baseline,
there was no loss of trabecular or integral bone in
the radius or tibia in any patients over 12 months.
Some negative changes were recorded in the
median bone density of compact bone of the
radius and tibia in the high-dose FP group, but
this was not thought to be clinically significant as
the changes did not exceed –2%. The only result
of borderline statistical significance was compact
bone density of the radius at 12 months, which
was in favour of BDP, although not thought to be
clinically significant (p = 0.048). Dual-energy 
X-ray absorptiometry of the lumbar vertebrae
showed no differences between the high-dose
treatments at 6 or 12 months. There were no
statistically significant differences between groups
on biochemical markers of bone formation or
resorption except for carboxy-terminal cross-
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µg/l) which suggested greater bone resorption
activity in patients taking FP than those taking
BDP (p = 0.031).
The other three trials did not report this outcome
measure.
Cross-over design, 1:2 dose ratio. Pauwels and
colleagues211 measured BMD in the lumbar spine
(L2 to L4) and hip (femoral neck, femoral
trochanter, and femoral Ward’s triangle) by dual-
energy X-ray absorptiometry. After 6 months the
mean end-point BMD (SE) in the lumbar spine
was 1.118 (0.016) and 1.116 (0.018) g/cm2 in the
FP and BDP groups, respectively. In the neck of
the femur the results for FP were 0.932
(0.015) g/cm2 and for BDP 0.912 (0.014) g/cm2.
The corresponding values for the trochanter were
0.736 (0.013) and 0.741 (0.013) g/cm2. The values
for Ward’s triangle were 0.728 (0.017) and
0.693 (0.018) g/cm2, respectively. The treatments
were not directly compared and no other values
were presented.
Pauwels and colleagues211 also reported
biochemical markers of bone metabolism. Mean
end-point (SD) values for osteocalcin were 1.72
(1.40) and 1.53 (1.02) ng/ml in the FP and BDP
groups, respectively (mean difference 0.28 ng/ml;
95% CI 0.12 to 0.44, p < 0.001).
Of the biochemical markers of bone metabolism
measured by Malo and colleagues,210 there was
only one statistically significant difference.
Osteocalcin was significantly lower when patients
were on BDP than FP. Mean end-point (SD) values
were 3.5 (1.9) and 2.8 (1.7) ngm/l, respectively,
p = 0.003.
Bootsma and colleagues212 did not report this
outcome measure.
Summary
Ten studies comparing FP with BDP at high doses
(according to the BTS/SIGN Guideline) were
identified. There was variability in design, length
of treatment, doses and size. The studies were
predominantly parallel-group in design, but three
trials used cross-over designs. Two parallel-group
trials compared 1500–2000 µg FP with
1500–1600 µg BDP in a nominal 1:1 dose ratio.
Five parallel group trials compared 500 –1000 µg
FP with 1000–2000 µg BDP in a nominal 1:2
(FP:BDP) dose ratio. The cross-over trials
compared 500–1500 µg FP with 1000–2000 µg
BDP in a 1:2 dose ratio.
Of the two studies comparing the drugs at a
nominal dose ratio of 1:1, one of the trials
reported significant differences in FEV1 and
morning and evening PEF, and exacerbations in
favour of FP. There were no statistically significant
differences between groups for use of rescue
medication and symptoms. The AEs profiles
seemed similar, except for cortisol levels, which
were significantly lower for FP.
The five parallel-group studies comparing FP and
BDP at a nominal 1:2 dose ratio found few
statistically significant differences in efficacy
outcomes. The AE profiles seemed similar. However,
cortisol levels were increased in the FP group and
the results for impact on BMD were mixed.
One of the three cross-over trials comparing FP
and BDP at a 1:2 ratio found a small, significant
increase in HRQoL. However, neither drug
demonstrated clear superiority on efficacy
outcomes. The AE profiles appeared similar.
HFA–BDP and HFA–FP (review Q2 – high-dose ICS)
Study characteristics
One study, by Aubier and colleagues,213 published
in 2001, compared high doses of HFA–BDP with
HFA–FP (Table 32). Both drugs were administered
as metered-dose aerosols with HFA propellants
(BDP – Qvar Easi-Breathe, 3M; no further details
of FP device provided). The study was a two-arm
trial comparing BDP against FP for 198 patients.
The drugs were compared in a nominal 1:1 daily
dose ratio (800 µg/day HFA–BDP versus
1000 µg/day HFA–FP).
The patients’ ages ranged from 19 to 78 years,
with mean ages in the trial arms of approximately
50–52 years. Patients in the two trial arms were
generally similar at baseline. However, the mean
eosinophil count was significantly higher in the
HFA–BDP group (p = 0.03) and the mean corrected
urine cortisol/creatine ratio was significantly
higher in the HFA–FP group (p < 0.05).213
The study was an open-label trial, without any
blinding of the patients or the researchers to the
drug treatments. The study did not report details
of the procedures for randomisation or concealment
of allocation. The study was designed to achieve
80% power to detect differences between the drugs
for the change in morning PEF from baseline.
The objective of Aubier and colleagues213 was to
test the equivalence of HFA–BDP with an HFA
formulation of FP. Their null hypothesis was that
the mean change from baseline in the morning
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T
ABLE 32
Study characteristics (HF
A BDP and HF
A FP)
Study
Design
Intervention
P
atients
Outcomes
Aubier 
et al.,
2001
213
RCT
P
arallel-group
Open-label
1.
BDP 800
µg q.d.
2.
FP 1000
µg q.d.
Delivery device: 
1.
HF
A MDI (Extrafine aerosol, Qvar Autohaler
, 3M)
2.
HF
A MDI (no further details reported)
Duration:
8 wks
Run-in period:
7–14 ±
2 days
Number randomised
ITT total 198
Mean age (range) (years)
1.
50.1
a
(19–76)
2.
51.9
a
(20–78)
Baseline FEV
1
% predicted
1.
71.7
a
2.
71.8
a
P
revious ICS treatment (drug and dose)
500–1000 
µg q.d. CFC BDP (or equivalent)
Change from baseline in morning
and evening PEF 
FEV
1
(litres)
Asthma symptom scores
Sleep disturbance scores
R
escue medication usage
a 
Assumed by the reviewers to be mean values (not stated in trial report).Assessment of clinical effectiveness
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PEF would differ between the drugs by more than
±25 l/minute. The remainder of the outcomes
were analysed using statistical tests to detect
significant differences between treatments.
Results
Lung function
Change from baseline to end-point in FEV1. The
mean change (SD) from baseline in FEV1 was
slightly larger for HFA–BDP than for HFA–FP [0.11
(0.5) versus 0.07 (0.49), respectively; p = 0.21].
Change from baseline in morning and evening PEF.
The mean (± SD, converted from SE by reviewers)
change from baseline to end-point (8 weeks) in the
morning PEF was 29.59 ± 52.16 l/minute for
HFA–BDP and 17.13 ± 53.68 l/minute for
HFA–FP. The difference (12.46 l/minute) had a
90% CI of –0.02 to 24.91, which was within the
defined equivalence interval of ±25 l/minute.
However, in the PP analysis the difference
exceeded the equivalence limits. The change from
baseline to end-point in evening PEF was
24.9 l/minute for HFA–BDP and 12.0 l/minute for
HFA–FP; this difference is not statistically
significant (p = 0.13; test of difference).
Symptoms
Aubier and colleagues213 reported that the mean
(± SD, calculated by reviewers) change from
baseline to end-point in the percentage of days
without asthma symptoms was 24.32 ± 44.1% for
HFA–BDP and 18.20 ± 39.4% for HFA–FP. This
difference between the drugs was not statistically
significant (p = 0.23; test of difference). However,
the change did differ significantly between the
drugs part way through the study (at 3 weeks): the
change in the days without asthma from baseline
to 3 weeks was 18.32 ± 34.2 for BDP and 6.84 ±
25.6 for FP (p = 0.03). Aubier and colleagues213
commented, without providing data, that changes
from baseline to end-point in the percentage of
days without wheeze, cough, shortness of breath,
chest tightness or nights without disturbed sleep
did not differ significantly between the treatments.
Use of rescue medication
Although Aubier and colleagues213 reported
change in use of rescue medication, this was not
presented as number of puffs per day, so is not
included here.
Exacerbations
Asthma exacerbations were not reported explicitly,
but worsening asthma symptoms resulted in the
withdrawal from treatment of four patients (see
below).
Adverse events
A slightly higher proportion of adverse effects
occurred among patients treated with HFA–FP
than among patients treated with HFA–BDP (24.8
versus 38.3%). Three patients in the HFA–BDP
group (7.8%) withdrew from the study due to AEs
(dysphonia and headache, cough and asthma
symptoms), and one patient in the HFA–FP
treatment withdrew due to AEs (dysphonia and
increasing asthma symptoms).
Summary
The systematic review included one parallel-group
RCT213 which compared 800 µg/day HFA–BDP
with 1000 µg/day FP in a nominal 1:1 dose ratio.
It was designed to demonstrate the
equivalence/non-inferiority of the two treatments
with respect to the primary outcomes. However,
there were limitations in methodology and the
quality of reporting was poor. The limited
information available suggests that there were few
differences in clinical efficacy or safety between
HFA–BDP and FP. The study demonstrated
equivalence/non-inferiority on the primary
outcome measure. For most of the outcomes,
HFA–BDP was favoured over the comparator but
the differences were generally small and not
statistically significant.
FP and BUD (review Q2 – high-dose ICS)
Study characteristics
Six parallel-group RCTs214–219 evaluated the
effectiveness of BUD compared with FP, published
between 1995 and 2005 (Table 33). One study219
reported additional data in a secondary
publication.220 Four studies were multi-centre
studies where study sample sizes ranged between
395 and 671 participants, and two studies were
single-centre studies where sample sizes ranged
between 59 and 197. Four of the trials reported
undertaking a power calculation, where adequate
power in the sample was met.214,215,217,219
Four included trials had two-arm comparisons of
BUD versus FP.214,215,217,218 The remaining trials
were three-arm comparisons; one had two FP
groups (at different doses)216 and the other had a
BDP treatment group (not described here).219
Two trials had a nominal dose ratio of 1:1,214,215
three a nominal dose ratio of 1:2217–219 and the
three-arm trial with two doses of FP had a 1:2
nominal dose ratio and a 1:1 nominal dose ratio
comparison.216 Of the three 1:1 nominal dose
ratio comparisons, two were of higher doses (one
comparing 2000 µg FP with 2000 µg BUD214 and
one 2000 µg FP with 1600 µg BUD216) and onewas of a lower dose comparison (800 µg FP versus
800 µg BUD215). In the four 1:2 nominal dose
ratio comparisons, the dose of FP was 1000 µg
compared with BUD 1600 µg in three216,218,219 and
FP 800 µg versus BUD 1600 µg in one.217
The devices used in four studies were DPIs (FP,
Flixotide Diskhaler, GSK; BUD, Pulmicort
Turbuhaler, AZ)214,215,217,219 and MDIs in two
studies (no further details of devices were reported
in either study).216,218 The treatment duration in
the studies ranged from 5 weeks215 to
12 months.218 Two of the three studies with 1:1
dose comparisons were of short duration
(5 weeks215 and 6 weeks,216 respectively) and one
of long duration (24 weeks).214 Two of the four
studies with 1:2 dose comparisons were of medium
duration (12 weeks)217,219 and one was a long-term
study.218 The fourth comparison was from a study
with a shorter 6-week duration.216
All included trials aimed to compare the clinical
efficacy and safety of the two drugs. The trial by
Ringdal and colleagues217 was reported to be an
equivalence trial, assessing morning PEF as their
primary outcome. The longer term study (by
Hughes and colleagues218) was designed to assess
the effect of long-term use of the drugs on
measures of bone markers and bone density. The
study by Kuna215 was designed to estimate the
minimal effective doses of the two drugs.
The ages of participants in the trials were similar,
with mean ages ranging from 41 to 53 years. The
severity of asthma varied across the six studies and
is reflected in the differences in the doses (see
above). In the 1:1 dose ratio comparisons
participants were described as mild to moderate in
severity in one trial215 and severe in two
trials.214,216 In the 1:2 dose ratio comparisons
participants were described as moderate to severe
in three trials217–219 and severe in one.216 This last
trial is the trial that also had a 1;1 dose ratio
comparison. In the included trials all or most
participants were already prescribed various ICS.
Baseline FEV1 % predicted varied in the included
trials and was related to the severity of the
participants.
The quality of reporting and methodology of the
included trials was generally good. Five of the six
trials were assessed to have used an adequate
method of randomisation; no details were
reported for the method of randomisation in the
one remaining trial.214 In addition, four of the
included trials were assessed to have an adequate
method of concealment of allocation; in the other
two trials the method was unclear.214,218 These
factors limit the possibility of selection bias. Five
studies reported that their analyses were based on
an ITT population, which minimises the
possibility of measurement bias.
Results
Lung function
Parallel design, 1:1 dose ratio. One trial216
reported data on change from baseline on FEV1,
although it did not report any measure of variance
around the point estimates. Adjusted for baseline
differences, the mean change from baseline after
6 weeks of treatment was 0.28 litres in the FP
2 mg/day arm compared with 0.12 litres in the
BUD 1.6 mg/day arm. The difference between the
study groups was shown to be statistically
significant, p < 0.05. This analysis was not on an
ITT population.
After 24 weeks, participants in the Heinig and
colleagues214 trial had similar end-point FEV1
values regardless of treatment [2.30 (SD
0.90) litres for FP 2 mg versus 2.30 (SD 0.90) litres
for BUD 2 mg]. Similar end-point values of FEV1
were also seen in both arms of the 5-week study by
Kuna.215 No point estimates were provided but the
mean FEV1 was 2.63 litres in the FP (800 µg) arm
compared with 2.61 litres in the BUD (800 µg)
arm. The study reported no statistically significant
difference between treatments, p = 0.69. In this
study, no statistically significant differences
between treatments were demonstrated on FEV1 %
predicted: FP 80.7% versus BUD 79.7%, p = 0.48.
The change in morning PEF was 3.36 (SD
43.62) l/minute in the FP arm of the Kuna trial215
and –0.81 (SD 41.05) l/minute in the BUD arm.
The treatment difference (4.17 l/minute) was not
statistically significantly different (95% CI –7.65 to
15.99). The evening PEF in the same study was
reported as an end-point value rather than the
change from baseline, and it can be seen that
these values were also not statistically significantly
different between the two treatment groups (FP
407 and BUD 392 l/minute, p = 0.08).
Parallel design, 1:2 dose ratio. Two trials216,219
reported data on change from baseline on FEV1.
Molimard and colleagues219 reported that the
mean change in FEV1 after 12 weeks was 0.28
(SD 0.49) litres in the FP arm compared with 0.21
(SD 0.4) litres in the BUD arm. Molimard and
colleagues219 found no statistically significant
differences between groups (p = 0.250), but the
significance test included a third treatment arm
not discussed here. In the trial by Ayres and
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T
ABLE 33
Characteristics of studies: FP versus BUD
Study
Design
Intervention
P
atients
Outcomes
Heinig 
et al.,
1999
214
RCT
Multi-centre
P
arallel-group
Double-blind
Drugs:
1.
FP 1000
µg b.d. (daily total 2000
µg)
2.
BUD 1200
µg a.m. and 800
µg p.m. (daily total 2000
µg)
Delivery device:
1.
DPI (Flixotide Diskhaler
, GSK) + placebo T
urbuhaler
2.
DPI (Pulmicort T
urbuhaler
, AZ) + placebo Diskhaler
Duration:
24 wks
Run-in period:
2 wks
Number randomised
395
Mean age (years)
1, 2. 48 
Baseline FEV
1
% predicted
Not reported
P
revious ICS treatment (drug and dose)
Not reported
FEV
1
PEF
Symptoms
Exacerbations
R
escue medication
AEs
K
una, 2003
215
RCT
:
Single-centre 
P
arallel-group
Double-blind
Drugs:
1.
FP 400
µg b.d.
a
(daily total 800
µg)
2.
BUD 400
µg b.d.
a
(daily total 800
µg)
Delivery device:
1.
DPI (Flixotide Diskhaler
, GSK)
2.
DPI (Pulmicort T
urbuhaler
, AZ)
Duration:
5 wks
Run-in period:
4–6 wks
Number randomised
197
Mean age (years)
1, 2. 41
Baseline FEV
1
% predicted
79.4
P
revious ICS treatment (drug and dose)
800–1600
µg b.d. ICS other than FP or BUD
Time to withdrawal
Morning PEF
FEV
1
T
olerability
Ayres 
et al.,
1995
216
RCT
Multi-centre
P
arallel-group
Double-blind
Drugs:
1.
FP 125
µg 4 puffs b.d. ex
actuator (daily total 1000
µg) 
2.
FP 250
µg 4 puffs b.d. ex
actuator (daily total 2000
µg) 
3.
BUD 200
µg 4 puffs b.d. ex
actuator (daily total 1600
µg) 
Delivery device:
1,  2, 3. MDI (no further details reported)
Duration:
6 wks
Run-in period:
2 wks
Number randomised
671
Mean age (years)
49 
Baseline FEV
1
% predicted
<80
P
revious ICS treatment (drug and dose)
BDP 1000–2000
µg q.d. or BUD
800–1600
µg q.d.
FEV
1
PEF (morning and evening)
Symptom-free days
Symptom-free nights
Daytime symptom score
Night-time symptom score
R
escue SABA
-free days
Asthma exacerbations
Morning plasma cortisol
Biochemical markers of bone
turnover
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T
ABLE 33
Characteristics of studies: FP versus BUD (cont’d)
Study
Design
Intervention
P
atients
Outcomes
Ringdal 
et al.,
1996
217
RCT
Multi-centre
P
arallel-group
Double-blind
Drugs:
1.
FP 800
µg q.d.
2.
BUD 1600
µg q.d.
Delivery device:
1.
DPI (Flixotide Diskhaler
, GSK
b
)
2.
DPI (Pulmicort T
urbuhaler
, AZ
b
)
Duration:
12 wks
Run-in period:
2 wks
Number randomised
518
Mean age (SD) (years) 
1.
47.6 (14.8)
2.
48.3 (14.0)
Baseline FEV
1
% predicted
1, 2. 45–90
P
revious ICS treatment (drug and dose)
BDP 400–2000
µg q.d., BUD 400–2400
µg q.d.
or FP 400–1000
µg q.d.
FEV
1
PEF (morning and evening)
Daytime symptom score
Night-time symptom score
% symptom-free days
% symptom-free nights
% rescue SABA
-free days
% rescue SABA
-free nights
Morning plasma cortisol
Hughes 
et al.,
1999
218
RCT
Single-centre
P
arallel-group
Open-label
Drugs: 
1.
FP 500
µg b.d. (daily total 1000
µg)
2.
BUD 800
µg b.d. (daily total 1600
µg)
Delivery device:
1, 2. MDI + large spacer (no further details reported)
Duration:
52 wks
Run-in period:
2 wks
Number randomised
59
Mean age (range) (years)
1.
50 (29–70)
2.
56 (25–68) 
Baseline FEV
1
% predicted
>30
P
revious ICS treatment (drug and dose)
BDP 1500–2000
µg q.d. or BUD 1600
µg q.d.
or equivalent doses of other ICS
BMD assessment
Biochemical markers of bone
turnover
Change in urinary free cortisol
level 
Change in plasma cortisol level
Molimard 
et al.,
2005
219
RCT
Multi-centre
P
arallel-group
Open-label
Drugs: 
1.
BDP 800
µg q.d.
2.
FP 1000
µg q.d.
3.
BUD 1600
µg q.d.
Delivery device:
1.
HF
A MDI (QV
AR Autohaler
, 3M)
2.
DPI (Flixotide Diskhaler
, GSK)
3.
DPI (Pulmicort T
urbuhaler
, AZ)
Only groups 2 and 3 considered here
Duration:
12 wks
Run-in period:
unclear
Number randomised
460 (although only 446 included in “ITT”
population
Mean age (SD) (years) 
1.
42.4 (14.1)
2.
42.1 (13.5)
3.
42.9 (13.8)
Baseline FEV
1
% predicted (±
SD)
1.
76.6 (±
18.5)
2.
76.7 (±
16.8)
3.
79.3 (±
18.0)
P
revious ICS treatment (drug and dose)
FP 
500
µg q.d., BUD 1000
µg q.d. or BDP
1000
µg q.d.
P
rimary outcome
Change from baseline in asthma
control score, assessed with
Juniper questionnaire (A
CQ),
incorporating FEV
1
% predicted
value and rescue medication
usage
Secondary outcomes
FEV
1
(litres)
AEs
a 
At 5-week intervals dose was reduced to 200 and then 100
µg b.d. if asthma control maintained.
b 
Not stated explicitly
, but deduced from the text.colleagues,216 the adjusted mean change from
baseline after 6 weeks of treatment was 0.22 litres
in the FP 1000 µg/day arm compared with
0.12 litres in the BUD 1600 µg/day arm. The
difference between the study groups was shown to
be statistically significant, p < 0.05. This analysis
was not on an ITT population.
The FEV1 at end-point in the Ringdal and
colleagues217 trial was 2.38 (SD 0.77) litres in the FP
arm and 2.27 (SD 0.77) litres in the BUD arm after
12 weeks of treatment. The treatment difference
was shown not to be statistically significantly
different [0.11 litres (95% CI –0.02 to 0.24)].
The change in morning PEF was shown to be
statistically significantly better after 12 weeks of
treatment with FP compared with BUD after
12 weeks of treatment with BUD in the Ringdal
and colleagues trial (p = 0.003).217 The change in
morning PEF was 20.90 l/minute (SD 37.92) and
12.40 (SD 35.45) l/minute, respectively [treatment
difference 8.50 l/minute (95% CI 2.18 to 14.83)].
This CI was not provided by Ringdal and
colleagues,217 and was calculated by a reviewer.
Ringdal and colleagues217 stated in their paper
that treatment groups were considered equivalent
if the 95% CI for the difference between
treatments was 15 l/minute. The CI presented
here falls within this limit, suggesting that the two
treatments are clinically equivalent.
Symptoms/health-related quality of life.
Parallel design, 1:1 dose ratio. The percentage of
symptom-free days in the Heinig and colleagues214
trial at end-point (after 24 weeks) showed a trend
for improved symptoms in the FP arm [29.90
(SD 38.70)%] compared with BUD [23.30 (SD
36.40)%]; the treatment difference was not
statistically significantly different between groups
[difference 6.60 (95% CI –1.48 to 14.68)].
Symptom ratings on a four-point scale in the Kuna
study215 showed no statistically significant
differences between treatment groups after
5 weeks of treatment. In the FP arm the rating at
end-point was 0.46 and in the BUD arm it was
0.56, p = 0.44.
Although Ayres and colleagues216 reported some
data on symptoms in their trial, inadequate
information was provided for the purposes of the
present review.
Parallel design, 1:2 dose ratio. Molimard and
colleagues219 reported data on the Juniper Asthma
Control Questionnaire (ACQ). This measure is a
seven-item questionnaire; six items evaluate day
and night symptoms and use of rescue medication
and one item evaluates FEV1 as a percentage
predicted value. The study reported that this is a
validated measure. Change from baseline was
shown to be similar between the two groups after
12 weeks of treatment [FP –0.8 (SD 1.0); BUD
–0.8 (SD 0.9)].
Although Ayres and colleagues216 reported some
data on symptoms in their trial for the comparison
between 1000 µg FP and 1600 µg BUD,
inadequate information was provided for the
purposes of the present review.
Use of rescue medication
Parallel design, 1:1 dose ratio. Although Ayres and
colleagues216 and Kuna215 reported some data on
use of rescue medication, this was not reported in
terms of puffs per day as required for the
purposes of the present review.
Parallel design, 1:2 dose ratio. Although Ayres and
colleagues216 reported some data on use of rescue
medication, this was not reported in terms of puffs
per day as required for the purposes of the
present review.
Exacerbations
Parallel design, 1:1 dose ratio. The proportion of
patients experiencing exacerbations in the Ayres
and colleagues trial216 was slightly higher in the
BUD 1.6 mg/day group than the FP 2 mg/day
group (16% FP versus 22% BUD, p-value not
reported).
Parallel design, 1:2 dose ratio. The proportion of
patients experiencing exacerbations in the Ayres
and colleagues trial216 was slightly higher in the
BUD 1600 µg/day group than the FP 1000 µg/day
group (17% FP versus 22% BUD, p-value not
reported).
Adverse events
Parallel design, 1:1 dose ratio. AEs were
experienced by 49% of the participants in the FP
arm and 51% of the participants in the BUD arm
of the Ayres and colleagues trial.216
Parallel design, 1:2 dose ratio. Three trials
reported the number of participants experiencing
an AE, and these data were combined in a meta-
analysis (Figure 12). Using a fixed-effects model,
the meta-analysis showed a trend to better 
odds of not having an AE in the BUD treatment
groups, but this was not statistically significant
[OR 1.20 (95% CI 0.95, 1.50)]. The duration of
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was of 6 weeks.
In the Ringdal and colleagues study,217 10/256
participants in the FP group and 13/262
participants in the BUD group discontinued due
to AEs. This was not statistically significantly
different [OR 0.78 (95% CI 0.34 to 1.81)].
Cortisol levels and bone mineral density
In the Hughes and colleagues study,218 no
statistically significant differences were found
between treatment groups on mean change in
urinary free cortisol levels (FP –14.8% versus BUD
–6.2%, p = not significant). The study also
reported that the mean change in serum cortisol
levels was not statistically significantly different
between groups, but no data were presented to
support this. No decline in BMD at the spine,
neck or trochanter were observed in participants
treated with either FP or BUD.
Summary
Six parallel-group RCTs214–219 evaluated the
effectiveness of BUD compared with FP. Two trials
had a nominal dose ratio of 1:1,214,215 three a
nominal dose ratio of 1:2217–219 and a three-arm
trial with two doses of FP had both a nominal 1:2
dose ratio and a nominal 1:1 dose ratio
comparison.216 The nominal 1:1 dose ratio
comparisons compared 800–2000 µg FP with
800–2000 µg BUD. The nominal 1:2 dose ratio
comparisons compared 800–1000 µg FP with
1600 µg BUD.
Parallel design, 1:1 dose ratio
On measures of lung function, the results
generally showed no statistically significant
differences between treatment with FP and
treatment with BUD, although in one trial a
significant difference in favour of FP was observed
on FEV1. This was not on an ITT population and
therefore may be subject to measurement bias. No
statistically significant differences between treated
groups were observed on measures of symptoms,
exacerbations or AEs.
Parallel design, 1:2 dose ratio
The results of the included trials generally showed
no statistically significant differences between
treatment with FP and treatment with BUD on
measures of lung function. In one trial, a
significant difference in favour of FP was observed
on FEV1; however, care is required in interpreting
these data as they were not on an ITT population
and therefore may be subject to measurement bias.
One other trial reported a difference in favour of
FP on morning PEF. This latter trial was an
equivalence trial and therefore power calculations
may have been based on testing equivalence
rather than superiority. However, the sample size
was large. No differences between study groups
were observed on measures of symptoms or
exacerbations, although data were limited on these
outcomes. There were no differences in the AE
profiles of the groups.
MF and BUD (review Q2 – high-dose ICS)
Study characteristics
One trial reported a comparison of MF and BUD,
by Bousquet and colleagues199 (Table 34). This
study had four treatment arms: 100 µg MF twice
daily plus placebo; 200 µg MF twice daily plus
placebo; 400 µg MF twice daily plus placebo; and
400 µg BUD twice daily. Daily dose ratios were
therefore 1:4, 1:2 and 1:1, respectively. Only the
Health Technology Assessment 2008; Vol. 12: No. 19
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Review: Corticosteroids – model Q2 – high-dose ICS
Comparison:  34 Q2A5 – BUD and FP (adults): parallel 1:2 ratio
Outcome: Adverse events
Study
or subcategory
FP
n/N
BUD
n/N
OR (fixed)
95% CI
Weight
%
OR (fixed)
95% CI
 Ayres et al., 1995
216      137/225            112/221  31.80     1.52 (1.04 to 2.21)
 Molimard et al., 2005
219      55/149              56/162  24.36     1.11 (0.70 to 1.76)
 Ringdal et al., 1996
217   158/256            161/262  43.84     1.01 (0.71 to 1.44)
Total (95% CI) 630                   645 100.00     1.20 (0.95 to 1.50)
Total events: 350 (FP), 329 (BUD)
Test for heterogeneity: 2 = 2.49, df = 2 (p = 0.29), I2 = 19.6%
Test for overall effect: Z = 1.55 (p = 0.12)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
FIGURE 12 Adverse events FP versus BUD, parallel 1:2 dose ratioAssessment of clinical effectiveness
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ABLE 34
Characteristics of studies (MF and BUD)
Study
Design
Intervention
P
atients
Outcomes
Bousquet 
et al.,
2000
199
RCT
Multi-centre
P
arallel-group
Evaluator
-blind
Active-
controlled
1.
MF 100
µg b.d. (daily total 200
µg) + placebo
2.
MF 200
µg b.d. (daily total 400
µg) + placebo
3.
MF 400
µg b.d. (daily total 800
µg) + placebo
4.
BUD 400
µg b.d. (daily total 800
µg)
Delivery device:
1, 2, 3. MF DPI (made by Schering-Plough) 
4. DPI (Pulmicort T
urbuhaler
, AZ)
Duration:
12 wks
Run-in period:
Not reported
Number randomised
730
Mean age (range) (years)
1.
39 (14–71)
2.
42 (14–76)
3.
41 (12–74)
4.
42 (12–76)
Baseline FEV
1
% predicted (SD)
1.
76.2 (0.7)
2.
77.1 (0.8)
3.
77.9 (0.7)
4.
76.0 (0.7)
P
revious ICS treatment (drug and dose)
ICS as previously prescribed (moderate to
persistent asthma)
P
rimary outcome
Change from baseline to end-
point in FEV
1
(litres)
Secondary outcomes
FVC 
PEF
Symptom scores
Nocturnal awakenings requiring
salbutamol use as rescue
medication
Daily salbutamol use
Physician evaluation of response
to therapy 
AEscomparison between 400 µg MF twice daily plus
placebo and 400 µg BUD twice daily is presented
here (i.e. the 1:1 dose ratio). The other
comparisons, which are within the ‘low-dose’
category, are presented in the section ‘MF and
BUD (review Q1 – low-dose ICS)’ (p. 49).
Patients in the MF arms took one inhalation from
each of two DPIs (either one active and one
placebo, or two active DPIs) in the morning and
again in the evening. Patients randomised to BUD
took one inhalation from each of two Turbohaler
DPI devices (Pulmicort Turbuhaler, AZ), morning
and evening. No placebo Turbohaler was
available, so only evaluators were blind to
treatment group allocation (no details of devices
reported; MF made by Schering-Plough).
Further details on the characteristics of this study
can be found in the section ‘MF and BUD (review
Q1 – low-dose ICS)’ (p. 49).
Results
Lung function
The 400 µg twice daily MF group in the study by
Bousquet and colleagues199 showed a mean
change from baseline FEV1 that was statistically
significantly greater than change in the BUD
group (0.16 ± 0.03 litres for 400 µg twice daily
MF versus 0.06 ± 0.03 litres in the BUD group,
p < 0.05). Similarly, the end-point percentage of
predicted FEV1 was statistically significantly
different between the 400 µg twice daily MF 
group (83.0 ± 1.2%) and BUD (77.9 ± 1.1%),
p < 0.05.
Bousquet and colleagues199 did not find a
statistically significant difference between MF and
BUD in terms of change in morning PEF. The
change from baseline to end-point was
24.75 ± 5.3 l/minute in the BUD group compared
with 37.3 ± 5.2 l/minute in the 400 µg twice daily
MF group. Changes in evening PEF were not
presented, but were reported to be similar to
changes in morning PEF.
Symptoms
Bousquet and colleagues199 reported the change
from baseline in mean number of nocturnal
awakenings to be 0.41 in the 400 µg twice daily
MF group and 0.30 in the BUD group (p = not
significant).
Use of rescue medication
Bousquet and colleagues199 reported relief use of
salbuterol as change from baseline dose. The
change from baseline in the BUD group was
–33.90 µg/day, compared with –72.13 µg/day in
the –400 µg twice daily MF group. Although the
decrease in use in the MF group was greater than
that in the BUD group, the difference was not
statistically significant.
Summary
One parallel-group study compared MF with BUD
in a 1:1 daily dose ratio. In this trial there were
significant differences in FEV1 between 400 µg
twice daily MF and 400 µg twice daily BUD, but
not for morning PEF, symptoms or use of rescue
medication.
CIC and FP (review Q2 – high-dose ICS)
[Confidential information removed].
Study characteristics
[Confidential information removed].
TABLE 35 Characteristics of studies (CIC versus FP)
[Confidential information removed].
Results
[Confidential information removed].
Summary
[Confidential information removed].
MF and FP (review Q2 – high-dose ICS)
Study characteristics
One trial comparing MF and FP at high doses was
identified, by O’Connor and colleagues202
(Table 36). The study comprised four arms in which
three doses of MF (200, 400 and 800 µg/day) were
compared with one dose of FP (500 µg/day). The
comparisons of 200 and 400 µg/day MF with FP
are reported in the section ‘MF and FP (review Q1
– low-dose ICS)’ (p. 55). The comparison of
800 µg/day MF with 500 µg/day FP approximates a
rounded nominal dose ratio of 2:1.
O’Connor and colleagues202 employed DPIs for
both MF and FP, but these were of different types:
a newly-developed DPI inhaler (MF–DPI,
Schering-Plough) was used for MF whereas FP was
administered using a standard Diskhaler
formulation (Flixotide Diskhaler, GSK).
The study was a large-scale international dose-
ranging trial (with 60 centres in 20 countries). The
duration was relatively short, 12 weeks. The age of
patients included in the comparison ranged from
12 to 79 years, with a mean age per treatment
group of 42 years for MF and 40 years for FP. 
The enrolled patients had moderate persistent
asthma.
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ABLE 36
Characteristics of the study comparing MF and FP
Study
Design
Intervention
P
atients
Outcomes
O
’Connor 
et al.,
2001
202
RCT
P
arallel-group
Double-blind
(dosage) 
Evaluator
-blind
(medication)
Drug(s):
1.
MF 100
µg b.d. (daily total 200
µg)
2.
MF 200
µg b.d. (daily total 400
µg)
3.
MF 400
µg b.d. (daily total 800
µg)
4.
FP 250
µg b.d. (daily total 500
µg)
Delivery device:
1, 2, 3. MF DPI (made by Schering-Plough)
4. DPI (Flixotide Diskhaler
, GSK)
Duration:
12 wks
Run-in period:
1–2 wks
Number randomised
733
Mean age (range) (years)
1.
42 (14–75)
2.
42 (12–79)
3.
42 (12–75)
4.
40 (12–79)
Baseline FEV
1
% predicted
1, 2, 3. 75
4. 76
P
revious ICS treatment (drug and dose)
BDP 400–1000
µg q.d., BUD 400–800
µg q.d.,
flunisolide 500–1000
µg q.d., FP 200–500 or
triamcinolone acetonide 600–800
µg q.d.
P
rimary outcome
Mean change in FEV
1
from 
baseline to end-point
Secondary outcomes
PEF
FEF
25–75%
FVC
Asthma symptom scores
R
escue medication use
Nocturnal awakenings
Physician evaluation
AEsThe objective of the work was to compare the
effects of MF and FP when administered with a
drug-specific delivery device. The study design did
not permit effects of the drugs to be evaluated
independently of effects of the type of inhaler used.
Results
Parallel 2:1 dose ratio studies
The study by O’Connor and colleagues202 had a
parallel design and provided a single comparison
of high-dose (800 µg/day) MF with high-dose
(500 µg/day) FP, at a nominal dose ratio of
(approximately) 2.1.
Lung function
The change in FEV1 (mean ± SD) was 0.19 ±
0.54 litres for MF (800 µg/day) and 0.16 ±
0.54 litres for FP (500 µg/day). The change in
morning PEF (mean ± SD) was 30 ±
67.8 l/minute for MF (800 µg/day) and 32 ±
67.8 l/minute for FP (500 µg/day). Neither of these
differences between the drugs in lung function
outcomes was statistically significant.
Symptoms
The change from baseline in the number of
nocturnal awakenings was –0.06 for MF-treated
patients and –0.14 for FP-treated patients. This
difference was not statistically significant. The
change in the incidence of morning coughing,
morning wheezing or difficulty breathing also did
not differ statistically significantly between the MF
and FP patient groups.
Use of rescue medicine
The change from baseline in the use of albuterol
rescue medication was –38.10 µg/day for MF-
treated patients and –52.06 µg/day for FP-treated
patients. This difference between the treatments
was not statistically significant.
Exacerbations
Aggravated asthma was one of the most frequent
AEs leading to the discontinuation of treatment,
but was not reported separately from other AEs
(summarised below).
Adverse events
Fifty-five out of 184 patients (30%) who were
treated with 800 µg/day MF experienced
treatment-related AEs. Fifty-three out of 184
patients (29%) who were treated with 500 µg/day
FP experienced treatment-related AEs. Nine
patients who received 800 µg/day MF and eight
patients who received 500 µg/day FP did not
complete their treatment because of AEs. The
most frequent AEs leading to discontinuation were
aggravated asthma, bronchitis, pharyngitis and
upper respiratory tract infection.
Summary
One parallel-group RCT compared 800 µg/day
MF and 500 µg/day FP in a nominal 2:1 dose
ratio. This was one pair-wise comparison from a
four-arm trial. Overall, no differences in clinical
efficiency or safety between MF and FP were
observed when these drugs were compared at a
nominal dose ratio of 2:1.
Summary of Q2 – relative effectiveness of 
high-dose ICS
According to the BTS/SIGN Guideline, BDP and
BUD are comparable at the same daily dose. FP
and MF are comparable at half the daily dose of
BDP and BUD. It is assumed that CIC is also
comparable at half the daily dose of BDP and BUD.
Thus at Step 4 of the Guideline the following drugs
at the following doses (excluding considerations of
device) are equivalent: BUD 800 µg/BDP 800 µg/FP
400 µg/MF 400 µg/CIC 400 µg. The exception to
this is for HFA-propelled pMDI BDP compared
with FP, which, it is suggested,173 is equivalent at a
1:1 dose ratio rather than a 1:2 dose ratio. This is
due to the extra fine particle size resulting in
altered lung deposition. This applies to the QVAR
HFA BDP preparation, but may not apply to other
HFA BDP brands.
In general, all of the ICS in this assessment were
associated with favourable changes from baseline
to end-point across efficacy and safety outcomes.
However, when evaluated in pair-wise
comparisons, there were few statistically significant
differences between them in terms of the
outcomes prioritised for this assessment (although
it was not always possible to discern whether
significance testing had been performed). From
the head-to-head comparisons of these drugs,
there is little evidence to reject the hypothesis that
there is no difference in clinical effectiveness
between them.
As with review question 1, there were few
differences between the ICS (where statistical tests
had been reported). In some cases non-inferiority
was assessed and demonstrated.
● BDP versus BUD (two RCTs, 1:1 dose ratio) –
The only significant difference was for
exacerbations in favour of BUD.
● FP versus BDP (10 RCTs, two at 1:1 and eight at
1:2 dose ratio) – Significant differences in favour
of FP for lung function and exacerbations,
otherwise few significant differences.
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ratio) – No significant differences. Non-
inferiority demonstrated for lung function (in
ITT analysis, but not PP analysis).
● FP versus BUD (six RCTs, three at 1:1 and
three at 1:2 dose ratio) – FP significantly
favourable for lung function, from one RCT (at
1:1 and 1:2 rounded nominal dose ratios,
FP:BUD). No significant differences for AEs
based on meta-analysis of three RCTs.
● MF versus BUD (one RCT, 1:1 dose ratio) –
Significant difference in favour of MF for lung
function.
● CIC versus FP [Confidential information
removed].
● MF versus FP (one RCT, 1:2 dose ratio) – No
significant differences on any outcomes.
Tables 37–43 provide a visual illustration of the
results of pair-wise comparisons.
Review question 3a – ICS versus
ICS + LABA (ICS dose higher when
used alone)
To recap, 10 RCTs evaluated ICS versus ICS +
LABA, where the ICS alone arm used a higher
dose than that used in the combination inhaler
arm (Table 44). The following sub-sections describe
the characteristics and results of these trials.
ICS versus ICS + LABA (FP versus FP/SAL)
Study characteristics
Two RCTs evaluated the effectiveness of FP/SAL in
a combination inhaler compared with FP alone,
and were published in 2003221 and 2004.222 They
were both large, multi-centre studies, ranging in
size from 365 to 558 participants. The trials were
double-blind, parallel-group design, containing
two intervention arms (Table 45).
The trials differed in the doses of FP/SAL
administered to patients. Bergmann and
colleagues222 compared FP/SAL in a combination
inhaler with a total daily dose of 500 µg/100 µg
with FP given at a dose of 1000 µg/day. The total
daily doses of FP in the study by Busse and
colleagues221 were lower, with patients receiving
200 µg/100 µg FP/SAL in a combination inhaler
compared with 500 µg/day FP alone. Both trials
used Diskus inhaler devices (all by GSK) to deliver
both the combination drugs and the ICS alone
(Busse and colleagues221 used Advair and Flovent
Diskus; no further details are reported by
Bergmann and colleagues222).
The treatment duration was 12 weeks in the
Bergmann and colleagues study.222 Busse and
colleagues221 randomised participants to each of
the two treatments for either 12 or 24 weeks to
determine whether asthma control was maintained
for a longer period. The RCTs differed with 
respect to the study aims. Bergmann and
colleagues222 aimed to determine whether
combination therapy with FP/SAL was superior to
FP alone in terms of efficacy and tolerability. The
trial by Busse and colleagues221 was an equivalence
trial and was designed to evaluate whether FP/SAL
delivered via a combination inhaler was ICS-
sparing in patients requiring 500 µg/day FP for
asthma stability.
The mean age of participants was similar, ranging
from around 40 to 50 years. Patients in both trials
had previously been managed on medium-dose
ICS therapy of 500–1000 µg BDP or equivalent
(Table 45). Patients were described as having
moderate asthma in one trial,222 but severity was
not reported in the other trial. Baseline FEV1 %
predicted was similar, around 75–80%.
Bergmann and colleagues222 reported change in
morning PEF as their primary outcome measure.
The trial was designed to identify a difference of
15 l/minute between treatment groups with a
power of 80% at  = 0.05, requiring 174 patients
in each group. Busse and colleagues221 reported
the proportion of patients without worsening
asthma (i.e. those who did not withdraw from the
study because of lack of efficacy) as the primary
outcome. The study was designed such that a
sample size of 250 patients per treatment group
provided at least 80% power to ensure that a 90%
CI of the difference between survival proportions
at week 12 was contained within the margin of
equivalence ( = 0.15, assuming survival rates of
0.85 and 0.80 for FP/SAL and FP, respectively).
The quality of reporting and methodology of the
included RCTs was mixed. The trial by Bergmann
and colleagues222 was of good methodological
quality. The trial reported a randomisation
procedure that assured true random assignment to
treatment groups, and which was also adequately
concealed. The trial by Busse and colleagues221
was of lower quality. The study did not describe
the method of randomisation and the method to
conceal allocation to groups was unclear. The
analysis was reported to be by the ITT principle in
both studies.
Results
For a number of outcomes, Busse and
colleagues221 reported that differences between
treatment groups were within the 90% CI for
Assessment of clinical effectiveness
90R
esults
Study
, design,
ICS in
Lung function
Symptoms
AEs
duration, device,
each trial
R
escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
Ebden 
et al.,
81
BDP
1500
µg BDP)
cross-
over (no 
vs
wash-
out), 6 weeks, 
NSD
C
C
1600
µg BUD)
pMDI + spacer
, 
BUD
+
n 
= 28
2000
µg BDP 
K
aur 
et al.,
203
BDP
vs 
cross-
over
, 6 weeks,
NSD
2000
µg BUD)
MDI + spacer
, 
BUD
n
=1
5
C, results appear to be comparable between treatment groups, but no tests of statistical significance reported; 
n, number of events; NSD, no significant difference between trial
arms; NW
, nocturnal waking; SFD, symptom-free days; SFN, symptom-free nights; SS, symptom score (varies between studies); + ind
icates results favour this trial arm; blank cells
signify no data reported on that outcome.
Health Technology Assessment 2008; Vol. 12: No. 19
91
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
T
ABLE 37
BUD versus BDP (n
=
2 RCT
s)R
esults
Study
, design,
ICS in
Lung function
Symptoms
AEs
duration, device,
each trial
R
escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
1500
µg
 v
s
Fabbri 
et al.,
304
parallel, 
FP
+
+
+
+
70%
1500
µg
12 months, MDI, 
NSD
NSD
n
=
274
BDP
73%
2000
µg
Boe 
et al.,
205
parallel, FP
vs
3 months, DPI, 
NSD
NSD
NSD
F
C
1600
µg
n
=
134
BDP
500
µg
Lundbäck 
et al.,
207
FP
97 (50%)
vs
parallel, 6 weeks, 
NSD
NSD
NSD
NSD
NSD
1000
µg
MDI, 
n
=
585
BDP
+
89 (46%)
750
µg
Medici 
et al.,
191
parallel, 
FP
vs
12 months, MDI, 
NSD
C
1500
µg
n
=6
9
BDP
Barnes 
et al.,
206
FP
NSD
NSD
NSD
NSD
NSD
NSD
43 (52%)
parallel, 6 weeks, MDI, 
n
=
154
BDP
37 (51%)
1000 
µg
Lorentzen 
et al.,
208
FP
114 (72%)
vs
parallel, 12 months, 
NSD
2000
µg
MDI, 
n
=
213
BDP
39 (72%)
Egan 
et al.,
209
parallel, FP
C
2 years, MDI, n
=
3
3
BDP
F
Malo 
et al.,
210
FP
BDP
1000
µg,
cross-
over
, 4 months, 
NSD
NSD
1500
µg or 
MDI, 
n
=
6
7
BDP
2000
µg vs
P
auwels 
et al.,
211
FP
+
66.8%
FP half the 
cross-
over
, 
NSD
NSD
NSD
NSD
BDP dose
12 months, MDI, 
BDP
66.2%
n
=
340
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Study
, design,
ICS in
Lung function
Symptoms
AEs
duration, device,
each trial
R
escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
Aubier 
et al.,
213
parallel,
B
D
P
NSD
38.3%
800
µg BDP 
28 weeks, DPI, 
NSD
NID 
NSD
NSD
NSD
vs 1000
µg FP
n
=
503
(in ITT but 
FP
not PP)
24.8%
ITT
, intent-to
-treat population; NID, non-inferiority demonstrated; NW
, nocturnal waking; NSD, no significant difference betwee
n trial arms; PP
, per protocol population; 
SFD, symptom-free days; SFN, symptom-free nights; SS, symptom score (varies between studies); blank cells signify no data repor
ted on that outcome.
R
esults
Study
, design,
ICS in
Lung function
Symptoms
AEs
duration, device,
each trial
R
escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
750
µg FP vs
Bootsma 
et al.,
212
FP
1500
µg BDP
cross-
over
, 12 weeks,
NSD
NSD
NSD
NSD
MDI, 
n
=
21 BDP
C, results appear to be comparable between treatment groups, but no tests of statistical significance reported; F
, results appe
ar to favour this treatment group, but no tests of
statistical significance reported; 
n, number of events; NSD, no significant difference between trial arms; NW
, nocturnal waking; SFD, symptom-free days; SFN, sympt
om-free nights;
SS, symptom score (varies between studies); + indicates results favour this trial arm; blank cells signify no data reported on 
that outcome.
T
ABLE 38
FP versus BDP (n
=
10 RCT
s) (cont’d)
T
ABLE 39
HF
A BDP versus FP (n
=
1 RCT)
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esults
Study
, design,
ICS in
Lung function
Symptoms
AEs
duration, device,
each trial
R
escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
2000
µg FP
Heinig 
et al.,
214
parallel, 
FP
vs
24 weeks, DPI 
CF
2000
µg BUD 
(Diskhaler or 
T
urbuhaler), 
n
=
395
BUD
800
µg FP 
K
una
et al.,
215
parallel, 
FP
vs 
5 weeks, DPI 
NSD
NSD
NSD
NSD
800
µg BUD
Diskhaler or 
T
urbuhaler
, 
n
=
197
BUD
800–1000
µg 
Meta-analysis 
FP
FP vs 1600
µg
Ayres
et al.,
216
NSD
BUD
(1000 
µg FP arm), 
Molimard,
219
Ringdal
217
BUD
1000
µg FP 
Ayres 
et al.,
216
parallel,
1.
1000 
µg +
F
2000
µg FP
6 weeks, MDI, 
FP
1 vs 3
1 vs 3
1600
µg BUD
n
=
671
2. 2000 µg 
+
F
49%
FP
3.
BUD
2 vs 3
2 vs 3
51%
800
µg FP vs
Ringdal et al.,
217
FP
+
1600
µg BUD
parallel, 12 weeks, 
NSD
DPI (Diskhaler or 
T
urbuhaler), 
n
=
518
BUD
1000
µg FP vs
Molimard et al.,
219
FP
1600
µg BUD
parallel, 12 weeks, 
NSD
NSD
DPI (Diskhaler or 
T
urbuhaler), 
n
=
460
BUD
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T
ABLE 40
FP versus BUD (n
=
6 RCT
s)
continuedR
esults
Study
, design,
ICS in
Lung function
Symptoms
AEs
duration, device,
each trial
R
escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
800
µg MF vs
Bousquet 
et al.,
199
MF
+
F
800
µg BUD
parallel, 12 weeks, 
NSD
NSD
DPI, 
n
=
730
BUD
F
, results appear to favour this treatment group, but no tests of statistical significance reported; NSD, no significant differ
ence between trial arms; NW
, nocturnal waking; 
SFD, symptom-free days; SFN, symptom-free nights; SS, symptom score (varies between studies); + indicates results favour this t
rial arm; blank cells signify no data reported on that
outcome.
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T
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FP versus BUD (n
=
6 RCT
s) (cont’d)
R
esults
Study
, design,
ICS in
Lung function
Symptoms
AEs
duration, device,
each trial
R
escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
Hughes 
et al.,
218
FP
parallel, 52 weeks, 
MDI + spacer
, 
n
=
5
9
BUD
C, results appear to be comparable between treatment groups, but no tests of statistical significance reported; F
, results appe
ar to favour this treatment group, but no tests of
statistical significance reported; NSD, no significant difference between trial arms; NW
, nocturnal waking; SFD, symptom-free d
ays; SFN, symptom-free nights; SS, symptom score
(varies between studies); + indicates results favour this trial arm; blank cells signify no data reported on that outcome.
T
ABLE 41
MF versus BUD (n
=
1 RCT)
T
ABLE 42
FP vs CIC (n
=
3 RCT
s)
[Confidential information removed].R
esults
Study
, design,
ICS in
Lung function
Symptoms
AEs
duration, device,
each trial
R
escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
MF 800
µg vs
O
’Connor 
et al.,
202
MF
30%
FP 500
µg 
parallel, 12 weeks, 
NSD
NSD
NSD
NSD
DPI, 
n
=
733 
FP
29%
n, number of events; NSD, no significant difference between trial arms; NW
, nocturnal waking; SFD, symptom-free days; SFN, sympt
om-free nights; ; SS, symptom score (varies
between studies); + indicates results favour this trial arm; blank cells signify no data reported on that outcome.
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T
ABLE 43
FP versus MF (n
= 1 RCT)
T
ABLE 44
Breakdown of studies for review question 3a – ICS versus ICS
+
LABA (ICS dose
higher when used alone)
P
air-wise comparison
No. of RCT
s included
FP vs FP/SAL
2
BUD vs FP/SAL
3
BUD vs BUD/FF
4
FP vs BUD/FF
1
T
otal
10equivalence but failed to define what the
confidence limits were. In addition, it is not clear
whether the reported p-values were for a test of
difference or a test of equivalence.
For some outcome measures, sufficient data 
were reported in the two trials to be combined 
in meta-analyses. However, it should be noted 
that the doses of FP administered to patients in
the Bergmann and colleagues222 trial was twice
that administered in the Busse and colleagues
trial.221 This should be taken into consideration
when interpreting the results of the meta-analyses.
Lung function
Data on FEV1 were reported in different ways in
the two studies. Busse and colleagues221 reported a
mean change from baseline to end-point at 12
weeks in FEV1 of 0.07 (±0.17) litres in the FP/SAL
group compared with –0.03 (±0.17) litres
(p  0.001) in the FP group. In the subgroup of
patients who received treatment for 24 weeks,
improvements from baseline in FEV1 were 0.10
(± SEM 0.02) litres and 0.00 (± SEM 0.02) litres
(p  0.007) in the FP/SAL and FP groups,
respectively. The authors stated that differences
between treatments were within the 90% CIs for
equivalence (although the CIs were not reported).
Bergmann and colleagues222 reported a mean
change from baseline in FEV1 % predicted of
12.30% (± 1.70) in the FP/SAL group compared
with 8.40% (± 1.40) in the FP group, with no
statistically significant differences between groups
(p-value not reported).
Change in morning PEF (litres/minute) was
reported by both trials, and data at 12 weeks were
combined in a meta-analysis (Figure 13). Pooling
the data using a fixed-effects model showed a
statistically significant improvement with FP/SAL
treatment compared with FP [WMD 17.54 (95% CI
9.35 to 25.72); p < 0.0001]. Heterogeneity was not
statistically significant (p = 0.81, I2 = 0%).
Change in evening PEF (litres/minute) from
baseline to end-point at 12 weeks was also
reported by both trials. Combining the data in a
meta-analysis (Figure 14) using a fixed-effects
model showed a statistically significant
improvement with FP/SAL treatment compared
with FP [WMD 16.26 (95% CI 7.90 to 24.62);
p < 0.0001]. Heterogeneity was not statistically
significant (p = 0.90, I2 = 0%).
In the Busse and colleagues trial,221 the change
from baseline to end-point at 24 weeks in morning
PEF was 45.2 (± SEM 5.9) l/minute in the
combination treatment group compared with 32.5
(± SEM 6.8) l/minute in the FP group (p = 0.180).
Differences between groups in evening PEF 
(24-week data) were 49.4 (± SEM 5.9) l/minute
and 31.3 (± SEM 6.2) l/minute, respectively
(p = 0.039). For both morning and evening PEF,
differences between treatments were reported to
be within the 90% CIs for equivalence (the CIs
were not reported).
Symptoms
Data for the two trials on the change from baseline
to end-point at 12 weeks in symptom-free days were
combined in a meta-analysis (Figure 15). Pooling the
data using a fixed-effects model showed a
statistically significant improvement with FP/SAL
treatment compared with FP [WMD 7.46 (95% CI
3.02 to 11.90); p = 0.001]. Heterogeneity was not
statistically significant (p = 0.32, I2 = 0.9%).
For patients receiving treatment for 24 weeks,221
the mean change from baseline was 11.6 (± SEM
3.0) days for FP/SAL compared with 6.0 (± SEM
2.9) days for FP (p = 0.078). Differences between
treatments were within the 90% CIs for
equivalence (the CIs were not reported).
Total daily asthma symptom scores were reported
differently in the two trials, and therefore data
could not be combined in a meta-analysis. Busse
and colleagues221 used a six-point Likert scale
(0 = no symptoms, 5 = severe symptoms, no
reference supplied). Both treatments resulted in
improvements in the daily asthma symptom scores
at 12 weeks [–0.20 (± SEM 0.04) versus –0.12
(± SEM 0.04), p = 0.232 for FP/SAL versus FP,
respectively], and at 24 weeks [–0.22 (± SEM 0.06)
versus –0.14 (± SEM 0.06), p = 0.137 for FP/SAL
versus FP, respectively]. Differences between
treatments were within the 90% CIs for
equivalence (the CIs were not reported). In the
trial by Bergmann and colleagues,222 daytime and
night-time asthma symptoms were recorded using
a five-point rating scale (0 = none, 4 = severe, no
reference supplied), which were combined to give
a total asthma symptom score. Combined FP/SAL
therapy was statistically significantly superior to
double-dose FP with respect to the improvement
in asthma symptoms. The mean difference
between treatment groups at the 12-week end-
point was –0.5 points (95% CI –0.78 to –0.22,
p = 0.0005).
Quality of life
Data on HRQoL were reported in one trial222 using
a validated asthma quality of life questionnaire
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T
ABLE 45
Study characteristics (FP versus FP/SAL)
Study
Design
Intervention
P
atients
Outcomes
Bergmann 
et al.,
2004
222
RCT
Multi-centre
P
arallel-group
Double-blind
1.
FP/SAL 250
µg/50
µg b.d. (daily total 500
µg/100
µg)
2.
FP 500
µg b.d. (daily total 1000
µg)
Delivery device:
1, 2. DPI Diskus (GSK
a
) 
Duration:
12 wks
Run-in period:
2 wks
Number randomised
365
Mean age (±
SD) (years)
1.
49.8 (±
14.2)
2.
48.9 (±
13.9)
Baseline FEV
1
% predicted (±
SD)
1.
74.5 (±
19.3)
2.
75.7 (±
20.2)
P
revious ICS treatment (drug and dose)
BDP or BUD 800–1000
µg q.d. or 
FP 500
µg q.d.
P
rimary outcome
Change in morning PEF
Secondary outcomes
Evening PEF
FEV
1
(% predicted)
FVC
Asthma symptom score
% symptom-free days/nights
Use of rescue medication
AEs
Quality of life
Busse 
et al.,
2003
221
RCT
Multi-centre
P
arallel-group
Double-blind
1.
FP/SAL 100
µg/50
µg b.d. (daily total 200
µg + 100
µg)
2.
FP 250
µg b.d. (daily total 500
µg)
Delivery device: 
1.
DPI Advair Diskus (GSK)
2.
DPI Flovent Diskus (GSK)
Duration:
12–24 wks
Run-in period:
3 run-in periods:
10–14 days
5–28 days
26–30 days
Number randomised
558 (12 wks treatment 
n
=
250; 24
wks
treatment 
n
=
308)
Mean age (range) (years)
1.
38 (12–77)
2.
39 (12–72)
Baseline FEV
1
% predicted (±
SD)
1.
80.5 (±
9.7)
2.
80.9 (±
9.4)
P
revious ICS treatment (drug and dose)
Medium dose of ICS
BDP 504–840
µg q.d., BUD
400–800
µg q.d., FP 440–660
µg q.d.,
flunisolide 1000–1500
µg q.d. or
triamcinolone acetonide 1200–1600
µg q.d.
P
rimary outcome
P
roportion of patients with no 
worsening asthma
Secondary outcomes
FEV
1
(litres)
PEF (morning and evening)
Asthma symptom score
% symptom-free days
R
escue medication use
R
escue medication-free days
AEs
a 
Not stated explicitly
, but deduced from the text.Health Technology Assessment 2008; Vol. 12: No. 19
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Review: Corticosteroids – review Q3b – ICS alone (higher dose) vs ICS + LABA
Comparison: FP  +  salmeterol vs FP (higher dose) (adults): parallel
Outcome: Change in morning PEF (l/minute)
Study
or subcategory
FP + salmeterol
Mean (SD)
FP
Mean (SD)
WMD (fixed)
95% CI
Weight
%
WMD (fixed)
95% CI NN
Bergmann et al., 
2004
222   
170 52.00  (76.00)  177 36.00  (65.00)
281  36.70 (62.02)  277  18.50 (55.92)        
 30.16 16.00 (1.09 to 30.91)
Busse et al., 2003
221        69.84 18.20 (8.40 to 28.00)
Total (95% CI) 451 454 100.00 17.54 (9.35 to 25.72)
Test for heterogeneity: 2 = 0.06, df = 1 (p = 0.81), I2 = 0%
Test for overall effect: Z = 4.20 (p < 0.0001)
–100 –50 0 50 100
Favours FP Favours FP +
SAL
FIGURE 13 Change in morning PEF (l/minute), FP/SAL versus FP
Study
or subcategory
FP + salmeterol
Mean (SD)
FP
Mean (SD)
WMD (fixed)
95% CI
Weight
%
WMD (fixed)
95% CI NN
–100 –50 0 50 100
Favours FP Favours FP +
SAL
Review: Corticosteroids – review Q3b – ICS alone (higher dose) vs ICS + LABA
Comparison: FP  +  salmeterol vs FP (higher dose) (adults): parallel
Outcome: Change in evening PEFR (l/minute) 
Bergmann et al., 
2004
222
170 46.00  (73.00) 177 29.00  (65.00)
281 36.80  (62.02) 281 20.90  (61.50)
 32.96 17.00 (2.44 to 31.56)
Busse et al., 2003
221  67.04 15.90 (5.69 to 26.11)
Total (95% CI) 451 458 100.00 16.26 (7.90 to 24.62)
Test for heterogeneity: 2 = 0.01, df = 1 (p = 0.90), I2 = 0%
Test for overall effect: Z = 3.81 (p = 0.0001)
FIGURE 14 Change in evening PEF (l/minute), FP/SAL versus FP
Study
or subcategory
FP + salmeterol
Mean (SD)
FP
Mean (SD)
WMD (fixed)
95% CI
Weight
%
WMD (fixed)
95% CI NN
–100 –50 0 50 100
Favours FP Favours FP +
SAL
Review: Corticosteroids – review Q3b – ICS alone (higher dose) vs ICS + LABA
Comparison: FP  +  salmeterol vs FP (higher dose) (adults): parallel
Outcome: Change in symptom-free days (%)
Bergmann et al., 
2004
222
170 49.00  (38.00)  177 38.00  (40.00)
281  11.80 (33.53)  277    5.80 (29.96)    
 29.23 11.00 (2.79 to 19.21)
Busse et al., 2003
221  70.77   6.00 (0.73 to 11.27)
Total (95% CI) 451 454 100.00   7.46 (3.02 to 11.90)
Test for heterogeneity: 2 = 1.01, df = 1 (p = 0.32), I2 = 0.9%
Test for overall effect: Z = 3.30 (p = 0.0010)
FIGURE 15 Change in symptom-free days (%), FP/SAL versus FP(reference supplied). The questionnaire consists of
four dimensions: asthma symptoms, physical
activity, environment and emotions, and is scored
from 0 to 7 (0 = most severe impairment, 7 = least
impairment). The scores at week 12 were presented
as the average of the preceding 21 days.
Improvements were seen in both groups. For the
FP/SAL group, the mean change from baseline
quality of life score (mean score for all four
dimensions) was 1.1 compared with 0.8 for patients
in the increased dose FP group (values read from a
bar chart, no p-value given).
Use of rescue medication
Meta-analysis of the change in the use of
salbutamol or albuterol rescue medication (mean
number of puffs/day) at 12 weeks showed a
statistically significant difference in favour of
FP/SAL treatment (Figure 16). Using a fixed-effects
model, the WMD was –0.19 puffs (95% CI –0.36 to
–0.02, p = 0.02). However, heterogeneity was
statistically significant (p = 0.04, I2 = 75.2%).
Using a random-effects model, treatment with
FP/SAL was no longer statistically significantly 
superior to treatment with FP alone [WMD –0.32
(95% CI –0.78 to 0.14)], and heterogeneity
remained. Therefore, care needs to be taken 
in interpreting this outcome. Figure 16
provides an illustration of the direction of the
results.
For patients receiving treatment for 24 weeks,221
both treatments resulted in a reduced need for
supplemental albuterol. The mean change from
baseline was –0.43 (± SEM 0.11) for FP/SAL
compared with –0.21 (± SEM 0.07) for FP
(p = 0.022). Differences between treatments 
were within the 90% CIs for equivalence (the CIs
were not reported).
Exacerbations
In both studies, similar proportions of patients
experiencing exacerbations of asthma were
reported in each treatment group. In the
Bergmann and colleagues trial,222 one (0.6%)
patient in the combination therapy group
compared with four (2.3%) patients in the FP
group were reported as having an asthma
exacerbation (p-values not reported). In the Busse
and colleagues trial,221 proportions were 3% and
2% at 12 weeks (p = 0.820) and 2% and 0%
(p = 0.104) at 24 weeks in the FP/SAL and FP
groups, respectively.
Adverse events
Sufficient data on numbers of AEs were reported
in the two trials to be combined in a meta-analysis
(Figure 17). The fixed-effects model’s pooled OR
was 0.89 (95% CI 0.67 to 1.17) suggesting no
statistically significant difference between the two
treatments (p = 0.39). Heterogeneity was not
statistically significant (p = 0.25, I2 = 25.5%).
In the subgroup of patients who received
treatment for 24 weeks, the incidence of AEs was
also similar for the two treatment groups (44% of
FP/SAL patients and 47% of FP patients reported
one or more AEs).221
Discontinuations due to AEs were similar for the
two treatment groups in one trial.221 One patient
(<1%) receiving combination therapy and two
patients (<1%) receiving FP withdrew from the
study as a result of AEs (no p-value reported).
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Study
or subcategory
FP + salmeterol
Mean (SD)
FP
Mean (SD)
WMD (fixed)
95% CI
Weight
%
WMD (fixed)
95% CI NN
–1.0 –0.5 0 0.5 1.0
Favours FP Favours FP +
SAL
Review: Corticosteroids – review Q3b – ICS alone (higher dose) vs ICS + LABA
Comparison: FP  +  salmeterol vs FP (higher dose) (adults): parallel
Outcome: Change in rescue inhalations (puffs/day)
Bergmann et al., 
2004
222
170 –1.60  (1.90)  177 –1.00  (2.20)
281 –0.30  (1.17)  277 –0.18  (1.00)
 14.86 –0.60 (–1.03 to –0.17)
Busse et al., 2003
221  85.14 –0.12 (–0.30 to 0.06)
Total (95% CI) 451 454 100.00 –0.19 (–0.36 to –0.02)
Test for heterogeneity: 2 = 4.04, df = 1 (p = 0.04), I2 = 75.2%
Test for overall effect: Z = 2.25 (p = 0.02)
FIGURE 16 Change in use of rescue medication (puffs/day), FP/SAL versus FPSummary
Two large, parallel-group RCTs compared
200–500 µg/day FP and 100 µg/day SAL in a
combination inhaler with 500–1000 µg/day FP in
adult participants. The Busse and colleagues
study221 assessed clinical equivalence, and
although the general trend was that FP/SAL was
more effective than FP, for most relevant outcomes
the differences between treatments were within the
CIs for clinical equivalence (but the data to
support this were not provided).
Treatment with FP/SAL was significantly more
favourable than FP treatment alone on measures
of PEF but not FEV1. Data on symptoms were also
mixed, with combination treatment being
significantly more favourable in terms of change
in symptom-free days, but not quality of life.
Improvement in total daily asthma scores was
significantly better with FP/SAL therapy in one
trial, but not in the other. On the whole,
combination therapy was reported to be as safe as
double-dose FP. There were no statistical
differences between the two therapies for AEs, and
no observed differences for exacerbations or
discontinuations due to AEs where reported.
Although patients receiving FP/SAL had a
significantly reduced need for rescue medication,
the trials were statistically heterogeneous and this
difference did not remain when the data were
analysed in a random-effects model.
ICS versus ICS + LABA (BUD versus FP/SAL)
Study characteristics
Three RCTs, published between 2000 and
2004,223–225 evaluated BUD compared with
FP/SAL combination therapy (Table 46). All three
studies were multi-centre trials with two-arm
parallel designs. The number of subjects
randomised ranged from 349 to 398.
Two studies, by Johansson and colleagues224 and
Zhong and colleagues,225 compared the
combination of 200 µg/100 µg/day FP/SAL with
800 µg/day BUD (representing a low dose of
BUD). The third study, by Jenkins and
colleagues,223 compared the combination of
500 µg/100 µg/day FP/SAL with 1600 µg/day BUD
(representing a high dose of BUD). All doses
reported here are ex-valve.
In all three trials the BUD delivery device was a
Turbuhaler (Pulmicort Turbuhaler, AZ). All three
studies delivered the FP/SAL via a Diskus
combination inhaler (Seretide Accuhaler, GSK).
Two studies also used a placebo Turbuhaler with
the FP/SAL treatment and a placebo Diskus inhaler
with the BUD treatment.223,224 The studies were
relatively short, at 6, 12 and 24 weeks. Two of the
studies evaluated the superiority of FP/SAL
combination therapy compared with BUD.223,225
Zhong and colleagues225 assessed the efficacy and
safety of the treatments in patients with asthma
that was uncontrolled with low-dose ICS treatment.
Jenkins and colleagues223 compared treatment with
a combination of a LABA and ICS with another
ICS alone via a different inhaler. The third study
(Johansson and colleagues224) compared the
lowest strength of the combination treatment with
BUD at a four-fold higher dose in patients who
remained uncontrolled on existing therapy.
The age range of patients included in the RCTs
varied from 12 to 80 years, with mean ages from
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Review: Corticosteroids – review Q3b – ICS alone (higher dose) vs ICS + LABA
Comparison: FP  +  salmeterol vs FP (higher dose) (adults): parallel
Outcome: Adverse events
Study
or subcategory
FP + salmeterol
n/N
FP
n/N
OR (fixed)
95% CI
Weight
%
OR (fixed)
95% CI
 Bergmann et al., 2004
222   45/170    43/177
141/281 155/277
 28.49 1.12 (0.69 to 1.82)
 Busse et al., 2003
221  71.51 0.79 (0.57 to 1.11)
Total (95% CI) 451 454 100.00 0.89 (0.67 to 1.17)
Total events: 186 (FP + salmeterol), 198 (FP)
Test for heterogeneity: 2 = 1.34, df = 1 (p = 0.25), I2 = 25.5%
Test for overall effect: Z = 0.86 (p = 0.39)
0.1 0.2 0.5 1 2 5 10
Favours FP
+ SAL
Favours FP
FIGURE 17 Adverse events, FP/SAL versus FP36 to 48 years. All trial patients had previously
been treated with low- to medium-dose ICS. One
trial reported patients as having been previously
treated with 400–600 µg daily of FP or
800–1200 µg daily of BUD or BDP.223 Two trials
reported patients as having been previously
treated with a daily dose of 500 µg BUD or
BDP.224,225 In two of the studies the mean baseline
FEV1 % predicted is reported as between 68 and
77.223,224 The third study did not report FEV1 %
predicted.225 Johansson and colleagues224
described patients as suffering from mild to
moderate asthma, whereas the other two studies
described patients as suffering from moderate to
severe asthma.223,225
Two studies reported their primary outcome as the
mean morning PEF,224,225 whereas Jenkins and
colleagues223 did not specify a primary outcome.
The quality of the studies appeared to be good
overall. The three studies each aimed to achieve
90% power for demonstrating a difference of
15 l/minute in the PEF with 95% confidence, based
on the assumption that the maximum SD of the
PEF is 40 l/minute and that the minimum number
of subjects per treatment group would be 150. One
study provided no details of their randomisation
procedure,223 whereas the other two studies used
computer-generated randomisation codes.224,225
Johansson and colleagues224 provided full details
of blinding and concealment of treatment
allocation, whereas no details of treatment
allocation concealment were provided in the 
other two studies.223,225 All three studies reported
an ITT analysis, using the ITT population for
analysis.
Results
Some of the symptom scores reported by Jenkins
and colleagues223 were also summarised briefly in
a secondary publication by Lundbäck and
colleagues.226 Quality of life scores originating
from the study carried out by Jenkins and
colleagues are reported in a secondary publication
by Juniper and colleagues.227
Lung function
FEV1. Two studies reported the FEV1 at end-
point,223,224 one study reported the change in
FEV1 from baseline to end-point225 and one study
briefly mentioned the percentage predicted FEV1
at end-point.223
Johansson and colleagues224 reported that the
mean ± SD of the FEV1 at end-point (12 weeks)
was 2.79 ± 0.81 litres for FP/SAL and
2.83 ± 0.86 litres for low-dose (800 µg/day) BUD;
however, this difference was not tested statistically.
Jenkins and colleagues223 reported that the FEV1
at end-point (24 weeks) differed significantly
between FP/SAL (mean 2.53 litres) and high-dose
(1600 µg/day) BUD (mean 2.44 litres); the
treatment difference was 0.091 litres, (95% CI 0.0
to 0.17, p < 0.05). Zhong and colleagues225
reported a change in FEV1 from baseline to end-
point of 310 ml for subjects on FP/SAL and
280 ml for subjects on low-dose (800 µg/day) BUD.
This difference was not statistically significant
(p = 0.2614). Jenkins and colleagues223
commented (without presenting data) that the
percentage predicted FEV1 at end-point (week 24)
was higher for subjects in the FP/SAL group,
although the difference between treatments was
not statistically significant.
Morning PEF. The change from baseline in the
morning and evening PEF was reported in all
three studies but the data and statistics were
presented in different ways that preclude
combining the studies in a meta-analysis.
Johansson and colleagues224 reported a change in
the morning PEF from baseline to end-point
(12 weeks) of 383–426 l/minute in subjects
receiving FP/SAL and of 382–415 l/minute in
subjects receiving low-dose (800 µg/day) BUD.
Statistics presented by Johansson and colleagues224
appear to refer to the difference in morning PEF
between the drugs at end-point [11 l/minute (95%
CI 2 to 20 l/minute, p = 0.022)] rather than the
difference of the change in morning PEF from
baseline (10 l/minute). Accordingly, it is unclear in
that study whether the changes from baseline in
the morning PEF differed significantly between
the treatments. Johansson and colleagues224 also
reported that the predicted percentage morning
PEF differed significantly between the treatments,
with a change from baseline to end-point of
83–94% in the FP/SAL subject group and of
80–89% in the BUD subject group (95% CI 1 to
5%, p = 0.009).
Zhong and colleagues225 reported that the mean
change from baseline to end-point (6 weeks) in the
morning PEF was 52.4 l/minute for subjects on
FP/SAL (95% CI from 44.2 to 60.6 l/minute) and
29.9 l/minute for subjects on low-dose (800 µg/day)
BUD (95% CI from 22.2 to 37.6 l/minute). This
difference between the drugs was statistically
significant (p < 0.0001). At end-point, the least-
squares-adjusted mean morning PEF was
326 l/minute (95% CI 318 to 334 l/minute) for the
FP/SAL group and 303 l/minute (95% CI from 295
to 311 l/minute) for the BUD group (no p-value
reported).
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Characteristics of studies (BUD versus FP/SAL)
Study
Design
Intervention
P
atients
Outcomes
Jenkins 
et al.,
2000
223
Lundbäck 
et al.,
2000
226
Juniper 
et al.,
2002
227
RCT
Multi-centre
P
arallel-group
Double-blind
Double-dummy
1.
FP/SAL 250/50
µg b.d. (daily total 500/100
µg)
2.
BUD 800
µg b.d. (daily total 1600
µg) 
Delivery device:
1.
DPI Diskus (Seretide Accuhaler
, GSK) + placebo
T
urbuhaler
2.
DPI T
urbuhaler (Pulmicort T
urbuhaler
, AZ) + placebo
Diskus
Duration:
24 wks
Run-in period:
2 wks
Number randomised
353
Mean age (range) (years)
1.
45 (16–75)
2.
48 (14–80)
Baseline FEV
1
% predicted (range)
1.
68 (33–105)
2.
72 (37–109)
P
revious ICS treatment (drug and dose)
BUD 800–1200
µg q.d.
Change in PEF (morning and
evening)
Change in FEV
1
Symptom-free days and nights
% salbutamol-free days in each
group
% exacerbations
Johansson 
et al.,
2001
224
RCT
Multi-centre
P
arallel-group
Double-blind
Double-dummy
1.
FP/SAL 100/50
µg b.d. (daily total 200/100
µg)
2.
BUD 400
µg b.d. (daily total 800
µg)
Delivery device: 
1.
DPI Diskus (Seretide Accuhaler
, GSK) + placebo
T
urbuhaler
2.
DPI T
urbuhaler (Pulmicort T
urbuhaler
, AZ) + placebo
Diskus
Duration:
12 wks
Run-in period:
2 wks
Number randomised
349
Mean age (±
SD) (years)
1. 36 (±
16)
2. 36 (±
17)
Mean baseline FEV
1
% predicted (±
SD)
1.
77 (±
10)
2.
76 (±
11)
P
revious ICS treatment (drug and dose)
BDP or BUD up to 500
µg q.d.
P
rimary outcome
Morning PEF
Secondary outcomes
Evening PEF
R
escue salbutamol usage
Day
- and night-time symptom
scores
Asthma exacerbations
Zhong 
et al.,
2004
225
RCT
Multi-centre
P
arallel-group
Open-label
1.
FP/SAL 100/50
µg b.d. (daily total 200/100
µg)
2.  BUD 400
µg b.d. (daily total 800
µg)
Delivery device:
1.
DPI Diskus (Seretide Accuhaler
, GSK) 
2.
DPI T
urbuhaler (Pulmicort T
urbuhaler
, AZ)
Duration:
6 wks
Run-in period:
2 wks
Number randomised
398
Mean age (range) (years)
1.
46 (44–47)
2.
46 (44–47)
Mean baseline FEV
1
(litres)
1.
1.91
2.
1.90
P
revious ICS treatment (drug and dose)
Mild to moderate asthma (uncontrolled with
low
-dose ICS)
P
rimary outcome
Morning PEF
Secondary outcomes
Evening PEF
Use of rescue medication
Day
- and night-time asthma
symptoms scores
% symptom-free days and nights
FEV
1Jenkins and colleagues223 presented data on the
morning PEF for several periods during their 
24-week study. The closest data to the end-point
that they provided was for weeks 13–24. During
this period, the mean ± SD change in the
morning PEF from baseline (adjusted by ANCOVA
for sex, age and country) was 410 ± 4.49 l/minute
for subjects on FP/SAL and 384 ± 4.69 l/minute
for subjects on high-dose (1600 µg/day) BUD. The
difference between treatments of 26 l/minute (95%
CI 14 to 38 l/minute) was statistically significant
(p < 0.001). The corresponding figures for the
morning PEF averaged over the whole study
(weeks 1–24) showed a similar pattern, with a
mean ± SD change from baseline of
406 ± 3.67 l/minute for FP/SAL subjects and
380 ± 3.81 l/minute for BUD subjects. This
difference of 25 l/minute (95% CI 15 to
35 l/minute; p < 0.001) was statistically significant.
Evening PEF. Johansson and colleagues224
reported (without giving details) that the change
from baseline in the evening PEF was significantly
larger (by 11 l/minute) for subjects on FP/SAL
than for subjects on low-dose (800 µg/day) BUD
(95% CI 3 to 20 l/minute, p = 0.008). The
predicted percentage evening PEF was also
significantly larger in the FP/SAL subject group
(95 CI 1 to 5%; p = 0.003).
Zhong and colleagues225 reported that the mean
change from baseline to end-point (6 weeks) in the
evening PEF was 45.6 l/minute for subjects on
FP/SAL and 32.1 l/minute for subjects on low-dose
(800 µg/day) BUD. This difference between the
drugs was statistically significant (p = 0.0066).
For weeks 13–24 of their study, Jenkins and
colleagues223 reported a mean ± SD change from
baseline in the evening PEF (adjusted in ANCOVA
for sex, age and country) of 420 ± 3.85 l/minute
for subjects on FP/SAL and 401 ± 4.03 l/minute
for subjects on high-dose (1600 µg/day) BUD. This
difference of 19 (95% CI 9 to 29) l/minute was
statistically significant (p < 0.001). The
corresponding figures for the evening PEF
averaged over the whole study (weeks 1–24) show
a similar pattern, with a mean ± SD change from
baseline of 416 ± 3.14 l/minute for the FP/SAL
subject group and 398 ± 3.25 l/minute for the
BUD subject group. This difference of 18 (95% CI
9 to 26) l/minute was statistically significant
(p < 0.001).
Symptoms
All three studies223–225 reported the percentage of
symptom-free days and nights. Johansson and
colleagues224 reported the mean ± SD percentage
of symptom-free days and nights for weeks 1–4
and weeks 1–12 of their study but not at the end-
point. For weeks 1–4, the mean percentage of
symptom-free days was 46 ± 38% in the FP/SAL
subject group and 48 ± 38% in the low-dose
(800 µg/day) BUD treatment. Over the study as a
whole (weeks 1–24), there were 53 ± 38%
symptom-free days for subjects on FP/SAL and
55 ± 38% symptom-free days for subjects on BUD.
The mean percentage of symptom-free nights for
weeks 1–4 was 65 ± 37% for the FP/SAL subject
group and 66 ± 35% for the BUD subject group.
Over the study as a whole (weeks 1–12), the
percentage of symptom-free nights for the
respective drugs was 68 ± 36 and 72 ± 33%.
Johansson and colleagues commented that the
improvement in day- or night-time symptoms did
not differ between the drugs (no p-value
provided).
In their study, Zhong and colleagues225 reported
that the mean percentage of symptom-free days at
end-point (6 weeks) was 57% for subjects treated
with FP/SAL and 41.0% for subjects on low-dose
(800 µg/day) BUD. The corresponding
percentages of symptom-free nights for the
respective drugs were 65.9 and 47.7%. When
symptom-free days and nights were combined, the
mean percentage of symptom-free 24-hour
periods at end-point was 66.5% for subjects
treated with FP/SAL and 46.6% for subjects on
BUD. For each of these three outcomes (symptom-
free days, symptom-free nights and symptom-free
24-hour periods) the difference between the drugs
was statistically significant (p < 0.001).
Jenkins and colleagues223 did not report
symptoms at the end-point but did report the
mean percentage of symptom-free days for several
periods during their study. In the period closest to
the end of the study (weeks 13–24), the median
percentage of symptom-free days was 75% for
subjects who received FP/SAL and 40% for subjects
who received high-dose (1600 µg/day) BUD (these
data were estimated by the reviewers from
Figure 3a of Jenkins and colleagues223). The
respective median percentages of symptom-free
days over the whole study (weeks 1–24) for these
drugs were 60 and 34% (95% CI 2 to 11). For each
of these periods the difference in the percentage
of symptom-free days between the drugs was
statistically significant (p < 0.001). The differences
between drugs were also statistically significant for
other periods: weeks 1–4 (p < 0.001), weeks 5–8
(p < 0.001) and weeks 9–12 (p = 0.019), in all
cases with the highest percentage of symptom-free
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median percentage of symptom-free nights was
reported by Jenkins and colleagues223 only for the
overall study period (weeks 1–24). This was 86%
for subjects on FP/SAL and 79% for subjects on
BUD; the difference between the drugs was
reported as not being statistically significant.
Health-related quality of life
HRQoL was analysed in one study. Juniper and
colleagues227 calculated asthma quality of life
scores based on a 32-item AQLQ for a subset of
the subjects in the study reported by Jenkins and
colleagues223 (these were subjects who completed
both baseline and end-point questionnaires:
n = 55 for FP/SAL and n = 58 for BUD). Mean
scores were calculated for four domains: activity
limitation, asthma symptoms, emotional
functioning and environmental exposure, and also
an overall AQLQ score. A threshold score change
from baseline of 0.5 was used to represent a
clinically important change to identify subject
improvement (a decrease in the score of 0.5
from baseline), deterioration (a score increase of
0.5) or no change (a score change of –0.49 to
+0.49).
The mean ± SEM change in the overall AQLQ
score was 0.89 ± 0.11 for subjects treated with
FP/SAL and 0.44 ± 0.10 for subjects treated with
high-dose (1600 µg/day) BUD, indicating that a
clinically important improvement occurred only in
the former subject group (ANCOVA model with
country and baseline scores as covariates). The
difference of the baseline to end-point score
changes between the drugs was 0.45 ± 0.14, which
is statistically significant (95% CI 0.17 to 0.72,
p = 0.002). Improvements in all the AQLQ
domain scores were significantly greater for the
FP/SAL subject group than for the BUD group,
with the largest differences being in the symptoms
and emotional functions domains. Approximately
70% of the subjects on FP/SAL experienced an
improvement in their HRQoL scores, 30%
remained unchanged and none deteriorated. For
BUD, scores for 43% of subjects improved, 45%
remained unchanged and 12% deteriorated.
Use of rescue medication
All three studies223,226,227 reported the percentage
of salbutamol-free days and the percentage of
salbutamol-free nights, but did not report mean
puffs per day.
Exacerbations
Two of the studies reported asthma exacerbations.
Johansson and colleagues224 reported that seven
participants in the FP/SAL group and 10
participants in the low-dose (800 µg/day) BUD
group experienced exacerbations. Of these, three
in the FP/SAL group were withdrawn due to
exacerbations after randomisation.
Jenkins and colleagues223 reported that 65 patients
in the FP/SAL group and 58 patients in the high-
dose (1600 µg/day) BUD group experienced at
least one exacerbation. Of these subjects, 36 (20%)
and 27 (16%), respectively, had mild exacerbations
(95% CI 0.74 to 2.25, p = 0.382 for the difference
between treatments); 28 (16%) and 29 (17%),
respectively, had moderate exacerbations (95% CI
0.54 to 1.73; p = 0.913 for the difference between
treatments); and one (0.6%) and two (1%),
respectively, had severe exacerbations. Six of the
subjects treated with FP/SAL and five of the
subjects treated with BUD withdrew from the study
due to exacerbations after randomisation.
Adverse events
The numbers of subjects experiencing AEs in the
FP/SAL and in the BUD groups were not tested
statistically in the three studies but appear similar
between the drugs (Table 47). The largest
difference was in the comparison with high-dose
(800 µg/day) BUD (Johansson and colleagues224),
where six more subjects in the BUD group than in
the FP/SAL group experienced at least one AE (a
difference of 4%). Three serious AEs in the
FP/SAL group reported by Johansson and
colleagues224 were acute asthma, asthma
exacerbation and cough and sputum production.
The serious AEs reported by Zhong and
colleagues225 (one in each treatment group) and
by Jenkins and colleagues223 (six in each treatment
group) were not considered to be related to the
study treatment. Withdrawals due to AEs that were
possibly or probably related to the study treatment
(Table 47) included cough and sputum production
in one subject receiving FP/SAL (Johansson and
colleagues224), headache, palpitation and ankle
oedema in three FP/SAL subjects and rash and
chest pain in two BUD subjects (Zhong and
colleagues225). Jenkins and colleagues223 did not
specify whether seven withdrawals due to adverse
events in their study were related to the study
treatments.
Summary
Three parallel-group RCTs demonstrated larger
improvements in lung function outcomes for
subjects treated with 200–500 µg/day SAL +
100 µg/day FP than for subjects treated with
800–1600 µg/day BUD. Estimates of the FEV1 at
end-point, the change in FEV1 from baseline, the
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PEF at end-point and the change from baseline in
the PEF were larger in the FP/SAL group in all
cases, although statistically significant differences
were not reported in all studies. A notable finding
from the study of Jenkins and colleagues223 was
that the percentage predicted FEV1 differed
statistically significantly between the two drugs
prior to the end-point (at 4 weeks) but did not
differ statistically significantly at end-point
(24 weeks), highlighting the problem that short-
duration studies may not adequately predict
longer term clinical effects.
In cases where the frequency of symptom-free days
or nights and salbutamol-free days or nights
differed statistically significantly between the
drugs, the frequency was consistently highest for
the group that received FP/SAL. The AQLQ scores
were also statistically significantly in favour of the
FP/SAL treatment. Although Jenkins and
colleagues reported a larger number of
exacerbations in subjects receiving FP/SAL, the
difference between drugs was not statistically
significant.
Overall, the findings reported here favour FP/SAL
over BUD but all the studies were of relatively
short duration (6–24 weeks). Accordingly, the
longer term relevance of the findings is unclear.
ICS versus ICS + LABA (FP versus BUD/FF)
Study characteristics
One RCT, by Bateman and colleagues published
in 2003, evaluated the combination of BUD/FF
compared with FP alone.228 It was a multi-centre
study conducted in 37 centres across six countries,
involving the recruitment of 373 patients. Only
344 patients were randomised. The trial was a
double-blind, parallel-group design, containing
two arms.
Patients were randomised to BUD/FF 160/4.5 µg
twice daily (total daily dose 320/9 µg) or to FP
250 µg (twice daily) (total daily dose 500 µg). It
was reported that a BUD metered dose of 200 µg
was equivalent to 160 µg delivered dose. The
BUD/FF combination was delivered via a
combination inhaler (Symbicort Turbuhaler, AZ)
plus a placebo device, whereas the FP was
delivered via a Diskhaler (Flixotide Diskhaler,
GSK), plus a placebo device. The rationale of the
trial was to compare the efficacy of the
combination treatment with a higher dose of the
corticosteroid FP. The authors did not explicitly
state whether the intention was to test equivalence
or superiority. The primary outcome measure was
morning PEF. A power calculation is reported to
detect a significant difference between groups on
this outcome. Treatment lasted for 12 weeks.
The study included men and women aged
17–75 years, with a mean age of 42.6 years for the
BUD/FF group and 41.8 years for the FP group
(Table 48). All patients had previously received a
range of ICS therapy at a consistent daily dose of
200–1000 µg for at least 30 days. The authors
described patients as suffering from moderate
persistent asthma, with a mean baseline FEV1 %
predicted of 77.2% for the BUD/FF treatment
group and 79.2% for the FP treatment group.
On the whole, the study was of adequate quality.
The ITT analysis only included all subjects who
received at least one dose of study drug. Details of
the randomisation procedure and concealment of
allocation were lacking. The study provided
information of withdrawals and drop-outs for each
treatment group, but did not offer explanations
for all the reasons.
Results
Lung function
A significantly greater mean change from baseline
in morning PEF was reported for the BUD/FF
treatment group compared with the FP group
(27.4 versus 7.7 l/minute; p < 0.001). Similar
increases were also found for evening PEF (24.0
versus 6.8 l/minute; p < 0.001). Geometric means
of average FEV1 increased significantly across
clinic visits in the BUD/FF group compared with
the FP group (2.57 versus 2.46 litres, p < 0.001).
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TABLE 47 Adverse events reported in comparisons of FP/SAL against BUD (number of subjects experiencing at least one adverse
event)
Study AE Serious AE Withdrawals due to AE
FP/SAL BUD FP/SAL BUD FP/SAL BUD
Johansson et al.224 67 (38%) 65 (38%) 3 0 1 0
Zhong et al.225 47 (24%) 45 (24%) 1 1 3 2
Jenkins et al.223 25 (14%) 31 (18%) 6 6 3 4Health Technology Assessment 2008; Vol. 12: No. 19
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Characteristics of study (BUD/FF versus FP)
Study
Design
Intervention
P
atients
Outcomes
Bateman 
et al.,
2003
228
RCT
Multi-centre
P
arallel-group
Double-blind
Double-dummy
1.
BUD/FF 200/6
µg b.d. ex-valve (daily total 320/9
µg 
ex-actuator) + placebo
2.
FP 250
µg b.d. (daily total 500
µg) + placebo
Delivery device:
1.
DPI (Symbicort T
urbuhaler
, AZ) + placebo Diskhaler
2.
DPI (Flixotide Diskhaler
, GSK) + placebo T
urbuhaler
Duration:
12 wks
Run-in period:
2 wks
Number randomised
344
Mean age (range) (years)
1.
42.6 (18–75)
2.
41.8 (17–74)
Baseline FEV
1
% predicted
1.
77.2
2.
79.2
P
revious ICS treatment (drug and dose)
Moderate to persistent asthma: 200–1000
µg 
ICS therapy daily
P
rimary outcome
PEF (morning)
Secondary outcomes
PEF (evening)
FEV
1
R
eduction in reliever medication
(inhalations/day)
% reliever
-free days
% symptom-free days
% night-time awakenings
% asthma control daysAssessment of clinical effectiveness
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Symptoms
The percentages of symptom-free days were
calculated from diary cards. A symptom-free day
was defined as a day and night without asthma
symptoms and no night-time awakening due to
asthma. Although the BUD/FF group had a
slightly higher percentage of symptom-free 
days than the FP group (60.4 versus 55.5%), 
these differences were not statistically significant
(no p-value reported). The percentage of 
night-time awakenings due to asthma was 
lower in the BUD/FF group than the FP group
(7.9 versus 9.6%), but the differences were 
also not statistically significant (no p-value
reported).
Use of rescue medication
Patients were provided with either terbutaline
sulfate or albuterol if preferred, as rescue
medication. There was a statistically significantly
higher reduction in reliever medication use
(inhalations/day) for the BUD/FF group 
compared with the FP group (0.31 versus 0.13,
p = 0.04).
Exacerbations
Bateman and colleagues228 reported that patients
treated with BUD/FF had a lower incidence of
mild asthma exacerbations than patients treated
with FP, occurring in 50 patients (29.8%) and 74
patients (42.0%), respectively. Mild exacerbations
were defined as awakening due to asthma on two
consecutive nights, morning PEF at least 20%
below that at baseline on two consecutive days or
the need to use at least four inhalations of reliever
medication. Severe asthma exacerbations, defined
as the need for oral corticosteroids, a 30%
decrease in PEF from baseline on two consecutive
days or discontinuation due to asthma worsening,
were reported to be low. The trial reported a lower
incidence of severe asthma exacerbations in
patients treated with the BUD/FF combination
compared with patients treated with FP alone,
occurring in 13 patients (8%) and 19 patients
(11%) respectively. No statistical tests were
reported.
Adverse events
Bateman and colleagues228 reported that AE
profiles were similar between the two treatments
(no data given on rate of AEs). Out of five 
serious AEs occurring during the trial, two were 
in the BUD/FF group and three in the FP 
group. No other data were supplied, but the
authors reported that the AEs were asthma
exacerbations and not considered to be treatment
related.
Summary
One large parallel-group RCT compared
500 µg/day FP with 400 µg/day BUD and
12 µg/day FF in a combination inhaler. There were
statistically significant differences between 
groups in favour of the combination inhaler 
on measures of morning and evening PEF, and
FEV1 (litres), and use of rescue medication, but
not for symptoms. There appeared to be a 
slightly lower incidence of mild exacerbations 
for the combination inhaler group, although 
this was not confirmed statistically. The 
incidence of severe exacerbations was low, and
appeared to be similar between treatments, as
were AEs.
ICS versus ICS + LABA (BUD versus BUD/FF)
Study characteristics
Four trials229–232 compared BUD/FF in a combined
inhaler with higher doses of BUD (Table 49).
There was considerable variation in overall design
and quality. The trials were all parallel group,
multi-national studies except that of Pohl and
colleagues,230 which was undertaken in a single
country. The number of participants randomised
ranged from 133 to 2760. The length of the trials
was between 20 weeks and 1 year. All were
designed as superiority trials but with different
aims and objectives depending on the specific
treatment comparisons.
The study by Lalloo and colleagues229 had two
arms comparing BUD 80 µg/FF 4.5 µg twice daily
with BUD 200 µg twice daily. Patients in the
combined treatment arm used a Symbicort inhaler
(Symbicort Turbuhaler, AZ), but the delivery
device for the other arm was not documented.
They used terbutaline as a reliever.
Pohl and colleagues230 compared two different
treatments, BUD 1280 µg/day (two inhalations
twice per day) and BUD 640 µg/FF 18 µg/day (two
inhalations twice per day) using either Symbicort
or Pulmicort Turbohalers (AZ). After week 4,
adjustable maintenance dosing was introduced.
The total number of inhalations per day was
adjusted in each group at the doctor’s discretion
depending on symptoms (two to four inhalations
per day in weeks 5–8, and one to four inhalations
per day in weeks 9–20). Participants were free to
choose between terbutaline and salbutamol as
reliever medication.
The O’Byrne and colleagues trial231 had three
arms. The first arm was BUD 80 µg/FF 4.5 µg
twice daily with the combination inhaler as
reliever. The second arm was BUD 80 µg/FF4.5 µg twice daily with terbutaline as reliever, and
the final arm was BUD 320 µg twice daily with
terbutaline as reliever. All study medication was
delivered by Turbohaler (BUD – Pulmicort
Turbuhaler, AZ).
There were two treatment arms in the study by
Scicchitano and colleagues.232 Patients in the first
group received ex-actuator doses of 320 µg BUD
plus 9 µg FF per day (metered doses of 400 and
12 µg, respectively). The drugs were delivered via
a combined DPI Turbohaler (Symbicort
Turbuhaler, AZ) as two inhalations each evening.
Patients could take up to 10 additional inhalations
per day as needed. Patients in the second
treatment arm took two inhalations of BUD twice
per day (total dose ex-actuator 640 µg/day,
metered dose 800 µg/day) delivered via a DPI
Turbohaler (Pulmicort Turbuhaler, AZ). Patients
were permitted to take up to 10 inhalations of
0.4 µg/day (metered dose 0.5 µg).
The ages of patients in the study by Lalloo and
colleagues229 ranged from 18 to 78 years (average
age around 40 years), had a baseline mean FEV1
% predicted of over 80%, and required ICS at a
dose between 200 and 500 µg/day (any brand)
prior to study entry. The patients’ ages in the
study by Pohl and colleagues230 ranged from 20 to
82 years (average age 45 years). Patients had a
baseline mean FEV1 % predicted in the mid-sixties
and all had a requirement for ICS or combination
therapy with a LABA as judged by the trial
investigator (it is not clear if they were actually
receiving this medication prior to the study). The
patients in the study by O’Byrne and colleagues231
included children (aged 4–11 years). The age
range of all patients was from 4 to 79 years. The
mean baseline FEV1 % predicted was 73%. Prior to
entry, children had to be treated with
200–500 µg/day of ICS and adults with
400–1000 µg/day. In the study by Scicchitano and
colleagues,232 patients had a mean age of 43 years,
ranging from 11 to 80 years. Patients suitable for
inclusion had moderate to severe asthma and had
previously received a mean ICS daily dose of
746 µg (range 250–2000 µg). The mean baseline
FEV1 % predicted was 70% and 83% of patients
were classified as having severe asthma.
All trials were classified as randomised controlled
and double-blind; however, details were generally
sparse in the reports. Neither Lalloo and
colleagues229 nor Scicchitano and colleagues232
provided any further details on randomisation,
concealment and blinding. In the study by Pohl
and colleagues,230 a computer-generated random
number list was used, but no other details are
available. O’Byrne and colleagues231 used a
computer-generated random number list (they
were randomised in balanced blocks and there
were separate lists for children and adults) and the
treatment delivery devices were indistinguishable –
no other details were available. All studies
reported using ITT analysis. However, the study
by Pohl and colleagues did not include patients
with missing data.
All were superiority trials. A primary outcome was
not specified in the study by Lalloo and
colleagues.229 In the study by Pohl and
colleagues,230 the primary outcome was the
number of people who had one or more treatment
failures. Both O’Byrne and colleagues231 and
Scicchitano and colleagues232 used time to first
severe asthma exacerbation as the primary
outcome.
Results
Meta-analysis was not possible due to insufficient
reporting of data. When reading this section it
also needs to be acknowledged that the study by
Pohl and colleagues230 was an adjustable
maintenance dosing study. Furthermore, one of
the three arms in the study by O’Byrne and
colleagues231 used the combination inhaler as both
maintenance and reliever. In addition, 12% of the
patients in this trial were aged between 4 and
11 years. However, the majority of results reported
by the trial were for all ages combined. Results
pertaining to children, where reported separately,
are presented in our accompanying assessment
report for the efficacy and safety of ICS in
children.181
Lung function
FEV1 (litres). Lalloo and colleagues229 reported
that mean FEV1 increased from baseline values in
both treatment groups. A comparison of the ratios
of geometric means from a multiplicative model
showed no significant between-group differences.
No values were presented. Pohl and colleagues230
found that improvements in FEV1 were
comparable: 0.36 and 0.47 for patients treated
with BUD/FF and BUD, respectively (p-values,
95% CIs and other measures were not presented).
In the trial by O’Byrne colleagues,231 the baseline
mean of FEV1 (range) was 2.14 (0.64 to 4.02), 
2.10 (0.62 to 4.50), and 2.13 (0.65 to 4.28) for
patients treated with BUD, BUD/FF and
terbutaline reliever, and BUD/FF as maintenance
and reliever, respectively. The mean of the data
over the 12-month period was used as the
treatment mean and analysed using ANCOVA with
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T
ABLE 49
Study characteristics (BUD versus BUD/FF)
Study
Design
Intervention
P
atients
Outcomes
Lalloo 
et al.,
2003
229
RCT
Multi-centre
P
arallel-group
Double-blind
1.
BUD/FF 80
µg/4.5
µg b.d. (daily total 160
µg/9
µg)
2.
BUD 200
µg b.d. (daily total 400
µg)
Delivery device:
1.
DPI (Symbicort T
urbuhaler
, AZ) 
2.
BUD inhaler not specified
Duration:
12 wks
Run-in period:
2 wks
Number randomised
467
Mean age (range) (years)
1.
42 (18–77)
2.
40 (18–78)
Baseline mean FEV
1
% predicted (range)
1.
82 (38–117)
2.
81 (42–157)
P
revious ICS treatment (drug and dose)
ICS at constant dose of 200–500
µg/day for at
least 1 month
FEV
1
FEV
1
% predicted
FVC
PEF (morning and evening)
Day
- and night-time symptom
scores
Use of reliever medication
Night-time awakenings
AEs
P
ohl 
et al.,
2006
230
RCT
Multi-centre
P
arallel-group
Double-blind
Adjustable
maintenance
dose (AMD)
1.
BUD 320
µg 2 puffs b.d. fixed dosing for wks 1–4 (daily
total 1280
µg). ADM from wk 4. 2–4 puffs/day
,
wks
5–8, then 1–4 puffs/day wks 9–20)
2.
BUD/FF 160
µg/4.5
µg 2 puffs b.d. (daily total
640
µg/9
µg). ADM from wk 4. 2–4 puffs/day
, wks 5–8,
then 1–4 puffs/day wks 9–20)
Delivery device:
1.
DPI (Symbicort, T
urbuhaler
, AZ)
2.
DPI (Pulmicort T
urbuhaler
, AZ)
Duration:
20 wks
Run-in period:
none
Number randomised
133
Mean age (range) (years)
1.
45 (20–82)
2.
45 (20–80)
Baseline mean FEV
1
% predicted (range)
1.
65 (39–85)
2.
67 (35–88)
P
revious ICS treatment (drug and dose)
ICS or ICS/LABA combination therapy within
the given starting dose
P
rimary outcome
The number of patients per
treatment group who
experienced 
1 treatment
failure
Secondary outcomes
FEV
1
PEF
HRQoL (SF
-36)
T
reatment satisfaction
Dose of study medication
% days patients required reliever
medication
AEs
continuedHealth Technology Assessment 2008; Vol. 12: No. 19
111
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
T
ABLE 49
Study characteristics (BUD versus BUD/FF) (cont’d)
Study
Design
Intervention
P
atients
Outcomes
O
’Byrne 
et al.,
2005
231
RCT
Multi-centre
P
arallel-group
Double-blind
NB. This trial
also examines
the effects of
the combination
inhaler as a
reliever
. 12%
are children
(4–11 years)
1.
BUD/FF 80
µg/4.5
µg b.d. (daily total 160
µg/9
µg) +
combination inhaler as reliever
a
2.
BUD/FF 80
µg/4.5
µg b.d. (daily total 160
µg/9
µg) +
terbutaline as reliever as needed
a
3.
BUD 320
µg b.d. (daily total 640
µg) + terbutaline as
reliever as needed
a
Delivery device:
1, 2. DPI (Symbicort T
urbuhaler
, AZ)
3. DPI (Pulmicort T
urbuhaler
, AZ) 
Duration:
12 months
Run-in period:
14–18 days
Number randomised
2760
Mean age (range) (years)
1.
35 (4–77)
2.
36 (4–79)
3.
36 (4–79)
Baseline mean FEV
1
% predicted (range)
1.
73 (43–108)
2.
73 (46–108)
3.
73 (49–100)
P
revious ICS treatment (drug and dose)
Adults 400–1000
µg q.d, children 200–500
µg
q.d.
P
rimary outcome
The time to first severe asthma
exacerbation
Secondary outcomes
FEV
1
PEF (morning and evening)
Asthma symptom scores
(day/night)
A
wakenings
R
eliever medication use
Symptom-free days
R
escue medication-free days
Asthma control days
Study drug use
AEs
Height (children)
Morning plasma cortisol
Mild exacerbations
Severe exacerbations requiring
medical attention
continuedAssessment of clinical effectiveness
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T
ABLE 49
Study characteristics (BUD versus BUD/FF) (cont’d)
Study
Design
Intervention
P
atients
Outcomes
Scicchitano
et
al., 2004
232
RCT
Multi-centre
P
arallel-group
Double-blind
Double-dummy
1.
BUD/FF
, 400
µg/6
µg
b
2 puffs q.d. (total
320
µg/9
µg/day
c
) + additional puffs as needed
2.
BUD 200
µg
b
2 puffs b.d. (total 640
µg/day
c
) +
terbutaline as needed 
Delivery device:
1.
DPI (Symbicort, T
urbuhaler
, AZ)
2.
DPI (Pulmicort T
urbuhaler
, AZ)
Duration:
52 wks
Run-in period:
2 wks
Number randomised
1890
Mean age (range) (years)
43 (11–80)
Baseline FEV
1
% predicted
70 (37–102%)
P
revious ICS treatment (drug and dose)
ICS 400–1600
µg/day
P
rimary outcome
Time to first severe asthma
exacerbation
Secondary outcomes
FEV
1
PEF (morning and evening)
Asthma symptom scores
(day/night/total)
A
wakenings
Symptom-free days
R
eliever medication use
R
eliever medication-free days
Asthma control days
AEs
Mild exacerbations
Severe exacerbations requiring
medical attention
a 
Children (aged 4–11 years) received half the stated maintenance dose, once daily
.
b 
Ex-valve.
c 
Ex-actuator
.the baseline value as covariate. The respective
values were 2.41, 2.43 and 2.51. The p-values for
the comparison were 0.09 and <0.001 for BUD/FF
with terbutaline compared with BUD and BUD/FF
as maintenance and reliever compared with BUD
respectively, Scicchitano and colleagues232
reported mean FEV1 throughout the study, but did
not report change from baseline. A statistically
significant mean difference between the groups of
0.1 litres was reported (p < 0.001). Patients using
the combined inhaler treatment of BUD/FF had a
mean FEV1 level of 2.54 litres, compared with
2.45 litres in those receiving BUD plus terbutaline.
Morning and evening PEF. Lalloo and
colleagues229 presented data on morning and
evening PEF. The baseline value was the average
value over the last 10 days of run-in and treatment
was the average value for the entire treatment
period. These were analysed using ANCOVA. For
morning PEF, the change from baseline was 16.5
and 7.3 l/minute for BUD/FF and BUD only,
respectively (other statistics for these values were
not provided). The between-group difference was
9.2 l/minute (95% CI 3.4 to 14.9 l/minute,
p = 0.02). For evening PEF, the change from
baseline was 13.7 and 4.2 l/minute, respectively;
the between-group difference was 9.5 l/minute
(95% CI 4.0 to 15.0, p < 0.001).
In the study by Pohl and colleagues,230 the mean
morning PEF for patients in the BUD/FF and
BUD treatment groups was 407 and 398 l/minute,
respectively; corresponding values for mean
evening PEF were 411 and 404 l/minute. Other
statistics for these values were not provided. No
baseline values were presented in the trial by
O’Byrne and colleagues.231 End-point values were
analysed using ANCOVA and were based on the
mean of data over the 12-month period. The
morning PEF was 339, 346 and 355 l/minute for
BUD, BUD/FF with terbutaline reliever and
BUD/FF as maintenance and reliever, respectively.
The p-values for the comparisons of BUD/FF with
terbutaline reliever versus BUD and BUD/FF as
maintenance and reliever versus BUD were all
<0.001, showing statistical significance. The
equivalent values for evening PEF were 345, 349
and 360 l/minute. As with morning PEF, between-
group comparisons showed statistical significance
(p < 0.001 for all comparisons). Other statistics for
these values were not provided.
Scicchitano and colleagues232 reported the mean
and range of treatment PEF values. People who
received BUD/FF had a mean treatment morning
PEF value of 372.1 l/minute (range
100–751 l/minute) compared with 348.5 l/minute
(range 93–805 l/minute) in the BUD with
terbutaline group. The mean difference of
20.3 l/minute (95% CI 17 to 24) was statistically
significantly different (p < 0.001). A slightly
smaller but still statistically significant difference
of 14 l/minute (95% CI 10 to 18) was seen between
the two groups’ evening PEF values (p < 0.001). In
the BUD/FF group, the treatment mean was
369.6 l/minute (range 99–720 l/minute) compared
with 354.7 l/minute (range 91–808 l/minute) in the
BUD with terbutaline group.
Symptoms
Symptom-free days. Lalloo and colleagues229
reported improvements in the proportion of
symptom-free days of 16% versus 10% for the
BUD/FF and BUD groups, respectively. The
estimated between-group difference was 6% (95%
CI 2 to 11%), which was statistically significant
(p = 0.007). The percentage of symptom-free days
(range) at baseline in the study by O’Byrne and
colleagues231 was 23.5% (0–100), 24.0% (0–100)
and 23.1% (0–100) in the BUD, BUD/FF with
terbutaline reliever and BUD/FF as maintenance
and reliever, respectively. End-point values were
analysed using ANCOVA, and were based on the
mean of data over the 12-month period. The
respective values were 46, 53 and 54%.
Comparisons of BUD/FF with terbutaline reliever
versus BUD and BUD/FF as maintenance and
reliever versus BUD were both statistically
significantly different (p < 0.001 for both
comparisons). Other statistics for these values were
not presented. Pohl and colleagues230 did not
present data on this variable. The percentages of
symptom-free days and nocturnal awakenings
reported by Scicchitano and colleagues232 ranged
from 0 to 100% for both treatment groups. In the
BUD/FF group, the mean on-treatment
percentage of symptom-free days was 41.7%,
compared with 34% in the BUD/terbutaline group.
This difference of 7.5 days (95% CI 5 to 10) was
statistically significantly different (p < 0.001).
Similarly, the difference in nocturnal awakenings
between groups was statistically significant (9.4 in
the BUD/FF group versus 13.0 in the
BUD/terbutaline group, p < 0.001).
Symptom scores. Pohl and colleagues230 did not
present data on this variable. Lalloo and
colleagues229 presented very limited data. Day-
and night-time symptoms were scored from 0 (no
symptoms) to 3 (severe symptoms). There were
reductions from the run-in baseline of 24% versus
6% for asthma symptoms (probably a combined
evening and morning score but it is not clear in
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BUD, respectively. Other statistics for this variable
were not presented.
O’Byrne and colleagues231 presented data on day-
and night-time symptom scores. The symptoms
were scored from 0 (no symptoms) to 3 (unable to
undertake normal activities/sleep)(no reference
supplied). Day- and night-time symptom scores at
baseline were not available. End-point values were
analysed using ANCOVA and were based on the
mean of data over the 12-month period. The 
p-values for daytime scores were 0.59, 0.50 and
0.48 for BUD, BUD/FF with terbutaline reliever
and BUD/FF as maintenance and reliever,
respectively. The p-values for the comparisons of
BUD/FF with terbutaline reliever versus BUD and
BUD/FF as maintenance and reliever versus BUD
were <0.001 and <0.001, respectively, showing
statistical significance. Corresponding values for
night-time symptom scores were 0.42, 0.36 and
0.31. The p-values were 0.01 and <0.001,
respectively. Other statistics for these values were
not presented.
Scicchitano and colleagues232 reported the mean
total asthma symptom score using a seven-point
scale (0–6; 0–3 for daytime score +0–3 for night-
time score, where 0 = no symptoms; no reference
was given for the scale used).The treatment means
were 1.08 in the BUD/FF group and 1.90 in the
BUD/terbutaline group, with a range of 0–6 in
both groups. The difference between groups was
statistically significant (p < 0.001).
Health-related quality of life
Pohl and colleagues230 measured HRQoL using
the Short Form with 36 Items (SF-36). Significant
and clinically relevant differences between the two
treatment groups were apparent in physical
functioning (6.0 units; p = 0.025) and emotional
role functioning (12.1 units; p = 0.035) with
participants in the BUD/FF group performing
better. The other studies did not report this
variable.
Use of rescue medication
In the study by Lalloo and colleagues,229 the
change from baseline in the number of inhalations
used in 24 hours was –0.33 and –0.1 in the
BUD/FF group and BUD group, respectively.
Other statistics for these values were not
presented. The between-group difference was –0.2
(95% CI –0.4 to 0), which was statistically
significant (p = 0.025). In the study by O’Byrne
and colleagues,231 the baseline mean of number of
inhalations per day was 1.69 (range 0.0 to 7.0),
1.69 (range 0.0 to 9.4), and 1.74 (range 0.0 
to 8.0) for patients treated with BUD, BUD/FF
and terbutaline reliever and BUD/FF as
maintenance and reliever, respectively. The
corresponding figures for night-time use were 
0.72 (range 0.0 to 3.7), 0.73 (range 0.0 to 6.6) and
0.72 (range 0.0 to 5.7), respectively. End-point
values were analysed using ANCOVA and were
based on the mean of data over the 12-month
period. Daytime values were 1.03, 0.84 and 0.73.
The p-values for the comparisons of BUD/FF with
terbutaline reliever versus BUD and BUD/FF as
maintenance and reliever versus BUD were all
<0.001, showing statistical significance. The
equivalent values for night-time were 0.43, 0.37
and 0.28, respectively. The p-value for the
comparison of BUD/FF with terbutaline versus
BUD was 0.003 and for the comparison of
BUD/FF as maintenance and reliever versus BUD
it was <0.001.
Other statistics for these values were not provided.
Neither Pohl and colleagues230 nor Scicchitano
and colleagues232 reported data for this outcome.
Exacerbations
In the study by Lalloo and colleagues,229 fewer
patients in the BUD/FF arm (110 out of 230)
experienced at least one mild asthma exacerbation
(defined as two consecutive mild exacerbation days,
which were defined as either night-time
awakenings, 20% decrease in PEF from baseline or
more than four inhalations of reliever medication in
a 24-hour period) compared with those in the BUD
group (136 out of 237). The patients in the BUD
group had a shorter time to first mild exacerbation,
p = 0.02, log-rank test. A Cox proportional hazards
model indicated that the estimated relative risk of
having a mild asthma exacerbation was 26% lower
for patients treated with BUD/FF (p = 0.02). There
were no between-group differences (7% in each
group) in the proportion of patients with severe
exacerbations (defined as the need for oral steroids,
or a 30% decrease in PEF on two consecutive days
or discontinuation due to asthma worsening) or
time to first severe exacerbation.
In the study by Pohl and colleagues,230 the
number of exacerbations was not documented very
clearly. However, in the BUD/FF group, five out of
63 (8%) of patients had treatment failures (all used
nebulised beta2 agonists); in the BUD group there
were two out of 63 (3%) patients (both were
treated with oral steroids). The rate of treatment
failure in the BUD group was less than the value
of 25% that had been assumed for the calculation
of the sample size.
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percentages of patients experiencing a severe
exacerbation (including a fall in PEF of 70% or
less of baseline on two consecutive days) were 28,
27 and 16% in the groups taking BUD, BUD/FF
with terbutaline and BUD/FF as maintenance and
reliever, respectively. Comparison of the BUD/FF
with the terbutaline group and the BUD group
showed no statistically significant difference
(p = 0.74). Comparison of the BUD/FF as
maintenance and reliever group with the BUD
group showed a statistically significant difference
(p < 0.0001). The percentages of patients
experiencing a serious adverse event requiring
medical attention were 19, 21 and 11% in the
groups taking BUD, BUD/FF with terbutaline and
BUD/FF as maintenance and reliever, respectively.
The p-values were 0.37 and <0.001 for the
comparison of BUD/FF with terbutaline with BUD
and of BUD/FF as maintenance and reliever with
BUD, respectively.
A statistically significantly lower percentage of
people in the Scicchitano and colleagues232
BUD/FF group reported an acute exacerbation
than those in the BUD/terbutaline group [18%
versus 27%; hazard ratio 0.61 (95% CI 0.50 to
0.74); p < 0.001]. Similarly, 14% of those in the
BUD/FF group had an exacerbation requiring
medical intervention, compared with 22% in the
BUD/terbutaline group. The hazard ratio was 0.61
(95% CI 0.49 to 0.75, p < 0.001).
Adverse events
In the study by Lalloo and colleagues,229 there
were no between-group differences in the profile
and frequency of all AEs. There were 134 AEs in
230 patients in the BUD/FF group and 128 AEs in
237 patients in the BUD group. There were five
serious AEs in the BUD/FF group and two in the
BUD group. Three patients withdrew from each
group because of AEs.
In the study by Pohl and colleagues,230 there were
74 AEs in the BUD/FF group and 81 in the BUD
group (the total number of patients included in
the analysis of each group is not stated). Three
patients reported serious AEs, two in the BUD/FF
group and one in the BUD group; none was
treatment related. A total of four patients withdrew
because of AEs (not split by group).
In the trial by O’Byrne and colleagues,231 the
proportion of patients experiencing one or more
AEs was 52 (57%) for BUD, 475 (52%) for BUD/FF
with terbutaline and 496 (54%) for BUD/FF as
maintenance and reliever. Corresponding
proportions of patients experiencing one or more
serious AEs were 48 (5%), 62 (7%) and 46 (5%),
respectively. Fourteen patients in the group taking
BUD/FF with combination reliever, 29 taking
BUD/FF with terbutaline and 24 in the BUD
group discontinued because of AEs. The study
reported no significant findings in plasma cortisol
in the subgroup of patients aged 12–80 years, but
data were not presented in sufficient detail to
include here.
No statistically significant differences between
groups were reported by Scicchitano and
colleagues232 for the rate of AEs, serious AEs or
withdrawals due to AEs. AEs were experienced by
56% of the BUD/FF group compared with 57% of
the BUD/terbutaline group (p = 0.677). The rate
of serious AEs was 6% in both groups (p = 0.846).
Discontinuations due to AEs were low: 3% of the
BUD/FF group and 4% of the BUD/terbutaline
group (p = 0.072).
Summary
Four parallel-group RCTs were identified which
compared 400–1280 µg BUD with 160–640 µg
BUD with 9–18 µg FF in a combination inhaler.
There was variability in the design, rationale and
reporting of the studies, prohibiting meta-analysis.
It is difficult to draw any firm conclusions from the
study by Pohl and colleagues230 as it was
underpowered to detect a difference in the
primary outcome. Overall, the combination
inhaler appeared to perform better than BUD
alone for most efficacy outcomes. In one trial
there were no significant differences in the
proportion of patients experiencing severe
exacerbations between BUD and the combination
inhaler, with terbutaline as relief in both groups.
However, exacerbations were significantly reduced
for patients taking the combination inhaler as
both maintenance and reliever compared with
BUD with terbutaline as a reliever. There did not
appear to be any difference in AEs between the
different combinations.
Summary of Q3a – ICS versus ICS + LABA 
(ICS dose higher when used alone)
Five RCTs evaluated FP/SAL combination inhaler
versus higher dose of ICS, and five evaluated
BUD/FF combination inhaler versus higher dose
of ICS. The general finding is that ICS + LABA 
in a combination inhaler is significantly superior
to increasing the dose of the ICS, across a 
range of outcomes. This applied to both of the
combination inhalers. Tables 50–53 provide a
visual illustration of the results of pair-wise
comparisons.
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esults
Study
, design,
ICS in
Lung function
Symptoms
AEs
duration, device,
each trial
R
escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
Meta-analysis,
FP
NSD
Bergmann 
et al.,
222
Busse 
et al.,
221
FP/SAL
+
+
+
+
Bergmann 
et al.,
222
FP
1000
µg FP vs 
parallel-group, 
500
µg/100
µg
12 weeks, 
NSD
FP/SAL
DPI, 
n
= 365
FP/SAL
+
F
F
500
µg FP vs 
Busse et al.,
221
parallel-
FP
200
µg/100
µg
group, 12–24 weeks, 
NSD
NSD
FP/SAL
DPI, 
n
= 558
FP/SAL
+
F
, results appear to favour this treatment group, but no tests of statistical significance reported; NSD, no significant differ
ence between trial arms; NW
, nocturnal waking; 
SFD, symptom-free days; SFN, symptom-free nights; SS, symptom score (varies between studies); + indicates results favour this t
rial arm; blank cells signify no data reported on that
outcome.
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FP versus FP/SAL (
n
= 2 RCT
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T
ABLE 51
BUD versus FP/SAL (
n
= 3 RCT
s)
T
ABLE 52
FP versus BUD/FF (n
= 1 RCT)
R
esults
Study
, design,
ICS in
Lung function
Symptoms
AEs
duration, device,
each trial
R
escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
500
µg Bateman 
et al.,
228
FP
FP vs
parallel-group, 
NSD
NSD
400
µg/9
µg
12 weeks, 
BUD/FF
DPI, 
n
= 344
BUD/FF
+
+
+
+
F
F
, results appear to favour this treatment group, but no tests of statistical significance reported; NSD, no significant differ
ence between trial arms; NW
, nocturnal waking; SFD,
symptom-free days; SFN, symptom-free nights; SS, symptom score (varies between studies); + indicates results favour this trial 
arm, blank cells signify no data reported on that
outcome.
R
esults
Study
, design,
ICS in
Lung function
Symptoms
AEs
duration, device,
each trial
R
escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
1600
µg Jenkins 
et al.,
223
BUD
18%
BUD vs
parallel-group, 
NSD
NSD
500
µg/100
µg
24 weeks, 
FP/SAL
DPI, 
n
= 353
FP/SAL
+
+
+
+
+
14%
Johansson 
et al.,
224
BUD
38%
parallel group,
CC
C
800
µg 
12 weeks, 
BUD
vs
DPI, 
n
=
349
FP/SAL
+
a
+
F
38%
200
µg/100
µg
Zhong 
et al.,
225
BUD
24%
FP/SAL
parallel group,
NSD
6 weeks, 
DPI, 
n
= 398
FP/SAL
+
+
+
+
24%
C, results appear to be comparable between treatment groups, but no tests of statistical significance reported; F
, results appe
ar to favour this treatment group, but no tests of
statistical significance reported; NSD, no significant difference between trial arms; NW
, nocturnal waking; SFD, symptom-free d
ays; SFN, symptom-free nights; SS, symptom score
(varies between studies); + indicates results favour this trial arm; blank cells signify no data reported on that outcome.
a 
See text. Chapter 3, R
esults, ICS versus ICS + LABA (BUD
versus FP/SAL), page 102, morning PEF
. 800
µg BUD 
vs 200
µg/
9
µg BUD/FF
O
’Byrne 
et al.,
231
parallel-group,
52 weeks,
DPI, 
n 
= 2760
NSD
1 vs 2
+
3 vs 1
+
2 vs 1
+
3 vs 1
+
2 vs 1
+
3 vs 1
+
2 vs 1
+
3 vs 1
+
2 vs 1
+
3 vs 1
+
2 vs 1
NSD
1 vs 2
57%
52%
54%
+
3 vs 1
R
esults
Study
, design,
ICS in
Lung function
Symptoms
AEs
duration, device,
each trial
R
escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
400
µg BUD 
Lalloo et al.,
229
BUD
NSD
54%
vs 200
µ
g/9
µ
g
parallel-group, 
BUD/FF
12 weeks, 
DPI, 
n 
= 467
BUD/FF
+
+
+
+
+
58%
1600
µg BUD
P
ohl 
et al.,
230
parallel-
BUD
81 events
vs 800
µg/
group, 20 weeks, 
C
F
F
C
18
µg AMD
DPI, n 
= 133
BUD/FF
+
74 events
BUD/FF
1. BUD
2. BUD/FF
a
3. BUD/FF
b
800
µg BUD 
Scicchitano et al.,
232
BUD
vs 400
µg/
parallel-group, 
NSD
9
µg
52 weeks, DPI, 
BUD/FF
n 
= 1890
BUD/FF
+
+
+
+
+
+
+
AMD, adjustable maintenance dose; C, results stated to be comparable between treatment arms, but no other data presented; F
, re
sults or to favour this trial arm but no significance
testing reported; NSD, no significant difference between trial arms; NW
, nocturnal waking; SFD, symptom-free days; SFN, symptom
-free nights; SS, symptom score (varies between
studies); + indicates results favour this trial arm; blank cells signify no data reported on that outcome.
a 
T
erbutaline only used as reliever in this arm.
b 
Combination inhaler used as both maintenance and reliever in this arm.
+
3 vs 1
T
ABLE 53
BUD versus BUD/FF (n
= 4 RCT
s)
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Review question 3b – ICS versus
ICS + LABA (ICS dose similar in both
groups)
To recap, nine RCTs evaluated ICS versus
ICS + LABA, where a similar ICS dose has been
used in both trial arms (Table 54). The following
sub-sections describe the characteristics and results
of these trials.
ICS versus ICS + LABA (FP versus FP/SAL)
Study characteristics
Six parallel-group RCTs evaluated the
effectiveness of FP/SAL in a combination inhaler
compared with FP alone.233–238 The trials were
published between 1999 and 2006 (Table 55). Four
were multi-centre studies and two single-centre
studies. Sample sizes were 54 and 282 in the two
single-centre studies236,237 and ranged between
349 and 3421 participants in the multi-centre
studies. All but one trial233 reported that a power
calculation was undertaken and sample sizes
suggest that adequate power was met. However, in
the Koopmans and colleagues study236 analysis was
based on sputum eosinophils as the primary
outcome, with lung function and symptoms as
secondary outcomes. The sample size of 54 may
not be powered for these secondary outcomes.
Four trials233,235,237,238 also included other
intervention arms, such as SAL monotherapy and
placebo, but these arms are not reported here.
One trial, the GOAL study by Bateman and
colleagues,234 stratified patients into three groups
based on previous ICS therapy. Data for the first
stratum (no previous ICS) are not reported here as
these patients do not meet the inclusion criteria of
the present review (i.e. only patients who had
received ICS prior to commencing LABA therapy
were included, in accordance with the BTS/SIGN
Guideline).
There was variability in the doses used in the
trials, with the FP dose varying from 200 to
1000 µg/day (both as monotherapy and combined
with SAL).
One trial compared 200 µg/day of FP with FP/SAL
combination 100/200 µg/day.235 Three trials
compared 500 µg/day FP with FP/SAL
500/100 µg/day.236–238 One trial compared FP
1000 µg/day with FP/SAL 1000/100 µg/day.233
In the GOAL trial by Bateman and colleagues,234
a variable dose was applied through two phases of
treatment therapy. In the stratum with participants
previously on lower dose ICS therapy
(500 µg/day) the FP/SAL arm in phase I was
stepped up between 200/100, 500/100 or
1000/100 µg/day, until total control was met or the
highest dose reached. Then, in phase II,
participants continued on the final dose reached
in phase I. The FP arm was similarly stepped up
between 200, 500 or 1000 µg/day (until control or
highest dose) in phase I and continued in phase
II. In the stratum with participants previously on
higher dose ICS therapy (500–1000 µg/day) the
dose ranges were 500/100 and 1000/100 µg/day
for both treatments and both phases of treatment,
respectively.
The treatment duration across the included trials
varied. Two trials lasted 12 weeks,235,238 one trial
lasted 28 weeks233 and three trials lasted
1 year.234,236,237 The inhaler devices used were
DPIs in all six trials. The aims of the trials were
mostly to compare the safety and efficacy of the
two treatments (and, in some cases, other
treatments). In the Bateman and colleagues234
study, where stepped-up doses of the treatments
were given, the aim was to compare the efficacy of
increasing doses of the two treatments to achieve
asthma control as defined by GINA/National
Institutes of Health guidelines (reference given).
The ages of participants in the six trials are likely
to be largely similar, but differences in methods of
reporting ages make summarising the data
difficult. Where reported, mean ages were in the
region of 34–50 years. One trial reported a mean
age of 40 years but a range of 9–83 years, and as
such may have included some children.234 The
severity of asthma was mild to moderate in three
of the trials236–238 and moderate in three.233–235
Baseline FEV1 % predicted was between 40 and
92% but in most trials was between 67 and 77%.
The quality of reporting and methodology of the
included RCTs was generally poor. The method of
randomisation was unknown in all but one
included study234 and the method to conceal
allocation to groups was similarly assessed to be
adequate only in this one trial. In the other trials
the method was either not reported or judged to
be an inadequate method. These factors, if
adequately met, reduce the risk of selection bias.
ITT analysis was assessed to be adequate in only
three included studies.233,234,237 This factor limits
the possibility of measurement bias.
Results
Lung function
FEV1 (litres). Four of the six studies reported
mean change from baseline in FEV1
(litres).233,235,237,238 In the Kavaru and colleagues235trial (FP doses of 200 µg/day) the mean change in
FEV1 was 0.51 (SD 0.46) litres in the combination
FP/SAL group compared with 0.28 (SD 0.46) litres
in the FP group [mean difference 0.23 (95% CI
0.09 to 0.37, p < 0.001)]. Two studies that treated
participants with FP doses of 500 µg/day (in the
combination and FP-alone arms, respectively)
showed greater improvement in patients treated
with combination treatment compared with FP
alone.237,238 In the Lundbäck and colleagues237
study this was not statistically significantly different
(actual p-values were not reported), and as no
measure of variance was reported these two studies
could not be combined to give a pooled treatment
effect. The treatment duration also differed
between these two studies; the study by Lundbäck
and colleagues237 was a 12-month study whereas
that of Shapiro and colleagues238 was shorter at
12 weeks. Lundbäck and colleagues237 reported that
the FEV1 change from baseline was 0.09 litres in
the FP/SAL group compared with 0.02 litres in the
FP arm. Shapiro and colleagues238 demonstrated a
mean change in FEV1 litres of 0.48 (SD 0.45) litres
in the FP/SAL arm compared with 0.25 (SD
0.45) litres in the FP arm (p = 0.003).
The study by Aubier and colleagues,233 which used
daily doses of 1000 µg FP in both combination
and monotherapy arms, found no statistically
significant difference between groups (figures
derived from graphs; FP/SAL 0.25 litres vs FP
0.18 litres, p = 0.061). This was a 28-week study.
FEV1 % predicted.F E V 1 % predicted was
reported in the trial by Koopmans and
colleagues236 but the data presented were only the
mean difference between the FP/SAL and FP
groups [2.7 (SE 1.5)%] and this was reported as
not statistically significantly different, p = 0.07.
Results for the Bateman and colleagues234 trial
were reported for the stratified groups and for the
two phases of treatments separately. In the lower
dose stratum the adjusted mean change in FEV1 %
predicted was 0.35% in the FP/SAL group in
phase I and 0.22% in the FP treatment group.
During phase II these were 0.37 and 0.24% for the
two treatments, respectively. In the higher dose
stratum the adjusted mean change in FEV1 %
predicted in phase I was 0.29% in the FP/SAL
group and 0.17% in the FP group. For phase II the
mean changes were 0.32 and 0.18%, respectively.
In each phase it is apparent that the combination
treatment gave higher rates of change but no
statistical analysis was undertaken of the two
groups in these two strata alone. Rather, data were
combined with data from the first stratum, the
latter not being relevant to the present review.
Morning PEF. Data on change in morning PEF
(l/minute) were reported in three of the included
RCTs233,235,238 but due to wide variations in the
doses meta-analysis was not appropriate. Using
daily fluticasone doses of 200 µg, the Kavaru and
colleagues trial235 demonstrated a statistically
significant difference in change in morning PEF.
The mean change was 52.50 (SD 49.44) l/minute
in the FP/SAL arm compared with 17.30 (SD
40.57) l/minute in the FP arm [mean treatment
difference 35.20 (95% CI 21.70 to 48.70,
p  0.025)]. The Shapiro and colleagues238 trial
similarly showed a statistically significant
difference in change in morning PEF between
combination treatment group and the FP alone
group [FP/SAL 53.50 (SD 50.40) l/minute versus
FP 15.20 (SD 41.40) l/minute, mean difference
38.30 (95% CI 24.10 to 52.50) l/minute,
p = 0.015]. The dose of FP in this study was
500 µg/day. Lundbäck and colleagues’ trial237 (also
using FP 500 µg/day) reported data on mean
change from baseline in morning PEF (l/minute)
but no measures of variance around the point
estimates were presented. The mean change was
38 l/minute in the FP/SAL group and 21 l/minute
in the FP group (p < 0.01).
Using higher doses of FP (1000 µg/day), Aubier
and colleagues233 also showed a statistically
significant difference in change in morning PEF,
although the magnitude of this difference was less
than in the other studies [FP/SAL 38.00
(SD 50.40) l/minute versus FP 22.00 (SD
51.40) l/minute, mean difference 16.00 (95% CI
5.04 to 26.95) l/minute]. This study was of 
28 weeks’ duration whereas the Kavaru and
colleagues235 and Shapiro and colleagues238
studies were of 12 weeks’ duration.
At end-point in the Koopmans and colleagues236
trial, morning PEF was 459 (SD 67.50) l/minute in
the FP/SAL arm compared with 419 (SD
67.50) l/minute in the FP arm. No statistical
analysis of the difference between groups was
undertaken.
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TABLE 54 Breakdown of studies for review question 3b – 
ICS versus ICS + LABA (ICS dose similar in both treatments)
Pair-wise comparison No. of RCTs included
FP vs FP/SAL 6
BUD vs BUD/FF 3
Total 9Health Technology Assessment 2008; Vol. 12: No. 19
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T
ABLE 55
Characteristics of studies (FP versus FP/SAL)
Study
Design
Intervention
P
atients
Outcomes
Aubier 
et al.,
1999
233
RCT
Multi-centre
P
arallel-group
Double-blind
Drugs:
1.
FP/SAL 500/50
µg b.d. (daily total 1000/100
µg)
2.
FP 500
µg + SAL 50
µg b.d. (daily total 1000/100
µg)
3.
FP 500
µg b.d. (daily total 1000
µg)
Only groups 1 and 3 relevant to this section
Delivery device:
1.
Diskus (Seretide Accuhaler
, GSK
a
) + placebo
2.
Diskus inhaler (Flixotide Diskhaler
, GSK
a
)
3.
Diskus inhaler (Flixotide Diskhaler
, GSK
a
) + placebo
Duration:
28 wks
Run-in period:
2 wks
Number randomised
503
Mean age (years)
1.
46
3.
50
Baseline FEV
1
% predicted (±
SD)
1.
73 (±
1.2)
3.
73 (±
1.4) 
P
revious ICS treatment (drug and dose)
BDP or BUD 1500–2000
µg q.d. or 
FP 750–1000
µg q.d.
PEF (morning and evening)
Daytime asthma score
Night-time asthma score
AEs
Serum cortisol
Urinary cortisol
Bateman 
et al.,
2004
234
RCT
Multi-centre
P
arallel-group
Double-blind
Stratified
Drugs:
Stratum 1: no ICS therefore not included here
Stratum 2: previous low ICS, use 
500
µg BDP or equivalent
daily
1.
FP/SAL – phase I: 100/50, 250/50 or 500/50
µg b.d. step-up
until total control or highest dose reached. Phase II:
continued on the final dose reached in phase I
2.
FP – Phase I: dose 100, 250 or 500
µg b.d. step-up until
total control or highest dose reached. Phase II: continued
on the final dose reached in phase I
Stratum 3: previous moderate ICS use >500 to 
1000
µg
BDP or equivalent daily
1.
FP/SAL – Phase I: 250/50 or 500/50
µg b.d. step-up until
total control or highest dose reached. Phase II: continued
on the final dose reached in phase I
2.
FP – Phase I: 250
µg or 500
µg b.d. step-up until total
control or highest dose reached. Phase II: continued on the
final dose reached in phase I
Delivery device:
1.
DPI (Seretide, Advair
, GSK)
2.
DPI (Flixotide Diskhaler
, GSK)
Duration:
52 wks 
Run-in period:
4 wks
Number randomised
3421
Mean age (range) (years)
Stratum 1:
1.
36.1 (12–80)
2.
36.4 (12–82)
Stratum 2:
1.
40.4 (12–78)
2.
40.3 (9–80)
Stratum 3:
1.
44.1 (12–83)
2.
42.7 (12–80)
Baseline FEV
1
% predicted (±
SD)
Stratum 1:
1.
77 (±
18.7)
2.
79 (±
18.8)
Stratum 2:
1.
78 (±
18.2)
2.
77 (±
18.4)
Stratum 3:
1.
75 (±
18.6)
2.
76 (±
17.6)
P
revious ICS treatment (drug and dose)
Continued on usual dose of ICS if any
P
roportion of patients who
achieved well-controlled
asthma during phase I
Cumulative proportion of
patients achieving control in
phase II
Dose of ICS
and time to
achievement of the first
well-controlled asthma
week
P
roportion of patients and
dose to achieve totally
controlled asthma
Time to achieve the first
totally controlled week 
Asthma quality of life (using
AQLQ)
Exacerbation rates 
Morning predose FEV
1
AEs
continuedAssessment of clinical effectiveness
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T
ABLE 55
Characteristics of studies (FP versus FP/SAL) (cont’d)
Study
Design
Intervention
P
atients
Outcomes
K
avuru 
et al.,
2000
235
RCT
Multi-centre
P
arallel-group
Double-blind
Drugs:
1.
FP/SAL 100/50
µg b.d. (daily total 200/100
µg)
2.
SAL 50
µg b.d. (daily total 100
µg)
3.
FP 100
µg b.d. (daily total 200
µg)
4.
Placebo b.d.
Only groups 1 and 3 reported here.
Delivery device:
1.
DPI Diskus (Seretide Accuhaler
, GSK
a
)
2.
DPI Diskus (GSK)
3.
DPI Diskus (Flixotide Diskhaler
, GSK
a
)
4.
DPI Diskus (GSK)
Duration:
12 wks
Run-in period:
2 wks
Number randomised
356
Mean age (range) (years) 
1.
38 (12–70)
2.
37 (12–67)
3.
39 (12–67)
4.
35 (12–66)
Baseline FEV
1
% predicted
1, 2, 3, 4. 64 
P
revious ICS treatment (drug and dose)
BDP 252–420
µg 6–10 puffs q.d. or flunisolide
1000
µg 4 puffs q.d. or FP 176
µg 4 puffs q.d.
FEV
1
(Under the 12-hour
serial curve relative to
baseline)
Morning predose FEV
1
P
robability that patients
remain in the study without
withdrawal for worsening
asthma
PEF
Daily patient-rated diary
card symptom scores
Albuterol use
Night-time awakenings
requiring albuterol
K
oopmans
et
al., 2006
236
RCT
Single-centre
P
arallel-group
Double-blind
Drugs:
1.
FP 250
µg b.d. (daily total 500
µg)
2.
FP/SAL 250/50
µg b.d. (daily total 500/100
µg)
Delivery device:
1.
DPI Diskus (Flixotide Diskhaler
, GSK)
2.
DPI Diskus (Seretide Accuhaler
, GSK)
Duration:
52 wks
Run-in period:
4 wks
Number randomised
54
Median age (range) (years)
1.
32 (19–57) 
2.
32 (21–59)
Baseline FEV
1
% predicted (±
SD)
1.
89.9 (±
14)
2.
88.8 (±
18)
P
revious ICS treatment (median daily dose)
(range)
1.
ICS 593
µg q.d. (200–1200)
2.
ICS 619
µg q.d. (200–1000)
FEV
1
PEF
Symptom scores
R
escue medicine use
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Characteristics of studies (FP versus FP/SAL) (cont’d)
Study
Design
Intervention
P
atients
Outcomes
Lundbäck 
et al.,
2006
237
RCT
Single-centre
P
arallel-group
Double-blind
Drugs:
1.
FP/SAL 250/50
µg b.d. (daily total 500/100
µg)
2.
FP 250
µg b.d. (daily total 500
µg)
3.
SAL 50
µg b.d.
Only groups 1 and 2 reported here
Delivery device:
1.
DPI Diskus (Seretide Accuhaler
, GSK
a
)
2.
DPI Diskus (Flixotide Diskhaler
, GSK
a
)
3.
DPI Diskus (GSK
a
)
Duration:
12 months
Run-in period:
2 months
Number randomised
282
Mean age (±
SD) (years)
1.
39.9 (±
11.9)
2.
39.1 (±
12.0)
3.
40.7 (±
12.3)
Baseline FEV
1
% predicted
1.
92.1
2.
93.0
3.
94.9
P
revious ICS treatment (drug and dose)
68% of patients had previously received ICS –
BUD median dose 500
µg or equivalent
No. of patients requiring an
increase in study
medication
No. of patients
experiencing 
2 exacerbations
Morning PEF
PEF diurnal variation
FEV
1
Day
- and night-time
symptom scores
R
escue medication use
AEs
Shapiro 
et al.,
2000
238
RCT
Multi-centre
P
arallel-group
Double-blind
Drugs:
1.
FP/SAL 250/50
µg b.d. (daily total 500/100
µg)
2.
FP 250
µg b.d. (daily total 500
µg)
3.
SAL
4.
Placebo
Only groups 1 and 2 reported here
Delivery device:
1.
Diskus (Seretide Accuhaler
, GSK
a
)
2.
Diskus (Flixotide Diskhaler
, GSK
a
)
3, 4. Diskus
Duration:
12 wks
Run-in period:
2 wks
Number randomised
349
Mean age (range) (years)
1.
38 (12–69)
2.
40 (12–67)
3.
39 (12–68)
4.
38 (12–69)
Baseline FEV
1
% predicted
1.
69
2.
66
3.
67
4.
68
P
revious ICS treatment (drug and dose)
BDP 462–672
µg q.d. or triamcinolone
acetonide 1100–1600
µg q.d. or FP 440
µg q.d.
or flunisolide 1250–2000
µg q.d.
FEV
1
(under the 12-hour
serial curve relative to
baseline)
Morning predose FEV
1
P
robability of remaining in
study
PEF
Symptom scores
Albuterol use
Night-time awakenings
Safety
a 
Not stated explicitly
, but deduced from the text.Evening PEF. Change in evening PEF was
reported in three included trials,233,235,238 but
differences in doses prevented a meta-analysis.
Using daily doses of 200 µg FP, the Kavaru and
colleagues trial235 demonstrated a statistically
significant difference in change on evening PEF
(as observed by the 95% CI). The mean change
was 35.00 (SD 43.84) l/minute in the FP/SAL 
arm compared with 18.00 (SD 12.40) l/minute in
the FP arm [mean treatment difference 17.00
(95% CI 7.42 to 26.58) l/minute, p  0.025]. 
The Shapiro and colleagues238 trial similarly
showed a statistically significant difference in
change in evening PEF between combination
treatment group and the FP alone group 
[FP/SAL 45.40 (SD 46.80) l/minute versus FP 7.90
(SD 40.50) l/minute, mean difference 37.50 
(95% CI 24.02, 50.98) l/minute p = 0.015]. 
The dose of FP in this study was 500 µg/day. 
In the study which used higher doses of FP
(1000 µg/day)233 there was a statistically 
significant difference in change in evening PEF,
although the magnitude of this difference was less
than in the previous studies [FP/SAL 31.00 
(SD 49.10) l/minute versus FP 13.00 
(SD 50.10) l/minute, mean difference 18.00 
(95% CI 7.33 to 28.67) l/minute, p < 0.01]. 
This study was of 28 weeks’ duration whereas 
the Kavaru and colleagues235 and Shapiro 
and colleagues238 studies were of 12 weeks’
duration.
In the trial by Koopmans and colleagues,236 the
mean change in evening PEF (l/minute) was only
reported in terms of the treatment difference. The
difference between FP/SAL and FP alone was 36
(SE 9) l/minute (p < 0.001).
Symptoms/health-related quality of life
Two of the included trials reported data on the
change from baseline in symptom-free days.235,238
One study used treatment doses of FP of
200 µg/day235 and the other 500 µg/day.238 In both
studies there was a statistically significant
difference between groups in favour of FP/SAL
combination therapy. In the Kavaru and
colleagues study,235 the mean change in
percentage of symptom-free days was 22.60
(SD 42.81) in the combination treatment arm
compared with 7.20 (SD 37.70) in the FP arm
[mean difference 15.40 (95% CI 3.35 to 27.45,
p  0.025)]. Corresponding values for mean
change in percentage of nights with no 
awakenings were 4.6 (SD 16.1) and 2.4 (SD 21.6)
[mean difference 2.2 (95% CI –3.50 to 7.90, no
statistically significant difference, no p-value
reported)].
In the Shapiro and colleagues238 study, the mean
change in percentage of symptom-free days was
33.80 (SD 41.40) in the FP/SAL arm compared
with 15.40 (SD 37.80) in the FP arm [mean
difference 18.40 (95% CI 6.19 to 30.61,
p = 0.015)]. Corresponding values for the
percentage of nights without awakenings were 7.2
(SD 17.1) and 2.8 (SD 21.6) [mean difference 4.4
(95% CI –1.60 to 10.40); p = 0.015)].
Symptom-free days were reported in the Aubier
and colleagues study233 but no measure of
variance was reported for the data. In the FP/SAL
treatment group the proportion of symptom-free
days was 38% compared with 28% in the FP group.
This was not statistically significantly different
between the two groups (no p-value given).
Three studies reported symptom scores.235,236,238 In
the study by Koopmans and colleagues236 morning
symptoms were measured on a five-point scale
(0–4; no further details reported). Only mean
differences were reported for the change over the
1-year treatment period. The mean difference
between the groups for morning symptoms was
–0.1 (SE 0.1; p = 0.02). Evening symptoms scores
were measured on a six-point scale (0–5; no further
details reported). The mean difference between
groups was –0.2 (SE 0.1; p = 0.01).
In the study by Kavaru and colleagues235
symptoms were measured on a six-point scale
(0 = no symptoms, 5 = symptoms that severely
interfered with daily activities, no reference
supplied). In the FP/SAL group there was a
change in score of –0.7 (SE 0.11) compared with a
change of –0.2 (SE 0.09) in the FP group
(p  0.025). Shapiro and colleagues238 also
reported changes in symptom scores using a
scoring system which appears to be identical with
that of Kavaru and colleagues.235 In the FP/SAL
group there was a change in score of –0.8 (SE
0.12) compared with a change of –0.4 (SE 0.09) in
the FP group (p = 0.015).
Bateman and colleagues234 reported data on the
AQLQ scale. Results were presented for the
stratified groups and for the two phases of
treatments separately. In the lower dose stratum,
the adjusted mean change in AQLQ score was 1.3
in the FP/SAL treatment group in phase I and 1.0
in the FP treatment group. During phase II
treatments these were 1.3 and 1.2 for the two
treatments, respectively. In the higher dose
stratum the adjusted mean change in AQLQ score
in phase I was 1.1 in the FP/SAL treatment group
and 0.8 in the FP treatment group. For phase II
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respectively. In each phase there were slightly
higher rates of change in the combination
treatment arms but no statistical analysis was
undertaken of the two groups in these two strata
alone, rather being combined with the data from
the first stratum which was not included in the
present review.
Use of rescue medication
Change in the use of rescue medication in terms
of inhalations per day was also shown to be
statistically significantly better with FP/SAL
treatment versus FP treatment alone in two trials.
In the Kavaru and colleagues trial235 there was a
–1.90 (SD 2.43) change in inhalations per day in
the combination treatment arm compared with a
–0.40 (SD 1.94) change in the FP treatment arm
[difference –1.50 (95% CI –2.16 to –0.84, p 
0.025)]. This trial used low doses of FP in both
treatment groups (200 µg/day). In the Shapiro and
colleagues trial238 (using doses of 500 µg/day of FP
in each treatment group) there was a –2.30 (SD
3.60) change in inhalations per day in the FP/SAL
group compared with a –0.90 (SD 1.80) change in
inhalations per day in the FP group [difference
–1.40 (95% CI –2.28 to –0.52), p = 0.015)].
The treatment difference between the FP/SAL
group and the FP group of the Koopmans and
colleagues trial236 for use of rescue medication was
–0.9 (SE 0.3) puffs per day. This difference was
reported to be statistically significantly different
(p < 0.001), but the study may have been
underpowered to detect a difference on this
outcome.
Exacerbations
Four of the trials reported this outcome, with
variability in definitions and limited reported
data. Shapiro and colleagues238 reported that 2
and 7% of patients withdrew due to clinical
exacerbations in the FP/SAL and FP groups,
respectively. A clinical exacerbation was defined as
requiring emergency room treatment,
hospitalisation or use of asthma medication not
allowed by the study protocol. In the trial by
Kavaru and colleagues,235 no patients in the
FP/SAL group withdrew because of clinical
exacerbations, compared with 4% of patients in
the FP group. The definition of clinical
exacerbation was the same as that used by Shapiro
and colleagues.238
In the trial by Lundbäck and colleagues,237
exacerbations were defined as any deterioration in
asthma that required an increase in rescue
medication use (SABA) over that used during the
run-in period of >6 puffs/day for 2 consecutive
days, or an increase of 2 doses/day in regular
inhaled medication (study medication or
additional ICS) for 2 days by the patient’s own
decision, or 2 days when asthma symptoms
prevented the patient’s work or normal activities.
If rescue medication was insufficient,
exacerbations were treated with oral prednisolone
(25 mg) for 5 days. The percentage of patients
experiencing two or more acute exacerbations was
4.2% for the FP/SAL combination compared with
17.4% for FP, p < 0.01.
Bateman and colleagues234 defined exacerbations
as deterioration in asthma requiring treatment
with an oral corticosteroid or an emergency
department visit or hospitalisation, based on the
GINA/National Institutes of Health guidelines.
The mean annual rates of exacerbations were low
in both treatment groups but were significantly
lower in the FP/SAL group in each stratum
(p  0.009). Rates for each stratum were not
reported.
Adverse events
Numbers of participants experiencing AEs were
reported in three trials.233,237,238 In the Shapiro
and colleagues238 trial, no AEs were experienced
in either treatment group. In the Lundbäck and
colleagues237 trial, 92/95 (96%) participants in the
combination treatment group and 88/92 (95%)
participants in the FP treatment group
experienced an AE. In the Aubier and
colleagues233 trial, 28/167 (16%) participants in
the FP/SAL arm experienced an AE compared to
32/165 (19%) participants in the FP arm. The
variation in the proportions of patients
experiencing AEs between the studies may be
related to differences in the way in which events
are classified by different studies.
Three trials233,235,238 provided data on numbers
discontinuing due to AEs. In the Shapiro and
colleagues238 trial, no participants were classed as
withdrawing due to AEs in either treatment arms.
In the Kavaru and colleagues235 trial, one
participant in the FP arm discontinued due to an
AE compared with no participants in the
combination arm. In the Aubier and colleagues233
trial, 16/167 (9%) participants in the FP/SAL arm
discontinued due to AEs (9%) compared with
22/165 (13%) in the FP arm.
Summary
Six parallel-group RCTs were identified that
compared FP/SAL in a combination inhaler with
Health Technology Assessment 2008; Vol. 12: No. 19
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from 200 to 1000 µg/day (both as monotherapy
and combined with SAL), and duration (between
12 weeks and 1 year).
FP/SAL treatment was generally more favourable
than FP treatment alone on measures of lung
function, and statistically significant differences
were reported in some studies. Data on symptoms
generally favoured the combination treatment but
this was not always statistically significant. Use of
rescue medication, where reported, was statistically
significantly different between treatment arms,
again in favour of the FP/SAL. Exacerbations,
which were defined and reported in a variety of
ways, appeared similar between treatments. In two
studies there were statistically significant
differences in favour of the combination treatment.
Generally similar rates of AEs and discontinuations
due to AEs were reported between the two
treatment options, where data were reported.
ICS versus ICS + LABA (BUD versus BUD/FF)
Study characteristics
Three trials were included in this
comparison239–241 (Table 56). All of them used
parallel-group designs and were published
between 2001 and 2006. All were international
multi-centre trials and generally large in size,
ranging from 362 to 1272 patients. The length of
treatment was 12 weeks in all three trials.
All trials had multiple arms, testing various
regimens. Buhl and colleagues240 compared two
regimens of BUD combined with FF against BUD.
In one of the regimens patients took two
inhalations (160/4.5 µg) once per day, whereas in
the other they inhaled twice per day (160/4.5 µg)
(a total daily dose of 320/9 µg). Patients receiving
BUD only took 400 µg/day. The trial by Kuna and
colleagues241 tested similar regimens, but with
higher doses. They compared BUD/FF (80/4.5 µg)
at two inhalations once per day (evening), 
BUD/FF (80/4.5 µg) at one inhalation twice per
day (total BUD/FF dose of 160/9 µg/day in both
groups) and BUD at 200 µg/day. The comparison
between the once- and twice-daily regimens of
BUD/FF in both of these trials is not relevant to
this review. Finally, one study, by Zetterström and
colleagues,239 compared BUD/FF in a combination
inhaler (160/4.5 µg, two inhalations twice daily;
total daily dose total 640/18 µg), with the two
agents in separate inhalers (200/4.5 µg, two
inhalations twice daily; total daily dose total
800/18 µg), and with BUD monotherapy [200 µg,
two inhalations twice daily (total 800 µg/day)]. For
the purposes of this section, only the combination
inhaler and the BUD monotherapy arms are
compared. A comparison of the combination
inhaler and the separate inhalers is given in the
section ‘BUD/FF in a combination inhaler versus
BUD + FF in separate inhalers’ (p. 139). In
summary, the three trials compared BUD/FF
combination inhaler with BUD. The dose of BUD
was similar in both comparisons, ranging from
200 to 800 µg/day.
In all studies a Turbohaler DPI was used to deliver
BUD/FF. Metered doses (ex-actuator) are reported
for some arms and delivered doses (ex-valve) for
others. This reflects changes in labelling, whereby
the combination inhalers (Symbicort Turbuhaler,
AZ – not explicitly stated in only one study,240 but
deduced from the text) express doses as delivered,
compared with the separate inhalers (BUD:
Pulmicort Turbuhaler, AZ – not explicitly stated in
any of the three studies, but deduced from the
text) for BUD/FF, which express doses as metered.
An inhalation of BUD/FF 160/4.5 µg from the
combination inhaler delivers the same quantity as
a 200-µg metered inhalation of BUD and as a 
6-µg metered inhalation of FF.
Two of the trials had similar rationales. The aim of
the study by Buhl and colleagues240 was to
evaluate the efficacy of once-daily combination
therapy compared with twice-daily combination
therapy and with once-daily BUD. It was
suggested that a “simple treatment regimen” (i.e.
one inhaler taken once per day) would be effective
in patients with moderate persistent asthma.
Similarly, Kuna and colleagues241 compared once-
daily combination therapy with twice-daily
combination therapy and with BUD alone, but
with lower doses and in patients with mild to
moderate asthma. The rationale was that patients
with milder chronic asthma, who may experience
fewer symptoms and who may underestimate their
condition, may be more likely to use their
medication if taken once per day. The third trial,
by Zetterström and colleagues,239 aimed to
compare the then new BUD/FF combination
inhaler with the two drugs administered in
separate inhalers and with BUD alone.
The average age of patients in the trials was
generally between 30 and 40 years, ranging from
18 to 80 years. All patients had previously been
treated with ICS, although doses varied across the
trials. One of the studies included patients who
were receiving ‘lower dose’ ICS (according to the
BTS/SIGN Guideline).1 Patients in the trial by
Kuna and colleagues241 were defined by the
authors as having mild to moderate asthma which
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T
ABLE 56
Study characteristics: BUD versus BUD/FF
Study
Design
Intervention
P
atients
Outcomes
K
una 
et al.,
2006
241
RCT
Multi-centre
Double-blind
Double-dummy
Drugs:
1.
BUD/FF 80/4.5
µg
a
2 puffs q.d. p.m. (daily total 160/9
µg)
2.
BUD/FF 80/4.5
µg
a
b.d. (daily total 160/9
µg)
3.
BUD 200
µg
b
q.d. p.m.
Delivery device:
1. DPI T
urbuhaler (Symbicort T
urbuhaler
, AZ) 
2. DPI T
urbuhaler (Symbicort T
urbuhaler
, AZ) 
3. DPI T
urbuhaler (Pulmicort T
urbuhaler
, AZ
c
) 
Duration:
12 wks
Run-in period:
2 wks
Number randomised
617
Mean age (range) (years) 
1.
45.8 (18–80)
2.
43.9 (19–80)
3.
45.1 (18–78)
Mean baseline FEV
1
% predicted
1.
79.3
2.
77.9
3.
78.3
P
revious ICS treatment (drug and dose)
ICS 200–500 µg q.d.
P
rimary outcome
Mean change in morning
PEF from baseline 
Secondary outcomes
Evening PEF
Symptom-free days
Use of reliever medication
Nocturnal awakenings
Asthma control days
FEV
1
AEs
Buhl 
et al.,
2003
240
RCT
Multi-centre
P
arallel-group
Double-blind
Double-dummy
Drugs:
1.
BUD/FF 160/4.5
µg
a
2 puffs q.d. (daily total 320/9
µg)
2.
BUD/FF 160/4.5
µg
a
b.d. (daily total 320/9
µg) 
3.
BUD 400
µg
b
q.d.
Delivery device: 
1.
DPI T
urbuhaler (Symbicort T
urbuhaler
, AZ
c
) 
2.
DPI T
urbuhaler (Symbicort T
urbuhaler
, AZ
c
) 
3.
DPI T
urbuhaler (Pulmicort T
urbuhaler
, AZ
c
) 
Duration:
12 wks
Run-in period:
2 wks
Number randomised
523
Mean age (range) (years) 
1.
42.7 (18–77)
2.
44.8 (18–74)
3.
45.5 (18–78)
Baseline FEV
1
% predicted
1.
77.1
2.
77.6
3.
77.6
P
revious ICS treatment (drug and dose)
ICS 400–1000
µg q.d.
PEF (morning and evening)
FEV
1
Day and night-time asthma
symptoms
T
otally daily asthma
symptom score
Night-time awakenings
Use of relief medication
Mild and severe
exacerbations
AEs
continuedAssessment of clinical effectiveness
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Study characteristics: BUD versus BUD/FF (cont’d)
Study
Design
Intervention
P
atients
Outcomes
Zetterström
et
al., 2001
239
RCT
Multi-centre
P
arallel-group
Double-blind
Double-dummy
Drugs:
1.
BUD/FF 160/4.5
µg
a
2 puffs b.d. (daily total 640/18
µg)
(combination inhaler)
2.
BUD + FF 200
µg
b
+ 4.5
µg 2 puffs b.d. (daily total 800
µg
+ 18
µg) (separate inhalers)
3.
BUD 200
µg
b
2 puffs b.d. (daily total 800
µg)
Only groups 1 and 3 relevant here
Delivery device: 
1.
DPI T
urbuhaler (Symbicort T
urbuhaler
, AZ) + placebo
2.
DPI T
urbuhaler (Pulmicort T
urbuhaler
, AZ
c
) + placebo
3.
DPI T
urbuhaler (Pulmicort T
urbuhaler
, AZ
c
) + placebo
Duration:
12 wks
Run-in period:
2 wks
Number randomised
362
Mean age (range) (years)
1.
46.7 (18–78)
2.
44.7 (18–77)
3.
48.5 (21–78)
Baseline FEV
1
% predicted
1.
73.6
2.
74.7
3.
73.1
P
revious ICS treatment (drug and dose)
ICS 
	
500 
µg
PEF
FEV
1
Day
- and night-time
symptoms scores
Symptom-free days
Night-time awakenings
Asthma control days
Use of relief medication 
Mild and severe
exacerbations
AEs
a 
Ex-actuator
.
b 
Ex-valve.
c 
Not stated explicitly
, but deduced from the text.was not optimally controlled, despite taking
200–500 µg/day of inhaled steroids (unspecified as
to which steroid). The other two trials included
patients who had been managed on higher doses:
400–1000 µg/day of any corticosteroid in the trial
by Buhl and colleagues240 (patients described by
the authors as having moderate persistent
suboptimally controlled asthma) and 500 µg/day
in the trial by Zetterström and colleagues239
(patients described as having symptomatic asthma
despite treatment with ICS). Mean baseline FEV1
as a percentage of predicted was between 70 and
80% across the trials, suggestive of moderate
asthma.2
Only one of the trials specified a primary outcome
measure. Kuna and colleagues241 measured mean
change in morning PEF from baseline as their
primary outcome. A power calculation is reported
for this outcome. The remaining outcomes in
these and the other two studies comprised lung
function (FEV1 and PEF), measures of symptoms
(symptom scores, symptom-free days, nocturnal
awakenings), use of reliever medication, mild and
severe exacerbations and AEs.
In terms of methodological quality, the trials had
some limitations. Only one provided details 
of the randomisation procedure used and the
method used for concealment of allocation.239
However, in this particular study sealed envelopes
were used to conceal individual treatment codes
until data analysis. This method is potentially
open to subversion. All trials employed an ITT
analysis.
Results
Results are reported narratively by outcome in the
following sections. Meta-analysis was not possible
due to limitations in the trial data and to
differences in dose between the trials.
Lung function
All trials reported FEV1 in terms of litres, with
results generally favouring BUD/FF compared
with BUD. In the trial by Kuna and colleagues,241
increases in FEV1 (geometric mean) from baseline
to end-point were 0.08 and 0.12 litres for the
once- and twice-daily BUD/FF groups, respectively.
In the BUD group there was a decrease of
0.01 litres. No statistical significance values are
reported, although it is stated that there was a
3.8% difference between the two combination
inhaler groups and the BUD group in terms of
FEV1 as a percentage of the baseline value at end-
point (p < 0.05). In the trial by Buhl and
colleagues,240 there was no change in FEV1
between baseline and end-point for the once-daily
BUD/FF group, an increase of 0.12 litres in the
twice-daily group and a decrease of 0.06 litres in
the BUD group. There was a statistically
significant difference between the once-daily
group and the twice-daily group compared with
the BUD group in end-point values (2.32, 2.37
and 2.21 litres, respectively, p < 0.001). Increases
in FEV1 in the study by Zetterström and
colleagues239 were 0.19 litres for the combination
inhaler group and 0.11 litres for the BUD group.
The difference between the groups was statistically
significant for end-point values, 2.47 litres (95%
CI 2.40 to 2.55) and 2.35 litres (95% CI 2.28 to
2.43), respectively (p < 0.05).
FEV1 as a percentage of predicted was not
reported as an outcome in any of the trials.
All three trials reported changes from baseline in
morning PEF, and in all cases increases were
statistically significant for BUD/FF compared with
BUD. Increases of 23.4 l/minute (95% CI 18.1 to
28.6), 24.1 l/minute (95% CI 19.0 to 29.2) and
5.5 l/minute (95% CI 0.3 to 10.6) were reported
for the BUD/FF once-daily group, twice-daily
group and BUD group, respectively, in the trial by
Kuna and colleagues241 (p < 0.001 for both
combination inhaler groups compared with the
BUD group). In the trial by Buhl and
colleagues,240 statistically significant increases of
27.4 and 22.8 l/minute were reported for the once-
and twice-daily BUD/FF groups compared with the
BUD group (values not provided for this group)
(p < 0.001). Increases of 35.7 l/minute (95% CI
28.4 to 43.0) and 0.2 l/minute (95% CI –7.1 to 7.6)
were reported for the BUD/FF group and the
BUD group, respectively, in the trial by
Zetterström and colleagues239 (p < 0.01).
Evening PEF was also reported in all three trials.
As with morning PEF, increases were statistically
significant for BUD/FF compared with BUD.
Increases of 9.6 l/minute (95% CI 4.4 to 14.8) and
18.3 l/minute (95% CI 13.2 to 23.4) and a
decrease of 1.7 l/minute (95% CI –6.8 to 3.5) were
reported for the BUD/FF once-daily group, twice-
daily group and BUD group, respectively, in the
trial by Kuna and colleagues.241 The difference
was statistically significant for both combination
inhaler groups compared with the BUD group
(p < 0.01 and p < 0.001, respectively). In the trial
by Buhl and colleagues,240 increases of 11.8 and
18.8 l/minute and a decrease of 4.8 l/minute were
reported for the once-daily, twice-daily BUD/FF
groups and the BUD group, respectively. Mean
differences between the combination inhaler
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significant (p < 0.001). An increase of
24.8 l/minute (95% CI 18.2 to 31.4) and a
decrease of 3.7 l/minute (95% CI –10.3 to 3.0)
were reported for the BUD/FF group and the
BUD group, respectively, in the trial by
Zetterström and colleagues239 (p < 0.01).
Symptoms
Two of the trials reported asthma symptom scores.
Buhl and colleagues240 and Zetterström and
colleagues239 measured day- and night-time
symptom scores on a scale of 0–3 (0 = none;
3 = severe), and summed these to provide a total
score (0–6). In both studies there were statistically
significant differences favouring BUD/FF. In the
Buhl and colleagues study,240 scores decreased
(indicating fewer symptoms) by 0.24, 0.32 and 0.2
in the once- and twice-daily BUD/FF groups and
the BUD group, respectively. The difference in
end-point values was statistically significant for the
BUD/FF once-daily group compared with the
BUD group (p < 0.05), but not for the twice-daily
group compared with BUD. In the trial by
Zetterström and colleagues,239 scores decreased by
0.52 (95% CI, –0.65 to –0.39) and by 0.20 (95%
CI, –0.33 to –0.07) in the BUD/FF group and the
BUD group, respectively (p < 0.01).
All three trials reported the proportion of
symptom-free days, using slightly different
definitions. In all cases there were statistically
significant differences between groups favouring
BUD/FF. Kuna and colleagues241 defined a
symptom-free day as a day and a night with no
asthma symptoms and no night-time awakenings
due to asthma. The increase in percentage of
symptom-free days between baseline and end-
point was 12.2, 14.2 and 5.3% in the BUD/FF
once daily group, twice-daily group and BUD
group, respectively (p < 0.05 for end-point values
for both combination inhaler groups compared
with BUD). Buhl and colleagues240 used the
definition of a day and a night with a total
symptom score of zero. The increase in percentage
of symptom-free days between baseline and end-
point was 14.3, 14.7, and 11.9% for the once-daily,
twice-daily BUD/FF groups and the BUD group,
respectively (p < 0.05 for end-point values for
both combination inhaler groups compared with
BUD). Zetterström and colleagues239 used the
definition of days with a total asthma score of zero
and no night-time awakening. The increase in
percentage of symptom-free days between baseline
and end-point was 25.0% (95% CI 19.5 to 30.6)
and 8.0% (95% CI 2.4 to 13.6) for the BUD/FF
group and the BUD group, respectively (p < 0.01).
Night-time awakenings were reported in all three
trials. In the trial by Kuna and colleagues,241 the
reduction in the percentage of awakenings was 4.5,
4.7 and 5.9% in the BUD/FF once-daily group,
twice-daily group and BUD group respectively.
Differences between groups were not reported to
be statistically significant (no p-value provided).
Buhl and colleagues240 reported percentage of
nights with awakenings. There was a reduction of
4.6% for the BUD/FF once-daily group, an
increase of 2.1% for the twice-daily group and a
reduction of 1.4% for the BUD group. The end-
point value was statistically significant for the
twice-daily group compared with the BUD group
(p < 0.05). Zetterström and colleagues239 reported
changes in the percentage of night-time
awakenings due to asthma. Reductions were 8.4%
(95% CI –11.4 to –5.4) and 5.8% (95% CI –8.8 to
–2.7) for the BUD/FF group and the BUD group,
respectively. Differences between groups were not
reported to be statistically significant (no p-value
provided).
Use of rescue medication
All three trials reported this outcome, although
only two reported it in terms of puffs per day. For
both of these trials differences between groups
were statistically significant, in favour of BUD/FF.
In the trial by Buhl and colleagues,240 reductions
in the number of inhalations/day from baseline to
end-point were 0.37, 0.45 and 0.10 for the once-
daily, twice-daily BUD/FF groups and the BUD
group, respectively (p < 0.01 for the once daily
group compared with the BUD group; p < 0.001
for the twice daily group compared with the BUD
group). In the trial by Zetterström and
colleagues,239 reductions in puffs/day from
baseline to end-point were 0.99 (95% CI –1.29 to
–0.69) and 0.44 (95% CI –0.74 to –0.13) for the
BUD/FF group and the BUD group, respectively
(p < 0.01).
Exacerbations
Two of the trials reported this outcome. Buhl and
colleagues240 reported mild and severe
exacerbations. Mild exacerbations were defined as
two consecutive mild exacerbation days (for the
same criterion), the latter being defined as a
night-time awakening due to asthma, 20%
decrease in PEF from baseline or 4 inhalations
of reliever medication over a 24-hour period.
Severe exacerbation was defined as asthma
deterioration requiring oral corticosteroid
treatment, 30% decrease in PEF from baseline
on two consecutive days or discontinuations due to
worsening of asthma. Rates of severe
exacerbations were 8, 9 and 11% for the once-
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group, respectively. A similar pattern across
treatment groups was reported for mild
exacerbations (no data reported).
Zetterström and colleagues239 defined severe
exacerbations as the need for oral steroids,
discontinuations due to worsening asthma or PEF
<70% of run-in mean on two consecutive days.
Rates were 6.5 and 8.9% for the BUD/FF group
and the BUD group, respectively. The authors
reported that too few severe exacerbations
occurred during the study to detect differences
between the treatments.
Adverse events
The rate of AEs, where reported, appeared similar
between treatments. No statistical significance
values were reported in any of the trials.
In the trial by Kuna and colleagues,241 76 (38%),
78 (38%) and 74 (36%) of patients experienced at
least one AE in the BUD/FF once-daily group,
twice-daily group and BUD group, respectively.
Seven serious AEs were reported: two, one and
four in these study groups, respectively. The
proportion of patients experiencing at least one
AE in the trial by Buhl and colleagues240 was 71
(40%), 60 (34%) and 78 (46%) in the once-daily
and twice-daily BUD/FF groups and the BUD
group, respectively. None of the five serious 
AEs were considered to be related to treatment.
The number of patients experiencing at least 
one AE was not reported by Zetterström and
colleagues.239 However, it was reported that the
number, nature and intensity of AEs were similar
across the treatment groups. None of the five
serious AEs were considered to be related to
treatment.
Summary
Three large parallel-group RCTs compared
BUD/FF combination inhaler with BUD in
patients with mild to moderate asthma not
controlled despite regular treatment with ICS
(doses generally in the range 200–1000 µg/day).
The dose of BUD was similar in both
comparisons, ranging from 200 to 800 µg/day.
There were statistically significant differences
between treatment groups favouring BUD/FF in
nearly all outcomes (morning and evening 
PEF; symptom scores; symptom-free days; 
use of rescue medication; FEV1). Statistically
significant differences between treatments in
night-time awakenings were reported in 
only one of the three trials. The incidence of 
mild exacerbations (reported in one trial) and
severe exacerbations (reported in two of the trials)
appeared similar between treatments, although no
statistical significance values were reported. The
incidence of AEs appeared similar between
treatments (no statistical significance values
reported).
The trials therefore suggest that BUD/FF is
superior to BUD alone in controlling asthma in
patients with mild to moderate asthma symptoms
despite treatment with ICS.
Summary of Q3b – ICS versus ICS + LABA 
(ICS dose similar in both groups)
Six RCTs evaluated FP/SAL combination inhaler
versus a similar dose of ICS, and four evaluated
BUD/FF combination inhaler versus a similar dose
of ICS. In all trials the same ICS was used in both
comparators. ICS and LABA were statistically
superior to ICS alone across most outcomes.
Tables 57 and 58 provide a visual illustration of the
results of pair-wise comparisons.
Summary
As expected, adding a LABA to an ICS without
increasing the dose of ICS alone produces a
beneficial effect in terms of lung function,
symptoms and use of rescue medication. These
effects are apparent whether the ICS and LABA
combination used is FP/SAL or BUD/FF. Few trials
reported exacerbations, which might be expected
to exhibit a similar pattern. No difference in AEs
is noted for FP versus FP/SAL, but this effect is
less certain for BUD versus BUD/FF.
Review question 4 – ICS + LABA 
in combination versus separate 
inhalers
To recap, six RCTs compared ICS and LABA in a
combination inhaler with the two drugs delivered
in separate inhalers (Table 59). The following
subsections describe the characteristics and results
of these trials.
FP/SAL in a combination inhaler versus BUD + FF
in separate inhalers
Study characteristics
One parallel-group RCT242 evaluated the
effectiveness of FP/SAL in combination compared
with BUD + FF given concurrently and was
published in 2002 (Table 60). This study was a
multi-centre trial with 11 centres and the study
sample size was 428 participants. The study was
powered to assess non-inferiority of the FP/SAL
combination and adequate power in the sample
was met.
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Study
, design,
ICS in
Lung function
Symptoms
AEs
duration, device,
each trial
R
escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
Aubier 
et al.,
233
FP
19%
1000
µg FP vs 
parallel-group, 
NSD
NSD
1000
µ
g/
28 weeks, 
100
µ
g 
FP/SAL
DPI, 
n 
= 503
FP/SAL
+
+
16%
K
oopmans 
et al.,
236
FP
96%
parallel-group, 
NSD
52 weeks, 
DPI, 
n 
= 54
FP/SAL
F
+
+
+
95%
Lundbäck 
et al.,
237
FP
500
µg FP vs 
parallel-group, 
NSD
500
µg/
52 weeks, 
100
µg DPI, 
n 
= 282
FP/SAL
+
+
FP/SAL
Shapiro 
et al.,
238
FP
0
parallel-group, 
12 weeks, 
DPI, 
n
=
349
FP/SAL
+
+
+
+
+
+
+
F
0
K
avaru 
et al.,
235
FP
200
µg FP vs 
parallel-group, 
NSD
200
µ
g/100
µ
g
12 weeks, 
FP/SAL
DPI, 
n 
= 356
FP/SAL
+
+
+
+
+
+
F
Bateman 
et al.,
234
FP
parallel-group, 
V
ariable
52 weeks, 
DPI, 
n 
= 3421
FP/SAL
F
F
+
F
, results appear to favour this treatment group, but no tests of statistical significance reported; NSD, no significant differ
ence between trial arms; NW
, nocturnal waking; 
SFD, symptom-free days; SFN, symptom-free nights; SS, symptom score (varies between studies); + indicates results favour this t
rial arm; blank cells signify no data reported on that
outcome.
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FP versus FP/SAL (n = 6)R
esults
Study
, design,
ICS in
Lung function
Symptoms
AEs
duration, device,
each trial
R
escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
800
µ
g BUD vs 
Zetterström et al.,
239
BUD
800
µg/9
µg
parallel-group, 
C
BUD/FF
DPI, 
n
= 362
BUD/FF
+
+
+
F
+
+
+
F
1. BUD
2. BUD/FF 
q.d
3. BUD/FF 
b.d.
1. BUD
2. BUD/FF 
q.d
3. BUD/FF
b.d.
C, results stated to be comparable between treatment arms, but no other data presented; F
, results appear to favour this trial 
arm but no significance testing has been reported;
NSD, no significant difference between trial arms; NW
, nocturnal waking; SFD, symptom-free days; SFN, symptom-free nights; SS, 
symptom score (varies between studies); 
+ indicates results favour this trial arm; blank cells signify no data reported on that outcome.
400
µg BUD
vs 400
µg/9
µg
BUD/FF
Buhl 
et al.,
240
parallel-group, 
12 weeks, DPI, 
n
=
523
+
2 vs 1
+
3 vs 1
+
2 vs 1
+
3 vs 1
+
2 vs 1
+
3 vs 1
NSD
1 vs 2
+
3 vs 1
+
2 vs 1
+
3 vs 1
+
2 vs 1
NSD
3 vs 1
+
2 vs 1
+
3 vs 1
F
2 vs 1
F
3 vs 1
46%
40%
34%
200
µg BUD
vs 200
µg/
9
µg
BUD/FF
K
una 
et al.,
241
12 weeks, 
DPI, 
n
= 617
+
2 vs 1
+
3 vs 1
+
2 vs 1
+
3 vs 1
+
2 vs 1
+
3 vs 1
F
1 vs 2
1 vs 3
+
2 vs 1
+
3 vs 1
36%
38%
38%
T
ABLE 58
BUD versus BUD/FF (n
=
3 RCT
s)
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DPI (Seretide Diskus, GSK) in one trial arm with
BUD 800 µg/day (Pulmicort Turbuhaler, AZ – not
explicitly stated but deduced from the text) and
FF 12 µg/day also via DPI Turbuhaler in the
second trial arm. The treatment duration was
12 weeks.
The aim of the study was to compare the safety
and efficacy of the two groups to demonstrate
similar efficacy between treatments but using less
than one-third of ICS dose in the combination
therapy group.
The mean ages of the participants in the trial were
46.5 years in the FP/SAL group and 48.1 years in
the BUD + FF group. The severity of asthma was
moderate to severe, with participants on daily ICS
doses between 1000 and 1600 µg/day of BDP or
equivalent. The mean baseline FEV1 % predicted
in all participants was 69%.
The quality of reporting and methodology of the
study was generally good. The methods of
randomisation and allocation concealment were
assessed to be adequate. This factor minimises the
risk of selection bias in the trial. The study
reported that data were analysed on the ITT
population, but the method undertaken was
assessed to be inadequate. This factor, when
adequate, helps to minimise the risk of
measurement bias.
Results
Lung function
The Ringdal and colleagues trial242 presented 
data on the mean change from baseline in FEV1.
This was shown to be similar between the two
groups (FP/SAL 0.27, BUD + FF 0.26, difference
–0.01, 95% CI –0.09 to 0.07; p = 0.796),
suggesting that lower doses of the combination
therapy were not inferior to higher doses of
BUD + FF therapy.
Morning PEF changes from baseline were also
reported to be similar between the two groups, but
no p-value was reported for the ITT population
(FP/SAL 43 l/minute, BUD + FF 47 l/minute), only
for a PP population (not reported here).
Symptoms/health-related quality of life
Symptom-free days were reported to be similar
between groups in the Ringdal and colleagues
trial242 but no data were reported to support this.
The proportion of nights without awakenings was
only reported as a median and hence is not
reported here.
Use of rescue medication
Ringdal and colleagues242 reported that there were
no differences between the FP/SAL and BUD + FF
groups in the need for rescue medication, but no
data were presented to support this.
Exacerbations
The total number of acute exacerbations during
treatment was 129 in the FP/SAL arm and 206 in
the BUD + FF arm of the Ringdal and colleagues
trial.242 No statistical analysis was reported to have
been undertaken of the difference between the
groups. The mean rate of exacerbation per patient
per 84 days of treatment was 0.47 in the FP/SAL
group compared with 0.73 in the BUD + FF
group and was shown to be statistically
significantly different (ratio 0.64, 95% CI 0.51 to
0.80, p < 0.001).
Adverse events
There were 91 AEs in total in the FP/SAL group
and 78 in the BUD + FF group of the Ringdal
and colleagues’ trial.242 No analysis of statistical
significance was undertaken on these data. Serious
AEs were reported by two participants in the
FP/SAL group and three in the BUD + FF group.
Summary
One RCT compared 500 µg/day FP and
100 µg/day SAL with 1600 µg/day BUD and
24 µg/day FF. Lower doses of the combination
FP/SAL were shown to be similar to treatment with
higher dose BUD + FF on measures of lung
function. Rates of exacerbations were better in the
combination treatment arm than the separate
inhaler arm of the included trial. AEs appeared to
be greater in the FP/SAL arm but this was not
tested for statistical significance compared with the
BUD + FF arm.
FP/SAL in a combination inhaler versus FP + SAL
in separate inhalers
Study characteristics
Three parallel-group RCTs233,243,244 evaluated the
effectiveness of FP/SAL in combination compared
Assessment of clinical effectiveness
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TABLE 59 Breakdown of studies for review question 4 –
combination inhaler versus separate inhalers
Pair-wise comparison No. of 
RCTs 
included
FP/SAL (combination) vs BUD + FF (separate) 1
FP/SAL (combination) vs FP + SAL (separate) 3
BUD/FF (combination) vs BUD + FF (separate) 2
Total  6Health Technology Assessment 2008; Vol. 12: No. 19
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Characteristics of study (FP/SAL versus BUD + FF)
Study
Design
Intervention
P
atients
Outcomes
Ringdal 
et al.,
2002
242
RCT
Multi-centre
P
arallel-group
Double-blind
1.
FP/SAL 250/50 µg b.d. (daily total 500/100
µg) 
2.
BUD + FF 800
µg + 12
µg b.d. (daily total 1600
µg +
24
µg)
Delivery device:
1.
DPI (Seretide Diskus, GSK) + 2 placebo T
urbuhalers
2.
DPI T
urbuhaler (BUD – Pulmicort T
urbuhaler
, AZ
a
) +
placebo Diskus 
Duration:
12 wks
Run-in period:
2 wks
Number randomised
428
Mean age (SD) (years)
1.
46.5 (14.0) 
2.
48.1 (13.9) 
Baseline FEV
1
% predicted (SD)
1.
69.2 (10.7)
2.
69.0 (10.1)
P
revious ICS treatment (drug and dose)
BUD/BDP or flunisolide 1000–1600
µg q.d. or
FP 500–800
µg q.d.
Mean morning PEF
PEF (morning and evening)
PEF % diurnal variation 
Clinical FEV
1
Severity of exacerbations
Day
- and night-time
symptom scores
Night-time awakenings
Use of rescue salbutamol
Withdrawals from study
Asthma-related healthcare
resource utilisation
(Norwegian healthcare
system and costs – not data
extracted)
AEs
a 
Not stated explicitly
, but deduced from the text.with FP + SAL taken concurrently and were
published between 1998 and 1999 (Table 61). All
three studies were multi-centre trials with study
sample sizes ranging between 224 and 503
participants. None of the included trials reported
undertaking a power calculation.
All three included trials had comparisons of
FP/SAL in combination with FP + SAL separately.
One of the included trials, Aubier and
colleagues,233 also had a third arm comparison
with FP alone (reported in the ‘Review question 3b
– ICS versus ICS + LABA (ICS dose similar in
both groups)’; ‘ICS versus ICS + LABA (FP versus
FP/SAL)’, ‘Study characteristics’, p. 119. The three
trials used the same dose of SAL but varying doses
of FP. One trial compared FP/SAL 200/100 µg/day
with FP 200 µg/day + SAL 100 µg/day.243 Another
compared FP/SAL 500/100 µg/day with FP
500 µg/day + SAL 100 µg/day244 and the third
study FP/SAL 1000/100 µg/day with FP
1000 µg/day + SAL 100 µg/day.233
The devices used in all three studies were DPIs for
both the combination treatment groups (Seretide
Diskus, GSK) and the separate treatment groups
(Flixotide, Accuhaler, GSK, deduced from the text
of the paper by Aubier and colleagues233).
The treatment duration was 12 weeks in one
study243 and 28 weeks in the other two
studies.233,244
All three trials were reported to be assessing
whether the treatments given in combination
inhalers were clinically equivalent to the
treatments given in separate inhalers. Treatment
equivalence was tested using the 90% CI of the
difference between the combination and separate
therapies on morning PEF in all three included
trials,233,243,244 where a priori equivalence was
regarded as a 90% CI within ±15 l/minute
(reported to be defined and validated in previous
clinical studies, references given).
The ages of participants in the trials were
reasonably similar, ranging in the three studies
between 33 and 48 years. All trials reported that
their participants were symptomatic on their
previous ICS treatments, but on inspection of the
doses of the previous treatments patient severity
was likely to be different across the three trials.
These previous treatments were 400–500 µg/day of
BDP or equivalent drug in the Bateman and
colleagues trial,243 800–1200 µg/day BDP or
equivalent in the Chapman and colleagues trial244
and 1500–2000 µg/day BDP or equivalent in the
Aubier and colleagues trial.233 This would also be
reflected in the range of doses of FP and SAL
treatments given across the three trials as noted
above. Baseline FEV1 % predicted was reported as
being 73% in one trial.233 The other two trials
reported absolute FEV1 as 2.4243 and 2.5244 litres,
respectively, although this is reported as %
predicted (we assume this to be a typographical
error).
The quality of reporting and methodology of the
included trials was mixed. The method of
randomisation was reported and assessed as being
adequate in only one of the trials243 and not
reported in the other two trials.233,244 The means
by which allocation was concealed was not
reported in any of the three trials. Where
adequate, these factors minimise the potential for
selection bias in trials. Finally, the analysis was
reported to be by an ITT principle in all three
trials, but the method used was only assessed as
being adequate in two of these233,243 as participants
appeared to be excluded from some of the
analyses in the other trial.244 An ITT analysis
minimises the potential for measurement bias.
Results
Lung function
The adjusted mean change from baseline in FEV1
in the Aubier and colleagues study233 (estimated
from figures) was 0.25 litres in the combination
FP/SAL arm and 0.15 litres in the separate
FP + SAL arm at 28 weeks. This was not
statistically significantly different, p = 0.45. At
28 weeks the mean change from baseline in FEV1
in the Chapman and colleagues trial244 was
0.26 litres in the combination treatment group
and 0.24 litres in the separate inhaler group. The
90% CI of the treatment difference (-0.02) was –4
to –1. The FEV1 adjusted change from baseline
was also reported after 12 weeks of therapy in the
Bateman and colleagues trial.243 Although the
values appear to be similar, no statistical analysis
of equivalence or superiority was undertaken and
no measure of variance was reported (FP/SAL
0.20 litres, FP + SAL 0.17 litres).
The change from baseline in morning PEF was
measured for the first 12 weeks to be 38 (SD
50.4) l/minute in the FP/SAL arm compared with
36 (SD 49.7) l/minute in the FP + SAL arm of the
Aubier and colleagues trial.233 The 90% CI around
the mean difference (–2 l/minute) was –10 to
7 l/minute, p = 0.77. This was within predefined
equivalence limits (±15 l/minute). In the Chapman
and colleagues trial,244 the change from baseline
in morning PEF was also measured for just the
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T
ABLE 61
Characteristics of studies (FP/SAL versus FP + SAL)
Study
Design
Intervention
P
atients
Outcomes
Aubier 
et al.,
1999
233
RCT
Multi-centre
P
arallel-group
Double-blind
1.
FP/SAL 500/50
µg b.d. (daily total 1000/100
µg) 
2.
FP + SAL 500
µg + 50
µg b.d. (daily total 1000 + 100
µg)
3.
FP 500
µg b.d. (daily total 1000
µg) 
Only groups 1 and 2 reported here
Delivery device:
1.
DPI (Seretide Diskus, GSK) + placebo
2, 3. DPI Diskus (Flixotide, GSK
a
) + placebo
Duration:
28 wks
Run-in period:
2 wks
Number randomised
503
Mean age (range) (years)
1.
46 (12–78)
2.
48 (19–79)
3.
50 (12–76)
Baseline FEV
1
% predicted (±
SD)
1.
73 (±
1.2)
2.
73 (±
1.2)
3.
73 (±
1.4)
P
revious ICS treatment (drug and dose)
BDP 1500–200
µg/day or FP 750–1000
µg/day
PEF (morning and evening)
Daytime asthma score
Night-time asthma score
AEs
Serum cortisol 
Urinary cortisol
Bateman 
et al.,
1998
243
RCT
Multi-centre 
P
arallel-group
Double-blind
1.
FP/SAL 100/50
µg b.d.+ placebo (daily total 200/100
µg)
2.
FP + SAL 100
µg + 50
µg b.d. (daily total 200
µg +
100
µg)
Delivery device:
1.
DPI (Seretide Diskus, GSK)
2.
DPI (Flixotide, Accuhaler
, GSK
a
)
Duration:
12 wks
Run-in period:
2 wks
Number randomised
244
Mean age (range) (years)
1.
33 (12–78)
2.
33 (12–76)
Baseline FEV
1
% predicted
1.
75
2.
76
P
revious ICS treatment (drug and dose)
V
arious ICS therapies (no details)
PEF (morning and evening)
FEV
1
Use of rescue salbutamol
Day
- and night-time
symptom score
Chapman 
et al.,
1999
244
RCT
Multi-centre 
P
arallel-group
Double-blind
1.
FP/SAL 250/50
µg b.d. (daily total 500/100
µg) + placebo
2.
FP+SAL 250
µg + 50
µg b.d. (daily total 500
µg + 100
µg)
Delivery device:
1.
DPI (Seretide Diskus, GSK)
2.
DPI (Flixotide Accuhaler
, GSK) 
Duration:
28 wks
Run-in period:
2 wks
Number randomised
371
Mean age (range) (years)
1.
42.8 (13–73)
2.
41.4 (15–75)
Baseline FEV
1
% predicted
1.
75
2.
77
P
revious ICS treatment (drug and dose)
BDP or BUD 800–1200
µg q.d. or FP
400–600
µg q.d.
PEF (morning and evening)
FEV
1
Use of salbutamol
Daily and nightly symptom 
score
Compliance 
AEs
a 
Not stated explicitly
, but deduced from the text.first 12 weeks of therapy. This was reported to be
43 l/minute in the combination inhaler group and
36 l/minute in the separate inhaler group. The
treatment difference 90% CI was within the
equivalence definition of the study (–6), 90% CI
–13 to 0. The results of these studies suggest no
difference between treatment with a combination
inhaler and separate inhalers on morning PEF. In
the Bateman and colleagues trial,243 the adjusted
mean change in morning PEF was 47 l/minute in
the FP/SAL arm compared with 39 l/minute in the
FP + SAL arm after 9–12 weeks of therapy. The
difference between the two groups was not
statistically significantly different (p = 0.22),
although the study reports that the 90% CI of
weeks 1–12 combined (–17 to 0) was outside the
defined equivalence interval, showing superiority
of the combination treatment therapy.
The change from baseline in evening PEF was
measured for the first 12 weeks to be 31 (SD
49.1) l/minute in the FP/SAL arm compared with
26 (SD 48.4) l/minute in the FP + SAL arm of the
Aubier and colleagues trial.233 These figures were
not statistically significantly different (p = 0.27). In
the Chapman and colleagues trial,244 the change
from baseline in evening PEF was also measured
for just the first 12 weeks of therapy. This was
reported to be 36 l/minute in the combination
therapy group and 26 l/minute in the separate
therapy group. The treatment difference was
reported to be statistically significantly different
(p = 0.008) favouring the combination product. In
the Bateman and colleagues trial,243 the adjusted
mean change in evening PEF was 39 l/minute in
the FP/SAL arm compared with 34 l/minute in the
FP + SAL arm after 12 weeks of therapy. The
difference between the two groups was not
statistically significantly different (p = 0.39). The
equivalence interval was not defined on the
outcome of evening PEF, although the study stated
that the results were equivalent (we therefore
assume that this is because there is no evidence
that either treatment is superior).
Symptoms/health-related quality of life
The mean proportion of symptom-free days was
38% in both comparison groups in the Aubier and
colleagues trial233 (not statistically significantly
different), where data points were estimated from
figures in the publication. Similarly, the mean
proportion of symptom-free nights was not
statistically significantly different between the two
comparison groups (FP/SAL 58% versus FP + SAL
55%, estimated from figures) in the Aubier and
colleagues trial.233
Use of rescue medication
No appropriate data were reported.
Exacerbations
No appropriate data were reported.
Adverse events
Sufficient data on numbers of AEs were reported in
the two 28-week trials to be combined in a meta-
analysis (Figure 18). The severity of the participants’
asthma was likely to be slightly different as the
patients in the trial by Aubier and colleagues233
received higher doses than the patients in the
Chapman and colleagues trial,244 and this needs to
be considered when interpreting the results of the
meta-analysis. The fixed-effects pooled OR was 1.27
(95% CI 0.83 to 1.95; p = 0.27), suggesting no
statistically significant difference between the
combination FP/SAL treatment and the separate
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Review: Corticosteroids – review Q4 – combination inhalers vs separate inhalers
Comparison: FP  +  salmeterol combination inhaler vs FP + salmeterol separate inhalers (adults): parallel
Outcome: Adverse events
Study
or subcategory
Combined inhaler
n/N
Separate inhalers
n/N
OR (fixed)
95% CI
Weight
%
OR (fixed)
95% CI
 Aubier et al., 1999
233   28/167    24/171
160/180 164/191
 52.75 1.23 (0.68 to 2.23)
 Chapman et al., 1999
244  47.25 1.32 (0.71 to 2.44)
Total (95% CI) 347 362 100.00 1.27 (0.83 to 1.95)
Total events: 188 (Combined inhaler), 188 (Separate inhalers)
Test for heterogeneity: 2 = 0.02, df = 1 (p = 0.88), I2 = 0%
Test for overall effect: Z = 1.11 (p = 0.27)
0.1 0.2 0.5 1 2 5 10
Favours 
combined
Favours 
separate
FIGURE 18 Adverse events, FP/SAL versus FP + SALFP + SAL treatment. Heterogeneity was not
statistically significant (p = 0.88, I2 = 0%).
Data on discontinuations due to AEs were also
reported in the two 28-week trials and combined
in a meta-analysis (Figure 19). The fixed-effects
pooled OR was 1.18 (95% CI 0.67 to 2.07,
p = 0.57), similarly suggesting no statistically
significant difference between the combination
therapy and the separate therapies. Heterogeneity
was not statistically significant (p = 0.56, I2 = 0%).
Summary
Three parallel-group RCTs compared combination
use of 200–1000 µg/day FP/100 µg/day SAL with
separate use of 200–1000 µg/day FP and
100 µg/day SAL.
On measures of lung function, no statistically
significant differences were observed between
treatment with FP/SAL in a combination inhaler
compared with treatment with FP + SAL in
separate inhalers. These trials were mostly designed
to show equivalence, therefore results are in line
with this assumption. Similarly, where reported,
there were no statistically significant differences
between the two treatments on measures of
symptoms. The AE profiles of the two treatments
were not statistically significantly different.
BUD/FF in a combination inhaler versus
BUD + FF in separate inhalers
Study characteristics
Two RCTs239,245 evaluated the effectiveness of
BUD/FF in a combination inhaler compared with
BUD + FF administered via separate inhalers, and
were published in 2001239 and 2002.245 They were
both international, multi-centre studies with
sample sizes ranging between 362 and 586
participants. One study was double-blind and the
other open-label, both of parallel-group design
(Table 62).
The doses of BUD and FF were the same in the
two studies. One study245 compared BUD/FF in a
combination inhaler with a total daily dose of
640 µg/18 µg (160 µg/4.5 µg, two inhalations twice
daily) with BUD + FF delivered via separate
inhalers but with the same total daily dose of
640 µg + 18 µg (160 µg + 4.5 µg, two inhalations
twice daily). Zetterström and colleagues239 also
compared BUD/FF in a combination inhaler with
a total daily dose of 640 µg/18 µg (160 µg/4.5 µg,
two inhalations twice daily), with the two agents in
separate inhalers and a total daily dose of 800 µg
BUD + 18 µg FF (200 µg + 4.5 µg, two
inhalations twice daily). This trial also had a third
arm comparison with BUD alone (200 µg, two
inhalations twice daily; total 800 µg/day). For the
purposes of this section, only the combination
inhaler and the separate inhaler arms are
compared. A comparison of the combination
inhaler and the BUD monotherapy arms is given
in the section ‘ICS versus ICS + LABA (BUD
versus BDD/FF)’ (p. 126).
The devices used in the two trials were Turbohaler
DPIs for both the combination treatment groups
and the separate treatment groups (BUD/FF –
Symbicort Turbuhaler/Oxis Turbuhaler, BUD –
Pulmicort Turbuhaler; all AZ). In the Zetterström
and colleagues trial,239 metered (ex-actuator) doses
are reported for the separate inhalers and BUD
monotherapy arms, and delivered (ex-valve) doses
are reported for the combination inhaler. This
reflects changes in labelling for newer inhaled
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Study
or subcategory
Combined inhaler
n/N
Separate inhalers
n/N
OR (fixed)
95% CI
Weight
%
OR (fixed)
95% CI
0.1 0.2 0.5 1 2 5 10
Favours 
combined
Favours 
separate
Review: Corticosteroids – review Q4 – combination inhalers vs separate inhalers
Comparison: FP  +  salmeterol combination inhaler vs FP + salmeterol separate inhalers (adults): parallel
Outcome: Discontinuations due to adverse events
 Aubier et al., 1999
233 16/167 16/171
12/180      9/191
 63.69 1.03 (0.50 to 2.13)
 Chapman et al., 1999
244  36.31 1.44 (0.59 to 3.52)
Total (95% CI) 347 362 100.00 1.18 (0.67 to 2.07)
Total events: 28 (Combined inhaler), 25 (Separate inhalers)
Test for heterogeneity: 2 = 0.34, df = 1 (p = 0.56), I2 = 0%
Test for overall effect: Z = 0.57 (p = 0.57)
FIGURE 19 Discontinuations due to adverse events, FP/SAL versus FP+SALdrugs which require the delivered dose rather than
the metered dose to be reported. An inhalation of
BUD/FF 160 µg/4.5 µg from the combination
inhaler (Symbicort Turbuhaler, AZ) delivers the
same quantity as a 200-µg metered inhalation of
BUD (Pulmicort Turbuhaler, AZ) and a 6-µg
metered inhalation of FF from separate inhalers.
The treatment duration was 6 months in one
study245 and 12 weeks in the second study.239
Zetterström and colleagues239 aimed to compare
the then new BUD/FF combination inhaler with
the two drugs administered in separate inhalers
and with BUD alone. Rosenhall and colleagues245
also aimed to compare the combination inhaler
with treatment administered via separate inhalers,
but the focus in this study was more on the longer
term safety (and also efficacy) of the combination
inhaler, particularly in terms of HRQoL.
The ages of the participants in the trials ranged
from 18 to 81 years, with a mean age of
approximately 45 years in both studies. Patients in
both trials had previously received ICS therapy and
remained symptomatic. Previous treatment was
approximately 700 µg/day245 and 950 µg/day239 of
ICS in the two trials. The severity of asthma was not
specifically stated in either trial, but was likely to be
comparable across the studies based on previous
ICS therapy. Baseline FEV1 % predicted was around
94% in one trial245 and 74% in the other trial.239
Rosenhall and colleagues245 reported safety (AEs)
as their primary outcome measure, whereas
Zetterström and colleagues239 reported change in
morning PEF as the primary outcome.
The quality of reporting and methodology of the
included RCTs was mixed. In the Zetterström and
colleagues trial239 the method of randomisation
was reported and assessed as being adequate, and
the method used to conceal allocation to groups
was also adequate. In the Rosenhall and colleagues
trial,245 details of the randomisation procedure
and concealment of allocation were unknown. The
analysis was reported to be by ITT principle in
both trials.
Results
Lung function
Differences in the way in which measures of lung
function were reported by the two trials meant
that combining data in a meta-analysis was not
possible.
Only limited data on FEV1 were reported in the
trials. Zetterström and colleagues239 reported a
mean FEV1 of 2.28 litres at baseline and 2.47 litres
at end-point in the BUD/FF group (a change of
0.19 litres), compared with 2.33 litres at baseline
and 2.50 litres at end-point (a change of
0.17 litres) in the separate BUD + FF arm, with
no statistically significant difference between
groups (p > 0.05). Rosenhall and colleagues245 did
not report the data at end-point but stated that
the mean FEV1 increased by approximately 5–6%
compared with baseline in both the combination
inhaler and separate inhaler treatment groups.
Data on change in morning and evening PEF were
reported in one study.239 The change from
baseline in morning PEF was 35.7 (95% CI 28.4 to
43.0) l/minute in the BUD/FF combination inhaler
group and 32.0 (95% CI 24.5 to 39.4) l/minute in
the BUD + FF separate inhaler group. These
differences were not statistically significant
(p > 0.05). Similarly, the change from baseline in
evening PEF was 24.8 (95% CI 18.2 to
31.4) l/minute and 22.3 (95% CI 15.5 to
29.0) l/minute in the combination inhaler and
separate inhaler groups, respectively. Again, this
difference was not statistically significant
(p > 0.05).
Symptoms/health-related quality of life
Only the Zetterström and colleagues trial239
reported data on symptoms.
The mean change from baseline in percentage of
symptom-free days was 25.0% in the BUD/FF
combination inhaler group compared with 22.3%
in the BUD + FF separate inhaler group. The
difference was not statistically significant
(p > 0.05). Day- and night-time asthma symptoms
were recorded using a four-point rating scale
(0 = none, 3 = severe, no reference supplied), and
these were combined to give a total asthma
symptom score (0–6). Asthma symptoms were
shown to reduce in both groups with a change
from baseline of –0.52 vs –0.44 for BUD/FF
combination and separate BUD + FF respectively.
Again, there was no statistically significant
difference between treatment groups.
Rosenhall and colleagues245 did not report
specifically on symptoms, but did report data on
HRQoL using the MiniAQLQ. The MiniAQLQ
consists of four domains: symptoms, activity
limitations, emotional function and environmental
stimuli and is scored from 0 to 7 (0 = severe
asthma problems, 7 = mild/no problems;
reference supplied). The scores were presented as
the change from baseline to the average of the
values at weeks 13 and 26 (end-point).
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ABLE 62
Characteristics of studies (BUD/FF versus BUD + FF)
Study
Design
Intervention
P
atients
Outcomes
R
osenhall 
et al.,
2002
245
RCT
Multi-centre
P
arallel-group
Open-label
1.
BUD/FF 160/4.5
µg 2 puffs b.d.
a
(daily total 640/18
µg) 
2.
BUD
+
FF 160
µg + 4.5
µg 2 puffs b.d.
a
(daily total 
640
µg +18
µg)
Delivery device: 
1.
DPI (Symbicort T
urbuhaler
, AZ)
2.
DPI (Pulmicort T
urbuhaler + Oxis T
urbuhaler
, AZ)
Duration:
6 months
Run-in period:
Not reported
Number randomised
586
Mean age (range) (years)
1.
45.2 (18–81)
2.
44.4 (18–78)
Baseline FEV
1
% predicted (range)
1.
94.1 (37–149)
2.
95.4 (50–155)
P
revious ICS treatment (drug and dose)
ICS 400–1200
µg/day
P
rimary outcome
AEs
Secondary outcomes
FEV
1
FVC
AEs
Exacerbations
HRQoL
Zetterström
et
al., 2001
239
RCT
Multi-centre
P
arallel-group
Double-blind
Double-dummy
1.
BUD/FF 160/4.5
µg
a
2 puffs b.d. (daily total 640/18
µg)
2.
BUD+FF 200
µg
b
+ 4.5
µg 2 puffs b.d. (daily total 800
µg
+ 18
µg)
3.
BUD 200
µg
b
2 puffs b.d. (daily total 800
µg)
Only groups 1 and 2 reported here
Delivery device:
1. DPI (Symbicort T
urbuhaler
, AZ)
2,3. DPI (Pulmicort T
urbuhaler
, AZ
c
)
Duration:
12 wks
Run-in period:
2 wks
Number randomised
362
Mean age (range) (years)
1.
46.7 (18–78)
2.
44.7 (18–77)
3.
48.5 (21–78)
Baseline FEV
1
% predicted
1.
73.6
2.
74.7
3.
73.1
P
revious ICS treatment (drug and dose)
ICS 
	500
µg/day
PEF (morning and evening)
FEV
1
FVC
Day
- and night-time
symptom score
Symptom-free days
Night-time awakenings
Asthma control days
Use of rescue medication 
AEs
Exacerbations
a 
Ex-actuator
.
b 
Ex-valve.
c 
Not stated explicitly
, but deduced from the text.Improvements were seen in both groups. For the
BUD/FF combination inhaler group, the mean
change from baseline total MiniAQLQ score was
0.48 compared with 0.45 for patients in the
BUD + FF separate inhaler group. There was no
statistically significant difference between groups
(no p-value given).
Use of rescue medication
The mean reduction from baseline in the use of
terbutaline sulfate or salbutamol rescue
medication (number of puffs per day) was similar
in both treatment groups in the Zetterström and
colleagues trial (–0.99 versus –1.13 for BUD/FF
and BUD + FF, respectively, p > 0.05).239
Exacerbations
Sufficient data on numbers of serious AEs were
reported in the two trials to be combined in a
meta-analysis (Figure 20). However, it should be
noted that in the Rosenhall and colleagues trial,245
an exacerbation was defined as the need for oral
corticosteroids, and the authors did not describe
the severity of the exacerbations. In the
Zetterström and colleagues trial,239 a severe
asthma exacerbation was defined as the need for
oral steroids, discontinuation due to worsening of
asthma or PEF <70% of the run-in mean on two
consecutive days. In addition, the duration of
treatment was different in the two studies and
these factors will need to be considered when
interpreting the results of the meta-analysis. The
fixed-effect pooled OR was 1.00 (95% CI 0.65 to
1.54), suggesting no statistically significant
difference between the combination treatment and
the separate treatment (p = 0.33). Heterogeneity
was not statistically significant (p = 0.33, I2 = 0%).
Adverse events. Neither trial reported the total
number of AEs experienced by each treatment
group. In the Rosenhall and colleagues trial,245 at
least one AE was reported by 77% of patients
treated with the combination inhaler compared
with 69% treated with the separate inhalers.
Zetterström and colleagues239 reported that the
number, nature and intensity of AEs were similar
across groups.
Sufficient data on numbers of serious AEs were
reported in the two trials to be combined in a
meta-analysis (Figure 21). The duration of
treatment was different in the two studies and this
will need to be considered when interpreting the
results of the meta-analysis. The fixed-effect
pooled OR was 1.85 (95% CI 0.71 to 4.82),
suggesting no statistically significant difference
between the two treatments (p = 0.21).
Heterogeneity was not statistically significant
(p = 0.23, I2 = 31.9%).
Data on discontinuations due to AEs were also
reported in the two trials and combined in a meta-
analysis (Figure 22). The fixed-effects pooled OR
was 0.88 (95% CI 0.43 to 1.77), similarly
suggesting no statistically significant difference
between treatments (p = 0.71). Heterogeneity was
not statistically significant (p = 0.21, I2 = 36.0%).
Summary
Two parallel-group RCTs compared BUD and FF
in a combination inhaler with the the same doses
of the drugs used in separate inhalers. No
statistically significant differences were observed in
measures of lung function. Similarly, where
reported, there were no differences between the
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Study
or subcategory
Combined inhaler
n/N
Separate inhalers
n/N
OR (fixed)
95% CI
Weight
%
OR (fixed)
95% CI
0.1 0.2 0.5 1 2 5 10
Favours 
combined
Favours 
separate
Review: Corticosteroids – review Q4 – combination inhalers vs separate inhalers
Comparison: BUD and formoterol combination inhaler vs BUD and formoterol separate inhalers (adults): parallel
Outcome: Asthma exacerbations
 Rosenhall et al., 2002
245      59/390 27/196
  8/123  11/115
 74.16 1.12 (0.68 to 1.82)
 Zetterstrom et al., 2001
239      25.84 0.66 (0.25 to 1.70)
Total (95% CI) 513 311 100.00 1.00 (0.65 to 1.54)
Total events: 67 (Combined inhaler), 38 (Separate inhalers)
Test for heterogeneity: 2 = 0.94, df = 1 (p = 0.33), I2 = 0%
Test for overall effect: Z = 0.01 (p = 0.99)
FIGURE 20 Asthma exacerbations, BUD/FF versus BUD + FFtwo treatment groups on measures of symptoms or
HRQoL. Furthermore, the AE profiles of the two
treatments were also found to be comparable, with
no statistically significant differences between
them for serious AEs and discontinuations 
due to AEs.
Summary of Q4 – ICS + LABA in combination
versus separate inhalers
Three RCTs compared the FP/SAL combination
inhaler against the two drugs delivered in separate
inhalers. Two compared BUD and FF combination
inhaler against the two drugs in separate inhalers.
One compared FP/SAL combination inhaler
against BUD + FF in separate inhalers. There
were very few statistically significant differences
between the treatments across the various efficacy
outcomes. For some outcomes (e.g. lung function),
non-inferiority was demonstrated. Meta-analysis of
AEs found no statistically significant differences in
AEs, serious AEs and discontinuations in AEs.
Tables 63–65 provide a visual illustration of the
results of pair-wise comparisons.
Review question 5 – combination inhaler
compared with combination inhaler 
To recap, three RCTs compared the two
combination inhalers head-to-head (Table 66). The
following subsection describes the characteristics
and results of these trials.
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Study
or subcategory
Combined inhaler
n/N
Separate inhalers
n/N
OR (fixed)
95% CI
Weight
%
OR (fixed)
95% CI
0.001 0.01 0.1 1 10 1001000
Favours 
combined
Favours 
separate
Review: Corticosteroids – review Q4 – combination inhalers vs separate inhalers
Comparison: BUD  and formoterol combination inhaler vs BUD and formoterol separate inhalers (adults): parallel
Outcome: Serious adverse events
 Rosenhall et al., 2002
245 13/389   5/196
  4/123  0/115       
 92.81 1.32 (0.46 to 3.76)
 Zetterstrom et al., 2001
239   7.19 8.70 (0.46 to 163.38)
Total (95% CI) 512 311 100.00 1.85 (0.71 to 4.82)
Total events: 17 (Combined inhaler), 5 (Separate inhalers)
Test for heterogeneity: 2 = 1.47, df = 1 (p = 0.23), I2 = 31.9%
Test for overall effect: Z = 1.26 (p = 0.21)
FIGURE 21 Serious adverse events, BUD/FF versus BUD + FF
Study
or subcategory
Combined inhaler
n/N
Separate inhalers
n/N
OR (fixed)
95% CI
Weight
%
OR (fixed)
95% CI
0.1 0.2 0.5 1 2 5 10
Favours 
combined
Favours 
separate
Review: Corticosteroids – review Q4 – combination inhalers vs separate inhalers
Comparison: BUD  and formoterol combination inhaler vs BUD and formoterol separate inhalers (adults): parallel
Outcome: Discontinuations due to adverse events
 Rosenhall et al., 2002
245      11/389 9/196
  8/123  5/115
 70.65 0.60 (0.25 to 1.48)
 Zetterstrom et al., 2001
239      29.35 1.53 (0.49 to 4.82)
Total (95% CI) 512 311 100.00 0.88 (0.43 to 1.77)
Total events: 19 (Combined inhaler), 14 (Separate inhalers)
Test for heterogeneity: 2 = 1.56, df = 1 (p = 0.21), I2 = 36.0%
Test for overall effect: Z = 0.37 (p = 0.71)
FIGURE 22 Discontinuations due to adverse events, BUD/FF versus BUD + FFR
esults
Study
, design,
ICS in
Lung function
Symptoms
AEs
duration, device,
each trial
R
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Daily dose
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arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
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HRQoL
medication
Exacerbations
patients)
500/100
µg 
FP/SAL 
+
91 events
FP/SAL vs
Ringdal 
et al.,
242
combination
NSD
C
C
C
1600
+
24
µg
parallel-group 2 weeks,
BUD + FF
BUD + FF
78 events
DPI, 
n
= 428
separate
C, results appear to be comparable between treatment groups, but no tests of statistical significance reported; 
n, number of events; NSD, no significant difference between trial
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, nocturnal waking; SFD, symptom-free days; SFN, symptom-free nights; SS, symptom score (varies between studies); + ind
icates results favour this trial arm; blank cells
signify no data reported on that outcome.
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T
ABLE 63
FP/SAL in a combination inhaler versus BUD
+
FF in separate inhalers (
n
=
1 RCT)R
esults
Study
, design,
ICS in
Lung function
Symptoms
AEs
duration, device,
each trial
R
escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
Meta-analysis
FP/SAL 
Aubier 
et al.,
233
combination
NSD
Chapman 
et al.,
244
FP
+
SAL 
separate
1000/100
µg 
Aubier 
et al.,
233
FP/SAL
FP + SAL vs 
parallel-group, 28 
combination
NSD
NSD
NSD
NSD
NSD
1000
+
100
µ
g
weeks DPI, n
= 503
FP
+
SAL
NID
FP + SAL
separate
200/100
µg Bateman 
et al.,
243
FP/SAL 
FP/SAL vs 
parallel-group, 
combination
C
NSD
NSD
200
+
100
µg
12 weeks, 
FP
+
SAL 
FP + SAL
DPI, n
= 244
separate
500/100
µg Chapman 
et al.,
244
FP/SAL 
+
FP/SAL vs
parallel-group, 
combination
NSD
NSD
500
+
100
µg
28 weeks, 
FP + SAL
NID
FP + SAL
DPI, n
= 371
separate
C, results appear to be comparable between treatment groups, but no tests of statistical significance reported; 
n, number of events; NID, non-inferiority demonstrated; 
NSD, no significant difference between trial arms; NW
, nocturnal waking; SFD, symptom-free days; SFN, symptom-free nights; SS, 
symptom score (varies between studies); blank
cells signify no data reported on that outcome.
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T
ABLE 64
FP/SAL in a combination inhaler versus FP
+
SAL in separate inhalers (
n
= 3 RCT
s)R
esults
Study
, design,
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Lung function
Symptoms
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duration, device,
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escue
(% of
Daily dose
number randomised
arm
FEV
1
PEF morning
PEF evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
R
osenhall 
et al.,
245
BUD/FF 
77%
parallel-group, 
combination
C
NSD
open-label, 26 weeks, 
BUD + FF 
DPI, 
n
=
586
separate
69%
Zetterström 
et al.,
239
BUD/FF 
parallel-group, 
combination
NSD
NSD
NSD
NSD
NSD
NSD
C
12 weeks, DPI, 
BUD + FF 
n
=
362
separate
C, results appear to be comparable between treatment groups, but no tests of statistical significance reported; 
n,
number of events; NSD, no significant difference between trial
arms; NW
, nocturnal waking; SFD, symptom-free days; SFN, symptom-free nights; SS, symptom score (varies between studies); blank
 cells signify no data reported on that outcome.
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BUD/FF in a combination inhaler versus BUD
+
FF in separate inhalers (
n
= 2 RCT
s)
800/18
µg
BUD/FF vs
800
+
18
µg
BUD + FFBUD/FF versus FP/SAL
Study characteristics
Three large, parallel-group RCTs compared the
use of BUD/FF, delivered via a Turbohaler DPI,
with FP/SAL, delivered via a Diskus DPI (Table 67).
There were 706 patients in the 52-week trial by
FitzGerald and colleagues246 and 2143 in the 52-
week trial by Vogelmeier and colleagues.247 The
RCT by Aalbers and colleagues248 included 658
patients. For the first 4 weeks of treatment,
patients in the BUD/FF AMD group did not adjust
their dose. Aalbers and colleagues248 combined
the results for this period for the AMD and fixed
dose (FD) BUD/FF groups. Following this double-
blind month, there was a 6-month open-label
extension during which patients were treated in
the original three randomised groups, FD
BUD/FF, AMD BUD/FF or FD FP/SAL. Only data
from the 6-month extension phase will be
discussed here, since these are the only data
available for the three randomised groups.
The studies by FitzGerald and colleagues246 and
Vogelmeier and colleagues247 were two-arm trials.
However, Aalbers and colleagues248 reported a
three-arm trial comparing the FP/SAL arm with
either FD or AMD BUD/FF. The studies all used
the same standard doses of 250 µg FP and 50 µg
SAL, delivered twice per day. Patients in this arm
of the study by Vogelmeier and colleagues247 could
have the dose titrated up or down to improve
control, and were also given salbutamol as
required. Those in this arm of the study by
FitzGerald and colleagues246 were also required to
take two doses of placebo via a Turbohaler twice
per day. The standard doses of BUD/FF in the
trials by Vogelmeier and colleagues247 and Aalbers
and colleagues248 were 320 µg BUD and 9 µg FF
ex-actuator, delivered twice a day. Patients in the
Vogelmeier study247 could have their doses titrated
up or down to improve control, plus additional
inhalations for relief as needed. Doses for the
third arm of the Aalbers and colleagues248 study
were adjustable to 160–640 µg BUD and
4.5–18 µg FF ex-actuator twice daily. The study by
FitzGerald and colleagues246 started with a higher
dose of 400 µg BUD plus 12 µg FF ex-valve twice
per day, but these doses were halved after 4 weeks
and subsequently adjusted according to self-
management plans. Patients in this study arm were
also required to take a placebo via a Diskus DPI
twice per day (BUD/FF – Seretide Diskus, GSK;
FP/SAL – Symbicort Turbuhaler, AZ, for all studies).
The aim of the trial by Vogelmeier and
colleagues247 was to compare the effectiveness of
BUD/FF for maintenance (plus as-needed
medication) with FP/SAL plus salbutamol as rescue
medication. Aalbers and colleagues248 investigated
whether asthma control improved if patients
adjusted the maintenance dose of BUD/FF
according to asthma severity, compared with
traditional FD regimens of either this combination
or FP/SAL. Only comparisons between FP/SAL
and either dosing regimen of BUD/FF will be
included here; comparisons between FD and AMD
BUD/FF will not be discussed in any detail. The
aim of the FitzGerald and colleagues study246 was
to compare the efficacy of FD of FP/SAL with
AMD of BUD/FF.
Patients were of similar mean ages across the trials
(44–46 years), with age ranges of 12–84/85 years
reported by two trials247,248 and an SD of 14 years
reported by FitzGerald and colleagues.246 None of
the included studies commented on the severity of
asthma in the RCT populations, but all studies
reported mean baseline FEV1 values as a
percentage of the predicted normal value. In the
trial by Aalbers and colleagues,248 the mean
baseline FEV1 was 84% of the predicted normal
value. This was slightly lower in the study by
FitzGerald and colleagues,246 who reported a
mean baseline FEV1 value of 81% of the predicted
normal value. Mean baseline FEV1 was lowest in
the patients enrolled into the study by Vogelmeier
and colleagues247 (73%). This suggests mild to
moderate asthma, according to guidelines.
At entry to the study by Aalbers and colleagues,248
73% of all randomised patients already used
LABAs or combinations of these with ICS. All of
the patients in the study by FitzGerald and
colleagues246 had used either an ICS at a dose
equivalent to 200–500 µg BDP per day, 
combined with a LABA, or an ICS alone at a dose
equivalent to >500–1000 µg BDP per day for at
least 12 weeks before enrolment. Patients were
eligible for inclusion in the study by Vogelmeier
and colleagues247 if they had used at least 500 µg
BUD or FP per day, or at least 1000 µg/day of
another ICS for at least 1 month before study
entry.
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TABLE 66 Breakdown of studies for review question 5 –
combination inhaler versus combination inhaler
Pair-wise comparison No. of RCTs 
included
FP/SAL (combination) vs BUD/FF  3
(combination)
Total 3Assessment of clinical effectiveness
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T
ABLE 67
Characteristics of studies comparing BUD/FF with FP/SAL
Study
Design
Intervention
P
atients
Outcomes
Aalbers 
et al.,
2004
248
RCT
Multi-centre 
P
arallel-group
Double-blind 
Double-dummy
Open-extension
1.
BUD/FF FD 160/4.5
µg
a
2 puffs b.d. (daily total
800/24
µg) 
2.
BUD/FF AMD 160/4.5
µg
a
2 puffs b.d. (daily total
800/24
µg – adjustable to 1
puff b.d. at end of double-
blind – up to 4 puffs b.d. in open extension period for 
7–14 days if needed)
3.
FP/SAL 250/50
µg b.d. (daily total 500/100
µg)
Delivery device:
1, 2. DPI (Symbicort T
urbuhaler
, AZ)
3. DPI (Seretide Diskus, GSK)
Duration:
1 month (double-blind) + 6 months (open-label)
Run-in period:
10–14 days
Number randomised
658
Mean age (range) (years) 
46 (12–85)
Baseline FEV
1
% predicted
84–85
P
revious ICS treatment (drug and dose)
BUD 500–1200
µg (with or without
beta
2
agonist)
P
rimary outcome
Odds of having a well-controlled asthma
week, defined as: no night awakenings,
no exacerbations, no change in treatment
due to AEs
At least two of the following: asthma
symptom score >1 on 
2
days, 

2days,
with reliever use, 
4 reliever uses,
morning PEF 	80% of predicted every
day
Secondary outcomes
PEF (morning and evening)
Daytime symptom score
Nocturnal awakenings
R
eliever use
FEV
1
T
otal asthma control weeks, defined as:
asymptomatic, no night awakenings, 
no exacerbations, no reliever use,
no change in treatment due to AEs,
morning PEF 	80% of predicted every
day
Exacerbations (oral steroids for 	3
days,
ER visits and/or hospitalisation)
continuedHealth Technology Assessment 2008; Vol. 12: No. 19
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T
ABLE 67
Characteristics of studies comparing BUD/FF with FP/SAL (cont’d)
Study
Design
Intervention
P
atients
Outcomes
FitzGerald
et
al., 2005
246
RCT
Multi-centre 
P
arallel-group
Double-blind 
Double-dummy
1.
BUD/FF AMD 200/6
µg
b
2 puffs b.d. (daily total
800/24
µg – adjustable to 1 puff b.d. after 4
weeks – up
to 4 puffs b.d. for 7–14 days if needed) +
1 puff b.d.
placebo
2.
FP/SAL 250/50
µg 1 puff b.d. (daily total 500/100
µg) +
2 puffs placebo b.d.
Delivery device:
1.
DPI (Symbicort, T
urbuhaler
, AZ) + placebo Diskus
2.
DPI (Seretide Diskus, GSK
c
) + placebo T
urbuhaler
Duration:
52 wks
Run-in period:
2 wks
Number randomised
706
Mean age (±
SD) (years)
1.
44 (±
14) 
2.
46 (±
14)
Baseline FEV
1
% predicted (±
SD)
1.
81 (±
13)
2.
82 (±
21)
P
revious ICS treatment (drug and dose)
~200–500
µg/day BDP + LABA, or
ICS dose equivalent to
>500–1000
µg/day BDP
P
rimary outcome
Mean % symptom-free days (over 
24-hour period) on daily record card
Secondary outcomes
% rescue-free days
Daily rescue medication use
Daily asthma symptom score
% nights awoken due to asthma
Mean morning PEF
% well-controlled asthma weeks
Incidence of asthma exacerbations
(hospital treatment or oral corticosteroids,
either in the opinion of the investigator or
based on a morning PEF <70% of the
mean of the last 7
days in weeks 1–4 for
>2 consecutive days)
AEs
Compliance
V
ogelmeier 
et al., 2005
247
RCT
Multi-centre 
P
arallel-group
Open-label
NB. This trial
also examines
the effects of
the combination
inhaler as a
reliever
1.
BUD/FF 160/4.5
µg
a
2 puffs b.d. (daily total 800/24
µg–
titrated up to 4 puffs or down to 2 puffs to improve
control + additional inhalations for relief as needed)
2.
FP/SAL 250/50
µg
b.d. (daily total 500/100
µg – titrated
up to 500/50
µg b.d. or down to 100/50
µg b.d. to
improve control) + salbutamol relief
Delivery device: 
1.
DPI (Symbicort, T
urbuhaler
, AZ) 
2.
DPI (Seretide Diskus, GSK)
Duration:
52 wks
Run-in period:
2 wks
Number randomised
2143
Mean age (range) (years)
45 (12–84)
Baseline FEV
1
% predicted (range)
73 (28–115 across groups)
P
revious ICS treatment (drug and dose)
>500
µg/day BUD or FP
, or
>1000
µg/day of another ICS (with
LABA, if appropriate)
P
rimary outcome
Time to first severe exacerbation (defined
as hospitalisation/ER treatment, oral
steroids for 3
days, or an unscheduled
visit leading to treatment change)
Secondary outcomes
P
re- and post-terbutaline FEV
1
As-needed medication use
Symptoms (Asthma Control Questionnaire,
A
CQ-5)
HRQoL [AQLQ(S)]
AEs
Severe exacerbations (no. of days with
exacerbations and days with oral steroids)
AMD, adjustable maintenance dose; ER, emergency room; FD, fixed dose.
a 
Ex-actuator
.
b 
Ex-valve.
c 
Not stated explicitly
, but deduced from the text.The primary outcomes were different for the three
included RCTs. Aalbers and colleagues248 used the
odds of having a well-controlled asthma week,
defined as no night awakenings; no exacerbations;
no change in treatment due to AE; and at least two
other criteria relating to asthma score of >1 on
fewer than 2 days, fewer than 2 days or four
instances of use of relief medication, and morning
PEF rate higher than 80% of predicted value every
day. FitzGerald and colleagues246 reported the
mean percentage of symptom-free days as the
primary outcome measure, and Vogelmeier and
colleagues247 used time to first severe exacerbation.
All three studies reported adequate methods of
randomisation and concealment of allocation to
treatment groups. Two of the studies246,247 were
double-blind, but the study by Aalbers and
colleagues248 was open-label after an initial month
of double-blind treatment. Analysis of outcome
data by Aalbers and colleagues248 was on an ITT
basis, but the studies by FitzGerald and
colleagues246 and by Vogelmeier and colleagues247
excluded small numbers of randomised patients
from efficacy analyses.
Results
Lung function
Aalbers and colleagues248 reported mean change
from baseline in morning PEF as a secondary
outcome measure. FEV1 was only reported for the
first month of the study, which was not fully
randomised and so will not be discussed here.
Changes in morning PEF were estimated from a
graph. Mean values changed by 27.5 l/minute in
the BUD/FF AMD group, by 34 l/minute in the
BUD/FF FD group and by 35 l/minute in the
FP/SAL group. The study reported no statistically
significant differences between the three treatment
groups. Aalbers and colleagues also reported that
evening PEF was significantly lower in the
BUD/FF AMD group compared with both FD
groups. The mean difference between the BUD/FF
AMD group and the FP/SAL group was
8.4 l/minute (95% CI 0.7 to 16.1, p < 0.05).
FitzGerald and colleagues246 reported morning
PEF, but not FEV1, as measures of lung function.
The average morning PEF at end-point was
395 l/minute (SD 104) in the FP/SAL group and
390 l/minute (SD 100) in the BUD/FF group.
FitzGerald and colleagues246 then adjusted these
values using ANCOVA to allow for treatment,
baseline, group country, sex and age. The
resulting values (400.1 l/minute for the FP/SAL
group and 390.6 l/minute for the BUD/FF group)
were statistically significantly different (p = 0.006).
Vogelmeier and colleagues247 measured lung
function using pre- and post-terbutaline FEV1
changes from baseline, but did not report morning
or evening PEF. There was a statistically significant
difference between the two treatment groups for
both pre- and post-terbutaline FEV1 mean change
from baseline. The adjusted mean change from
baseline pre-terbutaline FEV1 was 0.17 litres in the
BUD/FF group and 0.14 litres in the FP/SAL
group (p = 0.066). For the post-terbutaline FEV1
mean change from baseline, values of 0.07 and
0.04 litres were reported for the BUD/FF group
and the FP/SAL group, respectively (p = 0.045).
Symptoms
Aalbers and colleagues248 measured asthma
symptoms using daytime symptom score and
number of nocturnal awakenings. Nocturnal
awakenings were reported by 12.5% of the
BUD/FF AMD group, 19.5% of the BUD/FF FD
group and 16% of the FP/SAL group. Significance
values were not reported for the differences
between the BUD/FF groups and the FP/SAL
group. Data were not reported for asthma symptom
scores, but were described as being comparable
between groups during the open-label phase.
Patients in the study by FitzGerald and
colleagues246 recorded daily asthma symptom
scores on a daily record card, from which mean
percentage of symptom-free days was calculated.
They also reported the percentage of nights at
end-point in which patients were awoken due to
asthma. The mean daily asthma scores at end-
point were 0.8 (SD 0.8) in the FP/SAL group and
0.9 (SD 0.8) in the BUD/FF group; no p-value was
reported. The median percentage of symptom-free
days at end-point was 58.8% [interquartile range
(IQR) 1.5, 90.6] in the FP/SAL group and 52.1%
(IQR 0, 83.5) in the BUD/FF group. The difference
between the two groups was statistically significant
(p = 0.034). There was no statistically significant
difference between the two groups in terms of
median percentage of night-time awakenings
(p = not significant). Patients in the FP/SAL group
were awakened by their asthma symptoms 1.1% of
the nights (IQR 0, 6.3), compared with 1.4% of the
nights in the BUD/FF group (IQR 0, 6.3).
Asthma symptoms were recorded on the ACQ-5 by
patients in the study by Vogelmeier and
colleagues.247 The questionnaire has five questions
on the burden of symptoms, and each question is
scored on a scale of 0–6 (where 0 = no symptoms).
There was no statistically significant difference
between the two treatment groups in mean
adjusted change from baseline in overall ACQ-5
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decrease (i.e. an improvement in symptoms).
Patients in the BUD/FF group had a mean
decrease of 0.64 points, compared with a mean
decrease of 0.58 in the FP/SAL group (p = 0.069).
Vogelmeier and colleagues247 considered these
changes to be clinically relevant (references cited).
Health-related quality of life
HRQoL was only reported by Vogelmeier and
colleagues,247 who used the AQLQ(S). The
questionnaire consists of 32 questions, each of
which is scored on a scale of 1–7 (7 = least
impairment) and then summed to give the total.
Vogelmeier and colleagues247 reported that a
change in AQLQ(S) overall score of at least 0.5 is
considered to be clinically relevant (references
cited). Both treatment groups had a mean
adjusted change from baseline in AQLQ(S) score
which indicated a clinically significant
improvement in quality of life. The BUD/FF group
had a mean increase of 0.60 points, compared
with a mean increase of 0.57 points in the FP/SAL
group (p = 0.51).
Use of rescue medication
Aalbers and colleagues248 reported the mean
number of occasions per day on which reliever
medication was used; an occasion was defined as
1 inhalations taken together, without waiting for
peak bronchodilator response to each inhalation.
The mean number of occasions per day during
run-in was 1.83 in the BUD/FF group and 1.76 in
the FP/SAL group and after 1 month the changes
from baseline were –0.86 and –0.81, respectively.
The difference between groups in the change from
baseline (0.04) was not statistically significant
(based on the 95% CI –0.12 to 0.21). FitzGerald
and colleagues246 reported daily rescue medication
use as the median daily puffs of salbutamol per
day. The FP/SAL had a median of 0.11 puffs per
day (IQR 0.02, 0.43), which was statistically
significantly lower than the 0.18 puffs taken by the
BUD/FF group (IQR 0.04, 0.59; p = 0.006).
Vogelmeier and colleagues247 reported, over the
entire treatment period, that patients receiving
BUD/FF for maintenance plus as-needed
medication used significantly (38%) less as-needed
medication than those receiving FP/SAL plus
salmeterol (mean numbers of inhalations per day
were 0.58 and 0.93 respectively; p < 0.001).
Exacerbations
All three studies reported the rates of asthma
exacerbations experienced by the patients in their
trials. Aalbers and colleagues248 defined an
exacerbation as an event requiring three or more
days of oral steroids, an emergency room (ER) visit
and/or hospitalisation. The rates of exacerbations
per month were 0.024 in the BUD/FF AMD group,
0.036 in the BUD/FF FD group and 0.041 in the
FP/SAL group. The rate reduction between the
BUD/FF AMD group and the FP/SAL group was
39.7% (95% CI 8.3 to 60.3%, p = 0.018).
FitzGerald and colleagues246 defined asthma
exacerbations as deterioration requiring hospital
treatment or treatment with oral corticosteroids,
either in the opinion of the investigator or based
on a morning PEF that was <70% of the mean of
the last 7 days (during the first 4 weeks), for more
than two consecutive days. The adjusted annual
mean exacerbation rate was statistically
significantly lower in the FP/SAL group than in
the BUD/FF group (0.18 versus 0.33, p = 0.008).
Vogelmeier and colleagues247 defined a severe
exacerbation as a deterioration requiring
hospitalisation or ER treatment, oral steroids for
at least 3 days or an unscheduled visit leading to
treatment change. The annual exacerbation rate
per patient was 0.24 for the BUD/FF group and
0.31 for the FP/SAL group (p = 0.0025).
Excluding unscheduled clinic visits, the annual
exacerbation rate per patient was slightly lower, at
0.19 for the BUD/FF group and 0.23 for the
FP/SAL group (p = 0.0023). Vogelmeier and
colleagues247 also reported the annual rate of
severe exacerbations due to ER
visits/hospitalisations per patient, which was 0.04
in the BUD/FF group and 0.05 in the FP/SAL
group (p = 0.38).
Adverse events
The studies by Aalbers and colleagues248 and
Fitzgerald and colleagues246 reported data on rates
of AEs, which were pooled for meta-analysis using
a fixed-effects model (Figure 23). (Both the AMD
and FD groups in the trial by Aalbers and
colleagues are entered into the meta-analysis.) 
The two trials showed small differences in
direction of effect, and statistical tests indicate that
heterogeneity is significant for this outcome
measure (2 = 5.33, p = 0.07; I2 = 62.5%). A
random-effects model was also used to pool the
trials, but resulted in the same 2 and I2 values.
The trials were of different length (7 months
versus 1 year), which could have had an effect on
the results. The OR from the pooled results was
1.09 (95% CI 0.87 to 1.36, p = 0.45) using the
fixed-effects model and 1.18 (95% CI 0.80 to 1.73,
p = 0.41) using the random-effects model. This
suggests that there is no statistically significant
difference between the two drug regimens, in
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heterogeneity suggests that this result should be
interpreted with caution.
The studies by FitzGerald and colleagues246 and
Vogelmeier and colleagues247 reported rates of
serious AEs. These were pooled for meta-analysis
using a fixed-effects model (Figure 24). Statistical
tests indicated that there was no significant
heterogeneity (2 = 0.02, p = 0.88; I2 = 0%).
Although the pooled results slightly favour
BUD/FF, the OR was 1.09 (95% CI 0.81 to 1.47)
and there was no statistically significant difference
between the two treatments (p = 0.57).
The studies by FitzGerald and colleagues246 and
Aalbers and colleagues248 reported rates of
withdrawals due to AEs, and these were pooled
using a fixed-effects model (Figure 25). Statistical
tests did not indicate any significant heterogeneity
(2 = 0.73, p = 0.69; I2 = 0%). Both of the studies
indicated a slightly higher rate of withdrawals due
to AEs in the BUD/FF arms, and the overall
treatment effect favours FP/SAL for this outcome,
with an OR of 0.78 (95% CI 0.50 to 1.21).
However, the difference between the two treatment
arms was not found to be statistically significant
(p = 0.27).
Summary
Three large, parallel-group RCTs compared the
use of fixed- or adjustable-dose BUD/FF, delivered
via a Turbohaler DPI, with fixed or adjustable
dose FP/SAL, delivered via a Diskus DPI. Daily
doses were approximately 800 µg BUD, 24 µg FF,
500 µg FP and 100 µg SAL. The studies were
generally of good methodological quality, but lack
of ITT analysis in the two of the studies246,247 and
lack of blinding in the six-month extension period
of the other trial248 may have allowed some bias to
affect the results. The trials tended to show
conflicting results for the drug comparisons,
suggesting that the two drug combinations are
probably of similar efficacy.
There were mixed results for measures of lung
function. Aalbers and colleagues248 reported no
statistically significant difference between the three
treatment groups in morning PEF change from
baseline value. However, evening PEF was
significantly lower in the BUD/FF AMD group
compared with the FP/SAL group. FitzGerald 
and colleagues246 reported similar average
morning PEF values in both treatment groups, but
found that values were statistically significantly
higher in the FP/SAL group after adjusting for
various factors. By contrast, Vogelmeier and
colleagues247 reported a statistically significantly
higher mean change from baseline FEV1 in the
BUD/FF group.
The three trials reported conflicting effects in
terms of asthma symptoms. One study reported
that daily symptom scores were similar in the
treatment arms, and another found no statistically
significant difference between the groups in ACQ-
5 score. By contrast, the third study found that the
median percentage of symptom-free days was
statistically significantly higher in the FP/SAL
group. Patients in the BUD/FF groups tended to
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Review: Corticosteroids – review Q5 – Combination inhaler vs combination inhaler
Comparison: FP  +  salmeterol combination inhaler vs BUD + formoterol combination inhaler (adults): parallel
Outcome: Adverse events
 FitzGerald et al., 2005
246 169/348 185/354
  74/112  124/219
  74/112  124/215
 62.22 0.86 (0.64 to 1.16)
 Aalbers et al., AMD arm
248  18.78 1.49 (0.93 to 2.40)
 Aalbers et al., FD arm
248   19.01 1.43 (0.89 to 2.30)
Total (95% CI) 572 788 100.00 1.09 (0.87 to 1.36)
Total events: 317 (FP + salmeterol), 433 (BUD + formoterol)
Test for heterogeneity: 2 = 5.33, df = 2 (p = 0.07), I2 = 62.5%
Test for overall effect: Z = 0.75 (p = 0.45)
FIGURE 23 Rate of adverse eventsrequire more rescue medication than those in the
FP/SAL groups. The rate of asthma exacerbations
per month was statistically significantly lower in the
BUD/FF AMD groups than in the FP SAL group in
two trials. However, the adjusted annual mean
exacerbation rate was statistically significantly lower
in the FP/SAL group than in the BUD/FF group in
the third trial. Results pooled for meta-analyses
indicated that there were no significant differences
between the treatment groups in rates of AEs,
serious AEs or withdrawals due to AEs.
Summary of Q5 – combination inhaler compared
with combination inhaler
Three RCTs compared the two combination
inhalers head to head. Results were mixed, with
the FP/SAL combination significantly superior on
some outcomes and the BUD/FF combination
superior on others. Meta-analysis found that there
were no significant differences between the
treatment groups in rates of AEs, serious AEs or
withdrawals due to AEs. Table 68 provides a visual
illustration of the results of pair-wise comparisons.
Related systematic reviews
Cochrane systematic reviews
Five Cochrane systematic reviews56,170–173
evaluating various ICS treatments for chronic
asthma in adults and children were identified in
searches. As mentioned in the section ‘Methods
for reviewing effectiveness’ (p. 23), this assessment
has attempted to build on these reviews. The
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Review: Corticosteroids – review Q5 – Combination inhaler vs combination inhaler
Comparison: FP  +  salmeterol combination inhaler vs BUD + formoterol combination inhaler (adults): parallel
Outcome: Discontinuations due to adverse events
 FitzGerald et al., 2005
246    6/348  11/354
13/112 27/219
13/112 31/215
 23.48 0.55 (0.20 to 1.50)
 Aalbers et al., AMD arm
248  35.39 0.93 (0.46 to 1.89)
 Aalbers et al., FD arm
248  41.13 0.78 (0.39 to 1.56)
Total (95% CI) 572 788 100.00 0.78 (0.50 to 1.21)
Total events: 32 (FP + salmeterol), 69 (BUD + formoterol)
Test for heterogeneity: 2 = 0.73, df = 2 (p = 0.69), I2 = 0%
Test for overall effect: Z = 1.10 (p = 0.27)
FIGURE 25 Rate of withdrawals due to adverse events
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Review: Corticosteroids – review Q5 – Combination inhaler vs combination inhaler
Comparison:  FP + salmeterol combination inhaler vs BUD + formoterol combination inhaler (adults): parallel
Outcome: Serious adverse events
 FitzGerald et al., 2005
246   9/348    9/354
88/1076 80/1067
 10.54 1.02 (0.40 to 2.59)
 Vogelmeier et al., 2005
247  89.46 1.10 (0.80 to 1.51)
Total (95% CI) 1424 1421 100.00 1.09 (0.81 to 1.47)
Total events: 97 (FP + salmeterol), 89 (BUD + formoterol)
Test for heterogeneity: 2 = 0.02, df = 1 (p = 0.88), I2 = 0%
Test for overall effect: Z = 0.57 (p = 0.57)
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3 vs 1reviews were published between 2000 and 2006
and are briefly described individually below.
It is important to note that these reviews had
slightly different inclusion criteria to the current
assessment (e.g. when comparing ICS and LABA
to ICS alone, the former could be delivered in
separate inhalers in addition to combination
inhalers). Further, the reviews included studies of
adults and children under the age of 12 years,
although there were comparatively few studies of
children. Their results are provided here as
context within which to interpret the results of the
current assessment.
Adams and colleagues170 – FP versus BDP or BUD
This review170 evaluated the effectiveness and
safety of three ICS – FP was compared with either
BDP or BUD. The review was first published in
Issue 1, 2001, and was last updated in May 2005
(searches up to January 2005). The review
included prospective RCTs of parallel or cross-
over design in both adults and children (aged
>2 years) with chronic asthma. The interventions
included any dose of FP compared with any dose
of BDP or BUD, with a treatment period of 1 week
or longer.
The review found 57 studies which met the
inclusion criteria, involving 12,614 participants.
Fourteen of the studies were in children, with the
remaining studies conducted in adolescents and
adults. The asthma severity of the participants in
the trials varied from mild (eight studies), mild to
moderate (12 studies), moderate (12 studies),
moderate to severe (16 studies), severe (six
studies) and mild to severe (two studies), with
severity being unclear in one trial. In the majority
of studies, some or all of the participants were
using regular ICS at the time of enrolment.
Results
Dose ratio 1:2. FP resulted in a significantly
greater absolute FEV1 compared with BDP/BUD
(mean difference 0.09 litres, 95% CI 0.03 to
0.15 litres). However, when reported as change from
baseline, there was no significant difference between
groups (mean difference 0.01 litres, 95% CI –0.02 to
0.05 litres). Similarly, there was no significant
difference between groups in absolute FEV1 %
predicted (mean difference 0.50%, 95% CI –1.28 to
2.28%) or change from baseline FEV1 % predicted
(mean difference –1.04%, 95% CI –3.55 to 1.47%).
Treatment with FP led to a significantly greater
morning PEF compared with BDP/BUD (mean
difference 9.32 l/minute, 95% CI 5.96 to
12.69 l/minute), but not evening PEF (mean
difference 4.67 l/minute, 95% CI –1.36 to
10.7 l/minute). When reported as change from
baseline, there was no significant difference
between groups (mean difference 1.68 l/minute,
95% CI –1.93 to 5.29 l/minute).
Symptoms and rescue medication use were widely
reported but differences in the reporting of these
outcomes precluded the pooling of data for meta-
analysis. The review only reported on specific AEs,
and data on morning plasma cortisol and 24-hour
urinary cortisol were limited. No significant
differences were observed between FP and
BDP/BUD for trial withdrawals (OR 0.76, 95% CI
0.53 to 1.09, 12 studies) or in the likelihood of
experiencing an asthma exacerbation (OR 0.75,
95% CI 0.52 to 1.08, three studies).
Dose ratio 1:1. A significant difference in absolute
FEV1 was found in favour of FP (mean difference
0.09 litres, 95% CI 0.02 to 0.17 litres). However,
when reported as change from baseline, there was
no significant difference between groups (mean
difference 0.04 litres, 95% CI –0.03 to 0.11 litres).
Morning PEF was significantly better with FP
compared with BDP (mean difference
8.78 l/minute, 95% CI 5.14 to 12.41 l/minute).
Evening PEF was also significantly better with FP
(mean difference 6.37 l/minute, 95% CI 2.75 to
9.99 l/minute).
Treatment with FP resulted in a significant
reduction in the odds of an asthma exacerbation
(OR 0.77, 95% CI 0.59 to 0.99, four studies).
However, when a random-effects model was
applied to the meta-analysis due to study
heterogeneity, the difference became insignificant.
No significant differences were observed between
FP and BDP/BUD for trial withdrawals (OR 0.72,
95% CI 0.38 to 1.35, five studies). Differences in
the reporting of measures of symptoms and rescue
medication use meant that relatively few of the
studies could be included in a meta-analysis.
There was no significant difference between
groups in the proportion of symptom-free days
(three studies), day- or night-time score (two
studies), the number of participants experiencing
symptom-free days or nights (two studies) or the
use of rescue medication use (two studies).
Lasserson and colleagues173 – FP versus
HFA–BDP for chronic asthma in adults and
children
This review173 aimed to determine the efficacy of
FP compared with HFA–BDP. The review was first
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in January 2006 (searches up to January 2006).
The review included RCTs of parallel or cross-over
design in both adults and children with chronic
asthma. The interventions included CFC– or
HFA–FP compared with HFA–BDP.
The review found eight studies which met the
inclusion criteria, involving 1260 participants.
Only one of the studies was conducted in children.
The HFA–BDP used in all the studies was extra
fine, and all the studies had a nominal dose ratio
of 1:1. Treatment duration ranged from 3 to
12 weeks. The majority of participants were adults
with baseline symptoms and lung function
indicating moderate asthma.
Results
Parallel trials. No significant difference in
change in FEV1 was observed between the
HFA–BDP and FP groups (WMD 0.04 litres, 95%
CI –0.03 to 0.11). Similarly, no significant
difference was observed in change from baseline
in morning PEF (WMD –2.31 l/minute, 95% CI
–12.53 to 7.91).
Differences in the way in which data were reported
meant that meta-analysis was not undertaken for
most of the other outcome measures. Individual
studies reported no significant differences between
treatment groups for symptom scores, HRQoL or
asthma exacerbations. Whereas three trials found
no difference in the use of rescue medication
(reported in various ways), one trial reported a
significant difference in the medians which
favoured FP (0.28 versus 0 puffs/day, p = 0.04). 
No significant difference was found in the 
rate of any AE [relative risk (RR) 0.88, 95% CI
0.72 to 1.08].
Cross-over trials. Of the three RCTs of cross-over
design, one was a fully published paper and two
were conference abstracts only. Therefore, there
are limited data to report in this category.
One trial reported no significant difference
between FP and HFA–BDP in FEV1 % predicted or
morning PEF. One trial also reported in the text
that there were no differences between treatment
groups in FEV1 or morning PEF but did not
present any data. The third study did not indicate
whether reported FEV1 data were significantly
different.
The trials in this category did not report any data
on symptoms, quality of life, rescue medication
use, asthma exacerbations or withdrawals.
Ni Chroinin and colleagues172 – LABAs versus
placebo in addition to ICS in children and
adults with chronic asthma
This review172 assessed the effectiveness and safety
of adding a LABA to ICS compared with ICS
alone. The review was first published in Issue 4,
2005, and was last updated in June 2005,
(searches up to April 2004). The review included
RCTs of parallel or cross-over design in both
adults and children (aged >2 years) with chronic
asthma who had previously received ICS therapy.
The interventions included a LABA (SAL or FF)
or placebo administered daily for at least 30 days,
added to ICS (e.g. FP, BDP, BUD, triamcinolone
acetonide). The dose of ICS had to be the same in
both the LABA and ICS alone groups.
The review included 26 studies involving 8147
participants which met the inclusion criteria and
provided data in sufficient detail. Eight of the
studies were in children, with the remaining
studies conducted in adolescents and adults.
LABA was added to BUD in seven trials, to BDP
in three trials, to BDP or BUD in one trial and to
FP in four trials, with the ICS being unspecified in
11 studies. Most of the studies used separate
inhaler devices for ICS and LABA (n = 19), and
the study duration was 4 months in most trials.
Participants in the majority of trials had
inadequate asthma control, and the severity of
asthma was mild (n = 8 trials) or moderate
(n = 18 trials). In adult studies, the mean age of
participants ranged from 35 to 48 years, whereas
in children the mean age ranged from 8.5 to
14 years.
Results
Compared with ICS alone, the addition of LABA
to ICS provided significantly greater improvement
in change from baseline FEV1 (WMD 0.170 litres,
95% CI 0.11 to 0.24 litres) and change in FEV1 %
predicted (WMD 2.79%, 95% CI 1.89 to 3.69%).
Similarly, treatment with ICS + LABA led to a
significantly greater improvement in change from
baseline in morning PEF (WMD 23.28 l/minute,
95% CI 18.38 to 28.18 l/minute) and evening PEF
(WMD 21.33 l/minute, 95% CI 14.53 to
28.12 l/minute).
Use of ICS + LABA significantly reduced daytime
symptoms (SMD –0.34, 95% CI –0.44 to –0.23, 5
studies), night-time symptoms (SMD –0.18, 95%
CI –0.31 to –0.05, two studies) and overall 
24-hour symptoms (SMD –0.28, 95% CI –0.45 to
–0.11, two studies). The addition of LABA was also
significantly more favourable in terms of change
from baseline in symptom-free days (WMD
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symptom-free nights (SMD 0.51, 95% CI 0.28 to
0.74, four studies). There were no significant
differences between groups in change in
percentage of nights with no awakenings or in
night-time awakenings.
The addition of LABA to ICS significantly 
reduced the need for rescue medication use in
terms of the change in overall 24-hour use 
(WMD –0.81 puffs/day, 95% CI –1.17 to –0.44,
eight studies). The addition of LABA also
significantly reduced the risk of asthma
exacerbations requiring systemic steroids by 19%
(RR 0.81, 95% CI 0.73 to 0.90, 17 studies). There
was no group difference in the risk of overall AEs
(RR 0.98, 95% CI 0.92 to 1.05, 11 studies), serious
AEs (RR 1.16, 95% CI 0.30 to 4.42, four studies)
or withdrawals due to AEs (RR 1.29, 95% CI 0.96
to 1.75, 23 studies).
Adams and colleagues56 – BDP versus BUD for
chronic asthma
This review assessed clinical outcomes in studies
which compared BDP with BUD delivered at the
same nominal daily dose. The review was
published in Issue 1, 2000, and was last updated
in November 1999 (searches up to 1999, month
not specified). The review included RCTs of either
parallel-group or cross-over design. Studies were
eligible for inclusion if they included adults or
children aged over 2 years old with chronic
asthma. The drugs could be delivered by different
devices (pMDI, MDI + spacer, DPI), and there
does not appear to have been any restriction on
the length of treatment period.
The review found 24 studies (five parallel-group
and 19 cross-over trials) published between 
1982 and 1988 which met the inclusion criteria.
Four of these were available only in abstract 
form and did not report any outcome data. 
Two of the citations were not assessed for the
review as they required translation. Eighteen of
the studies were conducted in adults and six
studies were in children, with a total of 1174
participants in the included trials. The level of
asthma control at randomisation was not well
described in the majority of studies and asthma
severity at baseline was not well documented. 
One study stated that patients had asthma of
moderate severity, one described patients as
having fairly severe asthma and two reported
severe asthma. In 20 of the studies, patients were
not previous regular users of oral corticosteroids
(OCS). In three of the studies, prior OCS use was
an inclusion criterion, and a proportion of
patients in another trial had received OCS
treatment at the time of enrolment. Twelve studies
lasted from 2 to 4 weeks, 10 treated patients from
6 to 12 weeks and one study treated patients for
2 years. One of the studies had a complex trial
design with treatment periods of variable length.
Only two of the cross-over trials had a wash-out
period. The majority of trials assessed doses of
400 µg/day (n = 10) or 800 µg/day (n = 7),
although one study assessed doses of 200 µg/day
and two studies used higher doses of
1500–1600 µg/day. An MDI device was used to
deliver both drugs in eight of the studies, but the
other 16 used different delivery devices for each
drug.
Results
Meta-analysis by Adams and colleagues56 found no
statistically significant differences between BDP
and BUD for any of the outcome measures
relevant to the present review. Results were
presented separately for cross-over trials with no
prior OCS, parallel-group trials, and cross-over
trials with prior OCS. Comparisons reported
below were for BDP versus BUD.
FEV1 was reported by six cross-over studies of
patients with no prior OCS and two parallel-group
studies. The weighted mean difference was
–0.08 litres (95% CI –0.27 to 0.12) in the cross-
over studies of patients with no prior OCS and
–0.02 (95% CI –0.23 to 0.20) in the parallel-group
studies. FEV1 predicted was also reported by two
cross-over studies of people with no prior OCS
[WMD –5.04 litres (95% CI –11.98 to 1.89)].
Morning and evening PEF reported in diary cards
also showed no statistically significant difference
between the two drugs. The pooled cross-over
trials where patients had no prior OCS had a
WMD of –2.99 l/minute (95% CI –28.43 to 22.45)
for morning PEF (six trials) and –5.47 l/minute
(95% CI –31.50 to 20.56) for the five trials
reporting evening PEF. Similar, non-statistically
significant differences were observed in three
cross-over trials whose patients had previously
received OCS. Corresponding analysis for one
parallel-group RCT found a WMD of –18.00
l/minute (95% CI –54.76 to 18.76) for morning
PEF and –8.00 l/minute (95% CI –49.29 to 33.29)
for evening PEF.
The studies reported asthma symptoms using a
range of measures, and no significant differences
between treatments were reported for any of these
measures. Meta-analysis of daily symptom score in
five studies found no statistically significant
difference between BDP and BUD [SMD 0.08
Health Technology Assessment 2008; Vol. 12: No. 19
157
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.(95% CI –0.22 to 0.39)]. Similarly, use of rescue
medication was not reported to differ statistically
significantly between the two drugs. AEs were not
pooled due to lack of clear reporting in the
original trials. One parallel-group study 
reported an RR of 1.76 (BDP versus BUD) for
withdrawal due to an asthma exacerbation 
(95% CI 0.44 to 7.10).
Greenstone and colleagues171 – combination of
LABA and ICS versus higher dose ICS in
children and adults with persistent asthma
This review assessed clinical outcomes in studies
which compared combination treatment of twice
daily LABA and ICS against use of a higher dose
of ICS. The review was published in Issue 4, 2005,
and was last updated in July 2005 (searches up to
April 2004). The review included RCTs of adults
or children aged over 2 years with chronic asthma,
with a minimum duration of 30 days’ treatment.
The review found 42 studies published as 26 full-
text papers and 16 abstracts, 13 of which provided
insufficient data to be included in the meta-
analysis. One of the trials had two intervention
groups compared with a control group, and these
were analysed as separate trials, so the review was
therefore based on data from 30 trials with 9509
participants. One trial was a cross-over study and
the rest were of parallel-group design. The
majority of trials (n = 27) were based on adult
participants and three focused on children.
Participants’ asthma was generally of moderate
severity, and was inadequately controlled at
baseline in all but two of the studies. Patients were
required to have used ICS for at least 1–3 months
before entry to all but one of the trials.
SAL was used as the LABA in 24 of the trials, with
FF being used in the other eight trials. Standard
doses of LABA were used in the majority of trials
(n = 27). Most of the trials (n = 25) used the same
ICS in both the LABA and control groups; 11
used CFC–BDP, four used BUD and 10 used FP.
Three trials compared FP and LABA with
CFC–BDP, BUD or HFA-BDP. One study
compared the combination of LABA and the
patients’ usual ICS to additional FP in the higher
ICS study arm, and one study compared BUD and
LABA with FP. The median ICS dose in the
combined LABA group was 400 µg/day (range
200–1000 µg/day) and 1000 µg/day (range
400–2000 µg/day) in the higher ICS dose 
group. ICS and LABA drugs were delivered 
via separate devices in 22 trials, but eight trials
used a combination device to deliver the 
drugs. Most of the trials lasted for 12 weeks 
(n = 14) or 24 weeks (n = 9), with others lasting
4 weeks (n = 1), 6 weeks (n = 1), 52 weeks (n = 3)
or 54 weeks (n = 1).
Results
The review’s main outcome measure was the risk
of exacerbation requiring systemic corticosteroids,
and this was reported by 15 of the trials. Pooled
data gave an RR of 0.88 (95% CI 0.77 to 1.02),
with no significant group difference [relative
difference = 2% (95% CI 0 to 4%)]. Although the
similarity between treatments did not meet
Greenstone and colleagues’ a priori definition of
equivalence,171 the upper CI was reported to
exclude the likelihood of a higher rate of
exacerbations in patients who received LABA.
Planned subgroup analyses found no effect of age
group (children versus adult), average baseline
severity, type of LABA ICS dose difference
between groups, ICS dose associated with LABA
and trial duration. However, meta-regression of 13
trials found two independent variables which
significantly reduced the risk of exacerbation [low
ICS dose used in combination with LABA
(p = 0.046) and trial duration of 24 weeks or less
(p = 0.01)].
Lung function showed a statistically significantly
greater improvement in the combination LABA
and ICS groups than in the high-dose ICS group.
Using pooled data from nine trials, the WMD in
FEV1 at end-point was 0.13 litres (95% CI 0.08 to
0.19). Similarly, change from baseline FEV1
showed a WMD of 0.10 litres (95% CI 0.07 to 0.12;
n = 7 trials) and FEV1 % predicted at end-point
had a WMD of 3.93% (95% CI 1.33 to 6.53;
n = 4 trials). The WMDs for morning and evening
PEF at end-point were 27.33 l/minute (95% CI
21.39 to 33.26; n = 14 trials) and 20.18 l/minute
(95% CI 12.75 to 27.62; n = 3 trials), respectively.
Patients treated with a combination of ICS and
LABA had statistically significantly better changes
from baseline total asthma symptom scores. Data
from five trials were pooled, giving an SMD of
–0.23 (95% CI –0.41 to –0.05). The percentage of
symptom-free days at end-point also favoured
combination therapy in pooled analysis of eight
trials [WMD = 11.9% (95% CI 7.37 to 16.44)].
Change in rescue inhalations over 24 hours
favoured the combination treatment group
(ICS + LABA) over the high-dose ICS group. Data
from eight trials were pooled to give an SMD of
–0.22 (95% CI –0.29 to –0.14). There were no
statistically significant differences between the
groups in daytime symptoms at end-point, night-
time symptoms, percentage of symptom-free days
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awakenings and quality of life as measured by the
Juniper Questionnaire. There were no group
differences in overall side-effects [RR = 0.93 (95%
CI 0.84 to 1.03); n = 15 trials], serious AEs
[RR = 1.54 (95% CI 0.72 to 3.21); n = 5 trials] or
withdrawals due to AEs [RR = 0.94 (95% CI 0.71
to 1.24); n = 18 trials].
Other systematic reviews
Two systematic reviews evaluating ICS treatments
for chronic asthma in adults and adolescents (aged
>12 years) were identified, published in 1999249
and 2004.250
Kankaanranta and colleagues250 aimed to review
systematically the evidence that supports different
treatment options for asthma, including increasing
the dose of ICS, and the use of add-on therapy
options such as a LABA, leukotriene antagonist or
theophylline. Jarvis and Faulds249 evaluated the
therapeutic efficacy of FP at doses 500 µg/day,
and included comparisons with placebo, non-
steroidal, anti-inflammatory agents, other ICS
drugs (BDP, BUD, flunisolide and triamcinolone
acetonide), and combination with SAL. Hence
both reviews evaluated therapeutic options which
are not relevant to the current assessment, and it
should be noted that the descriptions of the
methodology and results which follow are only of
those which are applicable here.
Kankaanranta and colleagues250 included 14
blinded RCTs with either parallel-group or cross-
over designs, whereas Jarvis and Faulds249
included double-blind, parallel-group RCTs, but
did not specify the study design in the search
criteria and so other study types may have been
included. In addition, the authors stated that
“large, well-controlled trials with appropriate
statistical methodology were preferred”, and it is
not clear whether smaller trials were excluded.
The number of studies included which are relevant
to our review was approximately 36, but this is not
clear. The number of participants was not
reported in either review. Participants included in
the reviews were adults or adolescents (one
review250 defined adolescents as aged >12 years)
with mild to moderate asthma249 or asthma that
was inadequately controlled with ICS250 (results
are reported for patients with mild and moderate
to severe asthma).
Neither of the reviews described their
methodology in any detail. Details of procedures
such as study selection, validity assessment and
data extraction were not reported in either review,
and assessment of publication bias was not carried
out in one review250 and not reported in the
other.249 Heterogeneity between studies was
partially described by Kankaanranta and
colleagues,250 but not by Jarvis and Faulds.249 Both
reviews were narrative and neither included a
meta-analysis. The quality of the reviews was
mixed. Kankaanranta and colleagues250 clearly
stated their research question, defined the search
strategy and the inclusion/exclusion criteria and
reported the number and type of included studies.
Jarvis and Faulds249 were not clear in stating their
research question, used only limited keywords in
their search strategy, did not clearly specify the
inclusion/exclusion criteria and were ambiguous in
their reporting of the number and type of studies
included in the assessment.
A brief summary of the main findings of each of
the reviews is outlined below.
Results
Kankaanranta and colleagues’ review main findings250
● In patients with moderate to severe asthma,
addition of FF was superior to the increase in
steroid dose in increasing FEV1 and morning
PEF, and was equal or superior to the four-fold
increase in ICS in reducing day- or night-time
symptom scores or rescue medication use.
● In patients with moderate to severe asthma,
addition of SAL was superior to the two- to
four-fold increase in the dose of ICS in
increasing FEV1 and mean morning PEF,
improving symptom scores and reducing the
need for rescue medication. However, a
statistically significant difference was not always
reached.
● A four-fold increase in the dose of BUD
reduced severe and mild asthma exacerbations,
as did the addition of FF to the lower dose of
BUD. Addition of FF to BUD in patients with
mild asthma significantly reduced the risk of
the first asthma exacerbation and severe
exacerbations.
Jarvis and Faulds’ review main findings249
● In one study, morning PEF and FEV1 increased
significantly in patients receiving FP (88 or
220 µg twice daily) compared with those
receiving BDP (168 µg twice daily). The
increase in rescue medication-free days was
significantly greater with BDP compared with
FP in one study, but there was no statistical
difference in the frequency of as-needed
salbutamol usage between the two groups.
● Mean improvement in morning and/or evening
PEF in patients with FP was similar to or
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morning PEF was significantly greater with FP
than with BUD in two studies. There was no
statistically significant difference in the frequency
of as-needed rescue medication usage between
groups. In one study, treatment with FP resulted
in a significant improvement in symptom-free
days and nights and rescue medication free days
and nights compared with BUD.
● There were no statistically significant differences
in FEV1 or morning PEF in patients treated
with FP + SAL in separate delivery devices
compared with FP/SAL combined in the same
delivery device in the two identified studies.
Summary
The review by Kankaanranta and colleagues250
found that addition of a LABA was more effective
than increasing the dose of ICS in improving
asthma control. However, they reported that
increasing the ICS dose was likely to be of small
magnitude. The review by Jarvis and Faulds249
found that FP was at least as effective as other ICS
(BDP and BUD) administered at twice the FP
dosage. The addition of inhaled SAL to FP
allowed the use of lower maintenance doses of FP
and was well tolerated.
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The purpose of this chapter is to:
1. Summarise existing published economic
evaluations that are relevant to the decision
problems specified in the project scope and
protocol.
2. Summarise the industry-submitted economic
evaluations provided as part of the NICE
appraisal process, with particular focus on
critically appraising those that are relevant to
the decision problems specified in the project
scope.
3. Describe the methods and results of the new
economic evaluation(s), cost comparisons and
other economic information which have been
generated to try and help the NICE Appraisal
Committee to consider the ‘value for money’
implications for the NHS of alternative
guidance on the use of corticosteroids in adults
with asthma.
Additionally, we outline and justify the approach
we have taken to assessing the cost-effectiveness or,
more broadly – given the lack of clear evidence of
differential effectiveness for all but one of the cost-
effectiveness research questions – the ‘value for
money’ to the NHS of the alternative asthma
treatments evaluated. We also explain why we have
not presented a comprehensive model-based
cost–utility analysis in the main body of the report
(although, for the purpose of exploring
uncertainty, we present a shortened version in
Appendix 10 for one of the research questions).
Finally, we attempt to provide an overview of the
economic evidence from the different analyses,
and comment on any consistent or conflicting
findings.
Systematic review of published
economic evaluations 
A systematic review of existing published economic
evaluations was undertaken.
The aims of this systematic review were to 
(1) identify and critically appraise any high-quality
economic evaluations of the same (or very similar)
decision problems to those specified in the NICE
appraisal scope, and which are from an NHS or
UK societal perspective, and (2) gain some
insights into the key ‘trade-offs’ or relationships
between resources, costs and health outcomes in
assessing the treatment of asthma, in order to
inform our own economic analyses.
Search strategy and critical appraisal
methods
Ten electronic databases including MEDLINE,
EMBASE and the Cochrane Library (Issue 1,
2006) were searched for cost-effectiveness studies
that assessed the cost-effectiveness of BDP, BUD,
FP dipropionate, CIC and MF used alone or in
combination with a LABA (SAL or FF) within their
licensed indications and the appropriate step of
the BTS/SIGN Guideline.1 The full search strategy
is shown in Appendix 3. The original searches
were conducted in April 2006 with updated
searches in October 2006.
A total of 723 titles and abstracts were screened
for inclusion in the review. These included studies
that were potentially relevant to the present
assessment and also those relevant to the related
technology assessment project on the clinical
effectiveness and cost-effectiveness of ICS and
LABAs for the treatment of chronic asthma in
children under 12.181 Of the titles and abstracts
screened, 58 were ordered as full papers and
assessed in detail.
Data extraction tables were designed to capture
the standard information required for critically
appraising the quality of methods of economic
evaluation251 and for judging the policy/decision
relevance of each study to this assessment.
Inclusion and exclusion criteria
Full, published cost-effectiveness analyses (CEAs),
cost–utility analyses (CUAs), cost–benefit analyses
and cost–consequence analyses were eligible for
inclusion in the cost-effectiveness review.
Results 
Fifty-eight full papers were assessed for inclusion
in the review. Of these, 15 met the inclusion
criteria and are summarised in the following
sections.
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Chapter 4
Economic analysesSummary of the included cost-effectiveness
studies
A total of 15226,252–265 published full-text studies
were judged as full economic evaluations and met
our inclusion criteria and involved adults with
asthma. All of the 15 studies were published after
1994. They are summarised in the following
section.
Appendix 7 provides more details of the study
designs, model features (where relevant) and main
results of the included studies.
Study types and settings
As Tables 69 and 70 show, of the 15 included
studies, four253,260,264,265 compared ICS
monotherapies with each other, and the rest
compared ICS plus a LABA with the same ICS as
monotherapy. There were also two other studies,
by Stempel and colleagues266 and Barnes and
colleagues,267 which compared FP with BUD,
which were excluded because they mixed
effectiveness evidence from both children and
adults with asthma, and did not report the results
for adults separately. It is also worth noting that in
these two economic evaluations, among the six
trials that were in adults there was substantial
heterogeneity in terms of inhaler device types,
asthma severity (mild, mild/moderate, to severe)
and prior ICS use (both steroid naïve and not).
None of this heterogeneity was recognised in their
methods of meta-analysis of average cost-
effectiveness ratios across the seven trials.
There is also duplicate publication in some of the
studies comparing FP with FP/SAL from the
Swedish health system perspective (with the
analyses by Pieters and colleagues262 and
Palmqvist and colleagues261 and Johansson and
colleagues257 also appearing in the paper by
Lundbäck and colleagues259). The wide variation
in the comparators in different studies, in terms of
both the drug types and daily dosages, is such that
few meaningful comparisons can be made between
studies.
Of the 11 studies which compared ICS against ICS
plus LABA, all except two (by Johansson and
colleagues256 and Jönsson and colleagues258)
involved adding a LABA to the same daily dose of
ICS as in the ICS monotherapy with which it is
compared. Given that the more realistic clinical
choice when faced with a poorly controlled asthma
patient already on ICS is between either
increasing their ICS dose or adding a LABA
(probably to the current ICS dose), the results of
these evaluations are therefore of limited clinical
relevance in the current context of the BTS/SIGN
Guideline.
There were no published economic evaluations
which compare CIC or MF with other ICS or ICS
plus LABAs.
For completeness, we have included the three
economic evaluations which we found that
compared ICS with ICS plus LABAs in separate
inhalers.252,258,262
Of the 15 economic evaluations, 12 were CEAs,
one260 was a CUA, one265 was a cost-minimisation
analysis (CMA) and one254 contained both CEA
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TABLE 69 Comparisons between each of the five ICS and the daily dosage (µg)
ICS as monotherapy
Study BUD BDP FP CIC MF
Booth et al., 1995253 800 400
Marchetti et al., 2004260 For moderate asthma
1000 400
800 1000
400 extra-fine  400
800 400 extra-fine
For severe asthma
1500 1000
1600 1500
800 extra-fine  1000
1600 800 extra-fine
Steinmetz et al., 1998264 500 1200
Venables et al., 1996265 400 400and CUA results. Some of the CEAs reported cost-
effectiveness ratios for more than one outcome
measure.
Four studies252–254,265 were analysed from a 
UK perspective (UK NHS). Of these, however,
only one was based on patient-level clinical trial
and resource use data specifically collected from
UK asthma patients. One252 was based on trials
conducted in the UK, Spain and seven other
countries and analysed from a societal 
perspective of the UK, Spain and Sweden. The
other studies were based mainly on patients in the
USA, “North America” (unspecified), or in 
various European countries. The common
convention of reporting that patients in trials
come from a stated number of “centres” in
different countries, without elaboration on
whether the patients’ care was mainly managed via
primary care or secondary care services, also limits
our ability to judge the relevance of many of these
clinical and cost-effectiveness studies to the UK
context.
Most studies were based on clinical effectiveness
results from a single clinical trial. The two
(excluded) studies by Stempel and colleagues266
and Barnes and colleagues,267 comparing BUD
with FP at half the dose.
The time horizon of the studies ranged from
6 weeks to 1 year. Discounting was applied only in
one study (and for utility only260). Most of the
studies were funded by pharmaceutical companies;
some also involved co-authors employed by such
companies.
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TABLE 70 Comparisons between ICS plus LABAs with ICS alone and the daily dosage (µg)
ICS as monotherapy ICS with LABA in combination  ICS with LABA in 
inhaler separate inhalers
Study BUD BDP FP CIC MF BUD/FF  FP/SAL  BUD/FF  FP/SAL
Symbicort Seretide
ICS + LABA in combination inhaler vs ICS
Briggs et al., 100 100/50
2006254 250 250/50
500 500/50
Ericsson et al., 400 400/12
2006255
Johansson et al.,  800/24 +  500/100 + 
2006256 additional additional 
inhalations as  inhalations as 
needed needed
Johansson et al., 200 200/100
1999257
Lundbäck et al., 200 200/100
1999259 500 500/100
1000 1000/100
Lundbäck et al., 1600 500/50
2000226
Palmqvist et al., 500 500/50
1999261
Price and Briggs,  200 200/100
2002263
ICS + LABA in separate inhalers vs ICS
Andersson et al., 200 200/24
2001252 800 800/24
Jönsson et al., 200  200/9
2004258 400 400/9
Pieters et al., 500 500/50
1999262In summary, although there are a number of
economic evaluations that could be relevant to the
current decision problem, the very wide variations
in health system settings and study perspectives,
drug comparators, dose levels, outcome measures
and model structures or trial designs and
durations, makes the evidence base relatively
uninformative.
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TABLE 71 Summary of published full-text economic evaluation studies in adults
Study Study type Analysis  Country, setting Comparatorsa Perspective
type
Andersson et al.,  Trial-based CEA UK, Spain, etc.,  BUD + FF  Society (Sweden, 
2001252 9 countries. Setting NR (separate inhalers) UK and Spain)
BUD
Booth et al.,  Trial-based CEA UK, in 57 general  FP UK NHS
1995253 practices BUD
Steinmetz et al., Trial-based CEA Germany.  Ambulatory  FP German  third-party 
1998264 or outpatient centres BUD payer
Venables et al.,  Trial-based CMA UK, in general practice.  FP UK NHS
1996265 Setting NR BUD
Briggs et al.,  Trial- and  CEA 44 countries.  FP/SAL UK NHS
2006254 regression  CUA General practice and  FP
model-based hospital clinics
Ericsson et al.,  Trial-based CEA 6 countries (4 in Europe).  BUD/FF Healthcare payer, 
2006255 Setting NR FP society and drug 
budget holder
Johansson et al.,  Trial-based CEA 16 countries (10 in Europe  BUD/FF Societal perspective
2006256 including the UK).  FP/SAL
Setting NR
Johansson et al.,  Trial-based CEA North American  FP/SAL Swedish healthcare 
1999257 clinical data. Setting NR FP system
Jönsson et al.,  Trial-based CEA 17 countries (15 in Europe). BUD + FF  Both healthcare 
2004258 Setting NR (separate inhalers) payer and society
BUD
Lundbäck et al.,  Trial-based CEA North America and  FP+SAL (both  Swedish healthcare 
1999259 Europe. Setting NR combination and  system
separate inhalers)
FP
Lundbäck et al.,  Trial-based CEA Sweden. Setting NR FP/SAL Swedish healthcare 
2000226 BUD system
Marchetti et al.,  Decision  CUA Italy. Setting NR BDP Both the Italian 
2004260 model-based BDP extra-fine healthcare system 
FP and society
BUD 
Palmqvist et al.,  Trial-based CEA North America.  FP/SAL Swedish healthcare 
1999261 Setting NR FP system
Pieters et al.,  Trial-based CEA France, Germany and  FP + SAL  Swedish healthcare
1999262 The Netherlands.  (separate inhalers) system
Setting NR FP
Price and Briggs,  Decision  CEA 42 centres in the USb. FP/SAL UK  healthcare 
2002263 model-based Setting NR FP system (implied by
results in £)
NR, not reported.
a LABA with ICS in combination inhalers, unless otherwise specified.
b Data from supplement of the trial by Kavuru et al.,268 Palmqvist et al.,261 Pieters et al.262 and Johansson et al.257 involve
duplicate publication of the cost-effectiveness comparisons reported in Lundbäck et al.259A summary of the published economics evaluation
studies in adults is given in Table 71.
Economic evaluations from a UK NHS
perspective
Of the 15 economic evaluations which met the
review’s inclusion criteria, only four were wholly
conducted from a UK NHS perspective,253,254,263,265
and another included an analysis from the UK
NHS perspective252 (and also from the Swedish
and Spanish health systems’ perspectives). All five
studies were funded by and included authors
affiliated with the manufacturers of the products
being evaluated; there is evidence that industry-
funded published CUAs are more likely to produce
favourable cost-effectiveness ratios.269
Summary information on the comparators, analysis
design and results are shown in Table 72. Only the
most recent study by Briggs and colleagues254
calculated an incremental cost per QALY, and two
of the studies are over a decade old.
The most recent UK NHS study, by Briggs and
colleagues254 based on the GOAL study (see
clinical effectiveness review),234 examined the
cost–utility of the combination of FP/SAL
compared with FP alone. The analysis was trial-
based but used regression models of individual
patient trial data to estimate costs by subgroup
(three prior levels of ICS usage), to estimate the
relationship between control status and costs, and
to allow “adjustment for the UK analysis using the
full GOAL dataset” (p. 533 of their paper).
Overall, this appears to be a good-quality
economic analysis, and is based on a complex trial
which uses innovative dose step-up rules, and
which also stratifies according to prior level of ICS
usage. However, limitations include a lack of detail
on the different regression analyses (e.g. goodness
of model fit to trial data), an unusually low cost
per “week-with-exacerbation” of £32, and
insufficient details on the methods used to derive
utility values from the AQLQ instrument scores. In
relation to the non-medication costs, for example,
it would have been useful to see both the whole
trial and UK-specific numbers and rates of
secondary care visits, and primary care visits in the
trial arms. It is well known that because of the
distinctive organisation of primary care in the UK,
patterns of self-care and urgent care-seeking from
GPs versus hospital services are different from
those in many other countries. The authors
acknowledge this to some extent, but in
combination with the very small differences in the
proportion of weeks spent with exacerbations
(0–1%) and given that exacerbations were not a
primary or secondary outcome of the main
trial,234 this probably deserved more description.
Another good-quality study comparing FP/SAL
with FF from an implicit (not stated) UK NHS
perspective, by Price and Briggs,263 mainly
emphasised the development of the five-state
Markov model, but also presented both
deterministic and probabilistic incremental cost-
effectiveness ratios (ICERs) for achieving
“successfully controlled weeks” (using a multi-
criteria definition of successful control
encompassing symptoms, lung function and
exacerbations). However, given that this study was
based on a single 12-week US-based trial of
FP/SAL combination inhaler with FP at the same
dose,235 and also did not use a more generic
measure of HRQoL, it is less relevant to the
present decision problem.
The economic analysis by Andersson and
colleagues,252 based on the FACET clinical trial,
was a cost–consequence analysis. It compared the
costs of BUD with FF or BUD (at the same dose)
alone with the average annual number of
symptom-free days, episode-free days, mild
exacerbations and severe exacerbations. However,
ICERs were only presented for symptom-free days
(and these have limited meaning in the context of
decision-making by NICE). This study did reveal a
very different cost breakdown between the
countries; in the UK the additional cost of adding
FF was only partially offset by reduced costs of
treating exacerbations and other medications,
whereas in Sweden and Spain the treatment cost
savings due to the reduced number of
exacerbations were greater than the additional
“study medication” costs. This highlights the risks
in generalising the results of cost-effectiveness
studies in this clinical area between different
national health systems.
The similar cost-effectiveness analyses by Booth
and colleagues253 (of FP 200 µg twice daily versus
BUD 400 µg twice daily) and by Venables and
colleagues265 (of FP 200 µg twice daily versus BUD
400 µg once daily versus BUD 200 µg twice daily)
were in a treatment setting which is highly relevant
to this technology review, but both are over
10 years old. In addition to only reporting average
cost-effectiveness ratios (cost per “successfully
treated week/day” with each treatment), they also
suffer from other important methodological
limitations, such as the very short time horizon of
8 weeks, omitting the non-medication care costs of
treating exacerbations and not being based on
RCTs.
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economic evaluations
In summary, only the economic evaluation by
Briggs and colleagues254 comparing FP/SAL 
with FP at various dose levels is sufficiently recent
and potentially relevant to the decision problem 
of this assessment. That is, it is from a UK 
health system perspective, involves two of the
Economic analyses
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TABLE 72 Published economic evaluations from a UK NHS perspective
Study Analysis  Recruitment/model,  Source of  Comparison, daily doses ICERa
year setting effectiveness
data
Andersson et al.,  1999 Not reported 1-year results of  (Separate inhalers) £2.86 per 
2001252 a 9-country RCT BUD 200 µg/FF 24 µg vs  SFD
(FACET study) BUD 200 µg
(Separate inhalers) £4.06 per 
BUD 800 µg/FF 24 µg vs  SFD
BUD 800 µg
Booth et al.,  1995 57 general practices  UK-based 8-week  BUD 800 µg vs  Not reported
1995253 in the UK RCT, of people  FP 400 µg
with no or low ICS
Briggs et al.,  2003–04 GP and hospital clinics 1-year results of a  Combination inhaler of  £7600 per 
2006254 44 country RCT FP (100 or 250 or  QALY
(GOAL study) 500 µg) + SAL 50 µg vs  (95% CI 
FP 100 or 250 or 500 µg £4800  to 
(previously no ICS) £10,700)
Combination inhaler of FP  £11,000 per 
(100 or 250 or 500 µg)/ QALY
SAL 50 µg vs FP 100 or  (95% CI 
250 or 500 µg (previously  £8600 to 
on low-dose ICS) £14,600)
Combination inhaler of FP  £13,700 per 
(100 or 250 or 500 µg)/ QALY
SAL 50 µg vs FP 100 or  (95% CI 
250 or 500 µg (previously  £11,000 to 
on moderate dose ICS) £18,300)
Price and Briggs,  2000 Trial: US treatment  12-week efficacy  Combination inhaler of  £20.83 per 
2002263 ‘centres’ and safety RCT in  FP/SAL 200/50 µg vs FP  successfully 
Model: health system  42 US ‘centres’ 200 µg controlled 
perspective week
(95% CI 
£–65b to
£113 per
successfully
controlled
week)
Venables et al.,  1996 General practices in  UK-based 8-week  BUD 400 µg vs BUD  Not reported
1996265 the UK RCT, of people  200 µg vs FP 200 µg
with no or low 
ICS – which 
showed no 
significant 
differences in any 
outcome
a All these ICERs are undiscounted and for ICS plus LABA compared with ICS alone.
b Negative because FP/SAL dominates FP .
Using same exchange rate as used in the published paper, of €1 = £0.613.relevant comparators and expresses effectiveness
in terms of HRQoL (and QALYs). Although there
are limitations of this study (see above), the
analysis appears to have been carried out, and is
mostly reported, according to currently accepted
standards of good practice for economic
evaluations. It also usefully defines subgroups 
on the basis of their previous level of use of ICS.
On the basis of ICER estimates ranging from
£4800 to £18,300 per QALY gained, they
concluded that achieving optimal asthma control
via a combination of FP and SAL would be a 
cost-effective use of NHS resources for people 
at all three levels of previous ICS usage 
(according to current levels of willingness to pay
for a QALY, as indicated by NICE decision-
making). However, their analysis pooled
effectiveness and resource use data from patients
in 44 countries. Although the multivariate
statistical analysis employed claims to have partly
adjusted for UK-specific factors, the
generalisability of the cost-effectiveness results to a
UK, dominantly primary care, treatment setting
may still be limited.
Review of cost-effectiveness
studies provided by industry
Seven submissions to NICE included CEA. Two of
these included CEA and five included CMA.
Submissions were made by GSK, AZ, Altana
Pharma, Meda Pharmaceuticals, Ivax
Pharmaceuticals and Trinity-Chiesi
Pharmaceuticals. Table 73 shows a summary of the
submissions received by industry through the
appraisal process. No submissions were received
for the ICS MF.
Below, a review of each of the manufacturers’
submissions (CEA, CMA) is presented. The 
reviews have been assessed using a checklist
suggested for critical appraisal of CEAs by
Drummond and colleagues251 and the
requirements of NICE for submissions on CEA
(reference case) by NICE270 and, where
appropriate, a suggested guideline for good
practice in model-based cost-effectiveness analysis
by Philips and colleagues.271
Review of the submission by
GlaxoSmithKline
Overview
The submission by GSK to NICE includes
economics commentary and CEA to support three
GSK products: BDP (Becotide), FP (Flixotide) and
FP/SAL (Seretide).
The submission includes some commentary on the
clinical equivalence of ICS products and the
presentation of some price estimates. The
submission does not include any CEA for BDP and
FP versus other ICS products, with a CMA
approach assumed due to clinical equivalence
across these products.
The submission is focused on four specific
research questions:
● Q1: For patients taking ICS alone, is FP the
most clinically effective ICS?
● Q2: For patients uncontrolled on ICS alone, is
switching to FP/SAL more clinically effective
than remaining on the same dose or increasing
the dose of ICS alone?
● Q3: Where a LABA and ICS are to be co-
prescribed, is FP/SAL in a combination inhaler
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TABLE 73 Summary of the submissions received from the drug manufacturers through the appraisal process
Manufacturer  Product Generic name Type of inhaler device Type of analysis 
GSK Becotide BDP pMDI CEA
Flixotide FP pMDI/DPI
Seretide FP/SAL
AZ Pulmicort BUD CEA
Symbicort pMDI
BUD/FF DPI
Altana Pharma  Alvesco CIC MDI  CMA
Ivax Pharmaceuticals Qvar BDP pMDI/MDI CMA
Meda Pharmaceuticals Novolizer BUD DPI  CMA
Trinity-Chiesi Pharmaceuticals Clenil Modulite BDP pMDI  CMA
Pulvinalmore clinically effective than FP + SAL
delivered in separate inhalers?
● Q4: In patients where combination therapy is
appropriate, what is the relative clinical
effectiveness of FP/SAL (Seretide) compared
with BUD/FF (Symbicort)?
The submission presents outline detail of a
systematic search of the literature on CEAs for the
treatment of asthma and modelling of asthma.
Appendix 9 of the submission provides
information on this review. The literature is
deemed unhelpful for the current submission and
the submission presents specific CEA, and a
‘generic’ cost-effectiveness model to address cost-
effectiveness in the context of questions 2–4, but
question 1 is not covered further (as above, a CMA
approach is assumed).
Model on cost-effectiveness of Seretide
In the submission, a new model is developed by
GSK to estimate the cost-effectiveness of the
alternative treatment scenarios. Below we outline
the approach taken for the GSK model and
provide an outline review.
The model presented is a simple two-state model
applying effectiveness data on the percentage of
symptom-free days (% SFDs), cost and outcome
data associated with the two health states of
‘symptom-free’ and ‘with symptoms’. The model is
essentially a spreadsheet calculation to estimate
cost-effectiveness from these related data across
alternative treatments. In the model, at a given
point in time, patients are either (1) symptom-free
or (2) with symptoms. Death is not included in the
model (due to an assumption of no differential
effect of treatments). Exacerbations are not
included in the model. The model is not a disease
progression model, and does not involve
transitions between the two health states over
time. The model presents a scenario, showing
occupancy of states “conditional on treatment
choice”, on the basis of a meta-analysis of the %
SFDs at the trial end-point. This end-point is
chosen as it was (1) commonly reported and
considered, (2) based on clinical opinion and (3)
judged to be more appropriate than lung function
for representing patients’ clinical response to
treatment. This reported end-point (% SFDs) was
taken to represent the proportion of time spent in
the symptom-free state (p. 52). The effectiveness
data are taken from a subset of trials reported in
the industry review of clinical effectiveness.
The model is based on a range of assumptions,
including the assumptions that:
● Alternative therapies have the same mortality
profile, and the same toxicity profile (including
long-term effects).
● The differential proportion of time patients
spend in the symptom-free state over their
treatment lifetime would be the same as the
differential proportion observed during the trial
period (even though clinical trials are mainly
12 weeks).
● Trial-based data are generalisable to wider
patient populations.
● There is no difference in effectiveness between
different inhaler devices. Here the submission
cites eight clinical trials to support the
assumption of the equivalence of devices (i.e.
MDI versus DPI; p. 10).
The submission states that the time horizon is
“nominally 1 year, corresponding to the duration
of the GOAL trial used to estimate costs and
utilities” (p. 53). However, given the nature of the
model, it is a ‘snap-shot’ or cross-sectional
approach to estimating CEA.
The model uses health state values of 0.97 for the
‘symptom-free’ health state and 0.85 for the ‘with
symptoms’ health state, a utility decrement of
0.12. These values are cited from the CEA study
for the GOAL RCT reported by Briggs and
colleagues.254 However, this study does not
provide information on the methods used for
estimating utility weights, citing a personal
communication only, for a study mapping AQLQ
to EQ-5D. The model works by placing
proportions of patients (or patient time) in each
health state, according to the effectiveness data,
and calculating QALY differences as the product
of these data [e.g. a 12.29% difference in %SFDs
(low-dose FP/SAL versus FP 200 µg/day) results in
a difference in QALYs between treatments of
0.014748].
Costs are comprised of the mean acquisition costs
for products and an estimate of the annual mean
‘other health service’ costs for symptom-free time
and time with symptoms. The latter ‘other’ cost
excludes primary treatment costs. The cost
estimates used for the health states are based on
data from the GOAL clinical trial, which are
comprised of resource use against secondary care
visits, primary care visits and rescue medication
used. The submission uses a linear regression
model to estimate a mean annual cost, which is
£79.83 for the health state ‘with symptoms’ and
£1.57 for ‘symptom-free’. The cost differences
between alternatives are as per the above example
for QALY differences, with estimated difference in
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difference in SFDs.
The model is developed for use in both adult and
child patient groups, and is arranged around 21
specific cost-effectiveness questions (five for
children, 16 for adults). All costs are reported in
UK£ 2006.
Model/cost-effectiveness results
The CEA is arranged around the comparison of
FP/SAL (at low, medium and high dose) to (1) ICS
alone (at low, medium and high dose), (2) ICS
plus LABA in separate inhalers (at low, medium
and high dose) and (3) BUD/FF (at low, medium
and high dose). The submission reports results for
different product costs and an average product
cost, hence the analysis results in approximately
65 different summary statistics. These are
summarised below.
FP/SAL versus ICS alone
● Low dose: FP/SAL 200 µg/100 µg per day versus
FP 200 µg/day, results in small differences in
incremental cost and QALYs, with an ICER
range of £6350–20,151.
● Medium dose: FP/SAL 500 µg/100 µg versus FP
400/500 µg/day, results in small differences in
incremental cost and QALYs, with an ICER
range of £12,100–24,020.
● High dose: FP/SAL 1000 µg/100 µg versus FP
1000 µg/day, results in small differences in
incremental cost and QALYs, with an ICER
range of £3660–£50,017.
● Low dose versus medium dose: FP/SAL
200 µg/100 µg/day versus FP 400–500 µg/day,
results in small differences in incremental cost
and QALYs, with ‘FP/SAL dominant’ in some
instances; an ICER range of £51–15,997 in
other cases.
● Medium dose versus high dose: FP/SAL
500 µg/100 µg/day versus FP 1000 µg/day,
results in small differences in incremental cost
and QALYs, with an ICER range of “FP/SAL
dominance” to £14,567 per QALY.
FP/SAL combination versus ICS + LABA in
separate components
● Low dose: FP/SAL 200 µg/100 µg/day versus
separate inhalers 200 µg + 100 µg/day (and
BUD + SAL – 400 µg/day), analysis shows
FP/SAL as less costly (range –£80 to –£281), but
with a small loss in utility (–0.0047), resulting in
estimates for separates at ICERs of
£16,519–59,442.
● Medium dose: FP/SAL combination
500 µg/100 µg/day versus separate inhalers
400–500 µg+100 µg/day (and also compared
with BUD + SAL 800–1000 µg/day), analysis
shows FP/SAL as less costly (range –£62 to
–£219), with a small utility gain (0.0044),
resulting in a profile for FP/SAL combination
inhaler dominating separates (comparators).
● High dose: FP/SAL combination
1000 µg/100 µg/day versus separate inhalers
1000 µg + 100 µg/day (and also compared with
BUD + SAL 1600–2000 µg/day), results showed
a varied cost profile (range –£343 to +128),
and a small utility loss for FP/SAL combination
(–0.0005), with separates (comparators)
dominating combination therapy in some cases
(where Seretide has increased cost) and in other
cases the separate products having a very high
ICER in excess of £166,000 per QALY.
FP/SAL (Seretide) versus BUD/FF (Symbicort)
In these analyses, CEA is only undertaken for one
of the scenarios, with the submission stating “data
not available” for the other scenarios/analyses.
Cost savings are estimated for those scenarios
without CEA:
● Low dose: FP/SAL 200 µg/100 µg/day versus
BUD/FF 400 µg/100 µg/day: no CEA (estimated
cost saving –£22 to –£183).
● Low dose: FP/SAL 200 µg/100 µg versus
BUD/FF 400 µg/200 µg/day: no CEA (estimated
cost –£11 to + £149).
● Medium dose versus high dose: FP/SAL
500 µg/100 µg/day versus BUD/FF
800 µg/100 µg/day: no CEA (estimated cost
saving –£357).
● Medium dose versus low dose: FP/SAL
500 µg/100 µg/day versus BUD/FF
800 µg/200 µg/day: CEA: FP/SAL stated to
dominate BUD/FF [small cost saving and very
small utility gain (0.0005)].
● Medium dose versus low dose: FP/SAL MD
500 µg/100 µg/day versus BUD/FF
800 µg/400 µg/day: no CEA (estimated cost
saving –£18).
● High dose versus low dose: fluticasone/SAL
1000 µg/100 µg/day versus BUD/FF
1600 µg/200 µg/day: no CEA (estimated cost
saving –£164 to –£427).
● High dose versus low dose: FP/SAL
1000 µg/100 µg/day versus BUD/FF
1600 µg/400 µg/day: no CEA (estimated cost
saving –£168 to –£431).
A number of factors are taken into account in the
analysis (e.g. dose, price), resulting in a range of
cost-effectiveness results. The TAR team suggest
that policy makers should take note of the specific
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of results. For example, where FP/SAL is said to be
dominant compared with BUD/FF, this is based on
a very small QALY gain (0.0005).
Appraisal of the cost-effectiveness analysis
undertaken
A critical appraisal checklist is given in Tables 74
and NICE reference case requirements in 
Table 75.
Review of modelling approach
Model structure/structural assumptions
The model structure is based around the clinical
end-point of difference in the % SFDs, and this is
assumed, in the submission, to be a reasonable
reflection of relative treatment effectiveness. This
may not be the case, with it reflecting only part of
the effectiveness profile of asthma treatments.
Other important elements of asthma control
include night-time disturbances [and data
Economic analyses
170
TABLE 74 Critical appraisal checklist of economic evaluation by GSK
Item Critical appraisal Reviewer comment
Is there a well- Yes 4 clinical questions stated (3 of which covered in CEA)
defined question?
Is there a clear description  Yes FP/SAL versus comparators (various options stated)
of alternatives?
Has the correct patient  Partial
group/population of 
interest been clearly stated?
Is the correct  Yes Other comparators could also be appropriate
comparator used?
Is the study type  Yes CEA model used (CUA results presented)
reasonable?
Is the perspective of  Yes Perspective stated as UK NHS
the analysis clearly stated?
Is the perspective  Partial  Submission appears to adopt a UK NHS and PSS perspective for costs 
employed appropriate? Cost: yes (consistent with NICE reference case). Perspective on outcomes is 
Outcomes: partial that of the patient, but not all effects are considered
Is effectiveness of the  Yes The CEA is based on clinical effectiveness data from a small number 
intervention established? of trials reporting the chosen economic end-point (% SFDs) – mainly
over 12 weeks. Although the study demonstrates effectiveness over
this one end-point, it does not discuss, in the context of CEA, the
other effectiveness end-points across treatments. The study assumes
that differences seen in trials can be generalised to the lifetime
treatment period
Has a lifetime horizon  No Nominal 1-year time horizon used (not lifetime)
been used for analysis  ICERS are based on 1-year cost and QALY differences
(has a shorter horizon 
been justified)?
Are the costs and  Partial  Costs appear to be consistent with perspective employed, but limited 
consequences information/justification  provided
consistent with the 
perspective employed?a
Is differential timing  No Nominal 1-year time frame used
considered?
Is incremental analysis  Yes
performed?
Is sensitivity analysis  Yes Yes, sensitivity analysis is undertaken; probabilistic analysis
undertaken and  No scenario analyses undertaken to consider different mean input 
presented clearly? parameters
PSS, Personal Social Services.
a More on data inputs for costs and consequences is given in the review of modelling methods below.presented in the submission indicate that
differences between percentage of symptom-free
nights (% SFNs) may be smaller than % SFDs],
lung function and exacerbations. The model
presented does not capture these items (at least
directly). The model structure used is said to be
based on the CEA for the GOAL clinical trial
presented by Briggs and colleagues;254 however,
the model differs from the approach of Briggs and
colleagues in a number of ways (e.g. importantly
Briggs and colleagues use patient-level data to
derive transition probabilities, their study uses a
composite measure of asthma control, and their
study captures exacerbations). The GSK model
estimates of cost-effectiveness are simple
spreadsheet calculations combining data on %
SFDs and data estimated for relative costs and
QALYs for patients in the health states used. The
model uses a two-state approach covering time in a
symptom-free state and time with symptoms. This
is a simplification of the disease process for
asthma, and is said to be driven by the availability
of data for comparative purposes, and on a review
of the general literature on modelling asthma
treatment. However, it may be that the end-point
chosen is more favourable for comparison of
FP/SAL (Seretide) with other alternative strategies.
For example, the effect of FP/SAL will be more
immediate on SFDs than it will be from ICS alone
(where impact will be felt over time). No discussion
of other outcomes, in the context of the CEA, is
provided in the discussing of model structure,
although there is brief coverage over the potential
use of lung function as an alternative approach.
When considering the above points, it is important
to acknowledge that the literature on modelling
cost-effectiveness in asthma treatment is sparse,
and although there are guidelines for the
treatment of asthma (e.g. the BTS/SIGN
Guideline1), it is generally difficult (given the
current evidence base) to structure and populate a
model which is driven by such guidelines.
Data inputs
The primary data inputs for effectiveness, costs
and outcomes are presented in the submission. In
the analysis, there is a lack of transparency in the
calculations for ‘other costs’. There are concerns
with the methods used to identify and measure the
‘other costs’ associated with the CEA. Data used
on resource for ‘other costs’ are taken from the
GOAL trial by Bateman and colleagues,234 but the
specific data used are not presented in the
submission. Furthermore, the generalisability of
this study (a multi-national RCT, covering 44
countries) to the current analysis is not discussed.
The GOAL CEA used data on resource use from
all 44 countries in the trial, using a UK indicator
variable in the analysis presented. However, this
issue is not discussed in the context of the current
analysis. Unit costs for the resource use are taken
from appropriate data sources. The submission
uses a regression model to estimate other costs,
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TABLE 75 NICE reference case requirements – GSK submission
NICE reference case requirement Critical  Reviewer comment
appraisal
Decision problem: as per the scope developed by NICE  Partial
(especially technologies and patient group)
Comparator: alternative therapies routinely used in the UK NHS Yes
Perspective on costs: NHS and PSS Yes
Perspective on outcomes: All health effects on individuals No Only SFDs were used to consider
QALY values
Type of economic evaluation: CEA Yes
Synthesis of evidence on outcomes: based on a systematic review Yes
Measure of health benefits: QALYs Yes
Description of health states for QALY calculations: use of a  Unclear Method for estimating health state 
standardised and validated generic instrument utilities is unclear
Method of preference elicitation for health state values:  Unclear Method of preference elicitation is 
choice-based method (e.g. TTO, SG, not rating scale) not reported
Source of preference data: representative sample of the UK public Unclear
Discount rate: 3.5% per year for costs and health effects NA
NA, not applicable; PSS, Personal Social Services; SG, standard gamble; TTO, time trade-off.based on an expected cost per week of £1.53 for
people with asthma symptoms, a mean annual cost
of £79.83. Where people with asthma are
symptom-free, this is reduced to £0.03, a mean
annual cost of £1.57. These cost estimates appear
to be very low and the submission does not offer
the opportunity to consider the appropriateness of
the resource use to the UK treatment group. The
submission has referred to the economic
evaluation undertaken alongside the GOAL
trial;254 however, the publication for that
particular evaluation does not offer detail on
resource use. The regression analysis employed in
the submission differs from that presented by
Briggs and colleagues.254
The cost for FP/SAL (Seretide) is based on its
availability in two different inhaler devices
(Accuhaler and Evohaler), with both prices from
the Drug Tariff, together with an average price,
used to generate a range of data on cost-
effectiveness. A drug ‘cost per day’ is estimated for
all treatment options. For example, in the model
the estimated costs per day for FP/SAL (Seretide)
200/100 via Accuhaler, FP/SAL 200/100 via
Evohaler and the average cost per day for these
are set at £1.04, £0.60 and £0.79, respectively. For
BUD/FF 400 (200/6), and ICS 400–500 (FP), the
daily costs are estimated at £0.63 and £0.62,
respectively. There are a range of approaches that
can be taken to estimate daily costs, and the
approach taken in the submission appears
reasonable for the current analysis (Appendix 10
of the submission presents the methods used).
There is a lack of transparency over the
calculation of health state utilities used in the
model (with a citation to a personal
communication). The general literature available
to inform on health state values for asthma is
sparse and undeveloped, and although the values
used for symptom-free in the analysis seem
relatively high (compared with some general
population age-related values), the important issue
is the incremental difference (0.12) used between
health state with symptoms and symptom-free.
The effectiveness data used in the CEA are from a
limited number of available trials, and this is
justified in the submission on the basis of a lack of
consistency in the reporting of common outcomes
across relevant trials. The use of these limited data
may introduce bias to the estimates used, but this
has not been discussed or considered in the
sensitivity analysis. The effectiveness data from the
trials are assumed to be generalisable to the
treatment group in England and Wales that are
the focus of policy analysis. In addition, the
treatment effect from short-term trials (mainly
12 weeks) is assumed to be appropriate over
longer periods (e.g. 1 year).
The meta-analysis reported in the analysis, to
inform the CEA, presents the trials used according
to the research question addressed. Where FP/SAL
is compared with same dose ICS, six trials from a
possible 14 are used (three trials applied to each
of three separate dosing options). Where FP/SAL
is compared with increased dose ICS, three from a
possible six trials present data on % SFDs, but
only two of these trials could be used in the CEA.
Where FP/SAL is compared with ICS + LABA
separates, there is one trial to inform each of the
three possible dosing regimens. Only one trial is
used (from two presented in the clinical review) to
consider the effect of FP/SAL versus BUD/FF.
Assessment of uncertainty
Uncertainty in the analyses is addressed using
probabilistic sensitivity analysis (PSA). The PSA
considered parameter uncertainty for mean
treatment effect and for ‘other cost’ and utility
model inputs. The report submitted does not
present discussion on results of the PSA
(additional material was submitted, providing a
cost-effectiveness plane and cost-effectiveness
acceptability curve for each of the 80+ analyses
undertaken). Additionally, the report does not
present any deterministic sensitivity analysis, or
address structural uncertainties via sensitivity
analyses. Heterogeneity of the treatment group
has not been considered against any defined
subgroups.
Model validation
The submission states that checks were undertaken
to consider the validity of the model, with a
rebuild undertaken using a different software
package. This presents evidence of the internal
consistency (logic) of the model structure and data
structure used.
Summary of general concerns
● The focus on % SFDs as a measure of asthma
control and treatment effect may be limited and
may not capture other important aspects of
asthma control and/or effectiveness data (e.g.
around exacerbations, quality of life).
● The use of a limited evidence base to populate
the model (e.g. small number of trials used to
derive effectiveness estimates).
● Assumptions over generalisability of trial data
and extrapolation of treatment effect are not
discussed.
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used for ‘other costs’.
● Concerns over the lack of transparency in
estimating health state utilities and other cost
estimates.
Review of the submission by 
Astra-Zeneca
Overview
The submission by AZ to NICE includes an
economic commentary and CEA to support two
AZ products: BUD (Pulmicort) and BUD/FF in
combination (Symbicort).
The submission includes some commentary on the
clinical equivalence of BUD with other ICS
products and the presentation of some price
estimates. The submission does not include any
CEA for BUD versus other ICS products. The
submission states that BUD is the most extensively
used ICS, and that “Pulmicort (budesonide) costs
are well within the normal range of costs for
maintenance asthma treatments with any ICS”
(p. 32). There is limited discussion of the relative
cost-effectiveness of different ICS products, with a
CMA approach assumed due to clinical
equivalence across these products.
The CEA presented in the submission is to
support the use of BUD/FF. The submission refers
to BUD/FF FD, BUD/FF AMD, and BUD/FF as
both main maintenance and reliever therapy
(SMART). The submission used BUD/FF FD as the
base case for CEA, working on the basis that
BUD/FF AMD and SMART have been shown to be
superior to BUD/FF FD. The submission compares
BUD/FF (covering the three BUD/FF dosing
regimens of FD, AMD and SMART) with the use
of ICS alone (high-dose FP), BUD + FF in
separate format and with FP/SAL (Seretide; GSK
combination product).
The submission consists of a brief discussion on
the literature (covering CEAs and modelling
studies) and the presentation of the methods and
results for a cost-effectiveness model developed for
the submission to NICE.
A literature search is reported covering CEAs on
BUD/FF. This search identified nine studies, all of
which are stated to show BUD/FF AMD or SMART
at an equivalent or increased efficacy compared
with BUD/FF FD (four studies), separates (three
studies), FP (high-dose ICS) (one study) or FP/SAL
(one study). All except one of these identified
studies is said to show cost savings from use of
BUD/FF.
Model on cost-effectiveness of BUD/FF
(Symbicort)
The submission reports a literature search to
consider modelling studies relevant for the
economic evaluation of asthma treatments. This
identified nine studies. There is no discussion
presented on these studies, other than that the
study published by Price and Briggs263 is reported
to be the most appropriate approach for CEA
considering the use of BUD/FF in UK practice.
Although the submission states that the approach
presented by Price and Briggs263 is the most
appropriate for the analysis of BUD/FF, it is also
stated to have a number of limitations and a new
model is developed by AZ for their submission.
Below we outline the approach taken for the new
model and provide an outline review of the
submission.
The model is developed to capture the difference
in exacerbations between comparisons and the
difference in time spent in a non-exacerbation
health state. It is a Markov-type model with four
health states: non-exacerbation, mild exacerbation,
severe exacerbation and treatment change. The last
state is an absorbing state which reflects withdrawal
from the treatment allocated. Where patients
withdraw from treatment (undergo treatment
change), they are subject to a second-line treatment
regimen and are modelled in a parallel process to
the main (first-line) model. When treatment is
changed, it is in line with recommendations in the
BTS/SIGN Guideline. The model uses a cycle of
4 weeks and has a time horizon of 1 year, with a 
5-year time horizon considered in a sensitivity
analysis. The model uses transition probabilities
derived from individual level patient data from a
UK clinical trial of a 12-week duration that
compared BUD/FF FD with BUD/FF AMD, (cited:
Ind and colleagues, 2004, unpublished AZ data).
The data on the relative effects of comparator
products (RRs for severe exacerbation, mild
exacerbation and treatment change) were derived
from unpublished clinical trial data for
comparators (data are not presented; they are
unpublished academic-in-confidence). Patient-level
trial data (over 12 weeks) allow the use of different
transition probabilities for BUD/FF over months
1–3, and thereafter a constant transit probability
matrix is used based on events occurring during
months 1–3. Analysis is presented for an asthma
treatment group aged 12 years and above. In the
model, all persons start in the ‘non-exacerbation’
(controlled) health state. The perspective of the
analysis is stated as UK NHS and PSS. Prices for
asthma treatment are at a 2005–6 price year.
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on EQ-5D tariff values. Health state descriptions
covering the health states used were collected from
a sample of asthma patients, and EQ-5D tariff
values for these states were used (the submission
cites Kind and colleagues, 1999).316
A monthly cost is applied in the model based on
asthma medication cost and health service
consultations and hospitalisations. Primary care
NHS resource use (consultations) are assumed to
be the same for each of the treatment options, and
are not included in the model.
The model assumes that exacerbations affect costs
and utilities for 1 week only, with the remaining 
3 weeks in that cycle based on non-exacerbation
status.
Model/cost-effectiveness results
The submission presents summary results for
outcomes and costs separately, in Tables 9 and 10,
respectively, and in an incremental analysis in
Table 11.
The submission presents results indicating that
over a 12-month period BUD/FF FD resulted in
very small incremental QALY gains, and
prevented more exacerbations than both ICS
alone and FP/SAL. Equivalence in effect was
assumed when compared to ICS plus LABA
separates. Over a 12-month period BUD/FF FD is
reported to have a lower total cost than FP/SAL
(cost saving of –£8185 per 1000 persons).
However, ICS alone is a lower cost compared to
BUD/FF FD (with ICS alone showing a cost
advantage of £245,152 per 1000 persons).
In the CEA results (Table 11), BUD/FF FD is
stated to dominate FP/SAL and to result in an
additional cost per QALY of £40,234 when
compared with ICS alone.
In the opinion of the TAR team, the differences in
QALY gains for all comparisons are very small when
considered at the level of the mean patient benefit
(e.g. 0.00037 when BUD/FF is compared with
FP/SAL), and the mean cost difference per patient is
also very small for comparisons with BUD/FF and
FP/SAL and ICS plus LABA as separates. It would
appear that any comparison rests on the
incremental costs and benefits associated with
exacerbations. The use of ‘non-exacerbation
months’ as an outcome will rest on the relative
importance that is placed on mild exacerbations, as
these are more frequent than severe exacerbations
(roughly twice as frequent) other than for FP/SAL.
Although AZ state that BUD/FF dominates FP/SAL
the TAR team would suggest that the difference
between the two treatments, which is of interest, is
the lower number of exacerbations predicted for
BUD/FF versus FP/SAL (per 1000 patients: BUD/FF
had 60.19 fewer severe exacerbations, with an
additional 10.28 mild exacerbations), with these
differences being small at the mean patient level.
Appraisal of the cost-effectiveness analysis
undertaken
A critical appraisal checklist is given in Table 76
and NICE reference case requirements in Table 77.
Review of modelling approach
Model structure/structural assumptions
The model structure is driven by the use of
exacerbation data, and the characterisation of a
‘non-exacerbation’ health state, using clinical trial
data. The non-exacerbation health state is made
up of patients who are without symptoms and
those patients with symptoms but not requiring
any intervention from a healthcare professional.
Mild exacerbation is defined as an exacerbation
requiring primary care intervention, including
oral corticosteroids if appropriate, but no
secondary care intervention. Severe exacerbation
(model state) is defined as an exacerbation
requiring secondary care intervention, including
hospital stay if appropriate.
Trial data have been used to estimate the
transition probabilities between these states (and
treatment change), but it is unclear how data may
have been interpreted from different clinical trials,
where methods may not have been homogeneous.
For the non-exacerbation state the correlation with
trial data is around controlled and symptom-free
days. As BUD/FF is marketed at a sub-maximal
dose with patients potentially able to use it as both
SABA and LABA, it is important to acknowledge
that the non-exacerbation state used in the model
is a combination of time with and without SABA
rescue medication. Definitions for mild and severe
exacerbations do not rely on use of SABA
medication. Trial data for frequency of mild
exacerbations are based on the use of oral
corticosteroids. For severe exacerbations the
frequency of events in the trials used is based on
exacerbations requiring hospitalisation or A&E
visit. Many of the data to inform the model
transitions have been taken from a limited
evidence base, with citations to unpublished data
on file at AZ.
The model structure is not discussed and justified
in the context of a coherent theory of asthma, and
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availability of data surrounding exacerbations for
BUD/FF and comparators. It may be that AZ have
adopted this approach due to the more positive
profile of BUD/FF (against exacerbation rates),
when the use of an outcome related more directly
to control, such as % SFDs, may have seemed
more favourable for comparator products (e.g.
FP/SAL). The submission indicates that a review of
published modelling studies was undertaken, but
no discussion is presented on alternative
approaches. Given the prominence in the clinical
and economic literature of outcome measures/data
around lung function and symptoms, it would
have been useful for some discussion of 
competing approaches for the modelling of
asthma treatment and cost-effectiveness to have
been presented.
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TABLE 76 Critical appraisal checklist of economic evaluation by AZ
Item Critical appraisal Reviewer comment
Is there a well-defined  Yes
question?
Is there a clear description  Yes BUD/FF versus comparators (various options stated)
of alternatives?
Has the correct patient  Partial Adult patients aged 12 years and over
group/population of  All patients in model start in non-exacerbation state (this may not be 
interest been clearly stated? the case in practice, with a proportion of patients being in an
‘uncontrolled’ asthma state)
Is the correct comparator  Partial Comparators used are all appropriate; however, other additional 
used? comparators could also be used
Is the study type reasonable? Yes CEA model used (CUA results presented)
Is the perspective of the  Yes Perspective stated as UK NHS and PSS
analysis clearly stated?
Is the perspective  Costs: yes Submission appears to adopt a UK NHS and PSS perspective for costs 
employed appropriate? Outcomes: partial  (consistent with NICE reference case)
Perspective on outcomes is that of the patient, but not all effects
considered (focus on ‘non-exacerbation’ state)
Is effectiveness of the  Partial The CEA is based on clinical effectiveness data from a limited number 
intervention established? of trials reporting the chosen economic end-point (exacerbation
related outcomes) – mainly over 12 weeks. Primary effectiveness data
(for BUD/FF transition probabilities) from only one UK RCT. The
study assumes that differences seen in trials can be generalised to the
lifetime treatment period
Has a lifetime horizon  No 1-year time horizon used (not lifetime)
been used for analysis (has  ICERS are based on 1-year cost and QALY differences
a shorter horizon been  5-year horizon in sensitivity analysis
justified)?
Are the costs and  Partial Costs appear to be consistent with perspective employed, but limited 
consequences consistent  justification provided, and may not include all relevant costs (e.g. 
with the perspective  primary care not included)
employed?a Consequences limited to exacerbations and non-exacerbation
months. Interpretation of non-exacerbation state from limited clinical
evidence
Is differential timing  No 1-year time frame used – no discounting. (In sensitivity analysis 3.5% 
considered? discount rate used)
Is incremental analysis  Yes
performed?
Is sensitivity analysis  Yes Yes sensitivity analysis is undertaken, probabilistic analysis.
undertaken and presented 
clearly?
a More on data inputs for costs and consequences is given in the review of modelling methods, p. 174.The model places emphasis on exacerbations and
exacerbation status (as a measure of control). The
assumption in the model is that exacerbations
affect utilities and costs for 1 week only.
Although not stated in the submission, the model
assumes the same toxicity profile for treatments
and the same profile for any longer term AEs.
The cycle length and time horizon are justified on
the basis of data available and an assumption that
mortality rates (longer term outcomes) are similar
across comparison treatments. Both of these
assumptions seem reasonable. However, treatment
effect is based primarily on 12-week trial data
(ASSURE trial), and the submission does not
discuss the assumption that this treatment effect is
assumed to continue for the period of the model
(1 year in base case), nor the generalisability of
the trial data (importantly that from the BUD/FF
trial used for transition probabilities) to the
broader treatment population.
There is also no statement in the submission on the
evaluation of the internal consistency of the model.
When making/considering the above points, it is
important to acknowledge that the literature on
modelling cost-effectiveness in asthma treatment is
indeed sparse, and although there are guidelines
for the treatment of asthma (e.g. the BTS/SIGN
Guideline1), it is generally difficult (given the
current evidence base) to set up a model which is
consistent with such guidelines.
Data inputs
The primary data inputs for effectiveness, costs
and outcomes are presented in the submission. For
effectiveness data, as above, the transition
probabilities are estimated from a limited evidence
base (BUD/FF FD arm of one RCT), and there is a
lack of transparency over the calculation of relative
treatment effect for comparator products.
Medication costs are based on trial data for the
number of inhalations per day and drug costs
from the Drug Tariff or eMIMs, and a weighted
average cost per inhalation was estimated across
the various drug formulations. Data on other costs
are presented clearly and, although including a
number of assumptions, appear reasonable. The
estimated cost for managing a mild exacerbation
was £50.42. The estimated cost for the
management of a severe exacerbation ranged
between £334 and £1752 (dependent on need for
hospitalisation).
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TABLE 77 NICE reference case requirements – AZ submission
NICE reference case requirement Critical  Reviewer comment
appraisal
Decision problem: as per the scope developed by NICE (especially  Yes
technologies and patient group)
Comparator: alternative therapies routinely used in the UK NHS Yes
Perspective on costs: NHS and PSS Yes
Perspective on outcomes: all health effects on individuals Partial Health effects partly limited to
effect of treatment on
exacerbation rate
Type of economic evaluation: CEA Yes
Synthesis of evidence on outcomes: based on a systematic review Yes
Measure of health benefits: QALYs Yes
Description of health states for QALY calculations: use of a  Yes
standardised and validated generic instrument
Method of preference elicitation for health state values:  Partial Method of preference elicitation is 
choice-based method (e.g. TTO, SG, not rating scale). explicit but a rating scale was used
Source of preference data: representative sample of the UK public Yes
Discount rate: 3.5% per year for costs and health effects NA Base case is 1-year analysis, no
discounting necessary. Sensitivity
analysis at 5 years, with 3.5% rate
used for costs and effects
NA, not applicable; SG, standard gamble; TTO, time trade-off.Although there may be some methodological
limitations with the health state utility study (as
with all studies of this nature) presented to inform
the mode, data on health state utilities are
consistent with the preferred approach of NICE,
and commercial in-confidence data are provided
to support this area of the model. The general
literature available to inform on health state values
for asthma is sparse and undeveloped.
Assessment of uncertainty
Uncertainty is addressed in the submission using
deterministic sensitivity analysis and PSA. PSA has
addressed parameter uncertainty in a number of
cases, (number of inhalations, utility values,
transition probabilities, RRs). However, although
the choice of distributions would seem to follow
accepted methods, in many cases the uncertainty
around parameter inputs is very small, with SEs
(around the mean) being very small [e.g. for
number of inhalations at 3.85, SE = 0.003; health
utility for non-exacerbation (without SABA) at
0.927, with SE at 0.016]. The report refers to the
use of probabilistic methods for transition
probabilities; however, it is unclear how the
probabilities were sampled (either rescaled to sum
to 1.00, or via some correlation matrix; the
submission states “normalised to give a sum of
one”, p. 99).
The assessment of uncertainty does not address
any issue of heterogeneity in the treatment group,
and certain structural and methodological
uncertainties are not addressed in the sensitivity
analysis (e.g. impact of exacerbations on 
patients).
The deterministic analysis presented indicates very
large changes in the cost per QALY results when
assumptions over the proportion of time without
SABA used are considered, and these results could
have been further explained, with a breakdown of
costs and consequences for these analyses (i.e. it
may be an issue related to very small incremental
costs and effects, or a more substantive effect in
analyses).
Summary of general comments on the
submission:
● The focus on exacerbations (rate) and non-
exacerbation defined control status may not
capture other important aspects of asthma
control and/or effectiveness data.
● There is the use of a limited evidence base to
populate the model, that is, the arm of one
RCT used to estimate the transition
probabilities for BUD/FF.
● There is a lack of transparency over the
estimation of relative treatment effect
(unpublished, ‘in-confidence’ data cited).
● There are a number of assumptions made over
the generalisability of the trial data, and issues
around the extrapolation of treatment effect are
not discussed.
Review of the submission by Altana
Pharma 
Overview 
The submission by Altana Pharma to NICE
includes economic analysis comprising a CMA
comparing CIC (Alvesco) versus FP (dose ratio
1:1), BDP (dose ratio 1:2) and BUD (dose ratio
1:2) within a UK context. The submission presents
a discussion on the clinical effectiveness data
available (some being commercial-in-confidence
data on file at Altana) to compare CIC with FP,
beclomethasone and BUD, and concludes that
CIC 160 µg once daily will be of comparable
clinical effectiveness to FP100 µg twice daily, BUD
200 µg twice daily and BDP 200 µg twice daily.
The submission also concludes that CIC 160 µg/day
will have a potentially lower overall cost to the UK
NHS and PSS budget. The annual drug cost for
patients prescribed CIC 160 µg/day daily is
estimated at £102.20. This cost is compared with
estimates of £73–219 for FP 200 µg/day, £73–138.70
for BUD 400 µg/day and £14–146 for BDP
400 µg/day. Drug costs are estimated based on prices
listed in the BNF (March 2006). The submission
states that in the majority of cases where costs for
comparators are lower than CIC 160 µg/day, they
are based on products that use CFC propellants
which will soon become obsolete (2007).272,273 In
Table 10 in the submission appendices, a range of
CFC-free products are listed for comparison; in five
of the 16 CFC-free comparisons the estimated cost
per year is lower than that presented for CIC. Costs
other than medication costs are assumed to be
constant across patients (regardless of the
comparator ICS) and these costs are not discussed
further in the submission.
The methodological rigour of the systematic
review methods used to identify and review the
clinical effectiveness data presented is open to
some bias. The methods are not clear in all cases,
and the search strategy is limited. Likewise, the
methods used to estimate and compare costs are
not comprehensive, and there are a number of
assumptions of resource use profiles.
In a cost analysis, CIC 160 µg/day is also compared
with the combination therapies of FP/SAL and
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160 µg/day is estimated to cost £8.40 per month,
with comparator doses of FP/SAL and BUD/FF at
£31.19 and £19 per month, respectively. However,
no discussion is presented on the clinical
effectiveness of CIC versus combination therapies.
Review of the submission by Ivax
Pharmaceuticals
Overview
The submission by Ivax Pharmaceuticals to NICE
includes a review of clinical effectiveness studies
and a review of existing cost-effectiveness studies
which compare a specific HFA-propelled BDP
product (Qvar) with a range of alternative ICS
products (BDP, HFA-propelled FP and BUD via
Turbuhaler). Three of the published cost-
effectiveness analyses are from a UK NHS
perspective, and the submission does not present
any CEAs in addition to these.
Review of CEAs of Qvar
The review of the cost-effectiveness of Qvar
summarises the results of three trial-based studies
which compared Qvar with other ICS preparations
from a UK NHS perspective:
1. BDP – published in 2002 (by Price and
colleagues274)
2. HFA-propelled FP – ERS conference poster
presentation only.
3. BUD via Turbuhaler – ERS conference poster
presentation only.
Table 78 summarises the main design features of
these analyses. None include estimation of the
longer term cost per QALY of using Qvar in place
of other ICS preparations. Limited sensitivity
analyses were also presented.
Cost-effectiveness results
The cost-effectiveness results of the studies
summarised in the submission are given in 
Table 79.
These cost-effectiveness results should be treated
with caution because they use resource use data
from a number of countries other than the UK,
where standard clinical care for people with
asthma may differ.
Review of the submission by Meda
Pharmaceuticals
Overview
The submission by Meda Pharmaceuticals to NICE
includes evidence summaries of the Novolizer
BUD (DPI) device’s technical performance,
tolerability and acceptability to patients and also
general discussion of the burden of asthma and
the role of BUD in asthma. The emphasis
throughout their report, including in their CMA,
is on the documented or estimated patient
benefits and NHS savings of the Novolizer device
compared with its main DPI competitor product,
the Pulmicort Turbuhaler. The majority of the
submitted material, and the whole of the
economic analysis, are therefore outside the scope
of the NICE appraisal, which is focused on
comparing different ICS drug compounds with
each other and selected ‘add-on’ therapies, rather
than the different formulations or different
delivery devices with the same compound.
Economic analyses
178
TABLE 78 Cost-effectiveness studies comparing Qvar with other ICS – study designs
Comparator Country, Patients Time Outcomes Costs
setting
BDP International,  n = 473 1 year SFDs Study drugs; other 
multi-centre HRQoL  respiratory drugs; 2 GP 
(AQLQ > 0.5) visits; hospitalisation and
A&E visits
HFA-propelled FP International,  n = 198 8 weeks Change in %  Study drugs; other 
multi-centre Age 18–75 years, SFDs respiratory drugs; 
on  2 GP visits
500–1000 µg/day 
(BDP equivalent)
BUD (Turbohaler) International,  n = 209 8 weeks Change in %  Study drugs; other 
multi-centre Age 18–75 years,  SFDs respiratory drugs; 
on  2 GP visits
500–1000 µg/day 
(BDP equivalent)Nevertheless, the submission does provide further
useful insights into the mediating role of inhaler
devices in the effectiveness of ICS and other
inhaled asthma medications. In particular, better
compliance with medication may result from
devices which are easier to use correctly, and which
also include features which clearly indicate correct
inhaler technique.
For completeness, in Tables 80 and 81 we appraise
the main features of the basic (two-page) economic
evaluation submitted by Meda Pharmaceuticals.
Review of the submission by 
Trinity-Chiesi Pharmaceuticals
Overview of the submission for Clenil Modulite
The submission by Trinity-Chiesi Pharmaceuticals
focuses on the clinical effectiveness and cost of
Clenil Modulite, an HFA-propelled BDP product
for use with pMDIs. The submission includes some
discussion of evidence of the clinical equivalence
of this product and the main CFC-propelled
equivalent products that are licensed for adults and
the presentation of a cost-minimisation comparison
with Qvar (another HFA-propelled BDP product
for use with pMDIs). There is also some discussion
on the changing regulatory environment for these
and related products, specifically the progressive
banning of CFC-propelled asthma medications
under the Montreal Protocol.
The submission is based on a systematic search of
the literature on a range of topics that include
clinical effectiveness, tolerability and safety and
cost-effectiveness of the product. Two equivalence
RCTs of the product relative to a standard CFC-
containing pMDI (Becotide) in adults with mild
and mild-to-moderate persistent asthma are
discussed.
Based on evidence summarised elsewhere in the
submission (three unpublished Phase 3 studies)
the cost-effectiveness section assumes the clinical
equivalence of Clenil Modulite with Becotide,
which is one of the alternative BDP preparations
available for inhalation via pMDI devices. It then
proceeds with a cost comparison between Clenil
Modulite and the only other CFC-free BDP
product that is currently licensed for use in the
UK, Qvar (also via HFA-propelled pMDI).
They used a time horizon of 1 year and calculated
the per patient incremental (NHS) medication
costs of Clenil Modulite compared with Qvar. In
addition to the cost of the drugs, the main cost
saving assumed to derive from switching to Clenil
Modulite is avoiding the need for two therapeutic
reviews, to retitrate and monitor response to new
dosages, when switching to Qvar. However, it
should be noted that this is an analysis of the
short-term benefits during the period when CFC-
containing products are withdrawn from the
market, and additionally comparisons are made
amongst BDP products, and it is therefore outside
the scope of the present review. Below we only
show the results without the assumed savings from
avoided therapeutic reviews.
Cost minimisation results
Table 82 summarises the cost of Clenil Modulite 
(at the four available dose levels) and the cost of
equivalent doses of Qvar. The cost difference
between using the two products, if the dose
equivalence ratio of 2:1 is correct, is negligible.
Overview of the submission for Pulvinal
The submission by Trinity-Chiesi Pharmaceuticals
to NICE focuses on the clinical effectiveness and
cost of the BDP product Pulvinal for use with its
own DPI device.
The submission includes some discussion of
evidence of the claimed clinical benefits of this
product over other DPI products that are licensed
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TABLE 79 Cost-effectiveness studies comparing Qvar with other ICS: base case results
Comparator Costs per patient (£) Effectiveness ICER
BDP Qvar = 226 166 SFDs; 44% of patients  Qvar both slightly cheaper and 
>+0.5 change in AQLQ more effective (more SFDs) than 
CFC–BDP = 231 128 SFDs; 36% of patients  CFC–BDP
>+0.5 change in AQLQ
HFA-propelled FP Qvar = 143 24% increase in SFDs Qvar both cheaper and more 
HFA-propelled FP = 164 18% increase in SFDs effective (greater increase in
SFDs) than comparator
BUD (Turbohaler) Qvar = 174 25% increase in SFDs Qvar both cheaper and more 
BUD = 219 12% increase in SFDs effective (greater increase in
SFDs) than comparatorfor adults, and also summarises some evidence
from published research literature to support the
cost-effectiveness of inhaler devices that are easier
to use or reduce dose wastage.
Analysis of cost of Pulvinal
No economic evaluation is presented in the
submission, but instead the estimated monthly and
annual costs for Pulvinal are compared with other
BDP, BUD and FP dry powder products.
Summary of the cost-effectiveness
submissions made by the manufacturers
Our review of the industry submissions highlights
a number of concerns in relation to providing a
comprehensive and reliable evidence base for
considering the present decision problem.
None of the submissions compared the cost-
effectiveness of all five of the ICS products licensed
for use in adults (and which are the scope for this
assessment). All six submissions presented a CMA
with a general assumption of an equivalent level of
clinical effectiveness across ICS products being
compared. The submissions by Ivax
Pharmaceuticals and Trinity-Chiesi Pharmaceuticals
were both limited to a presentation of the costs of
their respective BDP products, Qvar and Clenil
Modulite, respectively. Likewise, the submissions by
Altana Pharma and Meda Pharmaceuticals were
limited to their products, CIC (Alvesco) and BUD
(Novolizer) respectively.
The submissions by GSK and AZ for the cost-
effectiveness of ICS products were limited to a
CMA. The cost-effectiveness of the products
included in the current appraisal was not
apparent. Moreover, the methods used for
estimating the product costs varied across the
submissions, and were not transparent. This is
particularly pertinent, as most ICS named
preparations are usually sold in a variety of dose
strengths (e.g. 100, 200 or 400 µg per dose).
Therefore, there are usually a number of ways of
achieving any given daily dose of a particular
drug, with the method used to obtain the given
daily dose determining the presented cost of the
drug dose.
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TABLE 80 Critical appraisal checklist of economic evaluation by Meda Pharmaceuticals Ltd.
Item Critical appraisal Reviewer comment
Is there a well-defined question? No Implicitly compare the two device types
Is there a clear description of alternatives? Yes Novolizer (BUD) vs Turbohaler (BUD), both at 
a dose of 400 µg daily (=200 µg b.d.)
Has the correct patient group/population  No Not stated whether these typical doses are 
of interest been clearly stated? assumed to be for adults or children
Is the correct comparator used? No Comparison of devices not a part of NICE scope
Is the study type reasonable? Yes – CMA Assuming that claim of therapeutic equivalence with
Turbohaler is valid
Is the perspective of the analysis  No But implicitly NHS perspective
clearly stated?
Is the perspective employed appropriate? Yes
Is effectiveness of the intervention established? Yes (?) Depending on the quality of RCT by Chuchalin et al. 
Respiration 2002;69(6):502–8
Has a lifetime horizon been used for analysis  No CMA projects 1 year costs
(has a shorter horizon been justified)?
Are the costs consistent with the perspective  Yes Only drug provision costs are included
employed?
Are the consequences consistent with the  NA
perspective employed?
Is differential timing considered? NA
Is incremental analysis performed? Yes Calculates per person annual NHS savings of
switching from Turbohaler to Novolizer
Is sensitivity analysis undertaken and presented  No
clearly?
NA, not applicable.For the combination therapies of Seretide
(FP/SAL; GSK) and Symbicort (BUD/FF; AZ), 
more complex cost-effectiveness models were
presented. However, once again, both of the
models were developed from a product-specific
perspective.
Original economic analyses:
introduction and rationale
The systematic review of economic evaluations in
the section ‘Systematic review of published
economic evaluations’ (p. 161) identified a
number of limitations in the existing research
literature on the relative cost-effectiveness of the
five ICS, BDP, BUD, FP, CIC and MF, used as
monotherapy. The published cost-effectiveness
studies of FP or BUD in combination with LABAs
(SAL or FF) also had some limitations in the UK
NHS policy context, particularly within the
appropriate step of the BTS/SIGN Guideline.1
The CMAs and other cost analyses submitted by
industry mostly provide fairly selective evidence
pertaining to one or two of their own branded
products, as opposed to a broader assessment of
the relative effectiveness and cost-effectiveness 
of a broader range of alternative ICS drugs, 
or the cost-effectiveness of adding a LABA to ICS
under different clinical circumstances. Some also
did not fully meet the NICE reference case
requirements for CEAs (although often this was
partly because of the same lack of clear evidence
of differential effectiveness that we have
encountered).
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TABLE 81 NICE reference case requirements – Meda Pharmaceuticals Ltd submission
NICE reference case requirement Critical appraisal Reviewer comment
Decision problem: as per the scope developed  No Inhaler devices compared, (i.e. not BUD 
by NICE (especially technologies and patient group) with other ICS or ICS + LABAs)
Comparator: alternative therapies routinely used in the  Yes But assessing inhaler devices outside 
UK NHS NICE scope
Perspective on costs: NHS and PSS Yes Implicitly (source of costs = eMIMS)
Perspective on outcomes: all health effects on individuals NA CMA
Type of economic evaluation: CEA No CMA
Adequate time horizon No 1 year
Synthesis of evidence on outcomes: based on a  Yes (?) PubMed search obtained 1 trial; no stated 
systematic review inclusion or exclusion criteria
Measure of health benefits: QALYs NA CMA
Description of health states for QALY calculations:  NA CMA
use of a standardised and validated generic instrument
Method of preference elicitation for health state values:  NA CMA
choice-based method (e.g. TTO, SG, not rating scale)
Source of preference data: representative sample of  NA CMA
the UK public
Evidence on costs: prices relevant to NHS and PSS Yes Inhaler with drug and inhaler refill costs
only
Discount rate: 3.5% per year for costs and health effects No
NA, not applicable.
TABLE 82 Costs of Clenil Modulite and Qvar
Product Annual cost of  Annual cost of  Annual cost of  Annual cost of 
50 g doses (£) 100 g doses (£) 200 g doses (£) 250 g doses (£)
Qvar (at half the dose of Clenil Modulite) 14.13 28.25 61.87 61.87
Clenil Modulite 14.05 28.18 61.43 61.87For these reasons, we decided that it was necessary
to carry out further economic analyses. To address
the project scope and the comparators specified in
the project protocol, and in line with the clinical
effectiveness research questions, we used five cost-
effectiveness research questions which more
accurately express the various decision problems
that are implicit in the context of the BTS/SIGN
Guideline.
The cost-effectiveness research
questions
The two research questions relating to the 
cost-effectiveness of the five ICS as monotherapy
are:
Q1. At low doses (200–800 µg BDP/day or
equivalent), which is the most cost-effective of
the five ICS? (Step 2 of the Guideline).
Q2. At high doses (800–2000 µg BDP/day or
equivalent), which is the most cost-effective of
the five ICS? (Step 4 of the Guideline).
The three research questions relating to the cost-
effective use of ICS plus LABA are:
Q3. (a) Which is the more cost-effective 
approach to introducing a LABA into a
treatment regimen: to increase the dose of
ICS alone or to add a LABA to treatment
with the existing ICS dose? (Steps 2–3 of the
Guideline).
Question 3a is viewed as the more clinically
relevant of the original two sub-questions for
question 3, because if patients become
uncontrolled on a given dose of ICS alone,
staying on the same ICS dose is not a clinical
option; in the context of the BTS/SIGN
Guideline, either the ICS dose will be
increased or a LABA will be added to 
the existing dose of ICS. Although the 
clinical effectiveness literature contains 
some trials in which a LABA was added to 
the ICS treatment regimen without the
included dose of ICS alone being increased,
this sub-question 3b is therefore not
addressed in the cost-effectiveness 
evaluation.
Q4. Which is the more cost-effective treatment:
FP and SAL in a combination inhaler or
given in separate inhalers, and BUD and FF
in a combination inhaler or given in separate
inhalers? 
Q5. Which is the more cost-effective treatment:
FP/SAL in a combination inhaler or BUD/FF
in a combination inhaler? (at Step 3 of the
BTS/SIGN Guideline).
Types of analysis used
Given the lack of consistent evidence of
differential clinical effectiveness for questions 1, 2,
4, and 5, yet the relatively consistent effectiveness
evidence favouring combination inhalers over
increased doses of ICS, we have taken a different
approach to the economic analyses for each
research question. Although the cost-effectiveness
of asthma treatments can be assessed using more
sophisticated modelling approaches, the data
requirements and other challenges involved are
considerable (Appendix 10). For most questions,
the more pragmatic analytical approach used here
inevitably focuses on the relative costs rather than
the cost-effectiveness of the different drug
treatments compared.
For each of the questions, we present one of the
following types of analysis:
1. A cost comparison of the different ICS and ICS
plus LABA preparations (for those questions
where the clinical effectiveness review showed no
consistent evidence of differential effectiveness)
(for research questions 1, 2, 4 and 5).
2. A cost–consequence comparison, to summarise
the overall pattern of effectiveness differences
identified in the systematic review and place
them alongside the estimated current NHS
preventer medication costs for each of the
included trials (for research question 3a).
3. A tentative model-based incremental CUA, to
explore the uncertainty surrounding choices in
asthma drug treatment (particularly, here, the
choice of whether to add a LABA or increase
the ICS dose at Steps 2/3 of the BTS/SIGN
Guideline) (as an exploration of research
question 3a).
As mentioned, the review of the cost-effectiveness
literature on asthma did not identify any studies
whose results were applicable to either the
research questions of interest or the UK context.
Similarly, the limitations of published models of
asthma meant that they were not directly
applicable in the decision problems and policy
context of this review (or they relied on access to
individual patient data from trials). We therefore
developed a new model capable of addressing the
specific research questions outlined previously, in
the context of a UK adult population and the
BTS/SIGN Guideline.1 A brief summary of the
model design, input parameters and main
probabilistic outputs is given in Appendix 10. We
decided not to present the full methods and
results of the final model in the main body of the
report for the following reasons (although the
Economic analyses
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research question):
● a general lack of relevant, good-quality and
consistently reported trial evidence on the
asthma outcomes of interest
● an unavoidable over-reliance on exacerbation
rates as the central driver of transition
probabilities (NB: despite the inadequacy of
other common trial outcomes, such as lung
function or SFDs, as a basis for the CUAs for
this assessment)
● considerable uncertainty surrounding the model
outputs; in particular the sensitivity of central
estimate ICERs to very small changes in
effectiveness and medication cost assumptions
relating to the controlled asthma state.
Two additional literature reviews were undertaken,
mainly to inform the development of the
cost–utility model: one of existing decision models
for assessing treatment in asthma, and one of
studies reporting health state utility values
associated with defined asthma health states.
However, since we have chosen to present only an
abbreviated version of our cost–utility model and
analysis (as Appendix 10), these two reviews are
also presented in Appendices 8 and 9, respectively,
as background to that analysis and as a resource
for future modelling studies in this area.
Original economic analyses
Rationale for cost comparisons
Cost comparisons, like CMAs, should normally be
used when there is valid and reliable evidence of
equivalent effectiveness of the alternative
technologies being compared.251 However, as
previous sections of this report have concluded,
among different ICS for asthma there is little
conclusive evidence of equivalence. More often
instead, there is inconclusive evidence concerning
differential effectiveness.
Performing a cost comparison is not
straightforward, as it is difficult to derive a single
‘representative’ cost figure for each ICS. This is
because each drug is typically available in a range
of named preparations (e.g. from different
manufacturers, or for different inhaler devices),
and also because each named preparation is
usually sold in a variety of dose strengths (e.g. 100,
200 or 400 µg per dose). There can therefore be a
variety of ways of achieving any given daily dose of
a particular drug. This is especially an issue for
the long-established drugs such as BDP and BUD.
In order to generate single cost figures for each
ICS, we have made use of standard assumed ratios
regarding dose equivalence and made some other
simplifying assumptions to allow pooling of cost
estimates. Also, given the likely withdrawal of
CFC-containing products in the near future, we
have calculated these cost estimates both including
and excluding currently available CFC-containing
products (this is an issue for BDP and BUD
preparations only). During the period when 
CFC-containing products are withdrawn from 
sale in the UK, it is likely that the relative 
market shares of different named preparations will
also alter, because many patients will need to
switch between products, new products may
simultaneously enter the market and pack prices
may also change.
Methods for cost comparisons
The mean weighted and unweighted annual cost
of taking each type of ICS, or each
type/combination of ICS with a LABA, is
calculated in several stages.
First, we have calculated the mean annual per
patient cost of taking each specific named
preparation of each drug (or each combination of
drugs), in order to achieve a given level of daily
dosage. For each named preparation, this is
calculated as:
£ per dose × doses per day × No. days in year 
= (BNF £ pack price ÷ doses per pack) ×
(target daily dose + µg BDP–CFC equivalent
per dose) × 365
where ‘BNF £ pack price’ is the specific BNF per
pack price for a specific preparation (e.g. 50, 100,
200, 250 or 400 µg per dose).275 ‘Doses per day’ is
the number of doses of a given preparation
needed to achieve a particular target daily dose
level (e.g. 400 µg/day of BDP–CFC equivalent ICS;
see below).
Assumptions about target daily dosage
For adult patients with asthma, we have chosen to
estimate costs for two ‘low levels’ and one ‘high
level’ of daily dosage of ICS. The low-level dosages
we have costed are:
LDstart: low-dose starting dosage = 400 µg
CFC–BDP (or equivalent) per day
LDmax: low-dose maximum dosage = 800 µg
CFC–BDP (or equivalent) per day 
These equate to, respectively, the recommended
starting dose for adult patients stepping up from
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SABAs (i.e. those changing from Step 1 to Step 2
of the BTS/SIGN Guideline) and the
recommended maximum daily dose of ICS for
adults before an add-on therapy (such as a 
LABA) should be tried (i.e. Step 3, ‘Add-on
therapy’).
For the ‘high-level’ daily dosage we have costed
either 1500 or 1600 µg BDP–CFC (or equivalent)
per day. This is assumed to approximate the
median ICS dose of people being treated at Step 4
of the BTS/SIGN Guideline.
Assumptions about number of doses per day
For simplicity, and unless recommended otherwise
in the BNF, we assumed that the required daily
dose of an ICS was achieved as either one dose
taken twice daily or two doses twice daily. The
base-case assumptions are summarised in 
Table 83.
Assumptions about dose equivalence with
CFC–BDP
In order to compare the cost of alternative ICS
preparations, it is necessary to make some
assumptions about the likely equivalent dose that
would be required if controlled patients were
switching between preparations. Because of product
characteristics related to particle size and mode of
action, the same quantities of different active
ingredients do not achieve the same clinical
effectiveness. For the practical purposes of
informing dosage decisions when switching
patients between ICS products, both the GINA
Guidelines and the BTS/SIGN Guideline publish
ratios of dose equivalence. These are summarised
in Table 84.
It should be noted that these ratios are fairly
crude ‘rules of thumb’, for the main purpose of
aiding doctors in deciding the starting dose of any
new ICS drug when switching between drugs.
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TABLE 83 Base-case assumptions about number of doses per day
Daily dosage (BDP–CFC equivalent) (g) Taken either as Or as
400 100 µga × 4 doses 200 µga × 2 doses
800 200 µga × 4 doses 400 µga × 2 doses
1500 or 1600 250 µga × 6 doses 400 µga × 4 doses
a BDP–CFC or equivalent (see Table 84); except CIC (Alvesco) and MF (Asmanex), which are more usually prescribed as a
single daily dose.
TABLE 84 Base-case assumptions about dose equivalence with CFC–BDP
Drug Equivalent amount of BDP–CFC Ratio used in CMA
BTS/SIGN Guideline GINA Pocket Guide to Asthma
BDP HFA-propelleda ×2 ×2 ×2
BUD ~ ×1 Not stated ×1
BUD–DPI ~ ×1b ~ ×1 ×1
FP ×2 ×2 ×2
MF ×2c ×1.2d ×1.2 to 2
CIC Not established Not stated ×2e
Sources: Section 4.2.3 of the BTS/SIGN Guideline and Figure 7 (p. 19) of the GINA Pocket Guide 2005.
a Except Clenil Modulite, which has been designed to have equivalent potency as BDP–CFC preparations.
b Despite some evidence that BUD–DPI via turbohaler is more effective than same dose of BDP–CFC.
c Suggested, according to the BTS/SIGN Guideline, by “a relatively limited number of studies”.
d Based on stated equivalence in the GINA Pocket Guide of 400 µg MF with 500 µg BDP–CFC and 800 µg MF with 1000 µg
BDP–CFC.
e A suggested dose ratio for CIC has not been published in any publicly available documents. The only published systematic
review (March 2006), of a limited number (n = 5) of safety and efficacy trials suggests there is no additional benefit from
CIC compared with either FP or BUD, so it is potentially either as effective or twice as effective as BDP–CFC.276 The
assumption that 160 µg CIC (ex-actuator) = 200 µg CIC (ex-valve) = 400 µg BDP–CFC is based on information supplied
by Altana Pharmaceuticals and based on the fact that trials have tended to compare once-daily CIC with other ICS at a
dose ratio of 1:2. They may not necessarily, therefore, reflect the
relative doses actually used in the body of trials
that have examined the clinical effectiveness of the
different ICS drugs. Nor are they likely to reflect
possible differences in the de facto clinical
effectiveness within and between drugs due to
different concordance or ease of use associated
with different inhaler devices. In any case, it
should be remembered that after a switch between
drug treatments, clinical guidelines recommend
that the dose be adjusted upwards or downwards
until the minimum dose required to maintain
effective control is found.
However, to perform a cost comparison on the
basis of a basic assumption of equivalent
effectiveness, we have to make use of these
assumptions about how much of alternative ICS
preparations people would probably need to take
in order to maintain the same level of symptom
control.
Assumptions about the mix of named
preparations of each ICS drug 
For some of the types of ICS drug (notably BDP),
there is a wide range of named preparations,
available in different physical forms (aerosol versus
dry powder), for different inhaler devices, and
either propelled by CFC-containing or non-
CFC containing propellants. To compare between
ICS drugs, it is therefore necessary to generate a
single, average cost for a given level of daily
dosage.
We have used two methods for doing this: (1)
using an unweighted mean annual cost and (2)
using a weighted mean annual cost, weighted
according to the current (2005) market share in
terms of quantity of doses sold (in BDP–CFC
equivalent units).
The unweighted mean annual cost is calculated as
follows. First, for a given dose level (e.g. LDstart =
400 µg BDP–CFC equivalent), calculate the annual
cost of achieving this dose (e.g. all products
available as 100 µg BDP–CFC equivalent doses
and/or 200 µg BDP–CFC equivalent doses).
Second, sum the annual costs for these
preparations. Third, divide by the number of
preparations available at these doses (i.e. the
number of annual costs summed in step two).
The weighted mean annual cost is calculated as
follows. First, the adjusted quantity of each
product of each ICS drug is calculated. For a
product sold in 200-dose packs, for a drug where
most products are available in 200-dose packs, this
will simply be the quantity of packs sold (in
thousands, as listed in the Prescribing Cost
Analysis (PCA) database for 2005). However, for a
product of this drug sold in 100-dose packs, this
PCA quantity sold will be multiplied by 0.5
(= 100/200); similarly, for any products sold in
120-dose packs the PCA quantity sold will be
multiplied by 0.6 (= 120/200).
Second, using these adjusted sale quantities, total
quantities are summed for each drug (BDP, BUD,
etc.). For each drug, total quantities are also
calculated for three groupings of products: CFC-
propelled aerosols (pMDI–CFC), HFA-propelled
aerosols (pMDI–HFA) and products for dry
powder inhalers (DPI). These total quantities are
used as the denominators for the weighted mean
percentages and to calculate the proportion of
adjusted sales of each subgroup of products (e.g.
pMDI–HFA only, DPI only) accounted for by each
product.
This has allowed the calculation of several
different (weighted and unweighted) mean annual
costs to estimate drug prices by broad inhaler
type, and also according to whether the product
contains a CFC propellant or not. This is
particularly critical for estimating the mean
annual cost of BDP and BUD, since CFC-
containing products account for a substantial
market share of these drugs, and will probably 
be withdrawn from the market in the near 
future.
For each of the five ICS drugs, and for each of the
three dose levels, we have therefore estimated a
weighted and unweighted mean annual cost of:
● all CFC-propelled (pMDI) products (where they
exist)
● all HFA-propelled (pMDI) products (where they
exist)
● all dry powder (capsule and loose powder)
products
● all relevant products for that ICS (including
CFC-propelled products)
● all relevant products for that ICS (excluding
CFC-propelled products).
By ‘relevant’ products we mean those that achieve
the specified daily dose in two or four doses per
day, and excluding those specifically for use with
nebulisers.
Note that because the combination inhaler
products are only available in two named
preparations (Symbicort and Seretide), and in a
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the mean cost for each separate product (instead
of calculating an average cost across different
combination products).
Results
Research question 1
Cost comparison: what is the cheapest ICS drug
at treatment Step 2?
The cost comparisons presented below are
justified on the basis that we found no consistent
evidence of differential effectiveness in trials
comparing the two comparators of interest (see
the section ‘Review question 1 – effectiveness of
low-dose ICS’, p. 28). Tables 85 and 86 summarise
the unweighted and weighted mean annual cost of
the five ICS drugs, by inhaler and propellant type.
Figures 26 and 27 plot the weighted and
unweighted mean annual cost and the estimated
annual cost of using the cheapest and the most
expensive product for each drug.
They results show that overall BDP appears to be
the current cheapest ICS drug at starting low
doses (400 µg BDP–CFC equivalent per day),
costing on average £62 per year (weighted mean)
or £65 per year (unweighted mean). If CFC-
propelled products are excluded from the
available products, BDP is still the cheapest but at
a slightly higher annual cost. Excluding CFC-
propelled products, and using current prices,
causes a significant increase in the mean annual
cost of taking BDP at this dose level since CFC-
propelled products still account for over half of
the product types and quantities of BDP sold. In
contrast, for FP, MF and CIC no currently
available products are CFC propelled, so their
exclusion does not alter the calculated mean
annual cost. FP and MF are consistently the two
most expensive drugs – at almost twice to three
times the annual cost of taking BDP. It should be
noted that the apparent relatively low cost of CIC,
intermediate between BDP and FP, is strongly
dependent on the crude assumed dose
equivalence ratio of 1:2 with BDP–CFC products.
Tables 87 and 88 summarise the unweighted and
weighted mean annual cost of the five ICS drugs,
by inhaler and propellant type, when taken at
800 µg/day (BDP–CFC equivalent). Figures 28 and
29 plot the weighted and unweighted mean
annual cost and the estimated annual cost of using
the cheapest and the most expensive product of
each ICS.
Economic analyses
186
TABLE 85 Unweighted mean annual cost of ICS by drug if on 400µg BDP equivalent per day
Drug Preparations with same inhaler and  All preparations of drug (2006 £)
propellant type (2006 £)
pMDI with CFC pMDI with HFA DPI Including CFC-propelled Excluding CFC-propelled
BDP 45 60 98 65 79
BUD 76 NA 113 106 113
FP NA 66 149 133 133
MF NA NA 170 170 170
CIC NA 87 NA 87 87
NA, not applicable.
TABLE 86 Weighted mean annual cost of ICS by drug if on 400 µg BDP equivalent per day
Drug Preparations with same inhaler and  All preparations of drug (2006 £)
propellant type (2006 £)
pMDI with CFC pMDI with HFA DPI Including CFC-propelled Excluding CFC-propelled
BDP 50 61 121 62 90
BUD 76 NA 134 120 134
FP NA 66 142 106 106
MF NA NA 162 162 162
CIC NA 87 NA 87 87
NA, not applicable.Health Technology Assessment 2008; Vol. 12: No. 19
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FIGURE 26 Annual cost of 400 µg ICS per day by ICS drug, including all products. Cheapest products of each drug: BDP = Becotide
100 µg (200 D); BUD = Novolizer 200 µg (100 D Ref.); FP = Flixotide Evohaler 50 µg (120 D); MF = Asmanex Twisthaler 200 µg
(60 D); CIC = Alvesco 80 µg (120 D). Most expensive products of each drug: BDP = Becodisks 100 µg (120 D Ref.); BUD =
Pulmicort Turbohaler 100 µg (200 D); FP = Flixotide Disk 50 µg (60 D Ref.); MF = Asmanex Twisthaler 200 µg (30 D); CIC =
Alvesco 80 µg (120 D). D = number of doses in pack; Ref. = refill pack price where the same preparation is also available with inhaler
device included.
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FIGURE 27 Annual cost of 400 µg ICS per day by drug, excluding CFC-propelled products. Cheapest products of each drug: BDP =
Clenil Modulite 100 µg (200 D); BUD = Novolizer 200 µg (100 D Ref.); FP = Flixotide Evohaler 50 µg (120 D); MF = Asmanex
Twisthaler 200 µg (60 D); CIC = Alvesco 80 µg (120 D). Most expensive products of each drug: BDP = Becodisks 100 µg (120 D
Ref.); BUD = Pulmicort Turbohaler 100 µg (200 D); FP = Flixotide Disk 50 µg (60 D Ref.); MF = Asmanex Twisthaler 200 µg (30 D); 
CIC = Alvesco 80 µg (120 D). D, Ref.: see Figure 26.Economic analyses
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TABLE 87 Unweighted mean annual cost of ICS by drug if on 800 µg BDP equivalent per day
Drug Preparations with same inhaler and  All preparations of drug (2006 £)
propellant type (2006 £)
pMDI with CFC pMDI with HFA DPI Including CFC-propelled Excluding CFC-propelled
BDP 59 128 166 130 153
BUD 153 NA 227 212 227
FP NA 176 218 204 204
MF NA NA 249 249 249
CIC NA 204 NA 204 204
NA, not applicable.
TABLE 88 Weighted mean annual cost of ICS by drug if on 800 µg BDP equivalent per day
Drug Preparations with same inhaler and  All preparations of drug (2006 £)
propellant type (2006 £)
pMDI with CFC pMDI with HFA DPI Including CFC-propelled Excluding CFC-propelled
BDP 59 126 248 157 208
BUD 153 NA 268 225 268
FP NA 176 225 195 195
MF NA NA 235 235 235
CIC NA 204 NA 204 204
NA, not applicable.
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FIGURE 28 Annual cost of 800 µg ICS per day by drug, including all products. Cheapest products of each drug: BDP = Becotide
200 µg (200 D); BUD = Novolizer 200 µg (100 D Ref.); FP = Flixotide Evohaler 250 µg (120 D); MF = Asmanex Twisthaler 400 µg
(60 D); CIC = Alvesco 160 µg (120 D). Most expensive products of each drug: BDP = Becodisks 400 µg (120 D Ref.); BUD =
Pulmicort Turbohaler 200 µg (100 D) or 400 µg (50 D); FP = Flixotide Disk 250 µg (60 D Ref.); MF = Asmanex Twisthaler 400 µg
(30 D); CIC = Alvesco 160 µg (120 D). D, Ref.: see Figure 26.The results show that, overall at this dose level,
BDP appears to be the current cheapest ICS drug,
costing on average £157 per year (weighted mean)
or £130 per year (unweighted mean). If CFC-
propelled products are excluded from the
available products, BDP is still the cheapest
according to the unweighted mean, but FP
becomes the cheapest according to the weighted
mean amongst CFC-free products. Excluding
CFC-propelled products, and using current prices,
cause a substantial increase in the weighted mean
annual cost of taking BDP and BUD at this dose
level, since typically cheaper CFC-propelled
products still account for over half of the product
types and quantities of BDP sold. In contrast, for
FP, MF and CIC no currently available products
are CFC-propelled, so their exclusion does not
alter the calculated mean annual cost. Although
MF is the most expensive ICS drug according to
the unweighted mean costs, non-CFC BUD is the
most expensive if weighted according to the
quantities of different products sold. It should be
noted that the apparent relatively low cost of CIC,
intermediate between BUD and FP, is strongly
dependent on the crude assumed dose-
equivalence ratio of 1:2 with BDP–CFC products.
Research question 2
Cost comparison: what is the cheapest ICS at
Step 4 (high-dose ICS)?
The results presented below were conducted on
the basis that we found no consistent evidence of
differential effectiveness in trials comparing the
five comparators of interest at this dose level (see
the section ‘Review question 2 – effectiveness of
high-dose ICS’, p. 58).
Tables 89 and 90 summarise the unweighted and
weighted mean annual cost of the four ICS drugs
available at these high doses, by inhaler and
propellant type, when taken at 1500 or 1600 µg/day
(BDP–CFC equivalent). Figures 30 and 31 plot the
weighted and unweighted mean annual cost and
the estimated annual cost of using the cheapest and
the most expensive product for each ICS.
The results show that, overall at this dose level,
BDP appears to be the current cheapest ICS drug,
costing on average £260 per year (weighted mean)
or £198 per year (unweighted mean). If CFC-
propelled products are excluded from the available
products, BDP is still the cheapest according to
the unweighted mean, but FP becomes the cheapest
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FIGURE 29 Annual cost of 800 µg ICS per day by drug, excluding CFC-propelled products. Cheapest products of each drug: BDP =
Qvar 100 µg (200 D); BUD = Novolizer 200 µg (100 D Ref.); FP = Flixotide Evohaler 250 µg (120 D); MF = Asmanex Twisthaler
400 µg (60 D); CIC = Alvesco 160 µg (120 D). Most expensive products of each drug: BDP = Becodisks 400 µg (120 D Ref.); BUD =
Pulmicort Turbohaler 200 µg (100 D) or 400 µg (50 D); FP = Flixotide Disk 250 µg (60 D Ref.); MF = Asmanex Twisthaler 400 µg
(30 D); CIC = Alvesco 160 µg (120 D).D, Ref.: see Figure 26.Economic analyses
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TABLE 89 Unweighted mean annual cost of ICS by drug if on 1500 or 1600 µg BDP equivalent per day
Drug Preparations with same inhaler and  All preparations of drug (2006 £)
propellant type (2006 £)
pMDI with CFC pMDI with HFA DPI Including CFC-propelled Excluding CFC-propelled
BDP 148 186 290 198 269
BUD NA NA 540 540 540
FP NA 352 391 383 383
MF NA NA 499 499 499
NA, not applicable.
TABLE 90 Weighted mean annual cost of ICS by drug if on 1500 or 1600 µg BDP equivalent per day
Drug Preparations with same inhaler and  All preparations of drug (2006 £)
propellant type (2006 £)
pMDI with CFC pMDI with HFA DPI Including CFC-propelled Excluding CFC-propelled
BDP 139 NA 497 260 497
BUD NA NA 540 540 540
FP NA 352 425 385 385
MF NA NA 469 469 469
NA, not applicable.
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FIGURE 30 Annual cost of 1500 or 1600 µg ICS per day by drug, including all products. Cheapest products of each drug: 
BDP = Becloforte 250 µg (200 D); BUD = Pulmicort Turbohaler 400 µg (50 D); FP = Flixotide Disk 250 µg (60 D with device); 
MF = Asmanex Twisthaler 400 µg (60 D). Most expensive products of each drug: BDP = Becodisks 400 µg (120 D Ref.); 
BUD = Pulmicort Turbohaler 400 µg (50 D); FP = Flixotide Disk 250 µg (60 D Ref.); MF = Asmanex Twisthaler 400 µg (30 D). 
D, Ref.: see Figure 26.using the weighted mean annual cost. Excluding
CFC-propelled products, and using current prices,
cause a substantial increase in the weighted mean
annual cost of taking BDP at this dose level, since
the typically cheaper CFC-propelled products still
account for over half of the product types and
quantities of BDP sold. In contrast, for FP and MF
no currently available products are CFC-propelled,
so their exclusion does not alter the calculated
mean annual cost. On average, BUD (only
available as Pulmicort Turbohaler at this high dose
level) is the most expensive ICS drug according to
both the unweighted and weighted mean annual
costs counting all products of each ICS drug, and
whether CFC-containing products are excluded or
not. However, looking at the full range of costs
within each ICS drug type, there is wide variation
in the cost of FP, MF and especially BDP products.
Although the most expensive MF, BUD and BDP
products are very similar in annual cost, using the
cheapest CFC-free products for each drug varies
from £135 per year (BDP using Asmabec
Clickhaler 250 µg) to £447 (MF using Asmanex
Twishaler 400 µg) or £540 (BUD using Pulmicort
Turbohaler 400 µg).
Research question 3a
Which is the more cost-effective: to increase the
dose of ICS alone or to add a LABA to treatment
with a lower dose of ICS? (Steps 2–3).
The cost–consequence analysis presented below
was undertaken on the basis that the review of
clinical effectiveness found that ICS/LABA
combination therapy was generally more effective
than ICS as monotherapy when the dose ratio of
ICS was 2:1. This question was also the main focus
of our exploratory model-based CUAs
(Appendix 10), and we incorporate some insights
from that analysis below.
Chapter 3 on clinical effectiveness described and
summarised the general pattern of outcome
differences according to the particular ICS plus
LABA drugs being compared with ICS at a higher
dose. In this section, we repeat those summary
tables, but additionally (1) indicate the magnitude
of any measured differences in the common trial
outcomes, and (2) state what the annual cost of the
preventer drugs would be using the equivalent
products (in the UK) to those actually used in the
clinical trials.
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FIGURE 31 Annual cost of 1500 or 1600 µg ICS per day by drug, excluding CFC-propelled products. Cheapest products of each drug:
BDP = Asmabec Clickhaler 250 µg (100 D); BUD = Pulmicort Turbohaler 400 µg (50 D Ref.); FP = Flixotide Accuhaler 500 µg 
(60 D); MF = Asmanex Twisthaler 400 µg (60 D). Most expensive products of each drug: BDP = Becodisks 400 µg (120 D Ref.); 
BUD = Pulmicort Turbohaler 400 µg (50 D); FP = Flixotide Disk 250 µg (60 D Ref.); MF = Asmanex Twisthaler 400 µg (30 D). 
D, Ref.: see Figure 26.The UK equivalent products for trialled products
not available in the UK were assumed to be
Seretide Accuhaler (for Seretide Diskus),
Symbicort Turbohaler (for Symbicort Turbuhaler),
and for the ICS drugs: Flixotide Disk (for Flovent
or Flixotide Diskus). In one study, by Lalloo and
colleagues,229 the specific BUD DPI product used
was not stated, so for costing purposes we assumed
it would be Pulmicort Turbohaler in the UK
treatment setting.
The costs per dose for each product were 
obtained from the British National Formulary
(BNF) (No. 51, March 2006).275
Cost–consequence comparisons
There are five RCTs which compare FP/SAL with a
higher dose of FP or BUD. Of the two trials which
compared FP/SAL with higher dose FP only one
showed a significant difference in any outcome (a
+0.1 litres higher increase in FEV1 from baseline);
the other reported very small differences in AQLQ
score change and exacerbations but did not report
any tests of significance for these differences. For
the higher dose comparison, the annual
medication cost of FP/SAL combination
(500 µg/100 µg/day) is £35 less than the higher
dose of FP. In contrast, for the comparison at
lower doses, the annual cost of the FP/SAL
combination (200 µg/100 µg/day) is £92 higher
per year. For the three trials which compare
FP/SAL with BUD at higher dose, there seems to
be a more consistent pattern of significant
improvements in PEF (morning and evening) and
in SFDs and SFNs, favouring the combination
inhaler. However, for these trials, the estimated
annual cost of the FP/SAL combination varies
from being £94 cheaper to £109 more 
expensive than the alternative of BUD at a 
higher dose.
There are also five trials which compare BUD/FF
in a combination inhaler with higher dose FP (one
trial) or higher dose BUD (four trials). Again,
there appears to be a reasonably consistent pattern
of significant improvements in PEF (morning and
evening), and in symptom-free days with
combination therapy compared with an increased
dose of ICS alone. In these trials, the annual cost
of BUD/FF varies from being £163 cheaper to £66
more expensive than the ICS alone at higher daily
dose.
Overall, the comparisons in Tables 91–94 show that
although there are some consistent statistically
significant differences in clinical effectiveness,
which in general favour the use of combination
inhalers, they are often (but not always) cheaper
than increasing the ICS dose. Even in this
relatively small sample of trials, the variation in
dose levels and products compared is such that the
differences in annual medication costs vary widely.
These comparisons reinforce one of the broad
conclusions from the exploratory CUA that, on top
of small and uncertain differences in treatment
effectiveness, the considerable variations in
product costs within each drug type introduce so
much additional uncertainty that conventional
decision rules for making judgements about 
cost-effectiveness are almost worthless.
Also, it should be remembered that these
cost–consequence comparisons are strictly limited
to the particular ICS versus ICS plus LABA
comparators that have been included in existing
trials (and they therefore over-represent
comparisons with increased FP or BUD, and
include no comparisons with increased BDP or
other ICS), and also, for decision-making
purposes, suffer from the same limitations as any
single short-term trial-based economic
evaluation.277 Of course, they omit any potential
cost savings due to any exacerbations avoided, and
the value of potential quality of life gains due to
having more days and nights without asthma
symptoms (our model-based analysis has shown
that the latter factor, in particular, can greatly
influence cost-effectiveness estimates for this
comparison.) They therefore still only offer a
limited perspective on our original, broader, 
cost-effectiveness question.
Research question 4
Combination versus separate inhalers at Step 3
For the comparison of combination inhalers with
the same drugs delivered in separate inhalers,
clinical equivalence between the treatment
strategies can be assumed from the results of the
clinical effectiveness analysis. The cost
comparisons presented below are therefore
justified on the basis that we found no consistent
evidence of differential effectiveness in trials
comparing the comparators of interest (see 
the section ‘Review question 4 – ICS + LABA 
in combination versus separate inhalers’, 
p. 131).
As Tables 95 and 96 show, for both currently
available combination products (Seretide and
Symbicort), the combination ICS with LABA
product is cheaper than taking the same drugs in
separate inhalers at lower doses (800 µg/day or
less), but may be more expensive at higher doses.
For taking BUD with FF, using Symbicort via
Economic analyses
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C, stated as comparable between trial arms, but no other data presented; NSD, no significant difference between trial arms; NW
,
 nocturnal waking; SABA, short-acting beta-agonist
use; SFD, symptom-free days; SFN, symptom-free nights; SS, symptom score. 
a 
See text.
b 
R
esults favour this trial arm but no significance testing has been reported.
* 
p
< 0.05; ** p
< 0.01; *** p
< 0.001.
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T
ABLE 93
Consequences and cost of FP vs BUD/FF (
n
= 1 RCT)
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NSD, no significant difference between trial arms; NW
, nocturnal waking; SFD, symptom-free days; SFN, symptom-free nights; SS, 
symptom score; SABA, short-acting 
beta-agonist use.
* 
p
< 0.05; *** p
< 0.001.
NSD
NSDEconomic analyses
196
T
ABLE 94
Consequences and cost of BUD/FF vs BUD (
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ABLE 94
Consequences and cost of BUD vs BUD/FF (
n
= 4 RCT
s)
(cont’d)
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P
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et al.,
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BUD
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AMD, adjustable maintenance dose in which those receiving BUD had a mean of 560
µg/day
, metered (448
µg/day delivered), and those receiving BUD/FF had a mean of 1440/43
µg/day
, metered
(1152/35
µg/day delivered); C, results stated to be comparable between treatment arms, but no other data presented; 
mar
, combination inhaler used as both maintenance and reliever medication in this
arm; NSD, no significant difference between trial arms; NW
, nocturnal waking; SABA, short-acting beta-agonist use; SFD, symptom
-free days; SFN, symptom-free nights
; SS, symptom score
; 
to
,
terbutaline only used as reliever in this arm.
a 
All outcome and cost differences for O
’Byrne 
et al. are for BUD/FF compared with BUD. The cost of BUD/FF as a reliever medication (mean = 1 dose per day) is £101 per year
, compa
red with
terbutaline or salbutamol cost of only £5–25 per year
.
b 
R
esults favour this trial arm but no significance testing has been reported.
* 
p
< 0.05; ** p
< 0.01; *** p
< 0.001.
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NSDTurbuhaler is cheaper than taking Pulmicort via
Turbuhaler (at the same BUD dose) and taking FF
separately, except when taking 1200 µg BUD/day
as Pulmicort Turbohaler with Atimos Modulite, or
when taking 1600 µg BUD/day as Pulmicort
Turbohaler with any of the three FF products.
Depending on the exact preparation of FF used
(in combination with Pulmicort Turbohaler) and
the daily dose of BUD required, the combination
product may cost anything from £156 more to
£227 less per year.
For taking FP with SAL, using Seretide via
Accuhaler is also always cheaper than taking
Flixotide Accuhaler (at the same FP dose) and SAL
separately. The estimated annual savings vary from
£85 (if on 200 µg FP/day) and £298 (if on 1000 µg
FP/day). Similarly, using Seretide via Evohaler is
always cheaper than taking Flixotide via Evohaler
(at the same FP dose) and taking SAL separately.
Note that, as specified in our research question 4,
we have only assessed the comparative annual 
Economic analyses
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TABLE 95 Annual cost of combination versus separate inhalers: BUD with FF added
Combination or BUD FF Annual cost (£) by daily dose of BUD
200 g/day 400 g/day 800 g/day 1200 g /day 1600 g/day
Symbicort Turbohaler  201 231 462 694 925
(combination product)
Separate inhalers:  Atimos Modulite  296 363 498 634 769
Pulmicort Turbohaler,  10.1 µg
plus: Oxis 4.5 µg (or 9 µg)a 369 437 572 707 842
Foradil 12 µg 391 458 593 728 863
Difference in annual cost (separate minus combination)
Separate inhalers:  Atimos Modulite  +95 +132 +36 –60 –156
Pulmicort Turbohaler,  10.1 µg
plus: Oxis 4.5 µg (or 9 µg)a +169 +206 +110 14 –83
Foradil 12 µg +190 +227 +131 35 –61
a Oxis 4.5 µg and 9 µg are the same price per dose.
TABLE 96 Annual cost of combination versus separate inhalers: FP/SAL added
Preparation Taken as Annual cost (£) by daily dose of FP
200 g/day 500 g/day 1000 g/day
As dry powder
Flixotide Accuhaler 2 blisters/day 109 259 440
Serevent Accuhaler (or aerosol inhaler)a 2 blisters/dayb 356 356 356
Both (total) 465 615 796
Seretide Accuhaler (FP and SAL combined) 2 blisters/dayb 379 446 498
Difference in annual cost +85 +169 +298
As aerosol
Flixotide Evohaler 4 puffs/day 66 259 440
Serevent aerosol Inhaler 4 puffs/dayb 356 356 356
Both (total) 422 615 796
Seretide Evohaler (FP and SAL combined) 4 puffs/dayb 219 446 760
Difference in annual cost +203 +169 +36
a Serevent Accuhaler and aerosol inhaler are the same price per µg.
b Each blister contains 50 µg of SAL and each puff contains 25 µg of SAL.cost of the combination inhalers with the same
ICS and the same or broadly equivalent LABA. 
If the combination inhalers were compared 
with, for example, BDP plus LABA in separate
inhalers, the overall result we have stated may 
not hold.
Research question 5
FP/SAL versus BUD/FF at Step 3
The clinical effectiveness review did not identify
any consistent differences in effectiveness between
the two combination inhalers (see the section
‘Review question 5 – combination inhaler
compared with combination inhaler’, p. 143), and
so we believe it was reasonable to assume clinical
equivalence between these two treatment strategies.
Table 97 compares the cost of taking ICS with
LABA in the two currently licensed combination
inhalers, Seretide and Symbicort. In making the
comparison between these products we have
assumed that 400 and 800 µg (metered dose) of
BUD are equivalent to 200 and 500 µg of FP,
respectively, and also that 12 µg (metered) of
FF/day has effectiveness equivalent to 100 µg of
SAL/day. Although this assumption partly reflects
the levels of drugs used in the existing head-to-
head trials of Symbicort versus Seretide (which
compare Symbicort 800 µg BUD versus Seretide
500 µg FF/day), it should be noted that all these
trials involved Seretide Diskus (which is marketed
as Accuhaler in the UK), rather than Seretide
Accuhaler.
At the lower dose level, the cheapest combination
inhaler is FP/SAL as aerosol for pMDI (Seretide
Evohaler = £219 per year), but this is only slightly
cheaper than BUD/FF as a DPI (Symbicort
Turbohaler = £231 per year). At the higher dose
level FP/SS both as an aerosol for pMDI and as a
DPI (Seretide Evohaler and Seretide Accuhaler,
respectively) are the cheapest at £446 per year, but
this is only £16 cheaper than having the ICS
‘equivalent’ dose of BUD/FF Symbicort
Turbohaler.
Summary of the economic
analyses
The economic analyses and/or cost comparisons
are summarised for each of the cost-effectiveness
research questions (with the exact question wording
revised in the light of the clinical effectiveness
evidence and the infeasibility of formally assessing
cost-effectiveness for most questions).
Q1. What is the cheapest type of ICS at
Step 2 of the BTS/SIGN Guideline?
At low ICS doses at Step 2 of the Guideline, the
weighted mean annual cost of taking an ICS drug
at 400 µg BDP–CFC (or equivalent) varies over
three-fold from £53 for BUD to £170 for MF. The
weighted mean annual cost of taking an ICS drug
at a higher dose of 800 µg BDP–CFC (or
equivalent) varies from £157 for BDP to £235 for
MF. At this higher dose level currently available
BUD preparations cost on average £225 per year,
only slightly less than MF.
CFC-containing products are currently
considerably cheaper than the dry powder or
HFA-propelled alternatives for each drug. As a
consequence, and assuming pack prices and
relative market shares remain the same, when
CFC-containing products are withdrawn, the
weighted mean annual cost of taking BDP will
increase from £62 to £90 (at a 400 µg ICS/day
dose level) and from £157 to £208 (at a 800 µg
ICS/day dose level). Consequently, among non-
CFC-containing preparations FP is currently the
cheapest ICS in terms of weighted mean annual
cost, at £195 per year at the higher dose level.
With the unweighted mean annual costs, there is
still an increase in the cost of BDP and BUD
products when CFC-containing products are
excluded, but the ordering of the drugs from
cheapest to most expensive is less altered.
What these weighted averages conceal, however, is
very wide variations in the cost of individual
preparations for each drug. This is an issue
Health Technology Assessment 2008; Vol. 12: No. 19
199
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
TABLE 97 Annual cost (£) of combination inhalers compared
Combination product Taken as 400 ga BUD/day 800 ga BUD/day
Symbicort Turbohaler (BUD/FF) 2 puffs/day 231 462
200 g FP/day 500 g FP/day
Seretide Accuhaler (FP and SAL combined) 2 blisters/day 379 446
Seretide Evohaler (FP and SAL combined) 4 puffs/day 219 446
a Metered dose.particularly for BDP, BUD and FP products. For
example, currently the cheapest way of obtaining
800 µg of BDP/day is with Becotide 200 µg four
times daily (£0.0407 per dose = £59.42 per year);
the most expensive way is to use Becodisks 400 µg
twice daily (£0.3714 per dose = £271.13 per year).
Similarly, for obtaining 800 µg of BUD/day, the
cheapest product is Novolizer BUD 200 µg taken
four times daily (£0.0959 per dose = £140.01 per
year); the most expensive products are Pulmicort
Turbohaler 200 and 400 µg (£0.185 and £0.37 per
dose = £270.10 per year).
Q2. What is the cheapest type of ICS at
Step 4 of the BTS/SIGN Guideline?
At a dose level of either 1500 or 1600 µg of
BDP–CFC equivalent per day, BDP appears to be
the current cheapest ICS drug, based on either
weighted or unweighted mean annual costs
(costing £260 and £198 per year, respectively).
However, if CFC-propelled products are excluded,
FP becomes the cheapest ICS product according
to our estimated means, when weighted according
to current product market shares. Excluding CFC-
propelled products and using current prices causes
a substantial increase in the weighted mean
annual cost of taking BDP at this dose level.
Q3a. What are the relative costs and
consequences of taking ICS plus LABA
in a combination inhaler versus taking
an increased dose of ICS?
Alongside evidence of some relatively consistent
clinical effectiveness differences favouring
combination inhalers, they can often also be
cheaper than increasing the dose of ICS – at least
when based on those products used in the same
trials. However, we are cautious not to make any
firm cost-effectiveness conclusion from these
cost–consequence data, since this ‘result’ largely
depends on the specific dose levels and exact
products compared in these trials. Furthermore,
we have not factored in the other potential cost
advantages that might accrue to combination
inhalers if the relative reductions in exacerbation
rates measured in some trials were more certain.
Nor, as important, do they capture the potential
quality of life impacts of reducing the proportion
of days or nights with symptoms which some trials
show. When we do factor in such variables,
however, as we have done in our exploratory CUA
(Appendix 10), the major uncertainty in the cost
estimates remains, and the joint uncertainty
surrounding the cost and effectiveness estimates
available from the research literature prevents any
straightforward use of conventional rules for
interpreting cost-effectiveness ratios.
Q4. What is cheapest – taking ICS with
LABAs in combination or separate
inhalers? 
Overall, taking ICS with LABAs as either of the
two currently available combination products is
more frequently cheaper than taking the relevant
ingredient drugs in separate inhalers, especially at
the lower doses at which most patients are
managed. Taking FP with SAL, using Seretide via
Accuhaler, is also always cheaper than taking
Flixotide Accuhaler (at the same FP dose) and
SAL separately. The estimated annual savings vary
from £85 (if on 200 µg FP/day) and £298 (if on
1000 µg FP/day). Similarly, using Seretide via
Evohaler is always cheaper than taking Flixotide
via Evohaler (at the same FP dose) and taking SAL
separately.
For the combination of BUD/FF at doses up to
800 µg/day, taking the combination inhaler is
between £36 to £227 cheaper per year than taking
the equivalent ingredient drugs in separate
inhalers. However, at high doses (of 1200 µg/day
or greater) the combination product may cost as
much as £156 more per year than taking FF and
BUD separately, depending on the exact
preparation of FF used and the daily dose of BUD
required.
Q5. Which combination inhaler is the
cheapest? 
This comparison crudely assumed that 400 and
800 µg of BUD are equivalent to 200 and 500 µg
of FP, respectively, and also that 12 µg of FF/day
has effectiveness equivalent to 100 µg of SAL/day.
At the lower daily dose of 400 µg BUD or 200 µg
FP/day, Seretide Evohaler and Symbicort
Turbohaler are very similar in annual cost (£219
and £231), with Seretide Accuhaler being more
expensive than both of these (£379 per year). At a
dose of 800 µg BUD or 500 µg FP/day, the annual
cost of taking FP/SAL by either Seretide Evohaler
or Seretide Acuhaler is the same at £446, whereas
the combination of BUD/FF by Symbicort
Turbohaler is only slightly more expensive at
£462.
Economic analyses
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sthma is one of the most common chronic
conditions in the UK, with a prevalence of
approximately 5.2 million.11 Therefore, the
economic burden of asthma in both direct and in-
direct costs to the NHS is high. In 2005,
expenditure on corticosteroids for respiratory
conditions cost the NHS £436 million. Although
this was only 15th in terms of the number of
prescriptions issued, this is the third largest
component of the total cost of community-
dispensed drugs in England.
Estimates of the prevalence of treated asthma in
adults vary somewhat according to the source used
to obtain them. However, estimates from the
General Practice Research Database indicate that
the prevalence of adults being treated for asthma
ranged from 44.5 to 89.4 per 1000 patients for
men aged 15 years and over and from 52.2 to 88.0
per 1000 patients for women of the same age
group. In both sexes, prevalence was highest in
those aged over 65 years. Adolescents and adults
with asthma place various demands on the NHS
budget, ranging from the cost of prescribed asthma
medications to various levels of health service use
including GP and nurse consultations, A&E
department visits and hospital admissions. Each of
these is associated with a varying level of cost.
ICS therapy alone
The cost comparisons presented in this review
indicate that there are currently considerable
relative differences in the mean annual cost
between the different ICS preparations, and also
large cost differences between individual products
for each ICS drug. However, the absolute size of
these differences, of up to £200 per year, may not
seem excessive. From our systematic review of
clinical effectiveness, these differences do not
appear to be associated with any additional
treatment benefit which would offset the additional
cost of the more expensive options. Therefore,
unless there are other benefits associated with the
more expensive products (such as ease of correct
use), there may be little justification for the
sometimes considerable cost differences between
the five licensed comparators. There are potential
cost savings to be made for the NHS if suitable
patients who are currently treated with the more
expensive ICS drugs or preparations could be
switched to a cheaper option. Currently the largest
cost savings would be associated with switching all
patients to the cheapest BDP/BUD CFC-propelled
preparations available, depending on the target
daily dose required. However, this is not a realistic
treatment strategy as CFC-propelled devices are
due to be phased out in the near future, and there
are additional GP consultation costs associated
with a review to switch patients between treatment
strategies and drugs. With the phasing out of
CFC-propelled products, the cost of providing ICS
therapy to the NHS is likely to increase.
Additional costs will be associated with switching
patients who are currently on CFC-propelled
formulations to new preparations and the higher
costs associated with all non-CFC-propelled
preparations of ICS. The exact cost implications to
the NHS are difficult to project, as it is likely that
as CFC-propelled formulations are removed from
the market, the relative market share of non-CFC
formulations will change and new CFC-free
products may also enter the market. In order to
realise any potential cost savings, it may be
important to review patients’ ICS therapy in
routine GP or nurse consultations and examine
whether switches can potentially be made to
cheaper preparations of the same product, which
obviously has an associated cost in terms of patient
education, follow-up and any further treatment
changes that may need to be made if the
treatment regimen is unsuitable.
Additionally, it must be noted that any potential
cost savings made by switching patients between
either ICS drugs or individual preparations can
easily be offset by the costs incurred by potentially
higher exacerbation rates. The BTS/SIGN
Guideline states that patients and clinicians should
choose the preparation that most suits the
individual patient. This will be based not only on
the preparation, but also the suitability of the
device and the complexity of the treatment
regimen to an individual patient. It is therefore
necessary that any potential switches to cheaper
preparations should be done bearing in mind the
patient’s ability to use the different inhaler types.
This is particularly pertinent within both an
adolescent age group and in the elderly.
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Chapter 5
Factors relevant to the NHS and other partiesICS plus LABA
There are potential direct savings to the NHS if
patients using ICS and LABA in separate inhalers
switch to combination ICS/LABA products
delivered in the same inhaler. At doses lower than
1200 µg/day, taking Symbicort (BUD/FF) via
Turbohaler is associated with an estimated annual
saving between £36 and £227 compared with
taking Pulmicort via Turbohaler and taking FF
separately (the exact saving depending on the
specific preparation of FF used and the daily dose
of BUD required).
Taking Seretide (FP/SAL) via Accuhaler is
associated with an estimated annual saving of
between £85 (if on 200 µg FP/day) and £298 (if on
1000 µg FP/day) compared with taking Flixotide
and Serevent via Accuhaler. Likewise, using
Seretide via Evohaler is always cheaper than
taking Flixotide via Evohaler (at the same FP
dose) and taking SAL separately.
However, it is not clear to what extent the drugs
are currently prescribed in separate inhalers.
Given the concerns that the clinicians consulted
for this report have expressed about the potential
hazards of using LABAs without ICS, it is likely
that most ICS plus LABA therapy is not prescribed
in combination inhalers and so the potential for
cost savings in this area may be limited.
We are also aware from discussions with clinicians
for this report that there is an increasing tendency
to prescribe ICS and LABA in combination
inhalers instead of ICS alone at Step 2 of the
BTS/SIGN Guideline. Reasons given for this
practice include ease of use for patients, to get
both preventer and reliever therapy in one device
and concerns about overuse of reliever
medication, particularly LABAs, on their own. As
this practice is not in line with the Guideline,
assessing the effectiveness and cost-effectiveness of
this treatment strategy is outside the scope of this
report and has not been investigated. It is likely,
however, that a significant proportion of current
prescribing cost may reflect ICS and LABA use
that is not strictly according to the Guideline,
making the estimation of potential cost savings
more difficult.
Factors relevant to the NHS and other parties
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ndertaking this assessment has highlighted
the difficulties in assessing intervention
effects for the treatment of asthma. In the most
part these are a reflection of the complex nature
of the disease and the way that by necessity
outcomes are defined and measured within clinical
trials. In the sections below a brief summary of
these issues is outlined.
Assessing the effectiveness of
interventions for asthma
Asthma is a common chronic condition with a
number of definitions based on disease process,
clinical symptoms and their pattern over time and
response to external stimuli. Each definition
defines different populations in terms of severity,
the underlying pathological process and the likely
disease trajectory. Asthma is also partly defined by
the variation of symptoms over time, thus making
the detection of changes due to interventions
more difficult to identify.
In terms of outcomes of treatment for asthma,
death is very uncommon and so is not an
informative outcome measure for assessing the
effectiveness of treatment at the levels of severity
which are considered in this report. A wealth of
other outcome measures that are commonly
reported can broadly be divided into the
categories of lung function, symptoms, acute
exacerbations, use of rescue medication and AEs,
but no standardised measures are used consistently
in trials. Measures of lung function such as FEV1
and morning and evening PEF are among the
most commonly reported outcomes. However,
although FEV1 is widely reported in trials, it may
be expressed as absolute changes or % predicted,
thus preventing clear comparisons between results
of different studies. Symptoms are also widely
reported, but trials do not use consistent methods
for scoring symptoms or defining measures such
as SFDs or SFNs. For example, SFDs were defined
as diversely as “a 24-hour period with a symptom
score of zero” and “percentage of days without
cough/wheeze/shortness of breath/chest tightness”.
Very few studies provided any indication of
whether symptom measurement instruments had
been validated. Similarly, definitions of
exacerbations are highly heterogeneous, ranging
from those defined as a fall in PEF of at least 30%
on two consecutive days to those necessitating
emergency treatment at a healthcare institution.
This variety of definitions makes it very difficult to
compare the therapeutic activities of different anti-
asthma drugs on an outcome such as
exacerbations. Very few trials report HRQoL,
which, in addition to being important in its own
right, is needed to inform CUAs. Composite
outcomes are also reported, but again there is no
consistency across trials in the way in which such
outcomes are defined, thus preventing clear
comparisons being made across all relevant
technologies. Additionally, the way in which AEs
are defined is often poorly reported, and it is
often unclear as to which events are measured and
the severity of these. This limits the degree to
which comparisons of differences in the type and
rate of AEs can be made between trials.
Although lung function provides the most
objective assessment of response to treatment, and
probably more closely reflects the underlying
disease process, the clinical significance of
reported changes in lung function is not clear.
Disease severity also relates to the underlying
disease process, reflected in lung function and
symptoms, but is most commonly defined by 
level of medication. Patients on substantial
amounts of medication may be classified as 
having moderate or severe disease, but this
classification will give no indication of their level
of symptoms, which may be well or poorly
controlled.
The aim of treatment is to control symptoms 
and enable patients to lead as normal a life as
possible, so well-controlled asthma is a composite
concept that varies between patients and
professionals. It is dependent on any given
patient’s expectations for their lifestyle (e.g. being
active versus sedentary and a willingness to avoid
known trigger factors), in addition to their
acceptance of a regular treatment regimen. Each
individual therefore must balance these factors to
allow them to achieve an acceptable level of
symptoms and medication and an acceptable
lifestyle for them. Part of this balance is the extent
to which patients will adhere to a medication
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Chapter 6
Discussionregimen when they are symptom free; many will
adhere while they are symptomatic, but choose to
reduce treatment levels once symptom free. This
step down in treatment may be appropriate in
response to symptoms, but it may happen too
quickly and lead to a return of symptoms or an
exacerbation. Mild exacerbations may either be
managed by the patient alone by increasing
medication use, or be managed within a primary
care setting, leading to the wide variation in
definition referred to above. From the perspective
of assessing cost-effectiveness, however, it is
particularly important to be able to identify the
healthcare resource use associated with more
severe exacerbations. These are usually defined as
those exacerbations requiring hospital admissions
or attendance in emergency departments, but
many non-clinical factors influence admission to
hospital, particularly for both adolescents and the
elderly.
Assessing differences in healthcare costs for the
treatment of asthma is difficult, because of the
difficulty in deriving a single representative cost
for each drug. There are a range of alternative
products, available in a range of doses and
delivered by different devices for each drug.
Therefore, there can be a number of ways of
achieving any given daily dose of a particular
drug, with significant consequences for the cost of
delivering that dose. In order to make any
comparisons in terms of costs between the
different drugs, assumptions have to be made
regarding dose equivalence and the way in which
the target daily dose is achieved.
A further assumption must be made regarding the
context of the BTS/SIGN Guideline for assessing
intervention effects of the different comparators
under consideration. Although the Guideline is
well established and has been used for a number
of years within the UK, it is clear its many clinical
trials are not set within its context, and the
treatment regimens assessed do not fit neatly into
the Guideline steps. For example, a number of
trials have assessed different ICS in dose ratios of
1:2 (BDP–CFC equivalent) whereby the lower dose
comparator arm is within Step 2 of the Guideline
and the higher dose arm is at a dose level within
Step 4. Furthermore, use of the Guideline steps
for assessing intervention effects for only ICS and
ICS/LABA creates an artificial boundary between
the treatment choices possible within the context
of this assessment and those available in clinical
practice. Within this assessment, the effects of
stepping up effectively steroid-naïve patients
directly from Step 1 (SABA use only) to Step 3
(ICS and LABA) has not been reviewed, although
anecdotal evidence suggests that this does occur in
clinical practice, particularly if control of
nocturnal symptoms is poor. Additionally, the
effects of concomitant medication use, e.g. the
addition of a leukotriene receptor antagonist or
theophylline, for patients treated at Step 4 of the
Guideline has not been reviewed, despite the fact
that most patients would not be treated on high-
dose ICS alone at this step.
The two other areas that have not been formally
assessed in this assessment report are the issues of
device type and concordance, issues which are
inextricably linked. It is well recognised that a
large proportion of the asthmatic population has
difficulty in using particular inhaler devices. This
difficulty relates particularly to pMDIs and to a
lesser extent to DPIs. Both require the ability to
coordinate inhalation with activation of the
inhaler. However, within the context of a clinical
trial, only those patients who are able to use the
type of device under evaluation effectively will be
eligible for inclusion in the trial. Evidence for the
effectiveness of inhaled corticosteroids and beta2
agonists for asthma from clinical trials should
therefore be considered carefully for its
generalisability to the typical population with
asthma, as opposed to a subgroup of patients
selected for their ability to use the inhaler
effectively. Additionally, given the probable 
device-related variations in both compliance with
correct inhaler technique and adherence to
recommended daily doses, the rate of 
concordance with treatment regimens is likely 
to be considerably higher in clinical trials 
than in routine practice. Although concordance
rates were not formally assessed in the clinical
effectiveness review, they were around 70–95% 
in the trials where reported. This is considerably
higher than the rates observed in practice, for
which it is generally observed that approximately
50% of patients take the full amount of 
prescribed medication (see Chapter 1). This 
figure is likely to vary considerably depending 
on the level of support patients receive in 
primary care and from asthma specialist nurses
and their ability to use their prescribed inhaler
devices.
Limitations of the evidence base
There is a relatively large volume of evidence for
the efficacy and safety of ICS and LABAs. Trials of
these drugs have been conducted and published
over decades, as new drugs have been tested and
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characteristics, treatment strategies tested,
methodological quality and standards of
reporting. This is to be expected given the broad
remit of this assessment.
The trials identified vary in treatment duration
from around 6 weeks to 2 years, with the majority
lasting 12–24 weeks. These trials do not
adequately capture the longer term effects of ICS
and LABA therapy, particularly long-term AEs and
impact on BMD and growth, especially for
younger patients. Relatively few of the trials
followed up patients beyond 6 months to 1 year.
It is also not clear in the trials what constitutes the
minimal clinically significant change for many of
the reported outcomes such as lung function,
symptoms or exacerbations. Lung function
probably reflects the underlying disease process
more closely than symptom measures or HRQoL,
whereas exacerbations are probably only triggered
when lung function drops below a certain
threshold. Hence it is likely that lung function
changes may still be detectable at a point in the
disease process when patients have few, if any,
symptoms.
The wide range of possible outcome measures,
most with no widely accepted and standardised
method of measuring them, makes comparison
across studies difficult and combining studies in a
meta-analysis largely inappropriate. Trials have
also been conducted for a variety of reasons and
are not necessarily powered to detect superiority
of one ICS over another. It is also not always 
clear how well blinding is maintained when 
drugs are delivered through different devices,
although some trials report the use of placebo
devices. Reporting of baseline population
characteristics and outcome measures is frequently
poor or selective. Additionally, the patients
included in many of the trials may not necessarily
be representative of patients seen in routine
clinical practice. Entry criteria for many of the
trials generally favoured relatively younger,
healthier patients without co-morbidities (e.g.
cardiovascular disease, COPD), as they do in 
many clinical areas. Although some trials did
accept smokers, heavy smokers were often
excluded. Results were rarely reported separately
for smokers and extrapolation from the results of
non-smokers to this group is not advised. The
results of this assessment therefore may not be
generalisable to older patients with other
significant conditions, including advanced
irreversible airways disease.
Review of clinical effectiveness
Just under 70 RCTs were included in this
assessment, of which approximately half have been
included in Cochrane systematic reviews. This
assessment therefore adds to this body of
evidence, providing a systematic synthesis of these
drugs within the context of a comprehensive and
recognised care pathway. Below we discuss the key
findings according to Steps 2–4 of the pathway, in
the context of our five review questions.
Review question 1: which ICS is the
most effective at low doses? 
Twenty-two relevant RCTs of the efficacy and
safety of ICS at doses up to 800 µg/day BDP/BUD
or equivalent (corresponding to Step 2 of the
BTS/SIGN Guideline1) were identified. Within this
dose range there was a high degree of variability
in the doses used in the trials, ranging from
100/800 µg/day. There did not appear to be a
particular dose that was more commonly tested
than others.
Baseline populations, where sufficiently reported,
were generally appropriate for Step 2 of the
Guideline.
In general, all of the ICS were associated with
favourable changes across a range of outcomes.
However, there were few statistically significant
differences between them when evaluated in
pairwise comparisons at the accepted clinically
equivalent doses. The ICS can be considered
generally equivalent in clinical terms, although
few studies explicitly aimed to assess clinical
equivalence/non-inferiority.
The BTS/SIGN Guideline notes that BDP and BUD
are approximately equivalent in clinical practice.1
Similarly, the Cochrane review of BDP and BUD56
noted few significant differences between them. The
results of the current assessment generally accord
with these findings, although not all studies in the
Cochrane review were included in this assessment
and vice versa. In this assessment, when BUD and
BDP were compared (five studies, all at a nominal
1:1 dose ratio), the only significant differences
were for measures of lung function. There was a
significant difference in favour of BDP in FEV1
from a meta-analysis of two studies. However, for
morning and evening PEF there was a significant
difference in favour of BUD, although this was
reported in one small trial. AEs appeared similar.
The BTS/SIGN Guideline also notes that FP
provides equal clinical activity to BDP and BUD at
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increased potency for FP. In the Cochrane review
of FP compared with BDP or BUD,170 the only
significant differences between the drugs when
administered at a 1:2 dose ratio (FP:BDP/BUD)
were for FEV1 and morning PEF, which were in
favour of FP. There were few differences between
the drugs on other outcome measures, although
limitations in the reported data prohibited meta-
analysis of these outcomes. Results of the
comparison of FP with BDP in the current
assessment (comprising a sub-set of studies in the
Cochrane review, plus an additional study) were
similarly mixed. In general, there were few
significant differences between groups across
outcomes. All six of the included trials compared
the two at a nominal 1:2 dose ratio. However, in
one trial FP was shown to be statistically more
favourable on all of the efficacy measures, but in
this study FP was given at a slightly higher dose
ratio than 1:2, which may account for the more
favourable outcomes for it. Results of the
comparison of FP with BUD (five studies, all at a
nominal dose ratio 1:2) were also mixed.
Significant differences in favour of FP were
identified for symptoms, although this was only
from one trial. Meta-analysis of the proportion of
patients with an AE was significantly in favour of
BUD.
As yet there are no published Cochrane reviews of
the newer ICS, specifically CIC and MF, compared
with either each other or with the established
corticosteroids. This assessment is therefore one of
the first to review systematically their relative
safety and efficacy. One of the key findings is that
there is currently a limited evidence base for the
newer corticosteroids, and caution is therefore
advised when interpreting the results of trials.
Trials of CIC compared with BUD and FP were
included. However, no trials of CIC versus MF
were included.
Comparing CIC with BUD at a nominal dose ratio
of 1:2 (CIC:BUD, both via HFA pMDI) found no
significant differences. Furthermore, non-
inferiority was appropriately demonstrated for
measures of lung function. Caution is advised as
only one trial of this comparison was included,
although it was a multi-centre trial of over 400
participants.
When compared at a 1:1 dose ratio and delivered
by an HFA pMDI, there were no significant
differences between CIC and FP for any outcomes,
as demonstrated in one study. Non-inferiority was
also appropriately demonstrated for lung function. 
The BTS/SIGN Guideline1 notes that, from the
limited evidence available, MF (currently only
available as a DPI) is equivalent to twice the dose
of BDP (delivered by a CFC pMDI).
Unfortunately, no relevant trials comparing these
two drugs were identified which met the criteria
for inclusion in the current assessment. However, a
small number of trials were included which
compared MF with BUD and with FP.
When given at a 1:1 dose ratio (with both MF
400 µg and BUD 400 µg delivered by a DPI
inhaler), results from one trial showed statistically
significant differences in favour of MF on
measures of lung function, SFDs and use of rescue
medication. AEs were comparable. However, in
another trial, which used double the dose of both
drugs (thus on the borderline of Steps 2 and 4 of
the BTS/SIGN Guideline care pathway), only FEV1
was significant, suggesting that both drugs may
have approached a plateau in dose response
(other variables being equal). At a 1:2 dose ratio
(MF:BUD, from one trial), the only statistically
significant difference was for FEV1, in favour of
MF. The general finding, therefore, is that MF is
statistically superior to BUD on a range of
outcomes at the same nominal daily dose (under
800 µg per day), but this effect is diminished when
the dose of BUD is doubled. It should be noted
that this study did not compare BUD and MF at
the accepted clinically equivalent dose ratio.
In contrast to the comparison with BUD, there
were no statistically significant differences between
MF and FP at a 1:1 dose ratio. When delivered at
a 1:2 dose ratio (MF:FP), there were significant
differences for morning PEF and nocturnal
wakenings in favour of FP. Caution is advised in
interpreting this result, as only one trial of this
comparison was included, although it was a large
multi-centre international trial. On the basis of
this one trial, therefore, MF and FP at the same
daily dose appear to be generally comparable, at
least on the basis of absence of significant
differences. Doubling the dose of FP appears to
increase the likelihood of FP being more
favourable, a similar observation for the
comparison of CIC with FP.
Review question 2: which ICS is the
most effective at high doses? 
Twenty-four relevant RCTs of the efficacy and
safety of ICS at high doses in excess of 800 µg/day
(BDP/BUD or equivalent, corresponding to Step 4
of the BTS/SIGN Guideline) were included. There
was variability in the doses used in the trials,
ranging from 800 to 2000 µg/day (ex-valve) (lower
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the trials, where sufficiently reported, were
appropriate for this step of the Guideline, in that
they had previously been treated with ICS and
usually other medication such as LABAs,
leukotriene antagonists or theophyllines. It should
be noted that, according to the Guideline, these
high doses of ICS should not be prescribed on
their own. Other medication should be co-
prescribed. It is not always clear from the trial
reporting whether this is the case in the trials
reviewed here and the results should therefore
only be extrapolated to the Guideline context with
caution.
The results of comparisons of ICS at high doses
were similar to those of comparisons of ICS at low
doses in finding that there were few statistically
significant differences between the steroids.
For the comparison of BDP with BUD, the
evidence base was relatively limited, with only two
small short-term cross-over trials included. The
only significant difference was for exacerbations,
in favour of BUD (from one of the trials).
The comparison of FP with BDP was larger,
comprising 10 RCTs of varying length, dose,
design and size. All but two of these compared the
drugs at a 1:2 dose ratio (FP:BDP). Again, there
were few statistically significant differences
between them, consistent with our assessment of
these drugs at lower doses. Where significant
differences were found they were for measures of
lung function and for exacerbations, as reported
in one of the two studies (using a 1:1 dose ratio).
All but one of the 10 RCTs compared the steroids
using CFC pMDI inhalers, some with spacers.
However, we did identify one additional study
comparing HFA pMDI BDP with HFA pMDI FP at
a nominal 1:1 dose ratio (the BDP brand being
QVAR extra-fine Autohaler). Non-inferiority was
demonstrated for the primary outcome, morning
PEF in the ITT, but not the PP, analysis. There
were no statistically significant differences between
the treatments for the remaining outcomes. Based
on these studies, high doses of CFC pMDI FP
appear to result in comparable control to BDP at
half the dose. If using an HFA pMDI, similar
doses of the two drugs can achieve comparable
control. This is primarily based on absence of
significant differences, and methodological
limitations of the trials need to be taken into
account.
For the comparison of FP and BUD, the only
significant differences were for FEV1, which
favoured FP, reported in one of the six trials. This
applied whether they were compared at a 1:1 or a
1:2 dose ratio. Meta-analysis of three of the trials
showed no significant difference in AEs. This was
in contrast to meta-analysis of low-dose FP and
BUD, discussed earlier, where there was a
significant difference in favour of FP. It is not clear
whether this is an artefact of the dose ratios used
or study methods or whether there is another
explanation.
In common with the lower dose ICS comparisons
discussed earlier, there is a paucity of evidence on
the newer steroids at high doses. Trials comparing
CIC with FP were identified, all of which were
commercial-in-confidence. However, comparisons
with BDP, BUD or MF were lacking. The evidence
for CIC compared with FP was supplied by the
manufacturer of CIC, and is commercial-in-
confidence.
There was limited evidence for the efficacy and
safety of MF at high doses. When compared with
FP (one study) or BUD (one study), there was little
in the way of significant differences.
Review question 3: which is more
effective – an ICS or a combination
inhaler containing an ICS and a LABA? 
(a) ICS and LABA where the dose of the ICS is
higher when used alone, compared with the dose
in the combination inhaler
For patients who are inadequately controlled on
low-dose ICS, the options include increasing the
dose of the ICS up to the 800 µg/day dose
threshold for Step 3 of the Guideline, or adding in
a supplemental drug treatment. The BTS/SIGN
Guideline1 recommends a trial of an add-on
therapy for such patients before increasing the
ICS dose above 800 µg/day. The first choice is a
LABA. Other add-on therapies include
leukotriene receptor agonists and theophyllines,
which are outside the scope of this assessment.
In this assessment, 10 trials were included where
the dose of ICS was higher than the dose in the
combination inhaler arm. They varied
considerably in terms of length, aims and
methodological quality. Baseline populations,
where reported sufficiently, appeared appropriate
for this step of the Guideline in that they were not
steroid naïve. Half of the studies used the FP/SAL
combination inhaler, whereas the other half used
the BUD/FF combination inhaler. ICS doses, when
used in combination with LABAs, varied from 200
to 800 µg/day for BUD and from 200 to
500 µg/day for FP. When used alone, the ICS doses
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500 to 1000 µg/day for FP. In general, the ICS
dose when used alone was at approximately
double the accepted clinically equivalent dose that
was used in combination with the LABA.
The general finding from the trials assessed is that
ICS and LABA in a combination inhaler is
superior to increasing the dose of the ICS, across a
range of outcomes. This applied to both of the
combination inhalers evaluated in the trials. This
finding accords with the BTS/SIGN Guideline and
with the results of a Cochrane review.171 Morning
and evening PEF were significantly favourable for
combination therapy in all but one trial.
Combination therapy was also significantly more
favourable for reducing the need for rescue
medication (in terms of puffs per day) in all the
trials that reported this outcome. The three trials
that measured the impact on HRQoL all reported
significant differences in favour of combination
therapy. However, results for FEV1 were mixed, as
was the case for symptoms. The proportion of
patients experiencing AEs appeared comparable
across the trials. There were no significant
differences for two trials on this outcome when
pooled in a meta-analysis.
The general finding that ICS and LABA is more
effective than doubling the dose of ICS extends to
the use of combination inhaler being used for
both maintenance and symptom relief compared
with ICS alone. This was evaluated in one study231
which compared BUD/FF with BUD.
One of the findings of the Cochrane review was
that there was no significant difference between
treatments in terms of reducing exacerbations
requiring systemic corticosteroids. Results for
exacerbations from the current assessment,
comprising both mild and severe exacerbations,
were mixed. In some trials there were no
significant differences between treatments, in some
combination therapy was significantly more
effective and in others combination therapy
appeared favourable but no statistical tests were
reported to clarify the role of chance in the
findings.
It is important to note that the constituent ICS in
the combination inhalers were not always the same
as the ICS used alone, as was the case in four of
the 10 studies (e.g. BUD compared with FP/SAL).
However, the doses used in the ICS alone group
appear similar to the accepted clinically equivalent
dose of the same ICS as in the combination
inhaler. For example, in a trial of 800 µg/day of
BUD compared with 200 µg/day of FP/SAL, the
BUD dosage is approximately double the amount
that would have likely been used if the comparison
had been between FP and FP/SAL, based on the
potency ratio of 1:2 FP:BUD. This is likely to
lessen any confounding associated with differences
in dose. The results of this assessment do not
appear to differ for these studies compared with
those where the same ICS was used in both trial
arms. Although it seems intuitive that an ICS
should be tested against a combination inhaler
containing the same ICS, in clinical practice
patients at Step 2 of the care pathway may switch
from any of the five currently licensed ICS to a
combination inhaler in Step 3 (e.g. moving from
BDP to a combination inhaler containing FP/SAL).
As the evidence base we have assessed only
considers ICS alone at approximately double the
accepted clinically equivalent dose of the ICS in
the combination treatment, we cannot comment
on whether findings would be different if a higher
dose ratio were compared.
Further, it should also be acknowledged that these
findings are applicable only to DPIs as none of the
studies used a pMDI to deliver the drugs. This is
relevant to the FP/SAL combination inhaler which
is available as both a DPI and a pMDI.
(b) ICS and LABA where the dose of the ICS is
similar in both treatment arms
As discussed, the BTS/SIGN Guideline
recommends either increasing the dose of ICS or
adding in a supplemental drug, such as a LABA,
for patients uncontrolled on low doses of ICS.
However, a body of evidence exists comparing ICS
with ICS and LABA where the ICS dose is similar
in both strategies. These trials were conducted to
evaluate the safety and efficacy of the combination
inhalers compared with standard treatment with
ICS.
In this assessment nine such trials were included,
six evaluating the FP/SAL combination and four
evaluating the BUD/FF combination. In all trials
the same ICS was used in both comparators. As
was the case with the studies discussed in the
previous section, there was a great deal of
variation in terms of aims, treatment duration,
dose, size and methodological quality. The ICS
dose varied from 200 to 1000 µg/day for FP and
from 200 to 800 µg/day for BUD.
The aims of the trials varied. For example, some
compared once- or twice-daily combination
therapy with ICS alone. In one study the aim was
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two treatments to achieve asthma control. The
characteristics of the patients also varied. In some
trials patients were described as having moderate-
to-persistent asthma and in others as having mild-
to-moderate asthma. In general, patients enrolled
were those whose asthma was symptomatic, or
suboptimally controlled, and treated with ICS, as
appropriate for Steps 2–3 of the Guideline. The
results of these trials therefore cannot be
extrapolated to the situation of using ICS and
LABA in combination in steroid naïve patients,
which is outside the context of the Guideline and
not considered in this review.
The general finding was that ICS and LABA was
statistically superior to ICS alone across most
outcomes, as might be expected. In three of the
studies, all of which evaluated the FP/SAL
combination, there were no significant differences
for FEV1. There were no significant differences for
nocturnal wakenings in three trials. However, for
all other outcomes the combination inhaler was
superior to ICS alone. The proportion of patients
experiencing AEs appeared similar between the
treatments.
These findings resonate with those of a Cochrane
review which found that the addition of LABA to
ICS in patients who are symptomatic on low to
high doses of ICS reduced the rate of
exacerbations requiring systemic steroids, and
improved lung function, symptoms and use of
rescue medication.172
As was the case with the ICS and LABA compared
with higher dose of ICS studies, findings are
applicable only to DPIs as none of the studies used
a pMDI to deliver the drugs.
Review question 4: ICS and a LABA
administered in a combination inhaler
compared with separate inhalers
The scope for this assessment, as set by NICE,
includes the use of ICS and LABA in a
combination inhaler, but not in separate inhalers.
It should therefore be acknowledged that there is
a wider evidence base for the use of ICS and
LABA in separate inhalers compared with ICS
alone, as summarised by the Cochrane
Collaboration.171,172 The scope does, however,
include the use of ICS and LABA in a
combination inhaler compared with the two in
separate inhalers.
Six trials were included, three comparing FP and
SAL combination inhaler with separate inhalers,
two comparing BUD and FF combination inhaler
with separate inhalers and one comparing FP/SAL
in a combination inhaler with BUD + FF in
separate inhalers. The ICS doses were similar in
both treatment strategies, and ranged from 200 to
1000 µg/day for FP and 800 µg/day for BUD.
There were very few statistically significant
differences between the treatments across the
various efficacy outcomes. This applied to
comparisons involving both combination inhalers.
For some outcomes (e.g. morning PEF) non-
inferiority was demonstrated. The findings of this
assessment are in accord with the BTS/SIGN
Guideline, which states that there is no difference
in efficacy between ICS and LABA given in
combination versus separate inhalers. The two
treatment modalities were similar in terms of AEs.
Meta-analysis of AEs found no statistically
significant differences in AEs, serious AEs and
withdrawals due to AEs. The numbers of these
events were generally small, however.
Expert clinical opinion suggests that one of the
advantages of combination inhalers is that the risk
of patients taking LABAs on their own without
ICS is reduced. When ICS and LABA are
prescribed separately, it is suggested that the rapid
symptom relief provided by the LABA may mean
that some patients are less likely to routinely take
their ICS. The LABA will not have reduced the
underlying inflammation and patients may be at
increased risk of exacerbation. The BTS/SIGN
Guideline1 makes it clear that LABAs should not
be used without ICS.
Review question 5: combination inhaler
compared with combination inhaler 
Three head-to-head RCTs comparing the two
currently available ICS and LABA combinations
were included in this assessment. Daily ICS doses
were 800 µg for BUD and 500 µg for FP. Results
were mixed, with the FP/SAL combination
significantly superior on some outcomes and the
BUD/FF combination superior on others. In the
one trial that reported FEV1, BUD with FF was
significantly superior, as it was for SFDs. There
were no statistically significant differences between
groups in symptom scores, or HRQoL in one trial
whereas symptom scores were described as being
“comparable” between groups in another study. In
two trials BUD/FF was significantly superior in
terms of exacerbations, whereas in a third FP/SAL
was superior. Meta-analysis found that there were
no significant differences between the treatment
groups in rates of AEs, serious AEs or withdrawals
due to AEs. Again, it should be acknowledged that
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However, BUD/FF combination inhaler is only
currently available as a DPI.
Further trials comparing the two combination
inhalers may yield a more definitive answer to the
question of which is more effective. Our updated
literature search in October 2006 identified one
such study,278 although its methodology and
findings have not formally been assessed (see
Appendix 5 for a list of other relevant studies
identified by this search). Brief examination of this
large multi-centre, 6-month trial found that both
combination inhalers were associated with
favourable changes across outcomes, with no
significant differences between them. However, the
FP/SAL combination was significantly superior in
reducing the moderate/severe exacerbation rate.
Estimates of costs and exploring
cost-effectiveness
It was not possible to develop an appropriate and
valid cost–utility model for the treatment of
asthma with an ICS, used either alone or in
combination with a LABA at the appropriate steps
of the BTS/SIGN Guideline. The reasons for not
reporting the full model methods and results in
the main body of the report have been outlined
previously in the section ‘Original economic
analyses: introduction and rationale’ (p. 181). We
therefore adopted a cautious approach to the
economic analysis for this report, and present for
each question either a cost comparison or a
cost–consequence comparison. These two different
methods of analysis were used appropriately in
relation to the findings from the accompanying
clinical effectiveness review. A cost comparison of
the different ICS and ICS plus LABA preparations
was undertaken where the clinical effectiveness
review showed no consistent evidence of
differential treatment effects between the
comparators (research questions 1, 2, 4 and 5). A
cost–consequence comparison was undertaken
where the clinical effectiveness review indicated
that there were significant differences in effects
between the two comparators (research question
3a). Here the overall pattern of effectiveness
differences identified in the systematic review were
presented alongside the estimated current NHS
preventer medication costs for each of the
comparators in the trials.
Cost comparisons
These cost comparisons have been shown in the
section ‘Original economic analyses’ (p. 183).
They relied on a range of assumptions for arriving
at each mean annual cost of taking a particular
ICS or combination inhaler. In particular, they
used the conventional (GINA and BTS/SIGN)
dose equivalence ratios for different ICS drugs
and/or propellants, and used the 2005 community-
dispensed prescription sales data for weighting the
cost of different products within each drug type.
For these reasons they should be viewed as a form
of illustrative economic ‘what if ’ analysis: ‘If they
were equally effective, what would be the likely
differences in the annual cost of treatment?’
ICS versus ICS 
There are considerable differences in weighted
mean annual cost between the different ICS, and
also large cost differences between different
preparations of the same ICS. The annual cost
varies six-fold between different preparations of
BDP to there being no variation in the cost of CIC
as there is only one non-CFC-propelled
preparation currently on the market. The cost
differences between different BDP preparations
are smaller, however, if the (typically cheaper)
CFC-propelled preparations are excluded from
the analysis. At present, at the starting low dose of
400 µg/day BDP devices tend to be the cheapest,
and even when CFC-propelled devices are
excluded at this dose BDP still appears the
cheapest. At doses of 800 and 1500–1600 µg/day
BDP products appear to remain the cheapest
available. At these doses when CFC-propelled
products are excluded, then FP products tend to
be the cheapest of the ICS products available.
When non-CFC-propelled products are
considered, the mean annual cost of both BDP
and BUD increases, and the overall cost
differences between the five ICS drugs diminish.
As there are currently no CFC-propelled products
available for FP, CIC and MF, their costs remain
constant. However, although the use of weighted
averages may provide a useful measure for
comparing the cost for each ICS drug with each
other, they conceal the often considerable
variation in costs for each preparation of the ICS
drugs and the considerable overlap in costs
between the ICS. These basic results, which are
based on the weighted and unweighted averages,
are derived with a number of assumptions
necessarily being made. They should therefore be
viewed and interpreted with an appropriate
amount of caution.
Our systematic review of the published research
evidence has highlighted the fact that there is little
demonstrated difference in effectiveness between
the different ICS comparators under trial
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justification for the sometimes considerable cost
differences between different products containing
the five licensed drugs. However, other differences
between the products, such as inhaler device
characteristics and propellant taste, will probably
influence how effectively or easily they are used.
As previously discussed, there is a reasonable
percentage of the asthmatic population that has
difficulty in using certain types of inhaler devices.
Therefore, given the probable device-related
variations in both compliance with correct inhaler
technique and adherence to recommended daily
doses, the cost savings that could be realised by
using the cheapest ICS via the cheapest device (a
pMDI) could potentially result in an increase in
other healthcare resource use, through an increase
in exacerbations resulting from poorer control of
asthma. Although we cannot quantify this
theoretical increase, as discussed previously,
concordance with treatment in trials is around
80%, but in the general population of adolescents
and adults with asthma it may be that fewer than
50% take the full amount of prescribed medication
(see Chapter 1). Choosing a more expensive
delivery device that the patient prefers and can
easily use correctly might well improve
concordance, thus minimising other healthcare
resource use.
ICS and LABA versus ICS alone
The general findings from the clinical
effectiveness review indicated that combination
ICS and LABA therapy is superior to doubling the
dose of ICS alone, across a range of outcomes.
However, these effects are not consistent across all
outcome measures. The relative annual costs
associated with combination therapy versus an
increased dose of ICS alone are highly variable
and depend both on the dose required and the
particular delivery device used. These variations in
the costs of both ICS and LABA drugs mirror the
observations from the cost comparisons presented
for ICS drugs alone, that any generic conclusions
about cost-effectiveness of each ICS drug are not
possible, as they are confounded by the number
and varying prices of the different products
available for each drug.
ICS and LABA versus ICS and LABA
For both of the currently available combination
inhalers (Seretide and Symbicort), using the
combination inhaler is nearly always cheaper than
taking the same drugs in separate inhalers. The
cost savings associated with the use of combination
inhalers vary considerably depending on the exact
preparation of the drugs used and the dose
required. It can therefore be suggested that the
use of combination inhalers in preference to
separate inhalers would lead to further indirect
cost savings. As has previously been discussed,
there are no significant differences in effectiveness
between the two modes of drug delivery. The ease
of using a combination inhaler, which prevents use
of LABA alone without ICS, may lead to better
concordance. If symptoms are better controlled,
the need for rescue medications and healthcare
consultations due to exacerbations may well be
reduced.
At lower doses, the cheapest combination inhaler
is FP/SAL delivered as an pMDI, but this is only
slightly cheaper than BUD/FF delivered as a DPI.
At higher dose levels, both the FP/SAL
combination inhalers (pMDI and DPI) are slightly
cheaper than BUD/FF as a DPI. 
Summary of the cost comparisons
At present there are large variations in the costs
between the five ICS and two LABA products
available. These variations are dependent on both
the ICS or ICS/LABA dose required and the
preparation used. Currently, BDP CFC-propelled
preparations tend to be the cheapest on the
market, but there is a large variation in cost
between the different BDP preparations. As CFC-
propelled products are phased out, the overall cost
of ICS therapy is likely to increase. When only
non-CFC-propelled products are considered, then
there is less variation in the costs between the five
ICS drugs, although MF consistently appears to be
marginally more expensive than the other four
ICS products. It should be noted that although the
use of weighted averages can provide a useful way
of representing the major differences between the
drugs, these conceal the wide variations in the cost
of individual products containing each drug. They
will also inevitably be sensitive to year-on-year
shifts in the market share or price of individual
products. For this reason, we have presented both
weighted and unweighted mean costs for each cost
comparison.
Strengths and limitations of 
the assessment
Strengths and limitations of the
systematic review of clinical
effectiveness
In terms of strengths, this assessment has followed
transparent and accepted methods for conducting
systematic reviews. A protocol outlining the scope
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in the process. An expert advisory group
comprising clinicians specialising in respiratory
medicine, GPs and health economists has provided
advice throughout the assessment and commented
on a draft of this report.
The effect of inhaler devices was outside the scope
of the present assessment. However, in order to
reduce any potential confounding in the
assessment of the different comparators under
consideration, only trials in which the inhaler type
and propellant were the same in each of the trial
arms were included in the systematic review.
In terms of limitations, it was not possible to
report every outcome measure reported in each of
the included trials. As discussed earlier, there are
numerous ways of measuring and reporting
measures of asthma control. To achieve brevity, we
prioritised key measures from each of the relevant
outcomes. For example, of the various ways of
measuring lung function, we only reported FEV1
and morning and evening PEF, as these appeared
to be the most commonly used and clinically
meaningful. Consequently, in some trials the
primary outcome has not been reported in this
assessment if it was not a measure that had been
prioritised. Furthermore, some of the outcomes
that have been reported here may have been
secondary outcomes for which trials were not
necessarily powered to detect differences. This
should be borne in mind when interpreting the
findings.
It was not always possible to conduct meta-analysis
in order to provide a quantitative estimate of
treatment effect. This would have provided greater
statistical power to show potential differences.
Differences between studies in length and dose
meant that in many instances it was not
appropriate to pool studies. In cases where
pooling was appropriate poor reporting of the
results of the trials prohibited quantitative
synthesis (e.g. limited data available on the
variance associated with effect measures).
Consequently, much of the assessment of clinical
effectiveness has been reported narratively. It has
been challenging to summarise such a large
evidence base in this way.
The quality of reporting in the trial reports was
poor in places. For example, the brand name for
the inhaled steroids and the devices used to
dispense them were not always mentioned. It was
also particularly difficult to determine whether or
not a combination inhaler had been used, or
whether ICS and LABA had been delivered by
separate inhalers. Where possible, we contacted
authors for further clarification, but time did not
allow for this to be conducted routinely.
As discussed earlier, this assessment aimed to build
upon previously published evidence syntheses of
the efficacy and safety of ICS. The rationale was to
reduce duplication and to ensure that the project
was manageable. The Cochrane Airways Group
kindly made available data from their systematic
reviews. We performed data extraction and quality
assessment only on the trials that met our
inclusion criteria that were supplemental to the
Cochrane reviews. The completed data extraction
and quality assessment forms for these
supplemental studies are available in Appendix 4.
Further details of the remaining studies can be
found in the Cochrane reviews.56,170–173
Strengths and limitations of the
economic evidence and analyses
Economic analysis has been severely restricted as
we were unable to populate the cost–utility model
from the relevant trial data available to assess
cost–utility. Ideally, an economic evaluation in
asthma should capture the quality of life and cost
impacts both of different levels of control and
exacerbation severity and frequency, and also be
able to compare all potential treatments
concurrently. To some extent, therefore, all
existing evaluations, including those submitted by
industry sponsors to NICE, are limited.
Evaluations based solely on SFDs, for example,
may not adequately capture the full spectrum of
costs and disutility associated with other indicators
of poor control and exacerbations. Conversely,
evaluations dominantly based on exacerbations as
an outcome, including the exploratory analysis
carried out as part of this report, may not fully
reflect differences in costs and utility associated
with varying levels of ‘non-exacerbation’ asthma
control. In the absence of established models that
can include all relevant technologies in a single
evaluation and also capture the consequences of
differences in all levels of control, most
comparisons have focused on an analysis of the
costs associated with the mean annual treatment
costs for each ICS and LABA drug.
Strengths
The cost comparison approach that we adopted
was a pragmatic response to the lack of evidence
of differential clinical effectiveness for some
research questions. In the absence of a formal
model-based CUA or CEA, these comparisons
clearly illustrate the wide variation in possible
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product type/strength, daily dose and inhaler type.
Although we have chosen to show averages for
each ICS, we have put them in context by showing
both weighted and unweighted means and also the
cheapest and most expensive product for each ICS
at each dose level. With a view to other changes
currently taking place in the UK market for
asthma drugs, we have also generated estimates
with and without CFC-propelled products
included. Finally, for the comparison of combined
ICS with LABA versus ICS alone, our simple
cost–consequence analysis at least presents the
main clinical effectiveness review findings
alongside their estimated costs in a disaggregated
form.
Limitations
The main limitation of our economic analyses is
that they do not include a comprehensive model-
based CUA which integrates all relevant cost and
effectiveness evidence relevant to the decision
problems. This omission is partly due to the
nature of the published trial evidence base for
these decision problems, but is also to do with the
inherent challenges of modelling the full spectrum
of asthma outcomes, from symptom control and
quality of life impacts to severe exacerbations.
All of the cost comparisons discussed above have
involved a number of necessary simplifying
assumptions, including (1) the relative doses of
different ICS drugs which are currently assumed
to have equivalent effectiveness, (2) the exact mix
of products which would probably be used to
achieve any particular daily dose level of ICS or
ICS with LABA and (3) using 2005 community
prescription sales as a way of producing a
weighted mean annual cost for each group of 
drug preparations. For these reasons, and because
the range of available ICS and combination
products is currently undergoing considerable
change (with CFC-containing products being
phased out and some new HFA-propelled BDP
products recently entering the market), the
conclusions should be viewed with appropriate
and substantial caution.
Other considerations
As already discussed, the relevance to decision-
makers of trial-based evidence on the clinical
effectiveness of asthma treatments is often limited
by a range of factors to do with the characteristics
of the patients in the trials, or the inevitably
partial selection of drugs and inhaler devices that
have mostly been compared. The evidence base
may therefore be on comparisons between
technologies that are not relevant within current
clinical guidelines, focus on efficacy and safety
rather than ‘real-world’ (e.g. adherence-
diminished) effectiveness and be conducted in
patients who are specially selected to be able to
comply or who are monitored more thoroughly
than would be the case in routine clinical care.
Furthermore, the fact that most choices between
different asthma drugs involve a simultaneous
choice of inhaler type (or, choice of inhaler device
may effectively determine the asthma drug
‘chosen’), creates further difficulties in using an
evidence base which is largely aimed at comparing
either drugs or devices.
In addition to these difficulties, it may be that the
average effectiveness results that clinical trials
mainly produce are inappropriate in another more
fundamental way. Asthma drug treatment
decisions are inherently reversible. Also, the drugs
themselves are, in general, safe (certainly at the
low to moderate doses with which most people are
managed). This is why asthma treatment
guidelines are implicitly based on an iterative
approach of ‘trying out’ what works best in
achieving symptom control for individual patients.
Given such a clinical context, with the possibility
of multiple reversible clinical decisions, there may
be a legitimate argument for retaining the current
variety in products, in terms of both drug types
and inhaler devices, given acceptable variations in
average effectiveness and costs. In addition to
variations in people’s ability and willingness to use
different inhaler devices effectively, it may be that
there are subtle differences in people’s response to
the different ICS drugs themselves (or to the
addition of a LABA to an ICS) which mean that
some individuals, for example, respond more to
particular ICS compounds than others.
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here is a vast literature on the clinical and
cost-effectiveness of the five ICS used alone or
in combination with a LABA for the treatment of
chronic asthma in adults. Around two-thirds of the
RCTs included in this review compared ICS with
each other at doses within the range of Steps 2–4
of the BTS/SIGN Guideline. Within these steps,
the majority of the trials were of the three older
ICS: BDP, BUD and FP. Fewer trials assessed the
two newer ICS: MF and CIC.
The remaining studies assessed the effectiveness of
the addition of a LABA to an ICS compared with
an ICS alone, with the latter given either at the
same or an increased dose to that in the
combination inhaler. Further identified trials have
also examined the use of ICS and LABA therapy,
delivered through a combination inhaler or
through separate inhalers. 
ICS versus ICS
From the available evidence, the clinical
effectiveness and short-term safety of the five ICS
when used at the accepted clinically equivalent
dose ratios, at either Step 2 (low dose) or Step 4
(high dose) of the Guideline is broadly similar.
Although equivalence between the comparators
certainly cannot be assumed from the results,
there appear to be no consistent significant
differences between the comparators in effects
when delivered by the same delivery device and
propellant. As no cost–utility model could be used
to estimate cost-effectiveness, cost comparisons
were undertaken between the different ICS
preparations. These showed that there are no
consistent cost differences between the
comparators, as the costs depend on both the
required dose and the specific product used, which
includes the delivery device. In general, at a
typical starting dose of 400 µg/day BDP devices
currently tend to be the cheapest, and remain so
even when CFC-propelled devices are excluded. At
doses of 800 and 1500–1600 µg/day BDP CFC-
propelled products remain the cheapest available.
At these doses, when CFC-propelled products are
excluded, FP is then the cheapest of the ICS
products available. When CFC-free products are
considered, the mean annual cost of both BDP
and BUD increases, but the overall cost 
differences between the five ICS drugs diminishes.
For FP, CIC and MF, there are currently no 
CFC-propelled products available so their costs
remain unchanged. However, it should be
highlighted that the use of weighted and
unweighted averages to represent the cost
associated with each ICS tends to conceal the wide
variations in costs between the individual
preparations of each drug and the wide overlap in
costs between the drugs.
ICS versus ICS + LABA
The general findings from the clinical
effectiveness review indicated that combination
ICS and LABA therapy is superior to doubling the
dose of ICS alone, across a range of outcomes.
However, these effects are not consistent across all
outcome measures.
Alongside evidence of some relatively consistent
clinical effectiveness differences favouring
combination inhalers, we have shown they are
often also cheaper than doubling the dose of ICS.
However, we are cautious not to draw any firm
cost-effectiveness conclusion from these
cost–consequence data, since this ‘result’ largely
depends on the specific dose levels, and exact
products compared in these trials. Furthermore,
we have not factored in the other potential cost
advantages that might accrue to combination
inhalers if the relative reductions in exacerbation
rates measured in some trials were more certain.
Nor do they capture the potential quality of life
impacts of reducing the proportion of days or
nights with symptoms, which some trials show.
When such variables are factored in, as we have
done in our exploratory CUA (Appendix 10), the
major uncertainty in the cost estimates remains,
and the joint uncertainty surrounding the cost and
effectiveness estimates available from the research
literature prevents any straightforward use of
conventional rules for interpreting cost-
effectiveness ratios.
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Chapter 7
ConclusionsICS plus LABA versus ICS + LABA
Combination versus single inhaler
devices
There were no consistent differences in the
effectiveness of combination ICS plus LABA
therapy delivered concurrently compared to
delivery in separate inhalers. Cost comparison
between the two regimens showed that taking an
ICS with a LABA as either of two currently
available combination products (Symbicort and
Seretide) is cheaper than taking the relevant
ingredient drugs in separate inhalers.
The use of single inhaler therapy not only
provides a simpler treatment regimen, but may
also enhance concordance with maintenance ICS
therapy and reduce the likelihood of LABAs being
used without ICS. From this review, there appear
to be no significant clinical differences in
effectiveness between the two modes of treatment
delivery and potential cost savings to the NHS
with use of a combination inhaler compared with
separate inhalers. Therefore, in the general
context of long-term maintenance treatment, use
of a combination inhaler should be preferred to
prescribing the same drug ingredients in separate
inhalers.
Combination versus combination
inhaler devices
From the limited evidence available, the clinical
effectiveness of the two combination ICS and
LABA inhalers (Seretide and Symbicort) appears
to be similar when used at accepted clinically
equivalent dose ratios. The cost comparison that
was undertaken indicated that at lower dose levels,
the cheapest combination inhaler is FP/SAL as an
aerosol for pMDI (Seretide Evohaler), but this is
only slightly cheaper than BUD/FF as a DPI
(Symbicort Turbohaler). At this dose level, FP/SAL
as a DPI (Seretide Accuhaler) is the most
expensive of the three combination products
assessed. At the higher dose level, FP/SAL both as
an aerosol for pMDI and as a DPI (Seretide
Evohaler and Seretide Accuhaler, respectively) are
the cheapest combination products available, but
they are both only slightly cheaper than having
the ICS ‘equivalent’ dose of BUD/FF Symbicort
Turbohaler.
Research recommendations
Primary research
Future trials of treatment for chronic asthma
should standardise the way in which outcome
measures are defined and measured. There should
be a greater focus on patient-centred outcomes
such as HRQoL and symptoms. This will provide a
more meaningful estimation of the impact of
treatment on asthma control.
Most settings for the trials in this review were not
fully specified, making it difficult to generalise
them to primary care practice, where most
patients in the UK are treated. In addition, the
trial protocols often do not reflect the actual
treatment options that patients follow in routine
care. Outside trial settings, patients at Steps 2–3 of
the Guideline may alter their ICS dose either
under a self-management plan or in consultation
with their GP, effectively resulting in a variable
dose of ICS over time. In order to obtain more
accurate estimates of the effectiveness of ICS in a
UK setting, more patients from the UK should be
entered into trials and the setting fully specified in
terms of methods of recruitment and level of
routine care received during the trial. In addition,
trials should explicitly try to capture the changes
that individual patients may make in their ICS
dose over time.
For informing future CUAs and CEAs from a UK
NHS perspective, there is a need for longitudinal
studies which comprehensively track the care
pathways followed when people experience asthma
exacerbations of different severity. The most
recent studies of this kind in the UK are over
10 years old, and the NHS ‘service landscape’ for
people with urgent problems has changed
considerably during the intervening years (e.g.
NHS Direct, GP out-of-hours cooperatives, walk-in
centres).
Secondary research
AEs are also not well specified and reported in the
clinical trial literature reviewed here. Concerns
about the long-term adverse effects of the
different ICS do influence the choice of ICS by
both patients and clinicians, but most trials are not
of sufficient power or duration to provide
adequate data on differential adverse outcomes.
Further research synthesis, quantifying the adverse
effects of the different ICS, is required for
treatment choices by patients and clinicians to be
fully informed.
Initial searches undertaken for this assessment
indicate that there are at present no good-quality
systematic reviews available that have assessed all
potential long-term AEs associated with the
different ICS comparators. Published reviews have
tended to focus on the use of short-term RCT
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216safety data with a length of follow-up between 1
and 2 years. Therefore, to assess adequately the
longer term sequel of ICS use, future reviews
should aim to examine studies of longer term
follow-up, and use appropriate data sources such
as cohort, case–control studies and registry data
where available.
Standardisation of outcome measures 
The evidence base that was assessed in this review
was highly heterogeneous in terms of both the way
in which outcome measures had been defined and
measured and also in the level of reporting of the
trial results.
Methods of reporting in trials require
standardisation. In particular, where statistical
results are presented, means and SDs should be
provided. This will enable such studies to be
included in quantitative meta-analysis. The
statistical methods of analysis should also be
explicitly stated. In addition, the overall trial
methods should be explicitly documented and
reported, with adherence to the CONSORT
statement279 standard of reporting being made a
priority.
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